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ABSTRACT	  
The	   five-­‐year	   survival	   rate	   of	   patients	  with	   head	   and	   neck	   squamous	   cell	   carcinoma	  
(HNSCC)	  has	   remained	   stable	   at	   50%	  over	   the	  past	   five	  decades.	   Consequently,	   new	  
treatment	  options	  are	  required.	  In	  approximately	  90%	  of	  cases,	  over-­‐expression	  of	  the	  
tumour	  associated	  antigen	  ErbB1	  is	  seen.	  T4	  immunotherapy	  retargets	  T-­‐cells	  against	  
the	   extended	   ErbB-­‐receptor	   family	   and	   could	   be	   beneficial	   for	   HNSCC	   patients.	   T4	  
immunotherapy	   comprises	   the	   combined	   expression	   of	   the	   ErbB-­‐targeting	   chimeric	  
antigen	  receptor	  T28ζ	  and	  the	  chimeric	  cytokine	  receptor	  4αβ.	  Human	  T4+	  T-­‐cells	  have	  
a	   potent	   anti-­‐tumour	   effect.	   However,	   ErbB	   expression	   is	   not	   exclusive	   to	   tumour	  
tissue,	   raising	   the	   concern	  of	   toxicity	   in	  healthy	   tissue.	  Here,	   I	   have	   investigated	   the	  
potential	   toxicity	   of	   T4	   immunotherapy	   in	   a	   SCID/Beige	   immunodeficient	   mouse	  
model.	   Human	   T4+	   T-­‐cells	   are	   activated	   by	  mouse	   ErbB	   receptors	   and	   consequently	  
destroy	  both	  healthy	  and	  transformed	  mouse	  cells.	  Intravenous	  or	  intra-­‐tumoural	  T4+	  
T-­‐cell	   administration	   did	   not	   result	   in	   any	   clinical	   or	   histopathological	   toxicity.	  
However,	   intraperitoneal	  T4+	  T-­‐cell	  administration	  resulted	  in	  severe	  cytokine	  release	  
syndrome	  (CRS).	  Target	  recognition	  in	  the	  peritoneal	  cavity	  resulted	  in	  elevated	  levels	  
of	   serum	   human	   IL-­‐2	   and	   IFNγ,	   as	   well	   as	   mouse	   IL-­‐6.	   The	   severity	   of	   CRS	   is	  
hypothesized	  to	  be	  due	  to	  a	  combination	  of	   the	  T4+	  T-­‐cell	  dose,	  magnitude	  of	   target	  
recognition,	  and	  macrophage	  content	  within	  the	  peritoneal	  cavity.	  In	  keeping	  with	  this,	  
macrophage	  depletion	  ameliorates	  both	  IL-­‐6	  production	  and	  toxicity.	  Together,	  these	  
data	   show	   that	   the	   SCID/Beige	   mouse	   is	   an	   adequate	   model	   to	   study	   T4	  
immunotherapy	  related	  toxicity.	  Furthermore,	  these	  results	  suggest	  that	  there	  may	  be	  
a	  window	  for	  therapeutic	  application	  of	  T4+	  T-­‐cells	  since	  anti-­‐tumour	  efficacy	  has	  been	  
demonstrated	   at	   lower	   cell	   doses	   without	   the	   induction	   of	   toxicity.	   These	   findings,	  
support	  progression	   to	  a	  Phase-­‐I	   clinical	   trial	   in	  which	  patients	  with	   locally	   recurrent	  
HNSCC	  are	  treated	  with	  intra-­‐tumoural	  T4+	  T-­‐cells.	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   Colony-­‐stimulating	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  Eagle	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   Dimethyl	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   Deoxyribonucleic	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dsDNA	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  DNA	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  Coli	  
EBV	   Eppstein-­‐Barr	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  coupled	  dye	  
EDTA	   Ethylenediaminetetraacetic	  acid	  
EGF	   Epidermal	  growth	  factor	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   Epidermal	  growth	  factor	  receptor	  
EGFRvIII	   Epidermal	  growth	  factor	  receptor	  variant	  III	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   Enzyme	  linked	  immunosorbent	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EMA	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  molecule	  
EPG	   Epithelial	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  oncogene	  B	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  signal-­‐regulated	  kinase	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  activated	  cell	  sorting	  
FAR	   Foetal	  acetylcholine	  receptor	  
FasL	   Fas	  ligand	  
FBP	   Folate	  binding	  protein	  
FBS	   Foetal	  Bovine	  Serum	  
FcγR	   Fc	  gamma	  receptor	  
FcγR	   IgG	  Fc	  receptor	  
FDA	   Food	  and	  Drug	  Administration	  
FEP	   	  Fluorinated	  ethylene	  propylene	  
ffLuc	   Firefly	  Luciferase	  
FITC	   Fluorescein	  isothiocyanate	  
FL	   Follicular	  lymphoma	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FMS	   Macrophage	  colony	  stimulating	  factor-­‐1	  receptor	  
FR	   Folate	  receptor	  
G	   Gauge	  
G250	   Renal	  cell	  carcinoma-­‐associated	  antigen	  250	  
GALV	   Gibbon-­‐Ape	  Leukaemia	  Virus	  
GD2	   Diasialoganglioside-­‐2	  
Gen	   Generation	  
GM-­‐CSF	   Granulocyte	  macrophage	  colony-­‐stimulating	  factor	  
GMP	   Good	  manufacturing	  process	  
gp100	   Glycoprotein	  100	  
GTP	   Guanidine	  triphosphate	  
GvHD	   Graft	  versus	  Host	  Disease	  
GvHR	   Graft	  versus	  Host	  Response	  
h	   Human	  
H29D	   Human	   retroviral	   packaging	   cell	   line	   derived	   from	   HEK293	   cell,	  
expressing	  the	  MoMLV	  gag-­‐pol	  genes	  and	  the	  VSV-­‐G	  env	  gene	  
H2O	   dihydrogen	  mono-­‐oxide	  
H4	   Combined	  expression	  of	  HOX	  and	  4αβ	  
HACA	   Human	  anti-­‐CAR	  antibodies	  
HB-­‐EGF	   Heparin-­‐binding	  epidermal	  growth	  factor	  
HBS	   HEPES-­‐buffered	  saline	  
HCl	   Hydrochloric	  acid	  
HCM	   Human	  cardiac	  myocytes	  
HED	   Human	  Equivalent	  Dose	  
HEK	   Human	  embryonic	  kidney	  
HEK293	   Adenoviral	  5-­‐transformed	  HEK	  cells	  
HER	   Human	  Epithelial	  Growth	  Factor	  Receptor/	  Homologous	  EGF	  Receptor	  
Kinase	  
HIV	   Human	  immunodeficiency	  virus	  
HLA	   Human	  leukocyte	  antigen	  
HMEC	   Human	  mammary	  epithelial	  cells	  
HMW-­‐MAA	   High	  molecular	  weight	  melanoma-­‐associated	  antigen	  
HNSCC	   Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	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HOX	   HMGF2	  scFv	  –	   IgD	  hinge	  –	   IgG1	  Fc	  and	  hinge	  –	  CD28	  –	  OX40	  –	  CD3ζ	  
MUC1-­‐targeting	  CAR	  
HPMEC	   Human	  pulmonary	  microvascular	  endothelial	  cells	  
HPV	   Human	  Papillomavirus	  
HRE	   Human	  renal	  epithelial	  cells	  
HRP	   Horseradish	  peroxidase	  
HS	   Human	  serum	  
HSCT	   Haematopoietic	  stem	  cell	  transplant	  
HSMM	   Human	  skeletal	  muscle	  myoblasts	  
HUVEC	   Human	  umbilical	  vein	  endothelial	  cells	  
IC	   Intracellular	  
ICAM	   Intracellular	  adhesion	  molecule	  
ICOS	   Inducible	  costimulatory	  
IFN	   Interferon	  
Ig	   Immunoglobulin	  
IL	   Interleukin	  
IP	   Intra-­‐peritoneal	  
IRES	   Internal	  ribosome	  entry	  site	  
is	   in	  situ	  
IT	   Intra-­‐tumoural	  
ITAM	   Immunoreceptor	  tyrosine-­‐based	  activation	  motif	  
IU	   Infectious	  units	  
IV	   Intravenous	  
KCl	   Potassium	  Chloride	  
Km	  factor	   Weight	  (kg)	  /	  BSA	  (m2)	  
KOH	   Potassium	  hydroxide	  
L-­‐PHA	   Phytohaemagglutinin/Leucoagglutinin	  
L.Broth	   Luria-­‐Broth	  
LAK-­‐cells	   Lymphocyte	  activating	  killer	  cells	  
LB	   Luria-­‐Broth	  
LC	   Liposomal	  clodronate	  
LFA	   Lymphocyte	  function	  associated	  antigen	  
LMP	   Latent	  membrane	  protein	  
	   19	  
LP	  	   Liposomal	  PBS	  
LTR	   Long	  terminal	  repeat	  
Lymphodepl	   Lymphodepletion	  
m	   Mouse	  
M	   Metastasis	  
Ma	   Matrix	  
MA	   Matrix	  
mAb	   Monoclonal	  Antibody	  
MAGE	   Melanoma	  antigen	  
MAPK	   Mitogen-­‐activated	  protein	  kinase	  
MART	   Melanoma-­‐associated	  antigen	  recognized	  by	  T-­‐cells	  
MBS	   Membrane	  Binding	  Solution	  
MDM2	   Mouse	  double	  minute	  2	  
MeOH	   Methanol	  
MET	   Mesenchymal-­‐epithelial	  transition	  factor	  
MgCl2	   Magnesium	  Chloride	  
MgSO4	   Magnesium	  Sulphate	  
MHC	   Major	  Histocompatibility	  Complex	  
MHRA	   Medicines	  and	  Healthcare	  products	  Regulatory	  Agency	  
MLTC	   Mixed	  lymphocyte	  tumour	  cell	  culture	  
MMP	   Matrix	  metalloproteinases	  
MnCL2	   Manganese	  Chloride	  
MoMLV	   Moloney	  murine	  leukaemia	  virus	  
MOPS	   3-­‐(N-­‐Morpholino)-­‐propanesulfonic	  acid	  
MPC	   Magnetic	  particle	  concentrator	  
MPMEC	   Mouse	  Pulmonary	  Microvascular	  Endothelial	  Cells	  
MPMV	   Mason-­‐Pfizer	  monkey	  virus	  
MTD	   Maximum	  tolerated	  dose	  
MTT	   (3-­‐[4,5-­‐dimethylthiazol-­‐2-­‐yl]-­‐2,5-­‐diphenyltetrazolium	  bromide	  
MUC	   Mucin	  
MWS	   Membrane	  Wash	  Solution	  
N	   Node	  
NaCl	   Sodium	  Chloride	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NaOH	   Sodium	  Hydroxide	  
NC	   Nucleocapsid	  
NCAM	   Neural	  cell	  adhesion	  molecule	  
NCI	   National	  Cancer	  Institute	  
NEB	   New	  England	  Biolabs	  
NHBE	   Human	  bronchial/tracheal	  epithelial	  cells	  
NHL	   Non-­‐Hodgkin’s	  lymphoma	  
NIH	   National	  Institutes	  of	  Health	  
NK-­‐cells	   Natural	  killer	  cells	  
NKT-­‐cells	   Natural	  killer	  T-­‐cells	  
NPC	   Nasopharyngeal	  carcinoma	  
NRG	   Neuregulin	  
NSCLC	   Non-­‐small	  cell	  lung	  cancer	  
NY-­‐ESO	   New	  York	  Oesophageal	  antigen-­‐1	  
OK-­‐432	   multiple	  cytokine	  inducer	  derived	  from	  the	  low-­‐virulence	  SU	  strain	  of	  
Streptococcus	  pyogenes	  
OK-­‐MC	   OK-­‐432	  activate	  PBMCs	  
OK-­‐SC	   OK-­‐432	  activated	  spleen	  cells	  
OR	   Objective	  response	  
OS	   Overall	  survival	  
OSCC	   Oral	  squamous	  cell	  carcinoma	  
P28ζ	   J591	  svFv	  –CD28-­‐CD3ζ	  PSMA-­‐targeting	  CAR	  
P2A	   Porcine	  tescho	  virus-­‐1	  2A	  
P4	   Combined	  expression	  of	  P28ζ	  and	  4αβ	  
PAC	   Pancreatic	  adenocarcinoma	  
PAP	   Prostatic-­‐acid	  phosphatase	  
PBMCs	   Peripheral	  blood	  mononuclear	  cells	  
PBS	   Phosphate	  buffered	  saline	  
PCR	   Polymerase	  Chain	  Reaction	  
PD-­‐1	   Programmed	  death-­‐1	  
PE	   phycoerythrin	  
PEI	   Polyethylenimine	  
PerCP	   Peridinin-­‐chlorophyll-­‐protein	  complex	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PF	   Progression-­‐free	  
PFS	   Progression	  free	  survival	  
PG13	   Murine	   retroviral	   packaging	   cell	   derived	   from	   NIH	   3T3	   fibroblasts,	  
containing	  the	  MoMLV	  gag-­‐pol	  genes	  and	  the	  GALV	  env	  gene	  
PI3K	   phosphatidylinositol	  3-­‐kinase	  
PKC	   Protein	  kinase-­‐C	  
PLCγ	   Phospholipase-­‐Cγ	  
PLP	   PC3-­‐LN3-­‐PSMA	  
PR	   Partial	  remission	  
PR	   Partial	  response	  
PrEC	   Prostate	  epithelial	  cells	  
PSCA	   Prostate	  specific	  cell	  antigen	  
PSMA	   Prostate	  specific	  membrane	  antigen	  
PT	   Peri-­‐tumoural	  
R	   Receptor	  
r	   Recombinant	  
RbCl	   Rubidium	  Chloride	  
RCC	   Renal	  cell	  carcinoma	  
RCM	   Remaining	  complete	  media	  
RCR	   Replication-­‐competent	  retrovirus	  
RN	   RetroNectin	  
RNA	   Ribonucleic	  acid	  
ROR1	   Receptor	  orphan	  tyrosine	  kinase	  receptor	  1	  
rpm	   Revolutions	  per	  minute	  
RPMI	   Roswell	  Park	  Memorial	  Institute	  
RR	   Response	  rate	  
S100	   S100	  calcium	  binding	  protein	  
SAE	   Serious	  adverse	  event	  
SARS	   Severe	  acute	  respiratory	  syndrome	  
SC	   Subcutaneous	  
SCC	   Squamous	  cell	  carcinoma	  
scFv	   Single	  chain	  variable	  fragment	  
SCID	   Severe	  combined	  immunodeficiency	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SD	   Stable	  disease	  
SD	   Standard	  deviation	  
SDS	   Sodium	  dodecyl	  sulphate	  
SOC	   Super	  optimal	  broth	  with	  catabolite	  repression	  
SOFA	   Sequential	  organ	  failure	  assessment	  
SPECT	   Single	  photon	  emission	  computed	  tomography	  
SSX	   Synovial	  sarcoma	  X	  
STAT	   Signal	  transducer	  and	  activator	  of	  transcription	  
SV40	   Simian	  virus	  40	  
T	   Tumour	  
T1E	   EGF/TGFα	  chimera	  
T28ζ	   T1E-­‐CD28-­‐CD3ζ	  ErbB-­‐targeting	  CAR	  
T2A	   Thosea	  asigna	  virus	  2A	  
T4	   Combined	  expression	  of	  T28ζ	  and	  4αβ	  
T4luc	   Combined	  expression	  of	  T28ζ,	  4αβ	  and	  firefly	  Luciferase	  
TAA	   Tumour	  associated	  antigen	  
Tag72	   Tumour	  associated	  glycoprotein	  72	  
TBE	   Tris-­‐borate	  EDTA	  
TBI	   Total	  body	  irradiation	  
TCR	   T-­‐cell	  receptor	  
TGF	   Transforming	  growth	  factor	  
TH	   Helper	  T-­‐cell	  
TILs	   Tumour	  infiltrating	  lymphocytes	  
TM	   Melting	  Temperature	  
TMB	   Tetramethylbenzadine	  
TNF	   Tumour	  necrosis	  factor	  
TNM	   Tumour	  Node	  Metastasis	  
TNP	   2,4,6-­‐trinitrophenyl	  
TPBG	   Trophoblast	  glycoprotein	  
Treg	   Regulatory	  T-­‐cells	  
Tris-­‐Cl	   Tris(hydroxymethyl)amino	  methane	  
TSA	   Tumour-­‐specific	  antigen	  
tTa	   Tetracycline-­‐transactivator	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TTP	   Thymidine	  triphosphate	  
TTP	   Time	  to	  progression	  
UT	   Untransduced	  
v/v	   volume/volume	  
VEGF	   Vascular	  endothelial	  growth	  factor	  
VH	   Variable	  heavy	  chain	  
VL	   Variable	  light	  chain	  
VLA	   Very	  Late	  Antigen	  (Integrin	  α4β1)	  
VSV-­‐G	   Vesicular	  stomatis	  virus	  G	  
w/v	   weight/volume	  
WT-­‐1	   Wilm’s	  Tumour	  antigen-­‐1	  
Zap-­‐70	   Zeta-­‐chain	  associated	  protein	  70	  
α	   Anti	  
βc	   β-­‐chain	  
γc	   Common	  γ-­‐chain	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CHAPTER	  1 	  
INTRODUCTION	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1.1 Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	  
Head	  and	  neck	  cancer	  encompasses	  epithelial	  malignancies	  that	  arise	  in	  the	  paranasal	  
sinuses,	  oral	   cavity,	  nasal	   cavity,	  pharynx,	  and	   larynx	   (see	  Figure	  1-­‐1).	  Approximately	  
90%	   of	   head	   and	   neck	   cancers	   are	   squamous	   cell	   carcinomas	   (1).	   Globally,	   about	  
650,000	  cases	  of	  head	  and	  neck	  squamous	  cell	  carcinoma	  (HNSCC)	  are	  diagnosed	  every	  
year,	  leading	  to	  350,000	  deaths	  (2)	  making	  it	  the	  sixth	  most	  common	  cancer	  (3,	  4).	  The	  
median	  age	  of	  patients	  at	  diagnosis	  is	  early	  60s	  with	  a	  male	  predominance	  (2,	  5).	  The	  
mortality	  rate	  associated	  with	  the	  disease	  has	  remained	  unchanged	  over	  the	  past	  50	  
years	  with	  a	  5-­‐year	   survival	   rate	  of	   approximately	  60%	   (3-­‐5).	  Contributory	   factors	   to	  
poor	   prognosis	   include	   advanced	   stage	   of	   the	   disease	   at	   clinical	   presentation,	  
significant	  co-­‐existing	  co-­‐morbidities,	  high	  incidence	  of	  second	  primary	  carcinomas	  (6),	  
relapse	  at	   the	  primary	   site	  and	  distant	  metastases	   (7).	   The	  presence	  of	  one	  or	  all	  of	  
these	   factors	   renders	   a	   significant	   proportion	   of	   patients	   unsuitable	   for	   curative	  
treatment	  (6).	  
	  
Figure	  1-­‐1	  Areas	  of	  head	  and	  neck	  squamous	  cell	  carcinoma	  
Illustration	  of	  the	  areas	  in	  which	  HNSCC	  can	  occur,	  including	  the	  paranasal	  sinuses,	  nasal	  cavity,	  pharynx	  
(including	   nasopharynx,	   oropharynx	   and	   hypopharynx),	   larynx,	   tongue	   and	   salivary	   glands.	   	  ©	   Terese	  
Winslow	  LCC,	  U.S.	  Government	  has	  certain	  rights.	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1.1.1 Risk	  Factors	  
Head	   and	   neck	   squamous	   cell	   carcinoma	   can	   be	   considered	   as	   a	   heterogeneous	  
disease.	   The	   majority	   of	   patients	   have	   one	   of	   two	   distinct	   risk	   factor	   backgrounds,	  
namely	  high	  tobacco	  and/or	  alcohol	  consumption	  and	  human	  papillomavirus	  (HPV)	  or	  
Epstein-­‐Barr	  virus	  (EBV)	  seropositivity.	  
	  
1.1.1.1 Tobacco	  and	  Alcohol	  Consumption	  
Three-­‐quarters	   of	   the	   cases	   of	   HNSCC	   are	   believed	   to	   be	   related	   to	   tobacco	  
consumption	   (8).	   Consumption	   of	   more	   than	   20	   cigarettes	   a	   day	   (9),	   as	   well	   as	  
prolonged	   exposure	   to	   involuntary	   smoking	   (for	  more	   than	   15	   years)	   at	   home	   or	   at	  
work	  is	  associated	  with	  a	  higher	  risk	  (10).	  The	  risk	  added	  through	  tobacco	  use	  is	  larger	  
among	  women	  than	  among	  men	  (11).	  Cessation	  of	  smoking	  at	  the	  age	  of	  30	  reduces	  
the	  risk	  by	  90%,	  whereas	  stopping	  smoking	  at	  the	  age	  of	  50	  reduces	  risk	  by	  50%	  (12).	  
Chewing	  a	  variety	  of	  products	  (whether	  tobacco	  containing	  or	  not)	  was	  identified	  as	  a	  
risk	   factor	   for	   hypopharyngeal	   cancer	   in	   individuals	   who	   had	   never	   smoked	   (13).	  
Alcohol	  consumption	  increases	  the	  risk	  of	  HNSCC	  independent	  of	  the	  type	  of	  alcoholic	  
beverage	  (14,	  15).	  	  A	  combination	  of	  tobacco	  and	  alcohol	  use	  has	  a	  synergistic	  effect	  to	  
increase	  the	  risk	  of	  developing	  HNSCC	  (14).	  	  
	  
1.1.1.2 Human	  Papillomavirus	  and	  Epstein-­‐Barr	  Virus-­‐Related	  HNSCC	  
Infection	  with	  oncogenic	  HPV,	  mainly	  HPV	  type	  16	  and	  to	  a	  lesser	  extent	  type	  18,	  has	  
been	  associated	  with	  the	  pathogenesis	  of	  a	  subgroup	  of	  HNSCC	  cases	  (16).	  The	  HPV-­‐16	  
subtype	   accounts	   for	   90%	   of	   HPV-­‐associated	   HNSCC	   cases	   (17).	   Genomic	   DNA	   of	  
oncogenic	   HPV	   is	   detected	   in	   approximately	   26%	   of	   all	   HNSCC	   cases,	   and	   is	   most	  
consistently	  detected	  in	  oropharyngeal	  squamous	  cell	  carcinoma	  (OSSC)	  (16).	  Exposure	  
to	  HPV	  can	  precede	  the	  appearance	  of	  OSCC	  by	  10	  years	  or	  more.	  Oral	  HPV	  infection	  is	  
strongly	   associated	  with	   the	   risk	   of	   developing	   HNSCC,	   independent	   of	   tobacco	   and	  
alcohol	   use	   (16).	   Among	   light-­‐drinkers	   or	   never	   smokers,	   HPV	   seropositivity	   is	  
associated	   with	   a	   30-­‐fold	   increased	   risk	   of	   developing	   HNSCC,	   compared	   to	   HPV	  
negativity	   (18).	  Due	  to	   the	  different	   risk-­‐factor	  profiles,	  HPV-­‐16-­‐positive	  and	  HPV-­‐16-­‐
negative	   HNSCC	   should	   be	   considered	   as	   different	   cancers	   (19).	   HPV	   positivity	   is	   a	  
favourable	   prognostic	   factor	   in	   HNSCC.	   Tumours	   that	   are	   HPV	   positive	   show	   better	  
responsiveness	   to	   radiation	   and	   chemotherapy	   and	   additionally	   may	   be	   more	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susceptible	   to	   immune	   surveillance	   (20).	   HPV-­‐positive	   HNSCC	   is	   associated	   with	   a	  
lower	   risk	   of	   dying	   as	  well	   as	   a	   lower	   risk	   of	   recurrence	   compared	   to	   HPV-­‐negative	  
HNSCC	  (21).	  Consequently,	  HPV	  status	  of	  HNSCC	  is	  an	  important	  predictive	  biomarker	  
and	  needs	  to	  be	  taken	  into	  consideration	  during	  treatment	  design	  (5).	  
	   Infection	  with	   Epstein-­‐Barr	   virus	   (EBV)	   has	   also	   been	   associated	  with	  HNSCC,	  
especially	  undifferentiated	  or	  poorly	  differentiated	  nasopharyngeal	   carcinoma	   (NPC).	  
The	   primary	   EBV-­‐encoded	   oncogene	   latent	   membrane	   protein	   (LMP)	   1	   has	   been	  
identified	   as	   a	   potential	   central	   player	   in	   the	   initiation	   and	   progression	   of	   NPC.	  
Promotion	  of	  cell	  growth,	  downregulation	  of	  cell-­‐cell	  adhesion	  and	  upregulation	  of	  cell	  
motility	   have	   all	   been	   contributed	   to	   LMP1	   positivity,	   increasing	   the	   metastatic	  
properties	  of	  NPC	  (22).	  Plasma	  EBV	  DNA	  levels	  can	  be	  used	  as	  a	  prognostic	  marker	  for	  
NPC.	  Overall	  survival	  and	  relapse-­‐free	  survival	  are	  significantly	  worse	  in	  patients	  with	  
persistently	  detectable	  plasma	  EBV	  DNA,	  compared	  to	  patients	  with	  undetectable	  EBV	  
DNA	  after	   completion	  of	   radiotherapy	   (23).	   Similar	   to	  HPV	  seropositivity,	   there	   is	  no	  
confounding	   effect	   of	   EBV-­‐seropositivity	   in	   the	   association	   between	   tobacco	   and	  
alcohol	  consumption	  and	  NPC	  risk.	  Tobacco	  and	  alcohol	  consumption	  can	  be	  identified	  
as	   the	  cause	  of	  over	   two-­‐thirds	  of	  differentiated	  NPC,	  whereas	  EBV-­‐positive	  tumours	  
are	  generally	  poorly	  differentiated	  (24,	  25).	  
	  
1.1.1.3 Additional	  Risk	  Factors	  
Independent	  from	  the	  major	  risk	  factors	  presented	  above,	  poor	  dentition	  (26)	  and	  bad	  
oral	   hygiene	   (27)	   have	   also	   been	   associated	  with	   the	   risk	   of	   HNSCC.	   This	   is	   possibly	  
related	   to	   chronic	   oral	   bacterial	   infections	   (1).	  Dietary	   risks	   have	   revealed	   a	   positive	  
association	  with	  a	  Western	  dietary	  pattern	  and	  an	  inverse	  association	  with	  total	  fruit	  
and	   vegetable	   intake	   (28,	   29).	   Finally,	   a	   low	   socioeconomic	   status	   has	   also	   been	  
correlated	  to	  the	  incidence	  of	  HNSCC	  (30)	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1.1.2 Current	  Treatment	  Options	  for	  HNSCC	  
Treatment	   of	   HNSCC	   is	   individualised	   for	   patients	   based	   on	  multiple	   clinical	   factors	  
including	   primary	   tumour	   site,	   stage	   and	   resectability,	   as	   well	   as	   factors	   such	   as	  
swallowing	   and	   airway	   considerations,	   organ	   preservation	   and	   co-­‐morbidity	   (5).	  
Tumour	   stage	   is	   determined	   based	   on	   the	   tumour,	   node,	   metastasis	   (TNM)	   staging	  
system	  (see	  Table	  1-­‐1)	  and	  can	  be	  grouped	  in	  stages	  levelled	  I	  to	  IV	  (see	  Table	  1-­‐2)	  (31)	  
Accurate	  staging	  is	  considered	  the	  most	  important	  factor	  to	  guide	  therapeutic	  planning	  
(5).	  Approximately	  30%	  of	  patients	  present	  with	  early-­‐stage	  disease	  (stage	  I	  or	  II)	  (32)	  
whereas	   about	   60%	   present	   with	   locally	   advanced	   disease	   (stage	   III	   or	   IV).	   Distant	  
metastasis	  is	  present	  in	  about	  10%	  of	  patients	  at	  first	  presentation	  (5)	  
	  
Table	  1-­‐1	  TNM	  staging	  of	  HNSCC	  
	   Tumour	  (T)	   Node	  (N)	   Metastasis	  (M)	  
X	   Can	  not	  be	  assessed	   Can	  not	  be	  assessed	   Can	  not	  be	  assessed	  
is	   in	  situ	   	   	  
0	   No	  evidence	   No	  evidence	   No	  evidence	  
1	   Limited	  to	  one	  site	  	  
<2cm	  
1	  lymph	  node	  
<3cm	  
Distant	  metastases	  
2	   Limited	  to	  one	  site	  
2-­‐4cm	  
1	  or	  more	  lymph	  nodes	  
<6cm	  
	  
3	   Limited	  to	  one	  site	  
>4cm	  
1	  or	  more	  lymph	  nodes	  
>6cm	  
	  
4	   Invasive	  tumour	   	   	  
Exact	  criteria	  of	  TNM	  staging	   in	  HNSCC	  are	  determined	  by	  the	   location	  of	   the	  primary	  tumour,	  here	  a	  
summery	  is	  given	  based	  on	  the	  guidelines	  given	  in	  reference	  (31).	  TNM:	  Tumour,	  Node,	  Metastasis;	  is:	  in	  
situ	  
	  
Table	  1-­‐2	  Tumour	  stage	  level	  I-­‐IV	  based	  on	  TNM	  stage	  
	   Tumour	  (T)	   Node	  (N)	   Metastasis	  (M)	  
0	   Tis	   N0	   M0	  
I	   T1	   N0	   M0	  
II	   T2	   N0	   M0	  
III	   T1-­‐3	   N0-­‐1	   M0	  
IV	   T4	   N0-­‐3	   M0-­‐1	  
Exact	  criteria	  of	  TNM	  staging	   in	  HNSCC	  are	  determined	  by	  the	   location	  of	   the	  primary	  tumour,	  here	  a	  
summery	  is	  given	  based	  on	  the	  guidelines	  given	  in	  reference	  (31).	  is:	  in	  situ	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1.1.2.1 Early-­‐Stage	  Disease	  
The	  major	  line	  of	  treatment	  for	  early	  stage	  disease	  is	  surgery	  or	  radiation	  therapy.	  In	  
90%	  of	   stage	   I	  patients	  and	  70%	  of	   stage	   II	  patients,	   such	   treatment	   is	   curative.	  The	  
exact	   approach	   taken	  mainly	   depends	   on	   the	   site	   of	   the	   primary	   tumour.	   However,	  
surgery	   is	   often	   preferred	   to	   limit	   the	   long	   term	   complications	   related	   to	   radiation	  
therapy	  (5).	  
	  
1.1.2.2 Locally	  Advanced	  Disease	  
A	  combination	  of	   surgery,	   radiation	   therapy,	   chemotherapy	  or	   chemoradiotherapy	   is	  
the	   first	   line	   of	   treatment	   for	   patients	   with	   stage	   III	   or	   IV	   disease.	   In	   unresectable	  
locally	  advanced	  disease,	  chemoradiotherapy	  is	  the	  standard	  of	  care	  (32,	  33).	  Tumours	  
are	   considered	  unresectable	   if	   there	   is	   (impending)	   invasion	  of	  major	   vessels,	   at	   the	  
base	  of	  the	  skull	  or	  the	  prevertebral	  musculature	  (5).	  
	   At	   least	   50%	   of	   patients	   who	   present	   with	   locally	   advanced	   disease	   develop	  
locoregional	   or	   distant	   relapse	   within	   2	   years	   of	   the	   treatment.	   At	   this	   stage,	   few	  
patients	  are	  eligible	  for	  salvage	  surgery	  (34).	  Local	  recurrence	  can	  be	  due	  to	  outgrowth	  
of	  residual	  malignant	  cells	  after	  treatment	  or	  due	  to	  pre-­‐neoplastic	  mucosal	  epithelium	  
which	   surrounded	   the	  primary	   tumour	   (32).	   The	  main	  objective	  of	   treatment	   at	   this	  
stage	   is	   symptom	  palliation	   and	   survival	   extension.	   The	   standard	   first-­‐line	   treatment	  
for	   these	   patients	   is	   platinum-­‐based	   chemotherapy,	   giving	   patients	   a	   median	  
progression	   free	   survival	   (PFS)	   of	   2.7	   months	   (35).	   Clinical	   trials	   have	   combined	  
platinum	   based	   chemotherapies	   with	   the	   EGFR-­‐targeting	   antibody	   Cetuximab.	   As	   a	  
first-­‐line	   treatment,	   combined	   therapy	   with	   Cetuximab	   and	   platinum-­‐based	  
chemotherapy	   resulted	   in	   a	   significantly	   prolonged	   median	   overall	   survival	   (OS),	  
median	  PFS,	  and	  increased	  response	  rate	  (RR)	  (36).	  As	  a	  result	  of	  these	  data,	  the	  FDA	  
(Food	   and	   Drug	   Administration)	   and	   EMA	   (European	   Medicines	   Authority)	   have	  
approved	  of	  the	  use	  of	  Cetuximab	  in	  the	  treatment	  of	  HNSCC.	  	  The	  use	  of	  Cetuximab	  in	  
treatment	   of	   HNSCC	   is	   further	   detailed	   in	   paragraph	   1.2.4.	   There	   is	   no	   standard	  
second-­‐line	  therapy	  for	  patients	  with	  locally	  advanced	  disease.	  Without	  treatment,	  the	  
median	  survival	  for	  patients	  is	  11.5	  months	  after	  diagnosis	  (6).	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1.1.2.3 Side	  Effects	  
Acute	   as	   well	   as	   late	   side	   effects	   and	   complications	   can	   occur	   due	   to	   treatment	   of	  
HNSCC.	  Common	  acute	  effects	  in	  relation	  to	  radiation	  therapy	  are	  mucositis,	  increased	  
secretions,	   dysphagia,	   loss	   of	   taste,	   hoarseness	   caused	   by	   laryngeal	   oedema	   and	  
dermatitis	  (37).	  Swallowing	  function	  can	  improve	  within	  the	  first	  year	  after	  treatment	  
but	  may	  be	  permanent	  (38,	  39).	  Other	   late	  complications	   include	  osteoradionecrosis,	  
dental	   caries,	   subcutaneous	   fibrosis,	   thyroid	   dysfunction,	   sensorineural	   hearing	   loss,	  
pharyngeal	   or	   oesophageal	   stenosis	   and	   myelitis.	   In	   long-­‐term	   survivors,	   radiation-­‐
induced	  xerostomia	  occurs	  universally	  (40).	  	  
	   Side	   effects	   associated	   with	   chemotherapy	   include	   anaemia,	   neutropenia,	  
thrombocytopenia,	  hypomagnesaemia,	  fatigue,	  skin	  rash,	  anorexia	  and	  infection	  (36).	  
The	  combination	  of	  platinum-­‐based	  chemotherapy	  with	  Cetuximab	  has	  also	  resulted	  in	  
short-­‐term	  side	  effects	  in	  the	  form	  of	  rash	  and	  infusion-­‐related	  reactions	  (36).	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1.2 The	  ErbB	  Receptor	  Family	  
The	  avian	  erythroblastosis	  oncogene	  B	  (ErbB)	  tyrosine	  kinase	  receptor	  family	  consists	  
of	   four	   members,	   the	   epidermal	   growth	   factor	   receptor	   (EGFR;	   ErbB1),	   ErbB2	  
(Her2/Neu),	   ErbB3	   (Her3)	   and	   ErbB4	   (Her4)	   (41).	   This	   family	   constitutes	   a	   group	   of	  
single	  pass	   transmembrane	  growth	   factor	   receptors,	   in	  which	  an	  extracellular	   ligand-­‐
binding	   domain	   is	   linked	   to	   an	   intracellular	   signalling	   domain	   by	   a	   hydrophobic,	   α-­‐
helix-­‐structured,	   transmembrane	   region	   (42-­‐44).	   The	   ErbB2	   and	   ErbB3	   receptors	   are	  
distinct	   from	   the	   other	   family	   members	   in	   that	   no	   ligand	   has	   been	   discovered	   for	  
ErbB2	   while	   ErbB3	   has	   an	   impaired	   kinase	   domain	   (45).	   ErbB2	   is	   the	   favoured	  
dimerization-­‐partner	  for	  the	  other	  ErbB	  receptors,	  and	  ErbB3	  can	  be	  activated	  through	  
heterodimerisation	   with	   other	   ErbB-­‐receptors	   (46).	   ErbB4	   consists	   of	   two	   pairs	   of	  
naturally	   occurring	   isoforms,	   differing	   in	   their	   juxtamembrane	  domain	   and	  C-­‐termini	  
(47).	   Involvement	   of	   the	   receptor	   family	   in	   oncogenesis	   was	   first	   suggested	   by	   the	  
discovery	   that	   the	   avian	   erythoblastosis	   tumour	   virus	   encoded	   an	   aberrant	   form	   of	  
EGFR	  (48).	  
	  
1.2.1 Tumour	  Antigens	  
The	   involvement	   of	   the	   ErbB	   receptor	   family	   in	   cancer	   renders	   these	   molecules	  
candidate	   tumour	   antigens.	   There	   are	   different	   types	   of	   tumour	   antigens.	   Tumour	  
specific	  antigen	  (TSAs)	  are	  antigens	  which	  are	  exclusively	  expressed	  on	  tumour	  tissue,	  
such	   as	   mutant	   caspase	   (CASP)-­‐8	   (49)	   or	   EGFRvIII	   (50).	   Tumour	   associated	   antigens	  
(TAAs)	   are	   self-­‐antigen	   which	   are	   expressed	   on	   healthy	   tissue	   but	   are	   aberrantly	  
expressed	  on	  tumours	  (such	  as	  the	  ErbB-­‐receptor	  family).	  Some	  are	  associated	  with	  a	  
specific	  differentiation	   stage	  or	   lineage	   (for	  example	  carcinoembryonic	  antigen	   (CEA)	  
(51)	  or	  melanoma	  antigen	  (MAGE)-­‐1	  (52)).	  The	  cancer/testis	  antigens	  (CTA)	  are	  a	  group	  
of	  tumour	  antigens	  in	  which	  normal	  organ	  expression	  is	  restricted	  to	  germ	  cells	  in	  the	  
testis.	   In	  malignancy,	   gene	   regulation	   is	   disrupted,	   leading	   to	   aberrant	   expression	  of	  
these	  antigens	  by	  tumour	  cells.	  Cancer/testis	  antigens	  include	  New	  York	  oEsophageal	  
antigen	  (NY-­‐ESO)-­‐1,	  MAGE-­‐A	  and	  synovial	  sarcoma	  X	  (SSX)	  antigen	  (53).	  Finally,	  there	  
are	   virally	   encoded	   oncogenes	   (such	   as	   HPV-­‐derived	   E6	   or	   E7	   (54)).	   For	   clinical	  
applicability,	   the	   tumour	   antigen	   has	   to	   be	   important	   for	   tumour	   survival	   and	  
malignant	  behaviour	  and	  should	  preferably	  be	  expressed	  in	  a	  majority	  of	  patients	  (55).	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The	  ErbB	  receptor	  family	  is	  overexpressed	  on	  a	  vast	  range	  of	  solid	  tumours,	  making	  it	  
an	  interesting	  tumour	  antigen	  for	  targeted	  therapies.	  
	  
1.2.2 The	  Role	  of	  the	  ErbB	  Receptor	  Family	  in	  Healthy	  Tissues	  
The	  main	  function	  of	  the	  ErbB	  receptor	  family	  in	  normal	  tissues	  is	  to	  mediate	  cell-­‐cell	  
interactions	  in	  organogenesis	  and	  during	  adulthood.	  Absence	  of	  any	  of	  the	  four	  ErbB-­‐
receptors	   is	  not	  compatible	  with	   life,	  either	  due	  to	  embryonic	   lethality	  or	  death	  very	  
shortly	  after	  birth	  (56-­‐59).	  These	  outcomes	  reflect	  the	  fundamental	  roles	  which	  these	  
receptors	  play	  in	  the	  development	  of	  heart,	  brain,	  lung,	  gastrointestinal	  tract,	  liver	  and	  
skin	   (60,	  61).	  Signalling	   through	  the	  ErbB-­‐receptors	  has	   two	  key	  characteristics.	  First,	  
activation	  is	  ligand	  dependent	  (in	  the	  absence	  of	  mutations	  or	  gross	  over-­‐expression).	  
Second,	  ErbB	  receptors	  are	  obligate	  dimers,	  meaning	  they	  can	  only	  function	  in	  homo-­‐	  
or	  heterodimeric	  formations	  or	  oligomers	  thereof.	  	  
	  
1.2.2.1 ErbB	  Receptor	  Ligands	  
There	   are	   at	   least	   11	   different,	   but	   structurally	   related,	   growth	   factors	   that	   are	  
recognized	  by	  the	  ErbB	  receptors.	  Each	  receptor	  has	  its	  own	  group	  of	  activating	  ligands	  
(see	   Figure	   1-­‐2).	   Exclusive	   ligands	   for	   ErbB1	   are	   epidermal	   growth	   factor	   (EGF),	  
transforming	   growth	   factor	   alpha	   (TGFα)	   and	   epigen.	   Ligands	   for	   ErbB1	   as	   well	   as	  
ErbB4	   include	   heparin-­‐binding	   EGF	   (HB-­‐EGF),	   β-­‐cellulin	   and	   epiregulin-­‐1.	   Ligands	   for	  
ErbB3	   and	   ErbB4	   are	   neuregulin	   (NRG)	   -­‐1	   and	   -­‐2.	   Neuregulin-­‐3	   and	   -­‐4	   are	   exclusive	  
ligands	  for	  ErbB4	  (62).	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Figure	  1-­‐2	  ErbB	  receptors	  and	  their	  ligands	  
The	   ligands	   for	   each	   of	   the	   four	   receptors	   are	   detailed	   above	   each	   individual	   receptor.	  No	   activating	  
ligand	   has	   been	   identified	   for	   ErbB2,	   and	   ErbB3	   has	   a	   substantially	   impaired	   kinase	   domain.	   EGF:	  
epidermal	  growth	  factor,	  HB-­‐EGF:	  heparin-­‐binding	  epidermal	  growth	  factor,	  TGFα:	  transforming	  growth	  
factor	  alpha.	  
	  
1.2.2.2 ErbB	  Receptor	  Activation	  and	  Signalling	  
The	   extracellular	   domain	   of	   the	   ErbB-­‐receptors	   contains	   the	   ligand-­‐binding	   domain.	  
The	   extracellular	   domain	   consists	   of	   four	   separate	   domains,	   two	   large	   domains	   (L-­‐
domains,	  also	  referred	  to	  as	  domain	  I	  and	  III)	  and	  two	  smaller,	  cysteine	  rich	  domains	  
(S-­‐domains,	   also	   referred	   to	   as	   domain	   II	   and	   IV)	   (see	   Figure	   1-­‐3)(63,	   64).	   In	   the	  
absence	  of	  bound	  ligand,	  ErbB1,	  ErbB3	  and	  ErbB4	  adopt	  a	  ‘closed’	  conformation	  (see	  
Figure	   1-­‐3).	   In	   the	   closed	   conformation	   a	   ‘molecular	   tether’	   is	   formed	   through	   the	  
interaction	  of	  a	  loop,	  which	  protrudes	  from	  domain	  II,	  with	  specific	  residues	  in	  domain	  
IV	   (65-­‐67).	   This	   ‘molecular	   tether’	   can	   also	  be	   formed	  by	  binding	   to	   domain	   II	   of	   an	  
interacting	  ErbB-­‐receptor,	  therefore	  it	  is	  also	  referred	  to	  as	  the	  ‘dimerisation	  arm’	  (68,	  
69).	   Upon	   the	   binding	   of	   a	   ligand	   to	   domains	   I	   and	   III,	   the	   receptors	   undergo	  
conformational	   rearrangements,	   resulting	   in	   an	   extended	   ‘open’	   conformation.	   The	  
‘open’	   conformation	   enables	   the	   ‘dimerisation	   arm’	   to	   interact	   with	   an	   additional	  
ErbB-­‐receptor	   (see	   Figure	   1-­‐3).	   The	   extracellular	   domain	   of	   ErbB2	   differs	   from	   the	  
other	   receptors.	   ErbB2	   is	   constitutively	   in	   the	   extended,	   ‘open’	   state,	   exposing	   the	  
dimerisation	  arm	  (70,	  71).	  Due	  to	  this	  constitutive	  ‘open’	  state,	  ligand	  binding	  to	  ErbB2	  
is	  sterically	  hindered	  (72).	  However,	  ErbB2	  is	  the	  preferred	  heterodimerisation	  partner	  
of	  the	  other	  receptors,	  which	  can	  be	  explained	  by	  its	  constitutive	  ‘open’	  conformation	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(73,	   74).	   Homodimerisation	   of	   ErbB2	   is	   prevented	   by	   electrostatic	   repulsion	   (70).	   At	  
endogenous	  expression	  levels	  this	  repulsion	  is	  sufficient	  to	  prevent	  homodimerisation.	  
However,	  when	  ErbB2	   is	  overexpressed	  (as	  seen	   in	  many	  cancers),	   this	  repulsion	  can	  
be	  overcome	  through	  the	  interaction	  between	  other	  areas	  of	  the	  receptor	  (75).	  
	  
	  
Figure	  1-­‐3	  The	  ‘closed’	  and	  ‘open’	  conformation	  of	  ErbB	  receptors	  
Upon	   ligand	  binding	   to	  domain	   I	  and	   III,	   the	  ErbB	   receptors	  undergo	  a	  conformational	   transformation	  
from	  their	  ‘closed’	  to	  an	  ‘open’	  conformation.	  The	  ‘open’	  conformation	  exposes	  the	  ‘dimerisation	  arm’	  
allowing	  for	  dimerization	  with	  a	  second	  ErbB	  receptor.	  Image	  adapted	  from	  (46,	  76)	  
	  
However,	   it	   has	   been	   shown	   that	   the	   ErbB-­‐receptors	   can	   also	   form	   inactive	  
homo-­‐	  and	  heterodimers	  in	  the	  absence	  of	  ligand	  (77-­‐79).	  Because	  of	  the	  flexibility	  of	  
the	   extracellular	   domain	   (with	   the	   exception	   of	   ErbB2),	   the	   preformed	   dimer	   may	  
assume	  one	   of	   two	   structures	  with	   either	   high	   or	   low	   affinity	   for	   the	   ligand,	   due	   to	  
their	   ‘open’	   or	   ‘closed’	   conformation	   respectively	   (66,	   67,	   71).	   Ligand-­‐mediated	  
activation	   of	   preformed	   dimers	   may	   be	   explained	   by	   the	   ‘rotation/twist’-­‐model	  
proposed	   by	   Moriki	   et	   al.	   This	   model	   proposes	   that	   ligand	   binding	   induces	   flexible	  
rotation	  or	   twist	   of	   the	   juxtamembrane	   region	  of	   the	   receptor,	   thereby	   rotating	   the	  
transmembrane	   domains	   and	   dissociating	   the	   dimeric,	   inactive	   forms	   of	   the	  
intracellular	  domains.	  This	  rotation	  may	  be	  required	  for	  the	  intrinsic	  catalytic	  kinase	  to	  
become	   accessible	   to	   the	   tyrosine	   residues	   in	   the	   regulatory	   domain	   (79).	   Ligand-­‐
induced	  interaction	  of	  the	  two	  dimerisation	  arms	  may	  also	  induce	  the	  ‘rotation/twist’,	  
rearranging	   the	   symmetric	   structure	   of	   the	   intracellular	   domains	   and	   thereby	  
rearranging	  the	  dissociated	  kinase	  domains	  for	  activation	  (79,	  80).	  
	   Ligand-­‐mediated	   activation	   of	   receptor	   dimers	   induces	   the	   activation	   of	   the	  
tyrosine	   kinase	   domain	   contained	  within	   the	   intracellular	   part	   of	   the	   receptors	   (81).	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This	   results	   in	   the	   phosphorylation	   of	   tyrosine	   residues	   in	   the	   C-­‐terminal	   tail,	  which	  
serve	  as	  docking	  sites	  for	  signalling	  molecules	  that	  contain	  Src	  homology	  region	  2	  (SH2)	  
and	  phosphotyrosine-­‐binding	  (PTB)	  domains	  (82,	  83).	  The	  combination	  of	  the	  identity	  
of	  the	  ligand,	  and	  the	  dimerisation	  partner	  dictates	  which	  sites	  are	  phosphorylated.	  In	  
turn,	   this	  phosphorylation	  pattern	  determines	  which	  signalling	  proteins	  are	  engaged,	  
allowing	   for	   context-­‐specific	   responses	   (84,	   85).	   The	   main	   signalling	   pathways	  
downstream	   of	   ErbB	   activation	   include	   the	   phosphatidylinositol	   3-­‐kinase	   (PI3K)-­‐
activated	   Akt	   pathway,	   the	   Ras-­‐activated	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	  
pathway,	  the	  phospholipase	  Cγ	  (PLCγ)	  pathway	  and	  signal	  transducer	  and	  activation	  of	  
transcription	  (STATs)	  pathway	  (85-­‐87).	  Signalling	  through	  ErbB-­‐receptors	  results	  in	  cell	  
division,	   migration,	   adhesion,	   differentiation	   and	   apoptosis.	   Ligand	   binding	   also	  
induces	  receptor	  clustering	  and	  endocytosis,	   followed	  by	  either	  recycling	  back	  to	  the	  
cell	  surface	  or	  lysosomal	  degradation	  (88,	  89).	  After	  endocytosis,	  nuclear	  translocation	  
of	   the	   receptors	  may	  also	  occur	  where	   it	  may	   regulate	  gene	  expression	   (62,	  85,	  90).	  
The	  specific	  output	  that	  results	  depends	  on	  the	  cellular	  context,	  ligand	  specificity	  and	  
the	  nature	  of	  ErbB	  dimers	  formed	  (91,	  92).	  
	  
1.2.3 The	  Role	  of	  the	  ErbB	  Receptor	  Family	  in	  HNSCC	  
The	  ErbB	  receptor	   family	  plays	  a	  critical	   role	   in	  growth,	  survival,	   invasion,	  metastasis	  
and	   angiogenesis	   in	   HNSCC	   tumour	   cells	   (93).	   Cancers	   exploit	   the	   ErbB	   network	  
through	  the	  activation	  of	  the	  signalling	  network	  at	  different	  layers.	  This	  results	  in	  the	  
fact	   that	   in	  many	   tumours,	   the	   ErbB	   signalling	   pathway	   is	   hyperactivated.	   There	   are	  
several	   mechanisms	   through	   which	   this	   hyperactivation	   is	   induced,	   including	   the	  
overproduction	  of	  ligands	  and	  receptors,	  and/or	  constitutive	  activation	  of	  receptors	  as	  
a	   result	   of	   mutations.	   Four	   major	   signalling	   pathways	   downstream	   of	   the	   ErbB	  
receptors	  have	  been	  implicated	  in	  malignant	  cells.	  The	  first	  of	  these	  is,	  the	  Ras-­‐MAPK	  
pathway,	  which	  induces	  the	  phosphorylation	  and	  nuclear	  translocation	  of	  extracellular	  
signal-­‐regulated	  kinase	  (ERK)	  leading	  to	  activation	  of	  transcription	  factors	  and	  several	  
cytoskeletal	  proteins	  (94,	  95).	  The	  second	  is,	  the	  PI3K-­‐Akt	  pathway,	  which	  induces	  Akt	  
activation	  and	  translocation	  to	  the	  nucleus,	  resulting	   in	  altered	  gene	  transcription.	   In	  
parallel,	   other	   cytosolic	   proteins	   are	   activated	   by	   this	   pathway,	   which	   promote	   the	  
expression	  of	  mitochondrial	  anti-­‐apoptotic	  proteins	  and	  caspase	  inhibitor	  proteins	  (96,	  
97).	   The	   third	   is	   the	   phospholipase-­‐Cγ	   (PLCγ)	   and	   protein	   kinase-­‐C	   (PKC)	   pathway	   in	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which	  the	  activation	  of	  PKC	  results	  in	  cell	  cycle	  progression	  (98).	  The	  fourth	  pathway	  is	  
termed	  the	  signal	  transducer	  and	  activator	  of	  transcription	  (STAT)	  pathway.	  Activated	  
STAT	   proteins	   regulate	   the	   expression	   of	   genes	   that	   are	   vital	   for	   cell	   proliferation,	  
survival,	   transformation	   and	  progression	   to	   carcinoma	   (99).	   In	  HNSCC,	   STAT1,	   STAT3	  
and	   STAT5	   play	   significant	   roles,	   and	   STAT3	   has	   been	   implicated	   to	   function	   as	   an	  
oncogene	  (100).	  	  
	  
1.2.3.1 ErbB1	  
Overexpression	  of	  ErbB1	  is	  seen	  in	  more	  than	  80%	  of	  invasive	  HNSCC	  cases,	  compared	  
to	   normal	   adjacent	   mucosa	   (101).	   This	   overexpression	   is	   associated	   with	   increased	  
ErbB1	  copy	  number	  and	  worsened	  clinical	  prognosis	  (102,	  103).	  Local	  recurrence	  rate	  
in	  patients	  with	  overexpressed	  ErbB1	  is	  70%,	  compared	  to	  48%	  in	  patients	  with	  normal	  
ErbB1	   expression	   levels.	   Furthermore	   the	   5-­‐year	   survival	   rate	   in	   these	   patients	   is	  
reduced	  to	  20%	  compared	  to	  38%	  respectively	  (104).	  Overexpression	  of	  ErbB1	  is	  likely	  
to	  be	  an	  early	  event	  in	  HNSCC	  development	  (a	  30-­‐fold	  elevation	  of	  ErbB1	  mRNA	  can	  be	  
detected	   in	  normal	  mucosa	  of	  HNSCC	  patients),	   contributing	   to	  oncogenesis	  and	   the	  
concept	   of	   field	   cancerization	   (105).	   The	   overexpression	   of	   ErbB1	   is	   generally	   not	  
mediated	  by	  gene	  amplification,	  but	   rather	  due	   to	  mRNA	  overproduction	   (106,	  107).	  
Phosphorylated	  ErbB1	  has	  also	  been	  detected	  in	  the	  nucleus	  of	  multiple	  tumour	  types,	  
where	  it	  acts	  as	  a	  transcription	  factor	  that	  promotes	  the	  expression	  of	  proteins	  such	  as	  
cyclin-­‐D	   (90,	   108).	   In	   addition	   to	   ErbB1	   upregulation,	   an	   average	   5-­‐fold	   increase	   in	  
mRNA	  encoding	  the	  ErbB1	   ligand	  TGFα	  can	  be	  detected	   in	  HNSCC	  tumours.	  Levels	  of	  
TGFα	  in	  the	  tumour	  tissue	  are	  mildly	  elevated	  during	  early	  carcinogenesis,	  but	  do	  not	  
increase	   further	   as	   cells	   progress	   through	   to	   carcinomas,	   whereas	   ErbB1	   expression	  
increases	  progressively	  with	  the	  development	  of	  carcinomas	  (109,	  110).	  	  	  
One	  of	   the	  most	   common	   altered	   forms	  of	   ErbB1	   found	   in	  HNSCC	   and	  other	  
solid	   tumours	   is	   the	   EGFRvIII	   deletion	   mutant.	   EGFRvIII	   is	   the	   result	   of	   an	   in-­‐frame	  
deletion	  of	  exons	  2-­‐7	  of	  wild-­‐type	  ErbB1.	  This	  causes	  the	  deletion	  of	  a	  large	  portion	  of	  
the	  extracellular	  domain,	  and	  the	  insertion	  of	  a	  glycine	  at	  the	  fusion	  junction	  between	  
exon	  1	  and	  8.	  As	  a	  result	  the	  EGFRvIII	  has	  a	  distorted	  ligand-­‐binding	  region,	  lacking	  the	  
receptors	  dimerization	  arm.	  Consequently,	   the	  mutant	   receptor	  does	  not	  bind	   ligand	  
and	  cannot	  assume	  the	  closed	  tethered	  structure,	  making	  it	  constitutively	  active	  (111,	  
112).	   Expression	  of	   EGFRvIII	   has	   been	  detected	   in	   42%	  of	  HNSCC	   tumour	   tissue,	   but	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was	  consistently	  co-­‐expressed	  with	  normal	  ErbB1	  (113).	  Expression	  of	  EGFRvIII	  leads	  to	  
unregulated	  growth,	   improved	  survival,	  enhanced	   invasion	  and	  angiogenesis	   (114).	   It	  
has	  been	  associated	  with	  increased	  tumour	  growth	  and	  metastasis	  formation,	  as	  well	  
as	  an	  increased	  resistance	  to	  antitumor	  agents	  and	  survival	  (113,	  115,	  116).	  
	  
1.2.3.2 ErbB2/3	  
ErbB2	  and	  ErbB3	  are	  mutually	  dependent	  receptors	  and	  function	  in	  a	  complementary	  
manner	  (93).	  Neither	  the	  ErbB2	  nor	  the	  ErbB3	  receptor	  alone	  can	  be	  activated	  through	  
ligands;	   however	   ErbB2/3	   heterodimers	   are	   the	  most	   active	   signalling	   dimers	   of	   the	  
family	   (117).	   In	   relation	   to	   cancer,	   the	   ErbB2/3	   heterodimer	   is	   considered	   the	  most	  
transforming	  and	  mitogenic	  of	  all	  dimers	   (91,	  118,	  119),	   increasing	  cell	  motility	  upon	  
ligand	  stimulation	  (120).	  	  
Reports	   on	   the	   overexpression	   of	   ErbB2	   in	   HNSCC	   have	   been	   very	  
contradictory,	   ranging	   from	  very	   few	  to	  all	   tested	  samples	   (121-­‐125).	   In	  cases	  where	  
overexpression	  was	  seen,	  it	  has	  been	  significantly	  associated	  with	  positive	  lymph	  node	  
status	  as	  well	  as	  advanced	  disease	  (126-­‐128).	  However,	  overexpression	  of	  ErbB2	  could	  
not	  be	  correlated	  with	  clinicopathological	  factors	  (122,	  123,	  129).	  Therefore	  the	  use	  of	  
ErbB2	  as	  a	  prognostic	  factor	  remains	  to	  be	  elucidated.	  The	  discrepancies	  seen	  between	  
studies	  may	  be	   contributed	   to	   the	   lack	  of	   a	   standardised	  method	   for	   the	  analysis	  of	  
ErbB2	  overexpression.	  
In	  77.5%	  of	  primary	  HNSCC	  samples,	  expression	  of	  ErbB3	  can	  predominantly	  be	  
detected	   in	  the	  cytoplasm,	  and	   less	   frequently	   (8.8%)	  on	  the	  tumour	  cell	  membrane.	  
However	   the	   membranous	   overexpression	   significantly	   increases	   to	   30.0%	   in	  
metastatic	  tissue	  (93).	  Membranous	  overexpression	  of	  ErbB3	  is	  significantly	  correlated	  
with	  worsened	  patient	  survival	   (93).	  Patients	  with	  ErbB2	  positive	  and	  ErbB3	  negative	  
tumours	  have	  a	  significantly	  prolonged	  survival	  (93).	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1.2.3.3 ErbB4	  
No	  significant	  levels	  of	  overexpression	  of	  ErbB4	  have	  been	  detected	  in	  HNSCC	  tissue.	  In	  
laryngeal	   carcinomas,	   overexpression	   of	   ErbB4	   was	   detected	   in	   25%	   of	   cases,	  
compared	   to	   a	   9%	   overexpression	   in	   benign	   lesions.	   Additionally,	   ErbB4	  
overexpression	  could	  not	  be	  associated	  with	  clinical	  and	  pathological	  characteristics	  of	  
disease	  (130).	  
	  
1.2.4 ErbB-­‐Targeted	  Treatment	  for	  HNSCC	  
The	  role	  of	  the	  ErbB	  receptor	  family	  in	  oncogenesis	  and	  their	  overexpression	  in	  a	  wide	  
range	  of	  solid	  tumours	  make	  them	  appealing	  candidates	  to	  develop	  targeted	  therapies	  
against.	   Targeted	   therapies	   include	   the	   use	   of	   small	   molecules,	   antibodies,	  
immunotoxins	  and	  cellular	  therapies.	  Currently	  the	  only	  Food	  and	  Drug	  Administration	  
(FDA)	   and	   European	   Medicines	   Agency	   (EMA)	   approved	   ErbB-­‐targeted	   therapy	   for	  
HNSCC	   is	   Cetuximab	   (131,	   132).	   Cetuximab	   is	   a	   high-­‐affinity	   humanized	  monoclonal	  
antibody	   (mAb)	   that	   binds	   with	   the	   extracellular	   domain	   of	   EGFR	   (133,	   134).	   The	  
binding	   affinity	   of	   Cetuximab	   and	   the	  natural	   ligands	  of	   ErbB1	   are	   similar.	  However,	  
Cetuximab	   is	  a	   receptor	  antagonist.	  Consequently,	  upon	  binding	   to	  EGFR,	  Cetuximab	  
prevents	   the	   activation	   of	   downstream	   signalling	   pathways,	   induces	   antibody-­‐
dependent	   cellular	   cytotoxicity,	   inhibits	   nuclear	   ErbB1	   transport	   and	   suppresses	   the	  
DNA-­‐dependent	  protein	  kinase	  (135-­‐137).	  Additionally	  it	  induces	  receptor	  dimerization	  
and	  downregulation	  of	  EGFR,	  preventing	  future	  activation	  resulting	  from	  binding	  of	  the	  
receptor’s	  natural	  ligands	  (138,	  139).	  	  In	  pre-­‐clinical	  studies,	  Cetuximab	  was	  shown	  to	  
decrease	   tumour	   cell	   proliferation	   and	   survival	   in	   vitro	   as	   well	   as	   reducing	   tumour	  
growth	  in	  vivo	  (137,	  140,	  141).	  	  
	   Besides	  affecting	  the	  signalling	  of	  ErbB1,	  the	  immunoglobulin	  (Ig)G1	  framework	  
of	  Cetuximab	  means	   that	   cells	   to	  which	   the	  antibody	  has	  bound	  become	   targets	   for	  
antibody-­‐dependent	   cell	   cytotoxicity	   (ADCC).	   Despite	   activity	   of	   this	   mechanism	  
against	  HNSCC	  cells	   in	  vitro,	   the	  efficacy	  seems	  to	  be	  dependent	  on	  the	  polymorphic	  
status	  of	   the	  Fc	   receptors	  expressed	  by	   the	   reacting	   immune	  cells	   (142-­‐144).	   Similar	  
ADCC	   in	   vitro	   has	   also	   been	   reported	   with	   the	   ErbB-­‐2	   targeting	   mAb,	   Trastuzumab	  
(145).	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1.2.4.1 Efficacy	  of	  Cetuximab	  Treatment	  
The	  FDA	  and	  EMA	  have	  approved	  clinical	  use	  of	  Cetuximab	  as	  a	  component	  in	  several	  
treatment	   regimens	   for	   HNSCC.	   Cetuximab	   is	   licensed	   as	   a	   primary	   treatment	   for	  
locally	  advanced	  disease,	  in	  combination	  with	  radiotherapy	  (146).	  The	  combination	  of	  
radiotherapy	   with	   Cetuximab	   significantly	   improves	   the	   median	   duration	   of	  
locoregional	  control	  (from	  14.9	  months	  for	  24.4	  months),	  median	  overall	  survival	  (OS)	  
(from	   29	   to	   49	   months)	   and	   reduces	   the	   risk	   of	   mortality	   by	   26%	   compared	   to	  
radiotherapy	   alone	   (146,	   147).	   The	   five-­‐year	   survival	   rate	   increased	   from	   36.4%	   to	  
45.6%	  after	   the	  addition	  of	  Cetuximab	  to	  high-­‐dose	   radiotherapy	   (148).	  Combination	  
of	  the	  two	  treatments	  did	  not	  increase	  the	  occurrence	  of	  grade	  3	  or	  4	  toxicity.	  Besides	  
infusion-­‐related	   reactions,	   interstitial	   lung	   disease,	   acneiform	   rash	   and	  
hypomagnesaemia,	  the	  treatment	  regimen	  was	  well	  tolerated	  (146).	  
Cetuximab	   is	  also	  approved	   for	   first-­‐line	   treatment	  of	  metastatic	  or	   recurrent	  
HNSCC	   in	   combination	   with	   platinum-­‐based	   chemotherapy.	   Patients	   treated	   with	  
Cisplatin	   in	   combination	   with	   Cetuximab	   exhibited	   a	   significantly	   higher	   objective	  
response	  rate	  when	  compared	  to	  patients	  treated	  with	  Cisplatin	  in	  combination	  with	  a	  
placebo	  (26%	  and	  10%	  respectively)	  (35,	  36).	  The	  benefit	  of	  this	  combination	  was	  also	  
evident	  in	  patients	  with	  disease	  progression	  after	  Cisplatin	  treatment	  alone	  (149,	  150).	  
After	   failure	   of	   platinum-­‐based	   chemotherapy,	   Cetuximab	   may	   be	   used	   as	   a	   single	  
agent.	   Administration	   of	   Cetuximab	   to	   patients	   who	   had	   disease	   progression	   after	  
platinum-­‐based	  chemotherapy	  resulted	  in	  a	  13%	  overall	  response	  rate	  (151).	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1.2.4.2 Toxicities	  Related	  to	  Cetuximab	  Treatment	  
Common	   toxicities	   observed	   at	   the	   recommended	   treatment	   dose	   of	   Cetuximab	   are	  
limited	  to	  hypersensitivity	  reactions	  and	  acneiform	  rash	  (neutrophilic	  folliculitis)	  (152-­‐
155).	  In	  patients	  with	  metastatic	  colorectal	  cancer	  (CRC),	  the	  occurrence	  of	  Cetuximab-­‐
induced	  skin	  toxicity	   (Cet-­‐ST)	  correlates	  with	  a	  better	  treatment	  response	  and	   longer	  
survival	  times,	  and	  can	  be	  used	  as	  an	  early	  predictor	  of	  treatment	  efficacy	  (156).	  This	  
correlation	  is	  not	  unique	  for	  Cetuximab.	  Similar	  relationships	  between	  skin	  toxicity	  and	  
efficacy	  have	  been	  reported	  in	  patients	  treated	  with	  the	  ErbB-­‐targeting	  tyrosine	  kinase	  
inhibitors	  Erlotinib	  or	  Gefitinib	  (157-­‐159).	  In	  the	  treatment	  of	  HNSCC,	  Cet-­‐ST	  has	  been	  
reported	  in	  up	  to	  77%	  of	  patients	  (35).	   Increased	  Cet-­‐ST	  and	  a	  trend	  toward	  reduced	  
risk	   of	   tumour	   progression	   in	   response	   to	   Cetuximab	   have	   been	   correlated	   to	   the	  
EGFR-­‐R521K	  genotype	  (a	  point	  substitution	  from	  G	  to	  A	  which	  results	  in	  an	  amino	  acid	  
substitution).	   This	   might	   be	   due	   to	   a	   difference	   in	   binding	   affinity.	   However,	   no	  
correlation	  with	  overall	  survival	  was	  detected	  (160).	  A	  significant	  association	  between	  
the	   development	   of	   skin	   rash	   (of	   at	   least	   grade	   2)	   and	   overall	   survival	   of	   HNSCC	  
patients	  has	  been	  reported	  in	  relation	  to	  Erlotinib	  treatment	  (161).	  
More	   severe	   side	   effects	  were	   seen	   in	   a	   phase	   II	   trial	   where	   Cetuximab	  was	  
combined	   with	   radiotherapy	   and	   Cisplatin.	   Five	   severe	   adverse	   events	   (SAEs)	   were	  
seen,	  including	  two	  deaths	  (one	  pneumonia	  and	  one	  unknown	  cause),	  one	  (non-­‐fatal)	  
myocardial	   infarction,	   one	   bacteraemia	   and	   one	   episode	   of	   atrial	   fibrillation	   (162).	  
However,	   the	   occurrence	   of	   these	   SAEs	   could	   not	   be	   conclusively	   attributed	   to	   the	  
addition	  of	  Cetuximab.	  
	  	   Other	   antibodies	   currently	   being	   investigated	   for	   the	   treatment	   of	   HNSCC	  
including	   the	  previously	  mentioned	  Trastuzumab	   (a	  humanized	   IgG-­‐1κ	  mAb	   targeted	  
against	   ErbB2)	   (163),	   as	   well	   as	   Panitumamab	   (a	   humanized	   IgG-­‐2	   anti-­‐EGFR	   mAb	  
which	   prevents	   binding	   of	   endogenous	   ligands	   to	   ErbB1)	   (164)	   and	   Zalutumumab	   (a	  
human	   IgG1	   mAb	   which	   blocks	   ErbB1	   signalling)	   (165).	   In	   addition	   to	   monoclonal	  
antibodies,	  there	  are	  several	  tyrosine	  kinase	  inhibitors	  under	  investigation	  such	  as	  the	  
previously	  mentioned	  Gefitinib	  (166,	  167)	  and	  Erlotinib	  (168,	  169),	  as	  well	  as	  Lapatinib	  
(170).	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1.2.5 Tumour	  Resistance	  against	  ErbB	  Targeted	  Therapies	  
Development	  of	   resistance	  against	  ErbB1	  blockade	  may	  be	  contributed	   to	  by	   several	  
mechanisms.	  First,	   this	  may	  result	   from	  aberrant	  activation	  of	  downstream	  signalling	  
pathways,	  especially	  the	  activation	  of	  ERK1/2	  due	  to	  KRAS,	  BRAF	  and	  NRAS	  mutations	  
(171-­‐173).	  A	  second	  mechanism	  involves	  the	  overexpression	  of	  other	  ErbB	  receptors.	  
This	   has	   been	   shown	   to	   correlate	   with	   a	   worsened	   clinical	   outcome	   compared	   to	  
tumours	   in	   which	   ErbB1	   alone	   is	   overexpressed.	   Consequently,	   a	   (combined)	  
treatment	  targeting	  several	  ErbB	  receptors	  at	  the	  same	  time	  might	  provide	  a	  possible	  
strategy	   to	   overcome	   tumour	   resistance	   (128,	   174).	   The	   combination	   of	   ErbB1	   and	  
ErbB2	   inhibition	   using	   a	   dual	   kinase-­‐targeting	   agents	   could	   overcome	   Cetuximab	  
resistance	   in	   an	   in	   vitro	   and	   in	   vivo	   model	   of	   bladder	   cancer	   (175).	   In	   studies	  
performed	   in	   non-­‐small	   cell	   lung	   cancer	   (NSCLC)	   and	   CRC	   cell	   lines,	   increased	  
activation	   of	   ErbB2	   signalling	   (either	   through	   ErbB2	   amplification	   or	   Heregulin	  
upregulation)	   leads	   to	   persistent	   ERK1/2	   signalling	   downstream	   of	   ErbB2	   and	  
consequently	  to	  Cetuximab	  resistance	  (176).	  In	  CRC	  patients,	  aberrant	  ErbB2	  signalling	  
is	  a	  mediator	  for	  both	  de	  novo	  and	  acquired	  Cetuximab	  resistance.	  Similarly,	  activation	  
of	  ErbB1	  signalling	  induces	  resistance	  to	  the	  ErbB2-­‐targeted	  mAb	  Trastuzumab	  in	  both	  
in	  vitro	  and	  in	  vivo	  breast	  cancer	  models	  (177).	  Resistance	  to	  Gefitinib	  was	  correlated	  
to	  high	  protein	  levels	  of	  phosphorylated	  ErbB2	  and	  total	  ErbB3	  (178).	  However,	  ErbB2	  
overexpression	  does	  not	  lead	  to	  Gefitinib	  resistance,	  potentially	  because	  in	  contrast	  to	  
Cetuximab,	   Gefitinib	   can	   also	   inhibit	   ErbB2	   signalling	   (179).	   Combined	   inhibition	   of	  
ErbB1	  and	  ErbB2	  with	  Cetuximab	  and	  Trastuzumab	  or	  a	  dual-­‐tyrosine	  kinase	  inhibitor	  
was	  able	   to	   restore	   sensitivity	   to	  Cetuximab	   (176).	  Afatinib	  and	  Dacomitinib	  are	   two	  
ErbB	  receptor	  family	  targeting,	  small-­‐molecule,	  irreversible	  inhibitors	  targeting	  ErbB1,	  
ErbB2	   and	   ErbB4	   simultaneously	   and	   which	   are	   currently	   under	   investigation.	   In	   a	  
phase	   II	   trial,	   Afatinib	   has	   shown	   a	   HNSCC	   control	   rate	   of	   38.9%	   in	   patients	   where	  
disease	   progression	   or	   toxicity	   was	   seen	   after	   Cetuximab	   treatment.	   Patients	   who	  
received	  Cetuximab	  after	  Afatinib	  treatment	  only	  showed	  18.8%	  disease	  control	  (174).	  
Dacomitinib	  as	  a	   first-­‐line	  treatment	   in	  metastatic/recurrent	  HNSCC	  showed	  a	  partial	  
response	  in	  11%	  and	  stable	  disease	  in	  63%	  of	  patients.	  Treatment	  was	  associated	  with	  
grade	  3	   adverse	   events	   including	  diarrhoea,	   fatigue,	   acneiform	  dermatitis	   and	  hand-­‐
foot	  skin	  reaction	  (174).	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Other	  mechanisms	  of	  resistance	  include	  the	  failure	  to	  inhibit	  PI3K/Akt	  signalling	  
which	  can	  be	  mediated	  at	  the	  level	  of	  substrate	  ErbB3,	  driven	  by	  ErbB2	  kinase	  activity	  
(180).	   Additionally	   overexpression	   of	   the	   proto-­‐oncogene	   Mesenchymal-­‐epithelial	  
transition	   factor	   (MET)	   has	   been	   shown	   to	   cause	  Gefitinib	   resistance	   through	   ErbB3	  
dependent	  activation	  of	  PI3K.	  Drug	  sensitivity	  could	  be	  restored	  after	  inhibition	  of	  MET	  
signalling	   (181,	   182).	   Upregulation	   of	   vascular	   endothelial	   growth	   factor	   (VEGF)	   is	  
induced	   through	   ErbB1	   activation	   and	   has	   been	   shown	   to	   induce	   tumour	   growth,	  
metastasis	   formation	  and	   treatment	   resistance	   (183,	  184).	  Combined	  anti-­‐ErbB1	  and	  
anti-­‐VEGF	   treatment	   suggests	   a	   synergistic	   effect	   and	   more	   robust	   response	   than	  
single-­‐agent	   treatment	   (185).	  Expression	  of	  EGFRvIII	  has	  been	  correlated	  with	  higher	  
expression	   levels	   of	   phospho-­‐STAT3,	   which	   treatment	   with	   Cetuximab	   was	   able	   to	  
decrease	  but	  unable	  to	  abrogate	  (116).	  	  
Tumour	  resistance	  against	  ErbB1	  targeted	  therapies	  can	  be	  overcome	  through	  
the	  simultaneous	  targeting	  of	  multiple	  ErbB	  receptors	  simultaneously.	  This	  provides	  a	  
rationale	   for	   the	   development	   of	   a	   single	   treatment	   in	   which	   the	   extended	   ErbB	  
receptor	   family	   is	   targeted.	   Tumour	   resistance	   against	   such	   a	   treatment	   should	   be	  
reduced	  compared	  to	  the	  targeting	  of	  a	  single	  ErbB	  receptor.	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1.3 Immunotherapy	  
Immunotherapy	  aims	  for	  targeted	  tumour	  cell	  killing	  using	  immune	  system’s	  cytotoxic	  
mechanisms.	   Multiple	   different	   approaches	   of	   immunotherapy	   exist,	   including	   both	  
the	  humoral	  and	  cellular	  components	  of	  the	  immune	  system.	  Here	  the	  focus	  will	  be	  on	  
adoptive	  cell	  therapies.	  
	  
1.3.1 T-­‐lymphocytes	  
T-­‐lymphocytes	   are	   defined	   by	   the	   surface	   expression	   of	   a	   T-­‐cell	   receptor	   (TCR),	   a	  
transmembrane	  heterodimer	  consisting	  of	  either	  and	  alpha	  and	  beta	  chain	  (αβ	  T-­‐cells),	  
or	   a	   gamma	   and	   delta	   chain	   (γδ	   T-­‐cells).	   The	   vast	   majority	   (95%)	   of	   peripheral	  
circulating	  T-­‐lymphocytes	  are	  αβ	  T-­‐cells.	  T-­‐cells	  are	  produced	  in	  the	  bone	  marrow	  and	  
then	  migrate	  as	  immature	  pre-­‐T-­‐cells	  to	  the	  thymus	  where	  they	  undergo	  maturation.	  
Immature	   progenitor	   cells	   are	   also	   referred	   to	   as	   pro-­‐	   T-­‐cells,	   or	   double-­‐negative	   T-­‐
cells	   due	   to	   the	   lack	   of	   CD4	   or	   CD8	   expression.	  Within	   the	   thymus	   some	  pro-­‐T-­‐cells	  
undergo	  TCR	  β-­‐gene	  recombination.	  When	  successful,	  a	  β-­‐chain	   is	  synthesized	  and	   is	  
co-­‐expressed	  with	  pre-­‐Tα	  to	  form	  the	  pre-­‐TCR	  complex	  on	  the	  pre-­‐T-­‐cell.	  Expression	  of	  
the	  pre-­‐TCR	  complex	  stimulates	  TCR	  α-­‐gene	  recombination	  for	  completion	  of	  the	  TCR.	  
At	  this	  point	  cells	  express	  both	  CD4	  and	  CD8	  and	  are	  referred	  to	  as	  double-­‐positive	  T-­‐
cells.	   Thereafter,	   the	  T-­‐cells	   undergo	  positive	   and	  negative	   selection.	  During	  positive	  
selection,	   T-­‐cells	   that	   do	   not	   recognize	   and	   MHC	   molecule	   in	   the	   thymus	   undergo	  
apoptosis.	   During	   positive	   selection,	   T-­‐cells	   that	   recognize	  MHC	   class-­‐I	   preserve	   the	  
expression	   of	   CD8	   and	   lose	   expression	   of	   CD4,	   whereas	   T-­‐cells	   that	   recognize	  MHC	  
class-­‐II	   preserve	   CD4	   expression.	   Thus,	   positive	   selection	   results	   in	   single-­‐positive	   T-­‐
cells	   that	  are	  either	  MHC	  class-­‐I	  or	  MHC	  class-­‐II	   restricted.	  During	  negative	  selection,	  
immature,	  double-­‐positive	  T-­‐cells	   that	   interact	  strongly	  with	  MHC-­‐peptide	  complexes	  
within	  the	  thymus	  undergo	  apoptosis	  or	  are	  directed	  towards	  a	  CD4+	  regulatory	  T-­‐cell	  
lineage	  (186-­‐188).	  
For	   T-­‐lymphocytes	   to	   be	   fully	   activated,	   to	   proliferate	   and	   secrete	   cytokines	  
antigen	   recognition	  and	  co-­‐stimulation	   is	   required.	  The	  TCR	   interacts	  with	   the	  major	  
histocompatibility	   complex	   (MHC)	   on	   the	   surface	   of	   cells.	   For	   stable	   and	   prolonged	  
interaction,	   co-­‐localisation	   of	   CD4	  with	  MHC-­‐class	   II	   or	   CD8	  with	  MHC-­‐class	   I	   in	   the	  
TCR-­‐complex	  is	  required.	  Additionally,	  co-­‐localisation	  of	  the	  four	  chains	  of	  CD3	  (δ,	  ε,	  γ	  
and	  ζ)	  with	  the	  TCR	  is	  required.	  MHC	  class-­‐I	  is	  expressed	  by	  virtually	  all	  nucleated	  cells	  I	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the	   body.	   Peptide	   expression	   upon	   MHC	   class-­‐I	   enables	   selective	   elimination	   of	  
infected	   nucleated	   cells.	   Expression	   of	   MHC	   class-­‐II	   is	   largely	   restricted	   to	   antigen	  
presenting	   cells	   (APCs).	   These	   cells	   are	   able	   to	   phagocytose,	   process	   and	   present	  
pathogens	  to	  T-­‐cells.	  Co-­‐stimulatory	  signals	  are	  required	  to	  ensure	  full	  activation.	  The	  
co-­‐stimulatory	   molecule	   CD28,	   the	   best	   understood	   co-­‐stimulatory	   molecule,	   is	  
constitutively	   expressed	   on	   human	   T-­‐lymphocytes	   (189,	   190).	   Other	   co-­‐stimulatory	  
molecules	  include	  OX40,	  4-­‐1BB	  and	  CD27	  (191,	  192).	  Their	  expression	  is	  more	  transient	  
than	  CD28,	  with	  peaks	  ranging	  from	  hours-­‐days	  after	  T-­‐cells	  encounter	  antigen.	  
	  
1.3.2 Immunological	  Tolerance	  
Immunological	   tolerance	   is	   the	  capacity	  of	   the	   immune	  system	  to	   respond	  to	  a	  wide	  
range	   of	   microbes,	   but	   not	   to	   self-­‐antigen.	   Tolerance	   can	   be	   divided	   into	   central	  
tolerance	   and	   peripheral	   tolerance.	   Central	   tolerance	   is	   a	   mechanism	   based	   on	  
tolerance	   to	   self	   antigens	   that	   are	   present	   in	   the	   generative	   lymphoid	   organs	   (bone	  
marrow	   and	   thymus).	   	   In	   immature	   T-­‐lymphocytes	   that	   strongly	   interact	   with	   self-­‐
antigen	  in	  the	  thymus,	  apoptosis	  is	  triggered	  before	  the	  cell	  can	  complete	  maturation	  
(negative	   selection).	   Alternatively,	   self-­‐antigen	   recognising	   CD4+	   lymphocytes	   can	  
develop	   into	   regulatory	   T-­‐cells,	   which	   can	   contribute	   to	   peripheral	   tolerance	   (193,	  
194).	  Peripheral	  tolerance	  occurs	  when	  mature	  lymphocytes	  recognize	  self-­‐antigen	  in	  
peripheral	   tissue.	   Several	   mechanisms	   contribute	   to	   peripheral	   tolerance.	   First,	  
lymphocytes	  can	  go	  into	  anergy,	  due	  to	  the	  lack	  of	  sufficient	  co-­‐stimulatory	  signalling.	  
Second,	  regulatory	  T-­‐cells	  can	  block	  the	  activation	  of	  potentially	  harmful	  lymphocytes	  
through	  cytokines	   (such	  as	   IL-­‐10	  and	  TGF-­‐β)	  or	   cell-­‐cell	   interaction.	  Third,	  activation-­‐
induced	  cell	  death	  through	  the	  production	  of	  apoptotic	  proteins	  or	  the	  upregulation	  of	  
death	   receptors	   and	   their	   ligands	   (such	   as	   Fas	   and	   FasL)	   (186).	   	   Because	   tumour	  
antigens	  are	  aberrant	   forms	  of,	  or	  aberrantly	  expressed	   self-­‐antigens,	   recognition	  by	  
lymphocytes	  results	   in	  tolerance	  rather	  than	  activation.	  However,	  some	  cancers	  have	  
shown	  to	  be	  moderately	  immunogenic.	  The	  suggestion	  of	  interplay	  between	  tumours	  
and	  the	  immune	  system	  resulted	  in	  the	  theory	  of	  ‘immunoediting’.	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1.3.3 Tumour	  Immunoediting	  
The	  concept	  of	  an	  interaction	  between	  tumours	  and	  the	  immune	  system	  dates	  back	  to	  
Ehrlich	   in	   1909.	  He	   suggested	   that	   transformed	   cells	   continuously	   arise	   in	   the	   body,	  
which	  the	  immune	  system	  recognises	  and	  destroys	  before	  they	  can	  become	  a	  clinically	  
detectable	   tumour	   (195).	   The	   concept	   that	   tumour	   cells	   could	   be	   recognised	   and	  
targeted	   by	   the	   immune	   system	   was	   later	   demonstrated	   in	   vivo.	   Mice	   could	   be	  
immunised	   against	   syngeneic	   tumour	   transplants,	   establishing	   the	   presence	   of	  
tumour-­‐specific	   antigens	   (TSA)	   (196,	   197).	   In	   1957	   the	   concept	   of	   ‘cancer	  
immunosurveillance’	  was	  hypothesised	  by	  Burnet	  and	  Thomas.	  They	  stated	  that	  ‘small	  
accumulations	   of	   tumour	   cells	   may	   develop	   and	   because	   of	   their	   possession	   of	   new	  
antigenic	  potentialities	  provoke	  an	  effective	  immunological	  reaction	  with	  regression	  of	  
the	  tumour	  and	  no	  clinical	  hint	  of	  its	  existence’	  (198,	  199).	  This	  hypothesis	  is	  supported	  
by	  follow-­‐up	  studies	  showing	  an	  increased	  incidence	  of	  (viral)	  tumours	  in	  patients	  who	  
were	   immunosuppressed	   after	   organ	   transplantation	   compared	   to	   the	   general	  
population	   (200-­‐203).	   Additionally,	   a	   positive	   correlation	   was	   found	   between	   the	  
presence	  of	  tumour	  infiltrating	  lymphocytes	  (TILs)	  and	  increased	  patient	  survival.	  In	  a	  
study	  amongst	  melanoma	  patients,	  the	  level	  of	  TILs	  was	  divided	  into	  three	  categories	  
(‘brisk’	  –	  present	  throughout	  the	  tumour	  and	   infiltrated	  across	  the	  entire	  base,	   ‘non-­‐
brisk’	   –	   present	   in	   one	   or	   more	   foci,	   and	   ‘absent’)	   (204).	   Patients	   with	   brisk	   TILs	  
showed	   up	   to	   three	   times	   longer	   survival	   than	   patients	   in	   the	   absent	   group,	   while	  
patients	   in	   the	   non-­‐brisk	   group	   had	   intermediate	   survival	   times	   (204,	   205).	   Similar	  
observations	  have	  been	  made	  in	  other	  solid	  tumours	  such	  as	  breast	  (206),	  ovary	  (207),	  
bladder	  (208),	  colon	  (209),	  prostate	  (210)	  and	  rectum	  (211).	  
	   Further	   studies	   into	   the	   interaction	   between	   tumour	   cells	   and	   the	   immune	  
system	  suggest	  that	  the	  presence	  of	  immune	  cells	  has	  an	  effect	  on	  the	  immunogenicity	  
of	   the	   tumour.	   Tumours	   formed	   in	   the	   absence	   of	   an	   intact	   immune	   system	   are	  
generally	   more	   immunogenic	   than	   tumours	   that	   arise	   in	   an	   immunecompetent	  
environment	   (212).	   Tumours	   are	   ‘imprinted’	   by	   their	   immunologic	   environment,	  
resulting	   in	   tumours	   that	   are	   better	   enabled	   to	   overcome	   the	   tumour-­‐suppressive	  
functions	  of	  the	  immune	  system	  (213,	  214).	  This	  suggests	  that	  the	  immune	  system	  has	  
a	   bilateral	   function	   in	   oncogenesis,	   host-­‐protection	   as	   well	   as	   tumour-­‐sculpting.	   To	  
incorporate	   these	   two	   functions	   of	   the	   immune	   system,	  Dunn	   et	   al.,	   introduced	   the	  
concept	  of	   immunoediting	   in	  2002.	   ‘We	  envisage	  the	  scope	  of	  this	  process	  to	  be	  very	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broad	  such	  that	  it	  can	  promote	  complete	  elimination	  of	  some	  tumours,	  generate	  a	  non-­‐
protective	  immune	  state	  to	  others	  or	  favour	  the	  development	  of	  immunologic	  anergy,	  
tolerance	  or	  indifference’	  (215).	  
	  
	  
Figure	  1-­‐4	  Tumour	  immunoediting	  
Schematic	  representation	  of	  the	  three	  phases	  of	  tumour	  immunoediting,	  elimination	  (a),	  equilibrium	  (b)	  
and	   escape	   (c)	   Reprinted	   by	   permission	   form	   Macmillan	   Publishers	   Ltd:	   Nature	   Immunology	   (215),	  
copyright	  (2002)	  
	  
Tumour	   immunoediting	   would	   be	   a	   process	   of	   three	   stages:	   elimination,	  
equilibrium	  and	  escape	   (Figure	  1-­‐4).	  The	  elimination	  phase	  encompasses	   the	  original	  
concept	   of	   immunosurveillance.	   In	   the	   cases	   where	   tumour	   cells	   are	   successfully	  
eradicated,	  there	  will	  be	  no	  progression	  to	  the	  second	  or	  third	  phase.	  The	  elimination	  
phase	  itself	  can	  be	  broken	  down	  into	  four	  different	  stages	  (Figure	  1-­‐5).	  A	  first	  response	  
in	   which	   natural	   killer	   (NK)	   cells,	   NK	   T-­‐cells	   (NKT)	   and	   γδ	   T-­‐cells	   accumulate	   at	   the	  
tumour	   site	   and	   interferon	   (IFN)y	   is	   produced.	   The	   IFNy	   induces	   a	   second	   response	  
through	   the	   induction	   of	   additional	   cytokines,	   anti-­‐proliferative	   effects	   and	   the	  
activation	   of	   cytocidal	   activity	   in	   macrophages	   and	   NK-­‐cells.	   In	   the	   third	   response,	  
tumour	  growth	  is	  controlled	  through	  the	  cytocidal	  activity	  of	  the	  macrophages	  and	  NK-­‐
cells.	  The	  final	  response	  is	  the	  expansion	  of	  tumour	  specific	  CD4+	  and	  CD8+	  T-­‐cells.	   In	  
the	  equilibrium	  phase,	  the	  immune	  system	  and	  remaining	  tumour	  cell	  variants	  enter	  a	  
dynamic	   equilibrium.	   Intra-­‐tumoural	   lymphocytes	   and	   cytokines	   exert	   a	   selective	  
pressure	   on	   the	   tumour	   cells,	   allowing	   the	  persistence	  of	   a	   genetically	   unstable	   and	  
rapidly	   mutating	   tumour.	   During	   the	   escape	   phase,	   tumour	   cells	   that	   have	   become	  
insensitive	   to	   immunologic	   detection	   and/or	   elimination	   expand	   uncontrollably,	  
resulting	  in	  clinical	  disease	  (215).	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Figure	  1-­‐5	  The	  four	  stages	  of	  the	  elimination	  phase	  
Immune	   cells	   accumulate	   at	   the	   tumour	   site	   and	   secrete	   IFNγ	   (a)	   which	   initiates	   an	   innate	   immune	  
response	   including	   chemokine	   production,	   the	   recruitment	   of	   further	   immune	   cells,	   direct	   anti-­‐
proliferative	  action	  of	  IFNγ	  and	  the	  activation	  of	  cytolytic	  activity	  of	  immune	  cells	  (b).	  	  Tumour	  growth	  is	  
kept	  under	  control	  while	  antigen	  specific	  lymphocytes	  develop	  (c)	  Tumour-­‐specific	  lymphocytes	  migrate	  
to	  the	  tumour	  and	  induce	  their	  cytotoxic	  effects	  (d).	  Reprinted	  by	  permission	  form	  Macmillan	  Publishers	  
Ltd:	  Nature	  Immunology	  (215)	  copyright	  (2002).	  
	  
Immunotherapy	  aims	  to	  tip	  the	  balance	  in	  favour	  of	  the	  immune	  system	  during	  
tumour	   immunosurveillance	   through	   the	  enhancement	  or	   redirection	  of	   anti-­‐tumour	  
responses	   (216).	   To	  effectively	  enhance	   the	  anti-­‐tumour	   response,	   an	  understanding	  
of	   the	   mechanism	   for	   immune	   evasion	   is	   vital.	   Tumours	   have	   several	   strategies	   to	  
silence	   immune	   responses.	   Tumours	   express	   self-­‐antigens,	   to	   which	   lymphocyte	  
responses	   are	   tolerized.	  Additionally,	   expression	  of	   tumour	   antigens	   can	  be	   reduced	  
through	  the	  downregulation	  or	  loss	  of	  major	  histocompatibility	  complex	  (MHC)	  class-­‐I	  
presentation.	   Antigen	   presentation	   by	   MHC	   molecules	   is	   crucial	   during	   the	   T-­‐cell	  
priming	   as	   well	   as	   the	   effector	   phase.	   Antigen	   presentation	   can	   be	   altered	   through	  
structural	  alterations	  in	  the	  MHC	  protein	  and	  through	  mutations	  and/or	  dysregulation	  
of	  genes	  involved	  in	  antigen	  processing	  (217,	  218).	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1.3.4 Immunoediting	  in	  HNSCC	  
The	  occurrence	  of	  immunoediting	  has	  also	  been	  identified	  in	  HNSCC.	  Downregulation	  
of	   human	   leukocyte	   antigen	   (HLA)	   class-­‐I	   expression	   is	   seen	   in	   about	   50%	   of	   cases	  
(219).	  Additionally,	  downregulation	  of	  IFN-­‐inducible	  components	  impair	  recognition	  by	  
cytotoxic	   lymphocytes.	   This	   downregulation	   has	   been	   linked	   to	   a	   poorer	   prognosis	  
(220).	   The	   microenvironment	   within	   the	   oral,	   nasal	   and	   laryngeal	   mucosa	   is	   rich	   in	  
immune	   cells	   and	   immunomodulatory	   factors	   (221).	   Tumours	   are	   generally	   well	  
infiltrated	  with	  T-­‐cells	  and	  dendritic	  cells	  (DCs)	  (221,	  222).	  Although	  tumour-­‐infiltrating	  
lymphocytes	  (TILs)	  are	  activated,	  they	  are	  functionally	  compromised	  at	  multiple	  levels	  
in	  comparison	  to	  circulating	  lymphocytes	  of	  healthy	  controls.	  The	  expression	  of	  the	  ζ-­‐
chain	  and	  ZAP-­‐70	  (zeta-­‐chain	  associated	  protein	  70)	  is	   low	  or	  absent	  in	  TIL	  cells	  (223,	  
224).	  Furthermore,	  TIL	  cells	  show	  decreased	  proliferation	   in	  response	  to	  mitogens	  or	  
IL-­‐2	  and	  are	  unable	  to	  destroy	  tumour	  target	  cells	  in	  vitro	  (221).	  There	  is	  an	  imbalance	  
in	   their	   cytokine	   profile,	   with	   an	   absence	   of	   IL-­‐2	   production	   (225).	   Finally,	   DNA	  
fragmentation	   has	   been	   observed	   in	   a	   proportion	   of	   TILs	   (224).	   The	   abnormal	  
functionality	  of	  T-­‐cells	  does	  not	  seem	  to	  be	  limited	  to	  the	  tumour	  microenvironment.	  
Circulating	   T-­‐cells	   from	   untreated	   HNSCC	   patients	   or	   patients	   who	   only	   underwent	  
surgery	  also	  exhibit	  below	  normal	  activity	  (226).	  Finally,	  apoptosis	  of	  CD8+	  lymphocytes	  
at	  the	  tumour	  site	  and	  depletion	  of	  reactive	  lymphocytes	  in	  the	  circulation	  have	  been	  
reported	   (227).	   However,	   TILs	   showed	   a	   greater	   spectrum	   of	   defects	   than	   seen	   in	  
circulating	  T-­‐cells	  from	  HNSCC	  patients.	  
	   The	   level	   of	   ζ-­‐chain	   expression	   in	   TIL	   cells	   proved	   to	   be	   a	   significant,	  
independent	  predictor	  of	  poor	  survival	  of	  patients	  with	  advanced	  disease.	  The	  5-­‐year	  
survival	  rate	  of	  patients	  with	  stage	  III/IV	  disease	  whose	  TILs	  did	  not	  express	  the	  ζ-­‐chain	  
is	   significantly	   shorter	   compared	   to	   patients	   with	   normal	   ζ-­‐chain	   expression	   (223).	  
Additional	  to	  TIL	  characteristics,	  numbers	  of	  intra-­‐tumoural	  DCs	  have	  also	  been	  related	  
to	   survival.	   A	   low	   number	   of	   infiltrating	   S100+	   DCs	   (mature	   monocyte-­‐derived	   DCs)	  
correlates	  with	  poor	  overall	  survival,	  disease-­‐free	  survival	  and	  time	  to	  recurrence.	  The	  
relationship	  between	  ζ-­‐chain	  expression	  and	  level	  of	  DC	  infiltration	  is	  not	  exclusive	  to	  
advanced	  disease,	  but	  proved	  also	   to	  be	  prognostically	   significant	   in	  early	   (stage	   I/II)	  
disease	  (221).	  	  
	   Ex	  vivo,	  HNSCC	  cells	  can	  induce	  signalling	  defects	  and	  apoptosis	  of	  activated	  T-­‐
cell	   (226).	   Additionally,	   circulating	   T-­‐cells	   of	   HNSCC	   patients	   undergo	   spontaneous	  
	   51	  
apoptosis	  ex	  vivo	  (227).	  The	  expression	  of	  Fas	  and	  Fas	  ligand	  (FasL)	  on	  tumour	  cells	  has	  
been	   implicated	   as	   a	   cause	   for	   T-­‐cell	   apoptosis	   (228).	   Nearly	   all	   T-­‐cells	   of	   HNSCC	  
patients	  express	  Fas	  (226).	  Apoptosis	  of	  tumour	  cells	  is	  disabled	  through	  impaired	  Fas	  
function	  due	  to	  an	  overexpression	  of	  inhibitory	  proteins	  including	  FAP-­‐1,	  cFLIP,	  IAP	  and	  
Bcl2	   (229).	   Additionally,	   FasL	   is	   difficult	   to	   detect	   on	   tumour	   cells,	   suggesting	   that	   it	  
might	   be	   actively	   cleaved.	   This	  may	   render	   FasL	   levels	   insufficient	   to	   induce	   tumour	  
cell	  apoptosis.	  The	  Fas/FasL	  interaction	  is	  therefore	  in	  favour	  of	  tumour	  cells	  and	  at	  a	  
disadvantage	  for	  the	  T-­‐cell	  population	  (226).	  	  
	   Head	  and	  neck	  tumours	  are	  generally	  well	  infiltrated	  and	  presence	  of	  functional	  
immune	   cells	   is	   associated	  with	   improved	   prognosis.	   These	   two	   parameters	   suggest	  
that	   the	   chances	   of	   patient	   survival	   could	   be	   improved	   through	   maintaining	   and	  
improving	  the	  immune	  cell	  functionality.	  
	  
1.3.5 Advantages	  and	  Disadvantages	  of	  different	  Immunotherapies	  
Immunotherapy	  can	  be	  broadly	  categorised	  into	  3	  different	  groups.	  	  
i) Specific,	   if	   the	   response	   of	   a	   certain	   aspect	   of	   the	   immune	   system	   is	  
enhanced	  against	  a	  TAA.	  This	  can	  be	  achieved	  for	  example	  through	  the	  use	  
of	   monoclonal	   antibodies	   or	   antibody-­‐dependent	   cell-­‐mediated	  
cytotoxicity.	  	  
ii) Non-­‐specific,	  when	   a	   broader,	  more	   general	   immune	   activation	   is	   elicited	  
such	  as	  the	  activation	  of	  NK-­‐cells,	  macrophages	  and	  granulocytes.	  	  
iii) Adoptive	  cell	  therapy	  (ACT),	  where	  autologous	  immune-­‐cells	  are	  activated,	  
enhanced	  and	  potentially	  selected	  or	  modified	  in	  vitro	  and	  then	  re-­‐infused.	  
Immune	  cells	  used	   for	  ACT	   include	   lymphokine	  activated	  killer	   (LAK)	   cells,	  
tumour	   infiltrating	   lymphocytes	   (TILs),	   dendritic	   cells	   (DCs)	   and	   T-­‐cell	  
receptor	  (TCR)	  or	  chimeric	  antigen	  receptor	  (CAR)	  transduced	  T-­‐cells	  (230).	  
	  
There	   are	   several	   different	   immunotherapeutical	   approaches	   which	   are	   being	  
investigated	   in	   order	   to	   enhance	   the	   cytotoxicity	   of	   the	   immune	   system	   against	  
tumour	  cells	  and	  overcome	  tolerance.	  Each	  of	  these	  approaches	  have	  their	  advantages	  
and	  disadvantages.	  
	   Vaccination	   is	  an	  attractive	  method	  of	  active	   immunization,	  which	  has	  several	  
approaches.	  Vaccination	  strategies	  include	  tumour	  cell	  vaccines,	  antigen	  vaccines,	  DNA	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vaccines,	  dendritic	   cell	   vaccines	  and	  virus	   targeted	  vaccines.	  There	  are	   currently	   two	  
approved	  vaccination	  treatments.	  Cervarix,	  a	  virus-­‐targeted	  vaccine	  aimed	  to	  prevent	  
HPV-­‐related	   cancers	   and	   Provenge,	   a	   dendritic	   cell	   vaccine	   using	   prostatic-­‐acid	  
phosphatase	  (PAP)	  pulsed	  DCs	  to	  treat	  prostate	  cancer.	  	  Advantages	  of	  vaccination	  are	  
that	   they	  are	  easily	  administered,	  can	  be	  aimed	  not	   just	   to	   treat	  but	  also	   to	  prevent	  
cancers.	  Additionally,	  vaccines	  do	  not	  have	   to	  be	  patient	   specific	  and	  can	  be	  applied	  
without	  significant	  side	  effects.	  Disadvantages	   include	  that	   irradiated	  tumour	  cells	  or	  
antigens	  used	  for	  vaccination	  can	  be	  destroyed	  by	  the	  patient’s	   immunesystem	  after	  
which	   it	   can	   return	   to	   a	   pre-­‐vaccinated	   state.	   Also,	   there	   might	   be	   a	   psychological	  
barrier	   for	   patients	   to	   be	   treated	   with	   irradiated	   tumour	   cells	   or	   tumour	   antigen.	  
Additionally,	   vaccination	  does	  not	  overcome	   tolerance	  and	   relies	  on	   the	  ability	  of	   T-­‐
cells	  to	  be	  sufficiently	  activated	  and	  infiltrate	  tumour	  in	  vivo	  (231).	  
	   The	  ex	  vivo	  expansion	  of	  T-­‐cells	  is	  an	  alternative	  approach	  to	  enhance	  immune	  
efficacy.	   Lymphokine	   activated	   killer	   cells	   (LAKs)	   are	   in	   vitro	   IL-­‐2	   stimulated	   PBMCs	  
(232).	   Clinical	   results	   have	   been	   achieved	   with	   LAK	   cells	   in	   colorectal	   carcinoma,	  
metastatic	   renal	   cancer,	   melanoma	   and	   other	   cancers	   (233-­‐235).	   A	   major	   general	  
advantage	  to	   the	  use	  of	  T-­‐cells	  population	   is	   the	  development	  of	  specific	  memory	  T-­‐
cells	  Other	  advantages	  of	  the	  LAK	  approach	  include	  that	  the	  treatment	  is	  autologous,	  
and	  therefore	  patient	  specific.	  	  Additionally,	  PBMCs	  can	  be	  obtained	  relatively	  easily..	  
However	   disadvantages	   include	   that	   there	   is	   no	   selection	   of	   tumour-­‐specific	  
lymphocytes	  and	  the	  approach	  relies	  on	  the	  natural	  presence	  of	  tumour-­‐specific	  T-­‐cells	  
and	  can	  therefore	  only	  be	  applied	  when	  targeting	  a	  naturally	  immunogenic	  tumour.	  	  
	   A	  more	   specific	  approach	   is	   the	  use	  of	   tumour	   infiltrating	   lymphocytes	   (TILs).	  
TIL-­‐based	  therapy	  has	  achieved	  good	  clinical	  responses	  in	  metastatic	  melanoma	  (236).	  
An	   advantage	   of	   TILs	   compared	   to	   LAKs	   is	   that	   they	   are	   a	   more	   tumour-­‐specific	  
population.	  However,	  TILs	  are	  more	  difficult	  to	  obtain	  and	  expand	  to	  required	  numbers	  
ex	   vivo.	  Similarly	   to	   LAKs,	   the	   approach	   relies	   on	   the	   natural	   immunogenicity	   of	   the	  
tumour.	  Both	  LAK	  and	  TIL	  based	  approaches	  do	  not	  overcome	  tolerance,	  but	  they	  rely	  
on	   efficacy	   based	   on	   a	   higher	   frequency	   and	  more	   activated	   tumour-­‐specific	   T-­‐cells.	  
The	   lack	   of	   overcoming	   tolerance	   limits	   efficacy,	   however	   it	   is	   also	   advantageous	   in	  
respect	  that	  it	  limits	  the	  risk	  of	  side	  effects	  due	  to	  targeting	  of	  healthy	  tissue.	  
A	  more	  specific	  approach	  is	  the	  use	  of	  tumour	  infiltrating	  lymphocytes	  (TILs).	  TIL-­‐based	  
therapy	  has	  achieved	  good	  clinical	   responses	   in	  metastatic	  melanoma	   (236,	  237).	  An	  
	   53	  
advantage	   of	   TILs	   compared	   to	   LAKs	   is	   that	   they	   are	   a	   more	   tumour-­‐specific	  
population.	  However,	  TILs	  are	  more	  difficult	  to	  obtain	  and	  expand	  to	  required	  numbers	  
ex	  vivo	  (238).	  Similarly	  to	  LAKs,	  the	  approach	  relies	  on	  the	  natural	  immunogenicity	  of	  
the	  tumour.	  Both	  LAK	  and	  TIL	  based	  approaches	  do	  not	  overcome	  tolerance,	  but	  they	  
rely	   on	   efficacy	   based	   on	   a	   higher	   frequency	   and	  more	   activated	   tumour-­‐specific	   T-­‐
cells.	  The	  lack	  of	  overcoming	  tolerance	  limits	  efficacy,	  however	  it	  is	  also	  advantageous	  
in	  respect	  that	  it	  limits	  the	  risk	  of	  side	  effects	  due	  to	  targeting	  of	  healthy	  tissue.	  
	   The	   proportion	   of	   tumour-­‐specific	   T-­‐cells	   can	   be	   enhanced	   through	   the	  
introduction	  of	  a	  tumour	  antigen-­‐specific	  TCR	  into	  a	  polyclonal	  T-­‐cell	  population.	  This	  
approach	  does	  not	   rely	  on	   the	  natural	   immunogenicity	  of	   the	   tumour	  and	  allows	   for	  
the	  expansion	  of	  a	  large	  tumour-­‐specific	  T-­‐cell	  population.	  The	  use	  of	  a	  TCR	  to	  re-­‐direct	  
T-­‐cells	  against	  the	  tumour	  allows	  both	  extracellular	  and	  intracellular	  tumour	  antigens	  
to	  be	  targeted.	  However,	   the	  approach	   is	  HLA	  dependent,	  meaning	  that	  cells	   remain	  
susceptible	   to	   immune	  evasion.	  Additionally,	   the	  HLA-­‐restriction	  means	   that	   the	  HLA	  
haplotype	  of	  the	  patient	  might	  restrict	  applicability.	  Currently	  most	  TCR	  transfers	  have	  
focussed	   on	   the	   most	   common	   HLA-­‐A2	   haplotype,	   thereby	   excluding	   patients	   with	  
different	  haplotypes.	  Introduction	  of	  a	  TCR	  circumvents	  central	  tolerance,	  however	  T-­‐
cells	   are	   still	   susceptible	   to	   peripheral	   tolerance.	   Finally,	   unpredictable	   toxicity	   can	  
occur	  due	  to	  mis-­‐pairing	  with	  the	  endogenous	  TCR	  (239).	  
	   An	   alternative	   method	   to	   re-­‐direct	   T-­‐cells	   is	   the	   use	   of	   Chimeric	   Antigen	  
Receptors	   (CARs).	   Similar	   to	   TCR-­‐based	   treatment	   this	   approach	  allows	   for	   the	   rapid	  
expansion	  of	  a	  tumour	  antigen-­‐specific	  population	  from	  an	  originally	  polyclonal	  T-­‐cell	  
population.	  In	  contrast	  to	  TCRs,	  CARs	  do	  not	  rely	  on	  HLA-­‐based	  target	  recognition	  and	  
are	   therefore	   applicable	   to	   a	   wider	   range	   of	   patients.	   However,	   this	   does	   exclude	  
intracellular	   antigen	   to	   be	   targeted	   by	   this	   approach.	   Due	   to	   the	   flexibility	   of	   CAR	  
design	   and	   the	   incorporation	   of	   co-­‐stimulatory	   domains,	   full	   T-­‐cell	   activation	   can	   be	  
achieved	   upon	   target	   recognition.	   	   Introduction	   of	   a	   CAR	   into	   a	   polyclonal	   T-­‐cell	  
populations	  circumvents	  tolerance,	  however	  this	  also	  increases	  the	  risk	  of	  toxicity	  due	  
to	  activation	  by	   target	   antigen	  expressed	  on	  healthy	   tissue	   (240,	  241).	  An	  additional	  
disadvantage	  of	  using	  a	  CAR	  is	  that	  an	  anti-­‐CAR	  immune	  response	  can	  develop	  against	  
for	  example	  murine	  elements	  in	  the	  binding	  moiety	  (242).	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1.3.6 Adoptive	  Cell	  Therapy	  
Here,	  the	  focus	  will	  lie	  on	  ACT,	  specifically	  the	  use	  of	  T-­‐cells	  for	  ACT.	  Consequently,	  the	  
history	  of	  this	  approach	  is	  reviewed	  briefly.	  In	  early	  studies,	  it	  was	  observed	  that	  the	  in	  
vitro	   stimulation	   of	   peripheral	   blood	   lymphocytes	   with	   IL-­‐2	   created	   so-­‐called	  
‘lymphokine-­‐activated	   killer	   cells’	   (LAK	   cells)	   (232).	   These	   cells	   were	   shown	   to	   be	  
effective	  in	  several	  pre-­‐clinical	  tumour	  models	  and	  highlighted	  the	  importance	  of	  dose,	  
adjuvant	  IL-­‐2	  treatment	  and	  host	  lymphodepletion	  through	  total	  body	  irradiation	  (TBI)	  
(243-­‐245).	  Additionally,	  it	  was	  shown	  that	  LAK	  cells	  cytotoxicity	  is	  induced	  in	  an	  MHC-­‐
independent	   manner	   and	   that	   efficacy	   is	   independent	   of	   the	   hosts	   natural	   T-­‐
lymphocytes	   (246,	   247).	   Adoptive	   immunotherapy	   using	   LAK	   cells	   and	   adjuvant	   IL-­‐2	  
have	   achieved	   partial	   and	   complete	   remission	   in	   colorectal	   carcinoma	   (233),	  
metastatic	   renal	   cancer	   (234),	  melanoma	   (235),	   colon	   cancer,	   renal-­‐cell	   cancer,	   lung	  
adenocarcinoma	  (248)	  and	  glioblastoma	  (249,	  250).	  However,	  in	  a	  direct	  comparison	  of	  
LAK	  cells	  in	  combination	  with	  high-­‐dose	  IL-­‐2	  versus	  high-­‐dose	  IL-­‐2	  alone,	  no	  significant	  
difference	  in	  outcome	  was	  seen	  between	  the	  two	  treatment	  regimens	  (251).	  	  
The	  most	  common	  side	  effects	  observed	  in	  these	  studies	  included	  hypotension,	  
weight	   gain,	   fluid	   retention,	   ‘capillary	   leak	   syndrome’	   anaemia	   and	   elevated	   serum	  
creatinine	   and	   liver	   enzymes	   (233,	   234).	   The	  majority	   of	   these	   side	   effects	   resolved	  
after	  the	  administration	  of	  IL-­‐2	  was	  stopped	  (248).	  	  Less	  frequent	  but	  more	  severe	  side	  
effects	  included	  cardiac	  events	  such	  as	  myocardial	  infarctions	  (235,	  250).	  
	   A	  more	  tumour-­‐specific	  adoptive	  T-­‐cell	   immunotherapy	  approach	  involves	  the	  
activation	   of	   tumour-­‐infiltrating	   lymphocytes	   (TILs).	   Tumour-­‐infiltrating	   lymphocytes	  
are	   isolated	  from	  resected	  tumour	  and	  subsequently	  activated	  and	  expanded	   in	  vitro	  
prior	   to	   reinfusion.	   TILs	   proved	   to	   have	   50-­‐100	   times	   more	   therapeutic	   potency	  
compared	   to	   LAKs	   (252).	   In	  pre-­‐clinical	  models,	   a	   combination	  of	   cyclophosphamide,	  
TILs	   and	   IL-­‐2	   administration	   proved	   highly	   successful	   in	   pre-­‐clinical	   models	   of	  
metastatic	   adenocarcinoma	   (252).	   	   It	   was	   also	   demonstrated	   that	   TILs	   could	   be	  
successfully	  expanded	  ex	  vivo	  (253).	  Objective	  response	  rates	  of	  20-­‐40%	  were	  seen	  in	  
clinical	  trials	  treating	  malignant	  melanoma	  and	  renal	  cell	  carcinoma	  (RCC)	  (254-­‐256).	  In	  
RCC,	   similar	   response	   rates	  were	   seen	  with	   IL-­‐2	   treatment	   alone,	   however	   that	  was	  
associated	   with	   a	   significant	   risk	   of	   life	   threatening	   toxicity	   (257-­‐259).	   	   For	   the	  
treatment	   of	   metastatic	   melanoma,	   TIL	   treatment	   in	   combination	   with	   IL-­‐2	   has	  
achieved	  a	  clinical	  response	  rate	  of	  50-­‐70%	  	  and	  prolongued	  progression-­‐free	  survival	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(236,	   237,	   260,	   261).	   A	   higher	   proportion	   of	   CD8+	   T-­‐cells	   and	   a	  more	   differentiated	  
effector	   phenotype	   of	   CD8+	   T-­‐cells	   and	   level	   of	   IFNγ	   production	   in	   response	   to	  
autologous	  tumour	  have	  been	  indicated	  as	  significant	  factors	  associated	  with	  objective	  
tumour	  regression	  (262,	  263).	  However,	  enrichment	  of	  CD8+	  T-­‐cells	   in	  culture	  did	  not	  
improve	   response	   rate,	   but	   suggested	   a	   preference	   for	   ‘young’	   TILs	   (231,	   263).	   TIL	  
therapy	  has	  its	  limitations,	  it	  can	  be	  difficult	  to	  obtain	  adequate	  cell	  expansion	  ex	  vivo	  
within	  the	  required	  timeframe.	  Additionally,	  ex	  vivo	  TIL	  outgrowth	  is	  achieved	  in	  only	  
approximately	  60%	  of	  patients	  and	  previous	  systemic	  therapies	  have	  a	  negative	  impact	  
on	  the	  achievement	  of	  outgrowth	  (238).	  Similarly,	  due	  to	  the	   low	   immunogenicity	  of	  
solid	  tumours,	  TIL	  therapy	  is	  less	  effective.	  
	  
1.3.7 Adoptive	  Cell	  Therapy	  in	  HNSCC	  	  
Several	   adoptive	   cell	   therapies	   for	   HNSCC	   using	   DCs	   or	   T-­‐cells	   have	   been	   tested	   in	  
Phase-­‐I	  clinical	   trials.	  Dendritic	  cell	  based	  vaccines	   involve	  the	  use	  of	  autologous	  DCs	  
loaded	  with	  tumour	  peptide,	  tumour	  lysates	  or	  tumour	  DNA	  to	  elicit	  tumour	  antigen-­‐
specific	   immunity	   in	  vivo.	  The	  use	  of	  antigen-­‐pulsed	  DCs	  allows	  for	  the	  induction	  of	  a	  
heterogeneous	   T-­‐cell	   population,	   targeting	   multiple	   tumour	   associated	   antigens	   or	  
peptides.	   In	   one	   trial,	   autologous	   DCs	   were	   pulsed	   through	   co-­‐cultivation	   with	  
autologous	   irradiated	   tumour	   cells.	   The	   resulting	   cytokine-­‐matured	   DCs	   were	  
administered	   intra-­‐nodally	   to	   four	   patients	   (after	   surgical	   resection	   of	   the	   tumour).	  
Immune	  responses	  were	  observed	  and	  little	  toxicity	  was	  reported.	  However,	  less	  than	  
10%	  of	  screened	  patients	  were	  eligible	  for	  treatment	  due	  to	  various	  reasons,	  including	  
the	   requirement	   for	   sufficient	   numbers	   of	   DCs	   and	   tumour	   products,	   and	   a	  
psychological	   resistance	  of	   the	  patients	   to	  having	   tumour	  products	   injected.	   (55).	  An	  
alternative	  to	  the	  use	  of	   irradiated	  tumour	  cells	   is	  transfection	  of	  autologous	  tumour	  
DNA	  into	  the	  patient’s	  DCs,	  however	  this	  still	  requires	  sufficient	  numbers	  of	  resected	  
tumour	  cells.	  A	  third	  approach	  is	  a	  multivalent	  p53	  loaded	  DC	  vaccine.	  The	  p53	  protein	  
is	  commonly	  overexpressed	  by	  tumour	  cells.	  Treatment	  of	  patients	  with	  various	  stages	  
of	   HNSCC	   has	   shown	   low	   toxicity.	   Vaccines	   were	   injected	   intra-­‐nodally	   as	   adjuvant	  
therapy	  and	  	  immunologic	  responses	  have	  been	  observed	  in	  several	  patients	  (55).	  	  
	   Besides	   DC	   vaccines,	   the	   potential	   of	   T-­‐cell	   based	   immunotherapies	   has	   also	  
been	  explored.	  The	  efficacy	  of	  three	  different	  patient-­‐derived	  T-­‐cell	  populations	  have	  
been	  compared	  in	  vitro,	  namely	  PBMC-­‐derived	  LAKs,	  IL-­‐2	  stimulated	  TILs	  (isolated	  from	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surgically	   resected	   tumour	   tissue)	  and	  mixed-­‐lymphocyte	   tumour	   cell	   culture	   (MLTC)	  
cells.	   The	   cytotoxic	   activity	   against	   autologous	   tumour	   cells	   of	   TILs	   proved	   twice	   as	  
high	  as	  LAKs.	  However,	  the	  strongest	  cytotoxicity	  was	  seen	  by	  MLTCs,	  which	  was	  three	  
times	  as	  high	  as	  LAKs	  (264).	  These	  in	  vitro	  results	  are	  encouraging	  for	  the	  application	  of	  
T-­‐cell	  based	  therapy	  in	  HNSCC	  patients.	  
	   In	  1993,	  Kubota	  et	  al	   reported	  on	  the	  use	  of	  allogeneic	  spleen	  cells	   (265)	  and	  
autologous	  PBMCs	  (266)	  for	  loco-­‐regional	  treatment	  of	  HNSCC.	  Allogeneic	  spleen	  cells	  
were	   derived	   from	   splenectomies	   performed	   on	   patients	   with	   gastric	   cancer.	   Cells	  
were	  activated	  using	  OK-­‐432	  (multiple	  cytokine	  inducer	  derived	  from	  the	  low-­‐virulence	  
SU	  strain	  of	  Streptococcus	  pyogenes)	  for	  48	  hours	  prior	  to	  injection.	  Two	  patients	  with	  
a	   large	   tumour	   mass	   with	   necrosis	   were	   treated	   by	   intra-­‐tumoural	   injection.	   The	  
necrotic	   centre	   of	   the	   tumour	   formed	   a	   cavity,	   into	  which	   the	   allogeneic	   cells	  were	  
injected	  to	  avoid	   the	  onset	  of	  a	  graft	  versus	  host-­‐response	   (GvHR).	  Patients	   received	  
OK-­‐432	   followed	   by	   17.4	   x	   106	   (patient	   2)	   or	   35.8	   x	   106	   (patient	   1)	   OK-­‐SC	   (OK-­‐432	  
activated	   spleen	  cells).	   Immunotherapy	  was	  given	  as	  adjuvant	   therapy	   in	  addition	   to	  
chemotherapy	   (patient	  1)	  or	  chemotherapy	  and	  radiotherapy	   (patient	  2)	  as	  a	  part	  of	  
pre-­‐operative	   treatment.	   A	  minor	   response	   was	   obtained	   in	   patient	   1	   and	   a	   partial	  
response	   in	   patient	   2.	   Treatment	   was	   not	   associated	   with	   any	   toxic	   side	   effects,	  
suggesting	  that	  adoptive	  cell	  therapy	  can	  be	  safely	  administered	  pre-­‐operatively	  (265).	  
In	   a	   similar	   trial,	   patients	  were	   treated	  with	   autologous	  OK-­‐432	   activated	   PBMCs	  by	  
injection	   into	   the	   superficial	   temporal	   artery	   or	   directly	   into	   the	   tumour,	   as	   part	   of	  
their	   pre-­‐operative	   treatment	   (266).	   Nineteen	   patients	   were	   treated	   with	   doses	  
ranging	  from	  3.1	  –	  112.3	  x	  106	  OK-­‐MCs	  (OK-­‐432	  activated	  PBMCs).	  Complete	  remission	  
was	   achieved	   in	   35%	   of	   patients	   and	   partial	   remission	   in	   53%	   of	   patients	   (with	   a	  
combination	  of	  immuno-­‐,	  chemo-­‐	  and	  radiotherapy).	  A	  minor	  response	  was	  observed	  
in	   two	   of	   three	   patients	   treated	  with	  OK-­‐MCs	   alone.	   In	   one	   of	   these	   patients,	   focal	  
necrosis	   of	   the	   tumour	   was	   observed	   at	   the	   site	   of	   injection	   as	   well	   as	   dense	  
infiltration	   of	   mononuclear	   cells	   around	   viable	   or	   degenerated	   cancer	   cells	   (266).	  
These	   results	   suggest	   functionality	   of	   adoptive	   T-­‐cell	   transfer	   through	   loco-­‐regional	  
administration,	  both	  as	  a	  single	  treatment	  as	  well	  as	  a	  part	  of	  combination	  treatment.	  
Yasumura	   et	   al.	   showed	   that	   autologous	   tumour	   specific	   cytotoxic	   T-­‐
lymphocytes	   (CTL)	   could	   be	   expanded	   in	   vitro	   and	   retain	   MHC	   class-­‐I	   dependent	  
autologous	  tumour	  cell	  destruction	  (267,	  268).	  In	  a	  phase	  I	  trial	  described	  by	  To	  et	  al.,	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an	   alternative	   method	   for	   the	   development	   of	   autologous	   tumour	   specific	   CTL	   was	  
used.	   Irradiated	   autologous	   tumour	   cells	   were	   injected	   intradermally	   and,	   after	   10	  
days,	  the	  draining	  lymph	  nodes	  were	  removed	  and	  lymphocytes	  isolated.	  After	  ex	  vivo	  
expansion,	  autologous	  lymphocytes	  were	  infused	  intravenously	  (IV)	  together	  with	  IL-­‐2.	  
Limited	  toxic	  effects	  were	  seen	  (fever,	  chills	  and	  emesis),	  all	  at	  grades	  1	  or	  2.	  However	  
no	  significant	  effect	  on	  survival	  duration	  was	  observed	  (269).	  	  
In	  an	  alternative	  approach,	  molecular	  targeting	  and	  adoptive	  cell	  therapy	  were	  
combined.	   Catuxomab	   is	   a	   trifunctional	   bispecific	   antibody	   that	   binds	   one	   arm	   to	  
epithelial	  cell	  adhesion	  molecule	  (EpCAM)	  positive	  cells,	  and	  the	  other	  arm	  to	  CD3+	  T-­‐
cells.	   This	   antibody	   has	   an	   intact	   Fc	   domain	   that	   can	   recruit	   several	   accessory	   cell	  
types.	  Complete	   remission	  was	  seen	   in	  1	  out	  of	  4	  patients	   treated	   intravenously	   (IV)	  
with	   peripheral	   blood	   mononuclear	   cells	   (PBMCs)	   after	   ex	   vivo	   opsonisation	   by	  
Catuxomab	  (270).	  	  
Together,	   these	   findings	   indicate	   that	   adoptive	   cell	   therapy	   is	   a	   feasible	   and	  
non-­‐toxic	  approach	  for	  treatment	  of	  HNSCC,	  but	  with	  limited	  efficacy.	  This	  emphasises	  
the	  fact	  that	  further	  development	  of	  adoptive	  cell	  therapy	  is	  required.	  
	  
1.3.8 Retargeting	  of	  T-­‐cells	  using	  T-­‐Cell	  Receptors	  
To	   overcome	   the	   limitations	   of	   TIL	   therapy,	   genetic	  manipulation	  was	   introduced	   to	  
rapidly	   redirect	   large	   polyclonal	   T-­‐cell	   populations	   to	   a	   tumour-­‐associated	   antigen	  
(TAA).	   There	   are	   two	   such	   approaches	   in	   common	   use	   whereby	   T-­‐cells	   can	   be	  
redirected	   through	   the	   introduction	   of	   either	   a	   novel	   αβ	   TCR	   or	   a	   chimeric	   T-­‐cell	  
receptor	   (cTCR).	   In	   1986,	   Dembic	   et	   al.	   demonstrated	   the	   feasibility	   of	   TCR	  
engraftment	  in	  a	  mouse	  model.	  The	  genes	  for	  the	  α	  and	  β	  chains	  of	  a	  murine	  TCR	  were	  
isolated	   from	   a	   cytotoxic	   T-­‐cell	   clone	   and	   transferred	   into	   a	   clone	   with	   a	   different	  
specificity.	   This	   successfully	   transferred	   the	   original	   T-­‐cell	   specificity	   through	   α/β	  
pairing	   of	   the	   ectopic	   TCR	   subunits	   (271).	   These	   results	   introduced	   the	   concept	   of	  
retargeting	   T-­‐cells	   against	   TAA	   through	   the	   introduction	   of	   a	   new	   TCR.	   T-­‐cells	   have	  
been	  successfully	  retargeted	  against	  several	  antigens,	   including	  melanoma-­‐associated	  
antigen	  recognized	  by	  T-­‐cells	  (MART)-­‐1	  (272),	  NY-­‐ESO-­‐1	  (273),	  p53	  (274,	  275),	  Wilm’s	  
Tumour	   antigen	   (WT)-­‐1	   (276,	   277),	   glycoprotein-­‐100	   (gp100)	   (278),	   mouse	   double	  
minute-­‐2	   (MDM2)	   (279),	   tyrosinase	   (280,	   281)	   and	   CEA	   (282,	   283).	   In	   clinical	   trials,	  
objective	  response	  rates	  have	  been	  seen	  in	  12-­‐30%	  of	  melanoma	  patients	  (282,	  284).	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Interestingly,	   it	   was	   also	   revealed	   that	   selection	   of	   TCRs	   with	   supra-­‐physiological	  
affinity	  for	  HLA,	  CD4+	  T-­‐cells	  were	  retargeted	  against	  HLA-­‐class	  I	  epitopes.	  Cytotoxicity	  
of	  CD4+	  T-­‐cells	  was	  comparable	  to	  that	  of	  CD8+	  cells,	  bypassing	  the	  need	  for	  CD8	  co-­‐
receptor	  binding	  (282,	  285).	  Retargeting	  with	  the	  use	  of	  TCRs	  has	  its	  limitations.	  HLA-­‐
restriction	   limits	   the	   number	   of	   patients	   for	   whom	   this	   treatment	   is	   available	   and	  
efficacy	   is	   dependent	   on	   sufficient	   HLA	   and	   co-­‐stimulatory	   receptor	   expression	   on	  
tumour	  cells.	  A	  major	  concern	  is	  the	  occurrence	  of	  autoimmunity	  due	  to	  cross-­‐pairing	  
with	  endogenous	  αβ	  TCR	  chains.	  Bendle	  et	  al.	  showed	  that	  such	  mis-­‐pairing	  could	  lead	  
to	   lethal	   autoimmunity	   in	   mice.	   Mis-­‐pairing	   could	   be	   reduced	   through	   several	  
mechanisms.	  Transduction	  of	  a	  monoclonal	  T-­‐cell	  population,	  addition	  of	  a	  disulphide	  
bond	  to	  promote	  improved	  dimerisation	  and	  the	  replacement	  of	  the	  internal	  ribosome	  
entry	   site	   	   (IRES)	   with	   a	   Porcine	   Tescho	   virus-­‐1	   2A	   (P2A)	   sequence	   all	   significantly	  
reduced	   the	  occurence	  of	  autoimmunity	   (239).	  Autoimmunity	  due	   to	  mis-­‐pairing	  has	  
also	  been	  reported	   in	  human	  studies	   (286).	  Additionally,	  cardiac	   toxicities	  have	  been	  
reported	  due	  to	  peptide	  cross-­‐recognition	  (287).	  Another	  concern	  involving	  the	  use	  of	  
high	   affinity	   TCR	   is	   the	   risk	   of	   auto-­‐immunity.	  Normally,	   T-­‐cells	  with	   high-­‐affinity	   for	  
self-­‐antigens	  are	  removed	  by	  negative	  selection	  in	  the	  thymus	  (288).	  	  
	  
1.3.9 Retargeting	  of	  T-­‐cells	  using	  Chimeric	  Antigen	  Receptors	  
In	  1987,	  Kuwana	  et	  al.	  aimed	  to	  study	  the	  difference	  between	  T-­‐cell	  and	  B-­‐cell	  antigen	  
recognition	   by	   replacing	   the	   structural	   variable	   (V)-­‐regions	   of	   TCRs	   with	   that	   of	  
Immunoglobulin	   (Ig)-­‐derived	   V-­‐regions.	   T-­‐cells	   expressing	   two	   transgenes,	   VHCα	   and	  
VLCβ	  could	  be	  activated	  by	  antigen	  expressing	  target	  cells	  (289).	  This	  discovery	  was	  the	  
first	  step	  in	  the	  development	  of	  CAR	  technology.	  Two	  years	  later,	  Gross	  et	  al.	  showed	  
IL-­‐2	  production	  and	  cytotoxic	  activity	   in	  T-­‐cells	   redirected	  against	  2,4,6-­‐trinitrophenyl	  
(TNP)	  as	  well	  as	  heterodimerisation	  with	  endogenous	  TCRα/β	  chains	  and	  CD3.	  These	  
results	  made	   them	   realise	   the	   clinical	   potential	   of	   redirecting	   cytotoxic	   T-­‐cells	   to	   kill	  
tumour	  or	  virally	   infected	  cells	   (290,	  291).	  One	  of	   the	   first	  challenges	   that	  had	   to	  be	  
overcome	  to	  allow	  for	  a	  broader	  application	  of	  the	  chimeric	  receptor	  technology	  was	  
the	   fact	   that	   it	   required	   the	   transduction	  of	  one	  cell	  with	   two	  separate	  vectors	   (one	  
containing	   VL	   and	   a	   second	   containing	   VH).	   Eshhar	   et	   al.	   developed	   a	   single-­‐chain	  
approach	  with	  the	  use	  of	  a	  single	  chain	  variable	  fragment	  (scFv)	  coupled	  to	  CD3ζ.	  In	  an	  
scFv,	   the	   VH	   and	   VL	   are	   joined	   with	   a	   flexible	   linker,	   while	   retaining	   the	   antibody’s	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specificity	   and	  affinity	   (292,	   293).	   This	   technique	  only	   required	   the	   transduction	  and	  
expression	  of	  one	  transgene.	  Because	  of	  the	  combination	  of	  the	  antibody-­‐like	  antigen	  
recognition	   with	   T-­‐cell	   activation,	   the	   technique	   was	   initially	   named	   ‘T-­‐body’.	   Since	  
then,	  it	  has	  also	  been	  referred	  to	  as	  ‘artificial	  T-­‐cell	  receptor’,	  ‘chimeric	  T-­‐cell	  receptor’	  
(cTCR),	  ‘chimeric	  immune	  receptor’	  (CIR)	  and	  the	  most	  widely	  used,	  ‘chimeric	  antigen	  
receptor’	  (CAR).	  
	   The	   general	   structure	   of	   CARs	   consists	   of	   four	   elements,	   the	   binding	  moiety,	  
the	  hinge	  or	  spacer	   region,	   the	  transmembrane	  domain	  and	  the	   intracellular	  domain	  
(see	  Figure	  1-­‐6).	  Details	  and	  function	  of	  the	  different	  elements	  are	  discussed	  below.	  
	  
	  
Figure	  1-­‐6	  Schematic	  representation	  of	  CAR	  structures	  
General	   structure	  of	   1st,	   2nd	   and	  3rd	   generation	  CARs.	   Serine/glycine	   linker	   is	   present	  when	   an	   scFv	   is	  
used	  as	  the	  binding	  moiety.	  The	  inclusion	  of	  a	  hinge	  is	  optional	  in	  all	  generations.	  Receptors	  form	  dimers	  
at	   the	   cell	   surface	   through	   disulphide	   bonds.	   Note:	   size	   of	   the	   elements	   in	   the	   images	   does	   not	  
correspond	  with	  the	  actual	  sizes.	  
	  
1.3.9.1 The	  Binding	  Moiety	  
Chimeric	   antigen	   receptors	   have	   been	   developed	   against	   a	  wide	   array	   of	   targets,	   as	  
summarized	   in	   Table	   1-­‐3.	   The	   specificity	   of	   the	   CAR	   is	   determined	   by	   the	   binding	  
moiety,	  it	  allows	  the	  CAR	  to	  recognize	  native	  cell-­‐surface	  antigen,	  independent	  of	  HLA	  
presentation	   and	   therefore	   also	   independent	   of	   the	   recipients’	   HLA	   haplotype.	  HLA-­‐
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independent	  recognition	  is	  an	  important	  advantage	  over	  TCR-­‐HLA	  based	  activation	  due	  
to	   the	   downregulation	   of	   HLA	   expression	   commonly	   seen	   on	   tumour	   cells	   (294).	  
Additionally,	   it	   makes	   treatment	   available	   to	   all	   patients,	   regardless	   of	   their	   HLA-­‐
haplotype.	  Antibody	  single	  chain	  variable	  fragments	  are	  most	  commonly	  used	  to	  allow	  
for	   target	   recognition	   and	   binding	   (295).	   Alternatively,	   ligands	   (296,	   297),	   peptides	  
(298),	  chimeric	   ligands	  (299),	  receptor	  derivatives	  (300)	  and	  single	  domain	  antibodies	  
(301)	   can	  also	   function	  as	   the	  binding	  moiety.	  These	  binding	  moieties	   target	   specific	  
tumour	  associated	  antigen.	  Recently,	  a	  more	  universal	  CAR	  design	  has	  been	  published,	  
using	  monomeric	   avidin	  as	   a	   targeting	  moiety.	   This	  CAR	  can	  be	  used	   in	   combination	  
with	   biotinylated	   antigen-­‐specific	  molecules	   (mAbs,	   scFv	   or	   tumour-­‐specific	   ligands),	  
increasing	  the	  flexibility	  in	  T-­‐cell	  targeted	  antigen	  specificity	  (302).	  	  
	   The	  choice	  of	  binding	  moiety	   is	   influenced	  by	  several	   factors.	  Antigen	  binding	  
by	   CARs	   generally	   involves	   a	   high-­‐affinity	   interaction.	   However,	   if	   the	   affinity	   is	   too	  
high,	   healthy	   tissue	   expressing	   low	   levels	   of	   the	   antigen	   may	   also	   be	   targeted,	  
increasing	  the	  risk	  of	   toxicity	   (303).	  The	  use	  of	  murine	  scFv	  sequences	   in	   the	  binding	  
moiety	   can	   induce	   immunogenicity.	   The	   formation	   of	   blocking	   antibodies	   has	   been	  
reported,	   compromising	  CAR	  effectiveness	   (242,	  304).	   The	  use	  of	  humanized	  or	   fully	  
human	  scFv	  sequences	  can	  eliminate	  this	  problem.	  The	  nature	  of	  the	  antigen	  can	  also	  
complicate	  targeting.	  Molecular	  heterogeneity	  due	  to	  aberrant	  glycosylation	  as	  seen	  in	  
Muc1	   for	   example,	   can	   affect	   the	   binding	   affinity	   of	   the	   CAR	   to	   the	   different	  
glycoforms	  (305).	  
	  
Table	  1-­‐3	  Tumour-­‐associated	  antigen	  targeted	  by	  CAR+	  T-­‐cells	  
Target	  Antigen	   Malignancies	   Development	  stage	   Reference(s)	  
B7-­‐H3	   Various	   Pre-­‐clinical	  (in	  vivo)	   (306)	  
B7-­‐H6	   Various	   Pre-­‐clinical	  (in	  vivo)	   (300)	  
CAIX	   RCC	   In	  vitro	   (307)	  
CD19	   B-­‐cell	   Phase-­‐I	  clinical	  trial	   (308-­‐323)	  
CD20	   B-­‐cell	   Phase-­‐I	  clinical	  trial	   (322,	  324-­‐327)	  
CD22	   B-­‐cell	   Pre-­‐clinical	  (in	  vivo)	   (328,	  329)	  
CD23	   Leukaemia	   Pre-­‐clinical	  (in	  vivo)	   (330)	  
CD24	   PAC	   Pre-­‐clinical	  (in	  vivo)	   (331)	  
CD30	   (N)HL	   Phase-­‐I	  clinical	  trial	   (332-­‐334)	  
CD33	   Myeloid	   Pre-­‐clinical	  (in	  vivo)	   (335-­‐337)	  
CD38	   B-­‐cell	  NHL	   Pre-­‐clinical	  (in	  vivo)	   (323,	  338-­‐340)	  
CD44v6	   Various	   Pre-­‐clinical	  (in	  vivo)	   (341)	  
CD44v7/8	   Cervical	   Pre-­‐clinical	  (in	  vivo)	   (342)	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CD70	   Various	   Pre-­‐clinical	  (in	  vivo)	   (343)	  
CD123	  (IL-­‐3Rα)	   Myeloid	   In	  vitro	   (344)	  
CEA	   Various	   Phase-­‐I	  clinical	  trial	   (345-­‐350)	  
EGFRvIII	   Various	   Phase-­‐I	  clinical	  trial	   (351-­‐353)	  
Target	  Antigen	   Malignancies	   Development	  stage	   Reference(s)	  
EGP-­‐2/EpCAM	   Various	   Pre-­‐clinical	  (in	  vivo)	   (354-­‐356)	  
EGP-­‐40	   Colon	   In	  vitro	   (357)	  
ErbB1/2/3/4	   Various	   Phase-­‐I	  clinical	  trial	   (299,	  358)	  
ErbB2	   Various	   Phase-­‐I	  clinical	  trial	   (240,	  331,	  349,	  
359-­‐364)	  
ErbB3/4	   HNSCC,	  Breast	   In	  vitro	   (296,	  297)	  
FAR	   Rhabdomyosarcoma	   In	  vitro	   (365)	  
G250/CAIX	   Renal	  cell	  carcinoma	   Phase-­‐I	  clinical	  trial	   (241,	  366-­‐369)	  
GD2	   Neuroblastoma	   Phase-­‐I	  clinical	  trial	   (327,	  370-­‐373)	  
GD3	   Melanoma	   Pre-­‐clinical	  (in	  vivo)	   (374,	  375)	  
HLA-­‐A1/MAGE1	   Melanoma	   In	  vitro	   (376)	  
HLA-­‐A2/NY-­‐ESO-­‐1	   Various	   Pre-­‐clinical	  (in	  vivo)	   (377)	  
HMW-­‐MAA	   Melanoma	   In	  vitro	   (378)	  
IL-­‐13Rα2	   Various	   Phase-­‐I	  clinical	  trial	   (379-­‐381)	  
Lewis	  Y	   Lung,	  ovarian	   Pre-­‐clinical	  (in	  vivo)	   (382-­‐386)	  
Mesothelin	   Various	   Phase-­‐I	  clinical	  trial	   (387-­‐389)	  
Muc1	   Breast,	  ovarian,	  
prostate	  	  
Pre-­‐clinical	  (in	  vivo)	   (305,	   363,	   390-­‐
392)	  
Muc16	   Ovarian	   Pre-­‐clinical	  (in	  vivo)	   (393)	  
NCAM	   Neuroblastoma	   Phase-­‐I	  clinical	  trial	   (394-­‐396)	  
NKG2D	  ligands	   Various	   Pre-­‐clinical	  (in	  vivo)	   (397,	  398)	  
PSCA	   Prostate,	  pancreatic	   Pre-­‐clinical	  (in	  vivo)	   (399-­‐401)	  
PSMA	   Prostate,	  tumour	  
vasculature	  
Phase-­‐I	  clinical	  trial	   (369,	   400,	   402-­‐
404)	  
ROR1	   B-­‐cell	   Pre-­‐clinical	  (in	  vivo)	   (405)	  
Tag72	   Gastrointestinal	   Phase-­‐I	  clinical	  trial	  	   (301,	  406-­‐409)	  
VEGF	  receptors	  
KDR/Flk-­‐1	  
Various	   Pre-­‐clinical	  (in	  vivo)	   (410,	  411)	  
αFR/FBP	   Ovarian	   Phase-­‐I	  clinical	  trial	   (304,	  412-­‐415)	  
αvβ6	  integrin	   Various	   In	  vitro	   (298)	  
κ-­‐Light	  chain	   B-­‐cell	  malignancies	   Phase-­‐I	  clinical	  trial	   (416)	  
5T4/TPBG	   Various	   Pre-­‐clinical	  (in	  vivo)	   (417)	  
Universal	  (biotin)	   Various	   In	  vitro	   (302)	  
CAIX:	   carbonic	   anhydrase	   IX,	   CD44v6:	   CD44	   exon	   v6,	   CEA:	   carcinoembryonic	   antigen,	   EGFRvIII:	  
epidermal	   growth	   factor	   variant	   III,	   EpCAM:	   epithelial	   cell	   adhesion	   molecule.	   EPG:	   epithelial	  
glycoprotein,	  FAR:	  foetal	  acetylcholine	  receptor,	  FBP:	  folate	  binding	  protein,	  G250:	  Renal	  cell	  carcinoma-­‐
associated	  antigen	  250,	  HMW-­‐MAA:	  high	  molecular	  weight	  melanoma-­‐associated	  antigen,	  HNSCC:	  head	  
and	  neck	  squamous	  cell	  carcinoma,	  IL-­‐13Rα2:	  IL-­‐13	  receptor	  alpha	  2,	  MAGE-­‐1:	  melanoma	  antigen,	  Muc	  
1/16:	  mucin	  1/16,	  NCAM:	  neural	  cell	  adhesion	  molecule,	  NHL:	  non-­‐Hodgkin’s	  lymphoma,	  NY-­‐ESO-­‐1:	  New	  
York	   Oesophageal	   antigen-­‐1,	   PAC:	   pancreatic	   adenocarcinoma,	   PSCA:	   prostate	   specific	   cell	   antigen,	  
PSMA:	  prostate	  specific	  membrane	  antigen,	  RCC:	  renal	  cell	  carcinoma,	  ROR1:	  receptor	  orphan	  tyrosine	  
kinase	   receptor	   1,	   Tag72:	   tumour	   associated	   glycoprotein	   72,	   TPBG:	   trophoblast	   glycoprotein,	   VEGF:	  
vascular	  endothelial	  growth	  factor,	  αFR:	  alpha	  folate	  receptor.	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1.3.9.2 The	  Hinge	  
Many	  CARs	  include	  a	  hinge	  or	  spacer	  region	  between	  the	  binding	  moiety	  and	  signalling	  
domain.	   The	  hinge	  provides	  a	   separation	  between	   the	  binding	  moiety	  and	   the	  T-­‐cell	  
membrane	   (418).	   	  Examples	  of	  spacer	   regions	   include	   immunoglobulin	  domains	  such	  
as	  the	  Fc	  region	  of	  IgG	  or	  the	  immunoglobulin-­‐like	  extracellular	  regions	  of	  CD4	  and	  CD8	  
(419).	   The	   importance	   of	   a	   spacer	   region	  with	   regards	   to	   the	   activation	   potential	   of	  
CARs	   is	   dependent	   on	   the	   target	   antigen.	   Guest	   et	   al.	   showed	   that	   while	   CARs	  
targeting	   5T4	   or	   neural	   cell	   adhesion	  molecule	   (NCAM)	   required	   an	   extracellular	   Fc	  
domain	   spacer	   region	   to	   generate	   maximal	   cytotoxicity	   and	   IFNγ	   release,	   in	   CARs	  
targeting	   CD19	   and	   CEA	   the	   addition	   of	   a	   spacer	   region	   reduced	   IFNγ	   release,	   but	  
cytotoxicity	  remained	  the	  same	  (419).	  A	  first-­‐generation	  ErbB2-­‐targeting	  CAR	  was	  only	  
functional	  with	  the	  inclusion	  of	  a	  hinge-­‐like	  CD8α	  segment	  (420).	  The	  influence	  of	  the	  
spacer	  region	  was	  also	  shown	  in	  other	  models,	  shortening	  of	  the	  spacer	  region	  (12AA	  
vs	   229AA)	   in	   the	   ROR1-­‐CAR	   was	   associated	   with	   superior	   cytokine	   secretion	   and	  
proliferation	   in	   response	   to	   tumour	   cell	   recognition	   (421).	   The	   same	   long	   and	   short	  
spacer	  regions	  were	  compared	  in	  an	  in	  vivo	  model	  with	  a	  CD19-­‐specific	  CAR.	  Only	  cells	  
transduced	  with	   the	   CAR	   containing	   the	   short	   spacer	   region	  were	   able	   to	   eradicate	  
xenograft	  tumours.	  T-­‐cells	  expressing	  the	  CAR	  containing	  the	  longer	  spacer	  region	  did	  
not	   show	  any	   efficacy,	  which	   could	  not	   be	   compensated	   through	  higher	   dosing	  or	   a	  
combination	   of	   CD28	   and	   4-­‐1BB	   costimulatory	   domains.	   A	   high	   rate	   of	   activation	  
induced	   cell	   death	   was	   seen	   in	   cells	   expressing	   the	   large	   spacer	   CAR	   (422).	   In	   an	  
human	   immunodeficiency	   virus	   (HIV)env-­‐specific	   CAR,	   the	   choice	   of	   hinge	   showed	   to	  
also	  be	  influential	  on	  the	  level	  of	  expression	  and	  turnover	  rate	  of	  the	  receptor	  (423).	  
The	   inclusion	   of	   an	   Fc	   spacer	   domain	   in	   a	   CD30	   targeting	   CAR	   increased	   the	   CAR’s	  
avidity	  to	  soluble	  ligand,	  but	  the	  equivalent	  receptor	  lacking	  the	  spacer	  region	  showed	  
higher	   activation	   upon	   binding	   to	   antigen-­‐positive	   cells.	   This	   suggested	   that	   the	  
increased	   avidity	   in	   the	   presence	   of	   soluble	   ligand	   may	   impair	   the	   binding	   to	  
membrane-­‐bound	  antigen	  (424).	  
The	  necessity	  and	  size	  of	  a	  hinge	  for	  optimal	  CAR	  functionality	  is	  dependent	  on	  
several	   factors.	   First,	   there	   is	   an	   optimal	   distance	   between	   T-­‐cell	   and	   target	   cells.	  	  
Membrane-­‐distal	   epitopes	   would	   not	   require	   a	   hinge,	   whereas	   when	   targeting	  
membrane-­‐proximal	   epitopes	   the	   absence	   of	   a	   spacer	   region	   would	   result	   in	   sub-­‐
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optimal	   activation	   (328).	   It	   was	   suggested	   that	   as	   the	   size	   of	   the	   CAR:ligand	   pair	  
increases,	   the	   efficiency	   of	   target	   lysis	   was	   decreased	   because	   of	   an	   enlarged	  
effector:target	   intermembrane	   distance,	   which	  would	   permit	   phosphatases	   to	   enter	  
the	   formed	  microclusters	   and	   dephosphorylate	   activated	  molecules	   of	   the	   signalling	  
cascade	   (328).	   Additionally,	   Lymphocyte	   function	   adhesion	   molecule	   (LFA)-­‐1:	  
intracellular	  adhesion	  molecule	  (ICAM)-­‐1	  interference	  could	  occur,	  resulting	  in	  a	  defect	  
in	  granule	  polarization	  and	  targeting	  (328).	  Although	  a	  size-­‐dependent	  component	  was	  
shown,	  this	  is	  not	  true	  for	  all	  target	  antigens.	  The	  inclusion	  of	  a	  hinge	  was	  required	  for	  
effective	   targeting	   of	  Muc1	   (305).	   Additionally,	   no	   difference	   in	   activation	   could	   be	  
seen	   when	   comparing	   the	   targeting	   of	   full	   CEA	   with	   a	   truncated	   version	   of	   CEA	  
(containing	  the	  target	  epitope).	  This	  suggests	  that	  it	  is	  not	  the	  size	  of	  the	  antigen,	  but	  
rather	   the	   accessibility	   of	   the	   epitope	   that	   is	   important.	   Added	   flexibility	   through	   a	  
spacer	  region	  might	  allow	  for	  better	  access	  of	  relatively	   inaccessible	  epitopes,	  where	  
as	  in	  case	  of	  an	  easily	  accessible	  epitope	  it	  might	  reduce	  binding	  (419).	  
Besides	  influencing	  CAR	  functionality,	  the	  hinge	  can	  also	  affect	  the	  interaction	  
with	   other	   elements	   of	   the	   immune	   system	   (425).	   The	   IgG1	   Fc	   spacer	   can	  mediate	  
cross-­‐activation	  of	  IgG	  Fc	  receptor	  (FcγR)	  expressing	  immune	  cells	  (such	  as	  monocytes	  
and	  NK-­‐cells)	  and	  CAR+	  T-­‐cells.	  This	  cross-­‐activation	  can	  result	   in	  both	  an	  unintended	  
innate	   immune	   response	   as	   well	   as	   a	   reduced	   anti-­‐tumour	   efficacy	   because	   of	  
activation	  induced	  cell	  death	  (AICD)	  induced	  by	  the	  ‘off-­‐target’	  activation	  of	  the	  CAR+	  
T-­‐cells.	   Fortunately,	   mutations	   in	   IgG	   Fc	   spacer	   can	   eliminate	   this	   cross-­‐activation	  
(425).	  
	   Cytotoxicity	   and	   cytokine	   production	   are	   dependent	   on	   the	   level	   of	   antigen	  
expression	  on	  the	  target	  cell,	  level	  of	  receptor	  expression	  on	  the	  effector	  cell	  and	  the	  
strength	  of	  the	  CAR-­‐mediated	  signal	  (426,	  427).	  Therefore,	  inclusion	  of	  a	  spacer	  region	  
is	   not	   a	   requirement	   for	   optimal	   T-­‐cell	   activation	   but	   should	   be	   investigated	   and	  
optimised	  for	  each	  individual	  construct.	  	  
	  
1.3.9.3 The	  Transmembrane	  Domain	  
The	   transmembrane	   domain	   is	   considered	   to	  mainly	   have	   a	   structural	   function.	   It	   is	  
often	   derived	   from	   natural	   T-­‐cell	   molecules	   such	   as	   CD3,	   CD4,	   CD8	   and	   CD28.	  
However,	  recently	  it	  has	  been	  shown	  that	  the	  transmembrane	  domain	  might	  also	  have	  
an	   influence	   on	   receptor	   function.	   The	   CD3ζ	   transmembrane	   domain	  was	   shown	   to	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play	  a	   vital	   role	   in	   the	   interaction	  between	   the	  CAR	  and	  endogenous	  CD3.	  The	  CD3ζ	  
transmembrane	   domain	   induced	   upregulation	   of	   cell	   surface	   CD3ε,	   allowed	   for	  
heterodimerisation	   with	   endogenous	   TCR	   and	   led	   to	   increased	   cytokine	   production	  
(428).	  
	  
1.3.9.4 The	  Intracellular	  Signalling	  Domain	  
T-­‐cell	   activation	   in	   response	   to	   target	   recognition	   is	   achieved	   with	   the	   use	   of	   the	  
intracellular	  signalling	  domain.	  It	  is	  the	  most	  extensively	  adapted	  element	  of	  the	  CAR,	  
aiming	   to	   optimise	   T-­‐cell	   activation.	   Generically,	   its	   evolution	   is	   often	   described	   in	  
three	  generations	  (see	  Figure	  1-­‐6).	  
	   In	  physiological	  T-­‐cell	  activation,	  TCRs	  co-­‐localize	  with	  CD3,	  which	   induces	  the	  
so-­‐called	  ‘signal	  1’	  activation	  stimulus.	  The	  CD3	  complex	  consists	  of	  dimers	  comprising	  
four	   subunits,	  namely	   ζ,	  δ,	  ε	  and	  γ	   (429-­‐431).	   In	  chimeric	   receptor	  constructs,	   it	  was	  
revealed	  that	  CD3ζ	  alone	  is	  able	  to	  induce	  early	  and	  late	  activation	  signals	  identical	  to	  
normal	  TCR/CD3	  signalling	   (431,	  432).	  Alternatively,	   the	  γ-­‐subunit	  of	   the	  high	  affinity	  
receptor	   for	   IgE,	   FcεR1	   is	   also	   capable	   of	   inducing	   ‘signal	   1’.	   In	   a	   direct	   comparison	  
between	   the	   two	   signalling	   components,	   CD3ζ	   was	   able	   to	   induce	   greater	   cytokine	  
production	   and	   cytotoxicity	   in	   vitro,	   as	  well	   as	   better	   tumour	   growth	   control	   in	   vivo	  
(433).	   This	   made	   CD3ζ	   the	   preferred	   element	   for	   CAR	   signalling	   in	   so-­‐called	   ‘first	  
generation’	  constructs.	  However,	  CD3ζ	  signalling	  has	  also	  been	  implicated	  in	  the	  high	  
levels	  of	  AICD	  in	  CAR+	  T-­‐cells.	  The	  occurrence	  of	  this	  problem	  was	  reduced	  greatly	  by	  
the	   insertion	  of	   inactivating	  mutations	   in	   two	  of	   the	   immunoreceptor	   tyrosine-­‐based	  
activation	   motif	   (ITAM)	   domains	   of	   CD3ζ,	   but	   this	   finding	   does	   spark	   debate	   as	   to	  
whether	  complete	  CD3ζ	  is	  the	  best	  inducer	  of	  signal	  1	  (364).	   	  
The	   low	   immunogenicity	  of	   tumours	   is	  not	   just	  due	   to	   the	  downregulation	  of	  
HLA,	  but	  also	  to	  the	  lack	  of	  the	  expression	  of	  costimulatory	  molecules	  that	  provide	  T-­‐
cells	  with	  activation	  ‘signal	  2’.	  This	  is	  illustrated	  by	  the	  fact	  that	  naïve	  T-­‐cells	  expressing	  
a	  first	  generation	  CARs	  could	  not	  be	  activated	  in	  vivo,	  whereas	  they	  could	  be	  activated	  
in	   vitro	   in	   the	   presence	   of	   high-­‐levels	   of	   IL-­‐2	   (420).	   Krause	   et	   al.	   demonstrated	   the	  
value	   of	   enhancing	   costimulatory	   signalling	   in	   T-­‐cells.	   Expression	   of	   a	   chimeric	  
molecule,	  which	  coupled	  an	  antigen-­‐specific	  scFv	  to	  the	  signal	  transduction	  domain	  of	  
CD28,	   enhanced	   cell	   survival	   and	   selective	   expansion	   of	   transduced	   cells	   (434).	   Co-­‐
expression	   of	   scFv-­‐CD28	   and	   scFv-­‐ζ	   chimeric	   receptors	   enabled	   the	   induction	   of	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maximal	  levels	  of	  IL-­‐2	  production	  in	  response	  to	  antigen	  recognition	  (435).	  Finney	  et	  al.	  
were	  the	  first	  to	  incorporate	  CD3ζ	  and	  CD28	  signalling	  within	  one	  CAR,	  generating	  the	  
first	  ‘second	  generation’	  construct.	  The	  inclusion	  of	  CD28	  led	  to	  a	  substantial	  increase	  
in	   IL-­‐2	   production	   (an	   indicator	   for	   signal	   2	   delivery)	   compared	   to	  CD3ζ	   alone	   (436).	  
Hombach	  et	  al.	  and	  Maher	  et	  al.	  showed	  that	  incorporation	  of	  CD28	  signalling	  was	  also	  
valuable	  in	  pre-­‐activated	  T-­‐cells.	  Second	  generation	  constructs	  targeting	  CEA	  or	  PSMA	  
improved	  cytokine	  production	  (IL-­‐2	  as	  well	  as	  IFNγ),	  and	  proliferation	  compared	  to	  first	  
generation	  constructs	   (403,	  437).	  The	  orientation	  of	  both	  signalling	  domains	  has	  also	  
been	  proven	  to	  be	  of	  importance.	  Optimal	  T-­‐cell	  activation	  seems	  to	  be	  achieved	  with	  
CD28	   in	   the	   transmembrane/juxtamembranous	   and	  CD3ζ	   in	   the	   distal	   position	   (403,	  
436).	  Additionally,	  the	  presence	  of	  CD28	  within	  the	  construct	  can	  protect	  CAR+	  T-­‐cells	  
from	  suppression	  mediated	  by	  regulatory	  T-­‐cells	   (Tregs)	   (313).	  Alternatively,	   the	  high	  
levels	  of	  IL-­‐2	  produced	  by	  T-­‐cells	  with	  CD28-­‐CD3ζ	  CARs	  may	  promote	  the	  infiltration	  of	  
Tregs,	  leading	  to	  poorer	  anti-­‐tumour	  response	  (438).	  
	   Second	   generation	   CARs	   may	   also	   be	   constructed	   using	   alternative	   co-­‐
stimulatory	  molecules,	   in	  addition	   to	  CD28.	  Constructs	  have	  been	  designed	   including	  
inducible	   costimulatory	   (ICOS)	   (439),	   OX40	   (308,	   439,	   440),	   4-­‐1BB	   (308,	   439,	   441),	  
CD27	   (442),	   DNAX-­‐activation	   protein-­‐10	   (DAP10)	   (308)	   or	   2B4	   (443).	   All	   second	  
generation	   CARs	   improve	   T-­‐cell	   function	   compared	   to	   constructs	   containing	   CD3ζ	  
alone;	   however	   there	   are	   differences	   depending	   on	  which	   co-­‐stimulatory	   element	   is	  
used.	   Incorporation	   of	   CD28	   generally	   results	   in	   the	   highest	   IL-­‐2	   production	   levels	  
(308),	   whereas	   4-­‐1BB	   seems	   to	   result	   in	   the	   highest	   multifunctionality	   of	   cytokine	  
production	  (387).	  In	  a	  comparative	  study	  ICOS	  induced	  the	  greatest	  cytotoxicity.	  ICOS	  
might	   also	   promote	   the	   persistence	   of	   Th17-­‐type	   CAR+	   T-­‐cells	   (439).	   In	   vivo,	   second	  
generation	  CARs	  containing	  CD28,	  CD27	  or	  4-­‐1BB	  elements	  showed	  improved	  survival	  
compared	   to	   first	   generation	   constructs,	   both	   in	  mouse	   (387,	   442,	   444)	   and	   in	  man	  
(320,	  445,	  446).	  A	  reduction	   in	  AICD	  and	   improved	  T-­‐cell	  survival	  might	  be	  the	  cause	  
for	  these	  observations.	  
	   The	   beneficial	   effect	   of	   including	   a	   costimulatory	   domain	   initiated	   further	  
studies	   investigating	  whether	   a	   combination	   of	   costimulatory	   domains	   could	   further	  
enhance	  functionality.	  With	  the	  combination	  of	  two	  costimulatory	  domains	  within	  one	  
construct,	   the	   ‘third	   generation’	   CAR	   was	   born.	   Third	   generation	   CARs	   combining	  
p56lck	  and	  CD28	  (447);	  OX-­‐40	  and	  CD28	  (305,	  440,	  448)	  or	  4-­‐1BB	  and	  CD28	  (305,	  326,	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387,	  404)	  have	  been	  described.	  However,	  the	  results	  obtained	  using	  combinations	  of	  
multiple	   co-­‐stimulatory	   elements	   are	   inconsistent.	   One	   study	   reported	   that	   the	  
combination	   of	   CD28	   and	   OX-­‐40	   enhanced	   cytotoxicity,	   expansion	   and	   proliferation	  
(440),	  whereas	  another	  only	  measured	  a	  reduction	  in	  IL-­‐10	  production	  but	  no	  change	  
in	  the	  production	  of	  other	  cytokines,	  cytotoxicity	  or	  expansion	  (448).	  The	  combination	  
of	   CD28	   with	   4-­‐1BB	   shows	   a	   more	   consistent	   improvement	   in	   (multifunctional)	  
cytokine	   release,	  and	   increased	  persistence	  and	  cytotoxicity	  both	   in	  vitro	   and	   in	  vivo	  
(326,	  387,	  404).	  Although	  increase	  T-­‐cell	  functionality	  is	  desirable	  with	  regards	  to	  anti-­‐
tumour	  effects,	  it	  also	  raises	  concern	  of	  increased	  toxicity.	  	  
	   There	  is	  no	  universally	  applicable	  ‘optimal	  CAR	  design’.	  Optimal	  functionality	  is	  
dependent	   on	   multiple	   factors	   and	   therefore	   design	   optimisation	   of	   all	   elements	   is	  
required	  for	  each	  individual	  target.	  
	  
1.3.10 Limitations	  of	  CARs	  
The	  major	  advantage	  that	  CAR-­‐mediated	  T-­‐cell	  activation	  has	  over	  TCR-­‐activation	  is	  the	  
HLA-­‐independent	   antigen	   recognition	   as	   well	   as	   the	   recognition	   of	   non-­‐protein	  
antigen.	   This	   circumvents	   the	   need	   for	   HLA-­‐matched	   gene	   transfer,	   allowing	   for	   the	  
use	   of	   one	   construct	   for	   all	   patients.	   Additionally,	   there	   is	   no	   risk	   of	   toxicity	   due	   to	  
mispairing	   with	   endogenous	   TCR	   (239,	   449).	   However,	   there	   are	   also	   limitations	   to	  
CAR-­‐mediated	  therapy.	  	  
	   First,	  unlike	  TCRs,	  CARs	  are	  only	  able	  to	  recognise	  antigen	  expressed	  on	  the	  cell	  
surface,	  thereby	  excluding	  TAA	  such	  as	  p53,	  MDM2	  and	  tyrosinase	  as	  targets.	  Second,	  
use	   of	   the	   CAR	   approach	   circumvents	   central	   (thymic)	   tolerance.	   This	   is	   not	   just	   a	  
concern	   for	   the	   CAR	   approach	   but	   also	   for	   TCR-­‐mediated	   therapy.	   Tumour	   antigen	  
expression	  is	  rarely	  exclusive	  to	  tumour	  cells,	  but	  more	  often	  results	  from	  expression	  
of	  higher	   levels	  or	  an	  aberrant	   form	  of	  a	  protein	   that	   is	  also	   found	   in	  healthy	   tissue.	  
The	   introduction	  of	  TCR	  or	  CAR	  transgenes	  circumvents	  central	   tolerance	   in	  order	   to	  
improve	   tumour	   targeting,	   but	   thereby	   also	   increases	   the	   risk	   of	   targeting	   healthy	  
tissue.	  Side-­‐effects	  due	  to	  antigen	  expression	  on	  healthy	  tissue	  (so-­‐called	   ‘on-­‐target’-­‐
toxicity)	   have	  been	   reported	   in	   studies	   targeting	   carbonic	   anhydrase	   IX	   (CAIX)	   (366),	  
ErbB2	   (240)	   and	   CD19	   (450).	   Third,	   peripheral	   tolerance	   is	   unaffected	   by	   ACT	   and	  
remains	  a	  potent	  factor	  by	  which	  efficacy	  can	  be	  reduced.	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   Recent	   clinical	   trials	   using	   CAR	   T-­‐cells	   have	   achieved	   remarkable	   preliminary	  
results	   in	  acute	  lymphoblastic	  and	  chronic	  lymphocytic	   leukaemia	  (317,	  321),	  but	  this	  
efficacy	   was	   associated	   with	   severe	   toxicity.	   Unfortunately,	   the	   majority	   of	   clinical	  
trials	  involving	  solid	  tumours	  in	  particular	  have	  not	  achieved	  such	  results.	  Issues	  such	  
as	  cell	  longevity,	  survival,	  homing,	  resistance	  to	  suppression	  and	  specificity	  still	  have	  to	  
be	  overcome	  to	  allow	  for	  a	  more	  reliable	  treatment.	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1.3.11 T4	  Immunotherapy	  
T4	  immunotherapy	  is	  an	  ErbB	  targeted	  adoptive	  T-­‐cell	  immunotherapy	  using	  cells	  that	  
have	  been	  transduced	  with	  two	  chimeric	  receptors.	  Respectively,	  these	  are	  a	  second-­‐
generation	  CAR	  named	  T28ζ	  (299)	  and	  a	  chimeric	  cytokine	  receptor	  named	  4αβ	  (391).	  
	  
1.3.11.1 The	  T28ζ	  Chimeric	  Antigen	  Receptor	  
T28ζ	   is	   a	   second	   generation	   CAR,	   containing	   CD28	   and	   CD3ζ	   signalling	   domains	   (see	  
Figure	   1-­‐7).	   Targeting	   of	   not	   just	   ErbB1	   receptor	   type	   but	   of	   the	   extended	   ErbB	  
receptor	  family	  is	  enabled	  through	  the	  use	  of	  the	  T1E-­‐peptide	  as	  the	  binding	  moiety	  of	  
the	  receptor	  (451).	  The	  signalling	  domain	  of	  T28ζ	  consists	  of	  the	  partial	  extracellular,	  
transmembrane	  and	  intracellular	  domain	  of	  CD28	  and	  the	  intracellular	  domain	  of	  the	  
CD3ζ	  chain	  (please	  refer	  to	  paragraph	  2.1.1.1	  for	  details).	  To	  maximize	  the	  probability	  
of	   signal	   cleavage	  at	   the	   junction	  with	   the	  TGFα	  N-­‐terminus,	   the	   leader	   sequence	  of	  
macrophage	  colony-­‐stimulating	  factor	  receptor	  (FMS)	  was	  placed	  upstream	  of	  the	  T1E	  
sequence	  (299).	  
	  
Figure	  1-­‐7	  Schematic	  representation	  of	  T28ζ	  
T28ζ	  is	  a	  second	  generation	  CAR.	  The	  binding	  moiety	  consists	  of	  the	  chimeric	  peptides,	  coupled	  to	  the	  
CD28	   hinge	   and	   transmembrane	   domain	   and	   the	   CD3ζ	   intracellular	   signalling	   domain.	   The	   receptor	  
forms	  dimers	  through	  disulphide	  bonds	  upon	  membrane	  expression.	  
	  
The	   T1E	   peptide	   is	   an	   epidermal	   growth	   factor	   (EGF)/	   transforming	   growth	  
factor	  alpha	  (TGFα)	  chimera	  (see	  Figure	  1-­‐8).	  Ligand-­‐ErbB	  receptor	  binding	  specificity	  
depends	   on	   the	   interaction	   between	   specific	   residues	   in	   the	   ligands	   with	   the	  
extracellular	  domains	  of	  the	  ErbB	  receptors.	  All	  ErbB	  growth	  factors	  share	  an	  EGF-­‐like	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domain,	  which	   is	  defined	  by	   three	  disulphide	  bridges,	  creating	   the	  A-­‐,	  B-­‐,	  and	  C-­‐loop	  
regions	  and	  additional	  linear	  N-­‐	  and	  C-­‐termini	  (451).	  Specific	  residues	  within	  the	  C-­‐loop	  
of	   EGF	  and	  TGFα	  are	   thought	   to	  be	  directly	   involved	   in	  binding	   to	  ErbB1	   (452,	   453).	  
Residues	   in	   the	  N-­‐terminus	  of	  TGFα	  also	  have	  direct	  contact	  with	  receptor	  domain	   I,	  
which	   is	   not	   the	   case	   for	   EGF	   (68,	   69).	   For	   Neuregulin	   (NRG)-­‐1	   binding	   to	   ErbB3,	  
residues	   in	   the	   N-­‐terminus	   and	   B-­‐loop	   have	   been	   indicated	   to	   be	   of	   primary	  
importance.	   In	   the	  T1E	  peptide,	   the	  N-­‐terminal	   linear	   region	  of	  EGF	   is	   replaced	  with	  
that	  from	  TGFα.	  The	  chimera	  maintained	  high	  affinity	  for	  ErbB1	  and	  additionally	  gained	  
the	  ability	   to	  bind	   to	  ErbB2/3	  heterodimers	  with	  a	  nearly	   identical	  affinity	  as	  NRG-­‐1.	  
The	   combination	   of	   the	   His4	   and	   Phe5	   residues	   in	   the	   N-­‐terminus	   of	   TGFα	  with	   the	  
Leu28	  residue	  in	  the	  B-­‐loop	  of	  EGF	  was	  identified	  to	  be	  essential	  for	  the	  high	  affinity	  of	  
the	  T1E	  chimera	  for	  the	  ErbB2/3	  heterodimers	  (454).	  Binding	  of	  T1E	  to	  ErbB3	  alone	  is	  
weak,	   suggesting	   that	   heterodimerization	  with	   ErbB2	   is	   required	   to	   stabilise	   the	   low	  
affinity	  binding	  with	  ErbB3.	  The	  weak	  binding	   to	  ErbB3	  alone	  has	  been	  attributed	   to	  
sub-­‐optimal	  sequences	  in	  the	  linear	  N-­‐terminus	  (455-­‐457).	  The	  use	  of	  the	  T1E	  peptide	  
as	   binding	   moiety,	   allows	   for	   targeting	   of	   the	   extended	   ErbB	   receptor	   family.	   As	  
mentioned	   previously,	   in	   paragraph	   1.2.5,	   targeting	   of	   multiple	   ErbB	   receptors	   can	  
reduce	  chances	  of	  tumour	  resistance	  and	  increase	  tumour	  control.	  	  
	  
T1E	   VVSHFNDCPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWEL	  
TGFα	   VVSHFNDCPDSHTQFCFH-­‐GTCRFLVQEDKPACVCHSGYVGARCEHADLLA	  
EGF	   -­‐-­‐NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR	  
Figure	  1-­‐8	  Amino	  acid	  sequence	  of	  the	  T1E	  peptide	  
	  
The	  specificity	  of	  T28ζ	   for	  all	  possible	  ErbB	  dimers	  was	  tested	  using	  the	  ErbB-­‐
negative	  haematopoietic	  cell	  line	  32D.	  Cells	  were	  engineered	  to	  express	  ErbB1-­‐4	  alone	  
and	   in	   all	   possible	   heterodimerisation	   combinations.	   Co-­‐cultivation	   of	   T28ζ+	   T-­‐cells	  
with	   the	   transduced	   32D	   cells	   revealed	   that	   T-­‐cell	   activation	   and	   subsequent	  
production	   of	   IL-­‐2	   and	   IFNγ	   was	   induced	   by	   all	   ErbB1	   containing	   homo-­‐	   and	  
heterodimers,	  as	  well	  as	  the	  ErbB2/3	  heterodimer,	  but	  not	  ErbB2	  or	  ErbB3	  alone.	  The	  
ErbB1/2	  heterodimer	   consistently	   achieved	  most	   efficient	   activation.	  Weak	   targeting	  
of	   ErbB4	   and	   ErbB4-­‐containing	   dimers	   was	   also	   seen	   (299).	   	   These	   results	   are	  
consistent	  with	  the	  reported	  binding	  properties	  of	  the	  T1E	  peptide	  (454).	  In	  vitro,	  T28ζ+	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T-­‐cells	   successfully	   destroyed	   a	   wide	   panel	   of	   ErbB+	   HNSCC	   cell	   lines,	   which	   was	  
accompanied	   by	   cytokine	   production	   (IFNγ),	   proliferation	   and	   enrichment.	   This	   was	  
dependent	  on	  the	  presence	  of	  both	  an	  ErbB+	  target	  as	  well	  as	  a	  signalling-­‐competent	  
CAR	   (299).	   In	   vivo,	   T28ζ+	   cells	   showed	  efficacy	   in	   several	   xenograft	  models,	   including	  
the	   slowly	   progressive,	   ErbB1/2+	   HN3	   tumour	   xenograft	   and	   the	   highly	   aggressive,	  
ErbB2/3+	   MDA-­‐MB-­‐435-­‐ErbB2	   (MDA-­‐MB-­‐435	   transduced	   with	   ErbB2)	   tumour	   model	  
(299).	  
	  
1.3.11.2 The	  4αβ	  Chimeric	  Cytokine	  Receptor	  
Survival	   and	   expansion	   of	   T-­‐cells	   following	   infusion	   is	   one	   of	   the	   challenges	   to	  
successful	   adoptive	   cell	   therapy.	   These	   properties	   are	   highly	   dependent	   on	   cytokine	  
stimulation,	  with	  IL-­‐2	  and	  IL-­‐15	  being	  the	  most	  potent	  stimulators.	  To	  stimulate	  in	  vivo	  
survival	   and	   expansion	   of	   T-­‐cells,	   ACT	   is	   often	   combined	   with	   a	   preceding	  
lymphodepleting	   regimen	   and	   high-­‐dose	   IL-­‐2	   administration	   after	   T-­‐cells	   infusion.	  
However,	   high-­‐dose	   IL-­‐2	   does	   not	   selectively	   stimulate	   the	   transferred	   T-­‐cells	   but	  
stimulates	  all	  lymphocytes	  and	  is	  associated	  with	  profound	  toxicity	  (458).	  To	  allow	  for	  
selective	   stimulation	   of	   transferred	   cells	   without	   profound	   toxicity,	   Wilkie	   et	   al.	  
developed	  a	  chimeric	  cytokine	  receptor	  (named	  4αβ)	  in	  which	  the	  ectodomain	  of	  the	  
IL-­‐4-­‐Rα	   is	  coupled	  to	   the	  endodomain	  of	   the	   IL-­‐2/IL-­‐15-­‐Rβ	   (see	  Figure	  1-­‐9)	   (391).	  Co-­‐
expression	  of	   4αβ	  with	   any	  CAR	   (or	   other	   transgene)	   of	   interest	   allows	   for	   selective	  
expansion	   and	   enrichment	   of	   transduced	   cells	   through	   stimulation	   with	   IL-­‐4.	   Co-­‐
expression	  of	  both	  receptors	  was	  achieved	  through	  the	  use	  of	  an	   intervening	  Thosea	  
asigna	  virus	  2A	  (T2A)	  peptide	  downstream	  of	  a	  furin	  cleavage	  site	  (391).	  
	   Interleukin-­‐4	  was	   chosen	  as	   a	   selective	   stimulus	   for	   two	  major	   reasons.	   First,	  
endogenous	  IL-­‐4	  plays	  a	  role	  in	  several	  tumour	  types.	  Second,	  IL-­‐4	  administration	  has	  
been	  tested	  as	  a	  therapeutic	  option	  for	  metastatic	  cancer	  in	  man.	  Cancer	  cells	  as	  well	  
as	  tumour	  infiltrating	  lymphocytes	  can	  produce	  endogenous	  IL-­‐4.	  Interleukin-­‐4	  is	  a	  Th2	  
lymphocyte-­‐derived	  differentiation	  and	  growth	  factor,	  which	  can	  also	  be	  produced	  by	  
mast	  cells	  and	  basophils	  (459).	  Interleukin-­‐4	  naturally	  interacts	  with	  two	  heterodimeric	  
receptors.	   The	   receptors	   have	   a	  mutual	   high	   affinity	   α-­‐subunit	   (IL-­‐4Rα),	  which	   upon	  
cytokine	  binding	  dimerizes	  with	  either	  γc	  (receptor	  type	  I),	  or	  with	  IL-­‐13Rα1	  (receptor	  
type	  II).	  Receptor	  type	  I	  is	  expressed	  by	  activated	  T-­‐cells,	  allowing	  for	  survival	  support	  
and	  limited	  proliferation	  through	  IL-­‐4	  stimulation.	  Fusion	  of	  the	  IL-­‐4Rα	  ectodomain	  to	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the	   endodomain	   of	   the	   IL-­‐2/15	   β-­‐chain	   (βc),	   allows	   for	   the	   delivery	   of	   a	  much	  more	  
potent	  mitogenic	  signal	  in	  T-­‐cells	  in	  response	  to	  IL-­‐4	  binding	  to	  4αβ	  (391).	  
	  
Figure	  1-­‐9	  Schematic	  representation	  of	  the	  chimeric	  cytokine	  receptor	  4αβ	  
The	  chimeric	  cytokine	  receptor	  4αβ	  is	  a	  combination	  of	  the	  IL-­‐4Rα	  ectodomain	  coupled	  to	  the	  IL-­‐2/15Rβ	  
endodomain.	  Upon	  binding	  with	   IL-­‐4,	   the	   receptor	  dimerizes	  with	  γc	  and	  signalling	   is	   induced	   through	  
JAK	  phosphorylation.	  
	  
Functionality	  of	  4αβ	  was	  proven	  using	   the	  mouse	  CD8+	  T-­‐cell	   cell	   line	  CTLL-­‐2.	  
These	   cells	   are	   highly	   dependent	   on	   IL-­‐2/15	   but	   are	   unresponsive	   to	   human	   IL-­‐4.	  
However,	  both	  human	  IL-­‐2	  and	  IL-­‐4	  elicited	  a	  dose-­‐dependent	  expansion	  of	  4αβ+	  CTLL-­‐
2	   cells	   (391).	   Enrichment	   and	   expansion	   of	   4αβ+	   human	   primary	   T-­‐cells	   was	   seen	  
consistently,	   regardless	   of	   which	   CAR	   it	   was	   co-­‐expressed	   with	   (the	  Muc1	   targeting	  
HOX,	  prostate	  specific	  membrane	  antigen	   (PSMA)	   targeting	  P28ζ,	  or	  T28ζ)	   (299,	  391,	  
460).	   Analysis	   of	   signal	   transducer	   and	   activator	   of	   transcription	   (STAT)-­‐
phosphorylation	  (STAT3,	  5	  and	  6)	  in	  4αβ+	  cells	  revealed	  that	  IL-­‐4	  elicits	  both	  IL-­‐4-­‐type	  
(STAT-­‐6)	   and	   an	   IL-­‐2/15-­‐type	   (STAT3/5)	   signalling	   (391).	   Cells	   do	   not	   show	   a	  
polarisation	   toward	   a	   Th2	   phenotype,	   possibly	   because	   cells	   are	   not	   exposed	   to	   IL-­‐4	  
prior	   to	   activation	   in	   combination	   with	   the	   signals	   delivered	   through	   4αβ.	   Culture	  
supplementation	  with	   IL-­‐4	  revealed	  to	  be	  superior	   in	  4αβ+	  T-­‐cell	  expansion	  over	   IL-­‐2.	  
This	  is	  probably	  due	  to	  an	  enhanced	  signalling	  potency	  delivered	  via	  4αβ/γc	  compared	  
to	  IL-­‐2/15	  βc/γc.	  This	  was	  confirmed	  by	  higher	  STAT3	  phosphorylation	  in	  response	  to	  IL-­‐
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4	  compared	  to	  IL-­‐2	  supplementation.	  Reasons	  for	  this	  can	  be	  the	  high	  affinity	  of	  the	  IL-­‐
4Rα	  for	  IL-­‐4	  as	  well	  as	  the	  constitutive	  expression	  of	  4αβ	  in	  combination	  with	  the	  up-­‐
regulation	   of	   γc	   in	   activated	   T-­‐cells.	   Co-­‐expression	   of	   CARs	   with	   4αβ	   and	   the	  
subsequent	  culture	  in	  IL-­‐4	  does	  not	  impair	  T-­‐cell	  cytotoxicity	  or	  the	  levels	  of	  cytokine	  
production	  (391).	  
The	  role	  of	  IL-­‐4	  in	  tumour	  development	  and	  immunotherapy	  is	  a	  ‘double-­‐edged	  
sword’.	  Iinterleukin-­‐4	  can	  inhibit	  cell	  growth	  and	  invasion	  through	  several	  mechanisms	  
such	   as	   the	   induction	   of	   apoptosis,	   inhibition	   of	   angiogenesis,	   downregulation	   of	  
matrix	  metalloproteinases	   (MMPs)	  or	   the	   induction	  of	  higher	  expression	  of	  adhesion	  
molecules	   (461-­‐464).	   However,	   in	  malignant	   neoplastic	   cells	   IL-­‐4	   can	   induce	   growth	  
through	   paracrine	   mechanisms	   (465).	   Additionally,	   it	   can	   inhibit	   cell-­‐mediated	  
immunity	  by	  antagonizing	  the	  effect	  of	  IFNγ	  (466).	  Serum	  levels	  of	  IL-­‐4	  are	  consistently	  
elevated	  in	  HNSCC	  patients,	  independent	  of	  tumour	  stage	  (467-­‐469).	  Production	  of	  IL-­‐4	  
is	  attributed	  to	  TILs	  and	  other	  inflammatory	  cells	  in	  the	  invasive	  front	  of	  tumours	  (465,	  
470).	  Supernatants	  of	   short-­‐term	  primary	  HNSCC	  cell	   cultures	  or	   tumour-­‐derived	  cell	  
lines	  showed	  no,	  or	  baseline	  levels,	  of	  IL-­‐4	  production	  (471,	  472).	  However,	  this	  could	  
be	   significantly	   enhanced	   through	   the	   supplementation	   of	   exogenous	   IL-­‐1	   (472).	  
Interleukin-­‐4	   is	   considered	   to	   have	   a	   stimulatory	   effect	   on	   tumour	   growth.	   Primary	  
tumours	  express	  variable	  levels	  of	  IL-­‐4	  receptor,	  in	  comparison	  to	  no	  IL-­‐4R	  expression	  
in	   benign	   lesions	   (465,	   473).	   In	   vitro,	   exogenous	   IL-­‐4	   showed	   to	   have	   a	   growth	  
stimulating	   effect	   on	   6	   out	   of	   13	   HNSCC-­‐derived	   tumour	   cell	   lines	   (465).	   In	   vivo,	   a	  
single	   nucleotide	   polymorphism	   (SNP)	   in	   the	   promoter-­‐region	   of	   the	   IL-­‐4	   gene,	  
affecting	   transcriptional	  activity,	  was	  associated	  with	  a	  higher	   risk	   for	  oral	   squamous	  
cell	   carcinoma	   (OSCC)	   (474).	   Additionally,	   in	   a	   phase	   I/II	   trial	   intra-­‐tumoural	  
administration	   of	   recombinant	   human	   IL-­‐4	   did	   not	   have	   any	   clinical	   benefit,	   but	  
disease	  progression	  was	  seen	  in	  one	  case	  (475).	  However,	  in	  OSCC	  IL-­‐4	  can	  also	  exert	  
an	   inhibitory	   effect	   through	   the	   down-­‐regulation	   of	  MMPs	   (461).	   The	   differences	   in	  
levels	  and	  effects	  of	   IL-­‐4	  could	  be	  due	  to	  the	  specific	  kinetics,	  metabolism	  or	  binding	  
protein	  modulation	  parameters	  of	  each	  individual	  tumour	  (476).	  
The	   use	   of	   IL-­‐4	   to	   expand	   T-­‐cells	   in	   vitro	   will	   not	   affect	   the	   tumour	  
microenvironment	  after	  T-­‐cell	  administration,	  therefore	  there	  is	  no	  risk	  of	  stimulating	  
tumour	  growth.	  However,	  the	  IL-­‐4	  naturally	  present	  in	  the	  tumour	  microenvironment	  
may	  stimulate	  survival	  and	  expansion	  of	  4αβ+	  T-­‐cells.	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1.3.11.3 T4	  –	  Combined	  Expression	  of	  T28ζ	  and	  4αβ	  
T4	   immunotherapy	   is	   the	   combined	  expression	  of	   T28ζ	   and	  4αβ	   in	   gene-­‐modified	  T-­‐
cells.	  As	  previously	  mentioned,	  co-­‐expression	  of	  both	  transgenes	   is	  achieved	  through	  
the	  use	  of	  an	  intervening	  T2A	  peptide	  downstream	  of	  a	  furin	  cleavage	  site.	  T4+	  T-­‐cells	  
are	  activated	  by	  a	  similar	  spectrum	  of	  ErbB	  combinations	  (all	  dimers	  containing	  ErbB1	  
and	   ErbB2/3	   heterodimer)	   and	   ErbB	   expressing	   tumour	   cell	   lines	   (299).	   Marked	  
enrichment	   of	   T4+	   T-­‐cells	   was	   achieved	   ex	   vivo	   in	   cultures	   supplemented	   with	   IL-­‐4.	  
After	  enrichment,	  co-­‐cultivation	  of	  T4+	  T-­‐cells	  with	  target	  tumour	  monolayers	  resulted	  
in	  monolayer	  destruction	  at	  an	  effector:target	  ratio	  <1	  (299).	  Activated	  cells	  produce	  
IFNγ	  and	  IL-­‐2,	  but	  small	  amounts	  of	  IL-­‐4.	  Production	  of	  IFNγ	  is	  enhanced	  by	  exogenous	  
IL-­‐4	  addition	  (299).	  	  
Patients	   are	   often	   immuno-­‐deprived,	   which	   could	   make	   transduction	   and	  
expansion	   of	   T-­‐cells	  more	   challenging.	   Reassuringly	   however,	   PBMCs	   from	   epithelial	  
ovarian	   cancer	   patients	   were	   successfully	   transduced	   and	   expanded	   and	   showed	  
efficacy	   against	   both	   ovarian	   cancer	   cell	   lines	   as	  well	   as	   autologous	   tumour	   spheres	  
(358).	  
In	   vivo,	   7.5	   x	   106	   T4+	   T-­‐cells	   proved	   to	   be	   equally	   effective	   against	   an	  
established	   (highly	   ErbB1+)	  HN3	   tumour	   as	   a	  dose	  of	   20	   x	   106	   T4+	   T-­‐cells.	   T4+	   T-­‐cells	  
were	  also	  highly	  effective	  against	   the	  aggressive	  ErbB2/3+	   tumour	  cell	   line	  MDA-­‐MB-­‐
435-­‐ErbB2	   (299).	   Combination	   of	   T4+	   T-­‐cells	   with	   adjuvant	   IL-­‐4	   slightly	   increased	  
efficacy.	  This	  could	  be	  due	  to	  an	  additive	  effect	  of	  both	  treatments	  (IL-­‐4	  alone	  also	  had	  
an	  anti-­‐tumour	  effect).	  Alternatively,	   IL-­‐4	  could	  have	   improved	   in	  vivo	  persistence	  of	  
T4+	  T-­‐cells	  (299).	   	   In	  an	  IP	  xenograft	  models	  with	  the	  ovarian	  cancer	  cell	   line	  SKOV-­‐3,	  
treatment	   with	   T4+	   T-­‐cells	   resulted	   in	   rapid	   tumour	   regression,	   followed	   by	   disease	  
progression.	   Repeated	   T-­‐cell	   administration	   resulted	   in	   improved	   tumour	   control	  
compared	   to	   a	   single	   treatment,	   but	   still	   resulted	   in	   tumour	   progression.	   Pre-­‐
treatment	   with	   the	   chemotherapeutic	   agent	   carboplatin	   lead	   to	   a	   significant	  
enhancement	   of	   anti-­‐tumour	   activity,	  which	  was	   further	   increased	  by	   a	  metronomic	  
carboplatin	   and	  T-­‐cell	   treatment	   regimen,	  using	  a	   relatively	   low	  dose	  of	   2.5	   x	   106	   T-­‐
cells.	  However,	  complete	  tumour	  eradication	  was	  not	  achieved	   in	  any	  of	  the	  models.	  
Mild	  and	  reversible	  weight	  loss	  was	  the	  only	  toxicity	  observed	  (358).	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1.4 Clinical	   Trials	  of	  CAR-­‐based	   Immunotherapy	  –	   the	  balance	  between	  
Efficacy	  and	  Toxicity	  	  
Pre-­‐clinical	  data	  suggests	   that	  CAR-­‐mediated	  adoptive	  T-­‐cell	   therapy	  has	  potential	  as	  
an	   immunotherapy	   for	   the	   treatment	   of	   a	   wide	   range	   of	   tumours.	  Multiple	   Phase-­‐I	  
clinical	   trials	  have	  been	  conducted	   in	  order	   to	  explore	   the	  safety	  and	  efficacy	  of	   this	  
therapy	   in	  man.	   Initial	   clinical	   trials	   showed	   little	   toxicity	  but	  also	   limited	  efficacy.	   In	  
order	   to	   improve	   efficacy,	   several	   adaptations	   were	   investigated	   to	   enhance	   co-­‐
stimulatory	  signalling	  and	  circumvent	  the	  ‘cytokine	  sinks’.	  However,	   in	  the	  process	  to	  
improve	  efficacy,	  increased	  toxicity	  was	  also	  encountered.	  Here,	  the	  advances	  made	  in	  
Phase-­‐I	   clinical	   trials	   are	  described,	   including	   their	   implications	   for	   both	  efficacy	   and	  
toxicity.	  
	  
1.4.1 Efficacy	  –	  T-­‐cell	  Expansion	  and	  Persistence	  
The	   first	   Phase-­‐I	   clinical	   trial	   results	   involve	   the	   use	   of	   CAR-­‐engineered	   T-­‐cells	   were	  
published	  by	  Kershaw	  et	  al.	  in	  2006	  (304).	  	  Patients	  with	  ovarian	  cancer	  were	  treated	  
in	   an	   intra-­‐patient	   dose	   escalation	   study	  with	   a	   first-­‐generation	  CAR	   targeting	   folate	  
receptor-­‐α.	   No	   evidence	   of	   anti-­‐tumour	   response	  was	   seen.	   Reasons	   for	   the	   lack	   of	  
efficacy	  included	  poor	  trafficking	  of	  T-­‐cells	  to	  the	  tumour	  site	  and	  limited	  persistence	  
of	   transfused	   cells.	   After	   transfusion,	   cells	   initially	   accumulated	   in	   the	   lungs	   and	  
subsequently	  migrated	   to	   the	   liver	   and	   spleen.	  Despite	   adjuvant	   IL-­‐2	   administration,	  
CAR+	  T-­‐cells	  were	  barely	  detectable	  3	  weeks	  after	   infusion	  (304).	  The	   lack	  of	  an	  anti-­‐
tumour	   response	  was	   linked	   to	   the	   lack	   of	   homing	   to	   the	   tumour	   as	  well	   as	   limited	  
cytotoxicity	   and	   persistence	   of	   the	   transfused	   T-­‐cells.	   	   Several	   techniques	   were	  
investigated	   to	   improve	   these	   elements	   in	   various	   clinical	   trials,	   as	   summarised	   in	  
Table	  1-­‐4.	  The	  best	   clinical	   responses	   so	   far	  have	  been	   reported	   in	   the	   treatment	  of	  
chronic	   lymphocytic	   leukaemia	   (CLL)	   and	   acute	   lymphoblastic	   leukaemia	   (ALL)	   with	  
CD19	  re-­‐targeted	  T-­‐cells	  (317,	  477).	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Table	  1-­‐4	  Phase-­‐I	  Clinical	  Trial	  results	  published	  to	  date	  
CAR	   Malignancy	   IL-­‐2	   Lymphodepl	   Efficacy	   Reference	  
aFR	  
1st	  Gen	  
Ovarian	  Cancer	   Yes	   No	   No	  OR	   (304)	  
aCAIX	  
1st	  Gen	  
RCC	   Yes	   No	   No	  OR	   (242,	  366)	  
aCD20	  
1st	  Gen	  





Lymphoma	   Yes	   Yes	   PR,	  PF	   (327)	  
aGD2	  
1st	  Gen	  





Neuroblastoma	   No	   No	   SD,	  PR,	  CR	   (394)	  
aCD19	  
1st	  Gen	  
FL	   Yes	   Yes	   No	  OR	   (322)	  
aCD20	  
1st	  Gen	  





Lymphoma	   Yes	  	   Yes	   OR,	  PR	   (312,	  319)	  
aErbB2	  
3rd	  Gen	  
Colon	  Cancer	   No	   Yes	   SAE	   (240)	  
aCD19	  
2nd	  Gen	  
CLL/ALL	   No	   Yes/No	   PR,	  SD,	  SAE	   (450,	  479)	  
aCD19	  
1st	  &	  	  
2nd	  Gen	  
NHL	   No	   No	   Transient	  SD	   (446)	  
aCD19	  
2nd	  Gen	  
ALL	   No	   Yes	   MRD-­‐,	  CR	   (317)	  
aCD19	  
3rd	  Gen	  
CLL	   No	  	   Yes	   PR,	  CR	   (320,	  445)	  
aCD19	  
3rd	  Gen	  
ALL	   No	   Yes	   CR	   (477)	  
Lymphodepl:	   lymphodepletion,	   Gen:	   generation,	   FR:	   Folate	   Receptor-­‐α,	   CAIX:	   carbonic	   anhydrase	   IX,	  
RCC:	   renal	   cell	   carcinoma:	   FL:	   follicular	   lymphoma,	   DLCL:	   diffuse	   large	   cell	   lymphoma,	   NHL:	   non-­‐
Hodgkin’s	   lymphoma,	   CLL:	   chronic	   lymphocytic	   leukaemia,	   ALL:	   acute	   lymphoblastic	   leukaemia,	   OR:	  
objective	   response,	  PR:	  partial	   response,	  PF:	  progression	   free,	  TTP:	   time	   to	  progression,	  CR:	   complete	  
response,	   SD:	   stable	   disease,	   SAE:	   serious	   adverse	   event,	   HSCT:	   hematopoietic	   stem	   cell	   transplant,	  
MRD:	  minimal	  residual	  disease.	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1.4.1.1 Enhanced	  Co-­‐Stimulatory	  Signalling	  
A	  possible	   reason	   for	   the	   limited	  persistence	  and	   cytotoxicity	  of	   transfused	  T-­‐cells	   is	  
the	  absence	  of	  sufficient	  co-­‐stimulatory	  signals	  when	  using	  first-­‐generation	  constructs.	  
In	  order	  to	  improve	  the	  co-­‐stimulation,	  Pule	  et	  al.	  compared	  Epstein-­‐Barr	  Virus	  (EBV)-­‐
specific	   and	   non-­‐specific	   T-­‐cells,	   which	   had	   both	   been	   re-­‐targeted	   against	   GD2.	  
Transduced	  EBV-­‐specific	  T-­‐cells	  were	  expected	  to	  be	  superior	  in	  survival	  and	  function.	  
Co-­‐stimulation	   can	  be	  provided	   to	   these	   cells	  ex	   vivo	   by	   co-­‐culture	  with	   EBV+	   B-­‐cells	  
and	   in	   vivo	   by	   encounter	   with	   (latent)	   viral	   antigens	   (370).	   Neuroblastoma	   patients	  
with	  EBV-­‐specific	  IgGs	  were	  treated	  with	  a	  single	  injection	  containing	  an	  equal	  amount	  
of	  CAR+	  EBV-­‐specific	  (C-­‐EST)	  and	  CAR+	  non-­‐specific	  (C-­‐NST)	  T-­‐cells,	  thereby	  acting	  as	  a	  
‘self-­‐control’.	  Prior	   to	   injection	  both	  cell	  populations	  were	  of	   similar	  phenotypes	  and	  
equivalent	   cytotoxicity	   against	   GD2+	   neuroblastoma	   cell	   lines.	   As	   early	   as	   24	   hours	  
after	   T-­‐cell	   injection,	   higher	   levels	   of	   C-­‐EST	   were	   detected	   compared	   to	   C-­‐NST	   and	  
which	  persisted	  for	  a	  period	  of	  up	  to	  6	  weeks	  after	   injection.	  Transfused	  C-­‐NST	  were	  
detectable	  up	  to	  3	  weeks.	  Additionally,	  C-­‐EST	  retained	  their	  cytotoxicity	  better	  than	  C-­‐
NST	  (370).	  However,	  in	  contrast	  to	  short-­‐term	  persistence,	  long-­‐term	  persistence	  of	  C-­‐
NST	  at	   low	   levels	  was	  more	   sustained	   compared	   to	  C-­‐EST	   (192	  weeks	  and	  96	  weeks	  
respectively).	   Persistence	   of	   either	   CAR+	   cell	   population	   was	   associated	   with	   a	  
significantly	  longer	  TTP	  in	  patients	  with	  active	  disease,	  due	  to	  a	  true	  difference	  in	  PFS	  
(372).	   Rather	   than	   EBV-­‐specificity,	   prolonged	   T-­‐cell	   persistence	   was	   shown	   to	   be	  
positively	  correlated	  with	  the	  number	  of	  CD4+	  T-­‐cells	  and	  central	  memory	  CD8+	  T-­‐cells	  
within	   the	  administered	   cell	   population	   (372).	   	   Similarly,	   in	   a	   trial	   targeting	  CLL	  with	  
CD19	   re-­‐targeted	   T-­‐cells	   the	   influence	   of	   cell	   phenotype	   on	   persistence	   was	   noted.	  	  
The	  persisting	  CD8+	  CAR+	  T-­‐cell	  population	  differentiated	  in	  vivo	  from	  a	  mainly	  effector	  
memory	  phenotype,	   to	  a	  mixed	  effector	  and	  central	  memory	  phenotype.	  The	   in	  vivo	  
persisting	  CD4+	  CAR+	  T-­‐cells	  were	  mainly	  of	  the	  central	  memory	  phenotype	  (320).	  
An	  alternative	  method	  to	   induce	  sufficient	  co-­‐stimulation	  to	  the	  administered	  
T-­‐cells,	  is	  the	  use	  of	  second	  generation	  CARs	  rather	  than	  first	  generation	  CARs.	  Savoldo	  
et	  al.	  compared	  the	  expansion	  and	  persistence	  in	  vivo	  of	  T-­‐cells	  transduced	  with	  a	  first	  
(CD3ζ	  alone)	  or	  second	  (CD28	  and	  CD3ζ)	  generation	  CD19-­‐targeting	  CAR	  (446).	  Patients	  
with	   relapsed	   or	   refractory	   NHL	   were	   treated	   with	   both	   CD19ζ	   and	   CD19-­‐28ζ	  
transduced	   T-­‐cells.	   Both	   cell	   populations	   were	   similar	   phenotypically	   and	   were	  
detectable	  in	  peripheral	  blood	  as	  early	  as	  3	  hours	  after	  injection.	  However,	  in	  contrast	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to	  CD19ζ	  transduced	  cells,	  CD19-­‐28ζ	  transduced	  cells	  were	  able	  to	  expand	  in	  vivo.	  Both	  
the	   CD4+	   and	   CD8+	   T-­‐cell	   populations	   were	   shown	   to	   contribute	   to	   the	   in	   vivo	  
expansion.	   Additionally,	   CD19-­‐28ζ+	   T-­‐cells	   were	   able	   to	   infiltrate	   cutaneous	   tumour	  
lesions	  in	  contrast	  to	  CD19ζ+	  T-­‐cells	  (446).	  	  
	  
1.4.1.2 Enhanced	  Cytokine	  Stimulation	  
Besides	   co-­‐stimulatory	   signalling,	   cytokine	   stimulation	   is	   also	   important	   for	   the	  
functionality	   of	   T-­‐cells.	   Increasing	   the	   cytokine	   stimulation	   to	   transfused	   T-­‐cells	   has	  
been	  pursued	  through	  the	  administration	  of	  adjuvant	  IL-­‐2	  or	  lymphodepletion	  prior	  to	  
T-­‐cell	  administration.	  Lymphodepletion	  removes	  the	  so-­‐called	  ‘cytokine	  sinks’,	  making	  
the	  cytokines	  more	  available	  to	  the	  transferred	  T-­‐cells	  because	  they	  are	  not	  consumed	  
by	  circulating	  lymphocytes.	  Additionally,	  lymphodepletion	  increases	  the	  production	  of	  
homeostatic	   cytokines	  and	   removes	  Tregs	   (480).	  Till	   et	  al.	   showed	   that	  adjuvant	   IL-­‐2	  
administration	  prolonged	  the	  persistence	  of	  their	  CD20	  re-­‐targeted	  T-­‐cells	  (using	  a	  first	  
generation	  CAR)	  from	  5-­‐21	  days	  (without	  IL-­‐2)	  to	  5-­‐9	  weeks	  (with	  IL-­‐2)	  in	  patients	  with	  
NHL.	  However	  no	  anti-­‐tumour	  response	  was	  seen	  (478).	  In	  a	  second	  trial	  by	  the	  same	  
group,	   T-­‐cells	   engineered	   to	   express	   a	   third	   generation	   CD20-­‐targeted	   CAR	   were	  
administered	   following	   lymphodepletion.	   The	   infused	   cells	   migrated	   to	   malignant	  
lymph	   nodes	   within	   24-­‐48	   hours,	   were	   detectable	   in	   bone	   marrow	   1	   month	   after	  
transfusion	   and	   persisted	   for	   9-­‐12	   months	   (327).	   Treatment	   resulted	   in	   1	   partial	  
response	  and	  2	  patients	  remained	  progression	  free	  for	  12	  months	  (327).	  Comparison	  
of	  the	  results	  of	  these	  two	  trials	  suggests	  that	  improved	  co-­‐stimulatory	  signalling	  and	  
lymphodepletion	   both	  may	   have	   contributed	   to	   an	   increase	   in	   efficacy.	   The	   positive	  
effect	   of	   lymphodepletion	   upon	   efficacy	   of	   CD19-­‐targeted	   T-­‐cells	   was	   confirmed	   by	  
Brentjens	   et	   al.	   In	   this	   trial,	   patients	   were	   treated	   with	   a	   CD19-­‐targeted	   second	  
generation	  CAR,	  with	  or	  without	  prior	  cyclophosphamide	  treatment.	  Lymphodepletion	  
increased	  CAR+	  T-­‐cell	  persistence,	  infiltration	  into	  tumour	  beds,	  allowed	  for	  migration	  
to	   the	  bone	  marrow	  and	   improved	  efficacy.	  Combined	   therapy	   led	   to	  a	   reduction	  of	  
peripheral	   lymphadenopathy	   and	   stable	   disease,	   whereas	   no	   objective	   disease	  
response	  was	  seen	  when	  patients	  were	  not	  lymphodepleted	  (479).	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1.4.1.3 Trafficking	  to	  Bone	  Marrow	  
In	  B-­‐cell	  targeted	  treatments,	  CAR+	  T-­‐cell	  migration	  to	  the	  bone	  marrow	  could	  also	  be	  
beneficial	  for	  T-­‐cell	  persistence.	  Kalos	  et	  al.	  reported	  persistence	  of	  CD19	  re-­‐targeted	  
T-­‐cells	   for	   at	   least	   6	  months	   (the	  maximum	  period	  of	   reported	   follow-­‐up)	   as	  well	   as	  
CAR+	   T-­‐cell	   trafficking	   to	   the	   bone	   marrow.	   Importantly,	   in	   this	   study	   the	   CAR	  
endodomain	  comprised	  a	  fusion	  of	  4-­‐1BB	  followed	  by	  CD3ζ.	  In	  the	  bone	  marrow,	  CAR+	  
T-­‐cells	   could	  be	   repeatedly	  activated	  by	  encounter	  with	  emerging	  progenitor	  B-­‐cells,	  
resulting	  in	  prolonged	  persistence	  (320).	  
	  	  
1.4.1.4 Immune	  Response	  against	  CARs	  
The	  efficacy	  and	  persistence	  of	  CAR+	  T-­‐cells	  can	  also	  be	  limited	  due	  to	  the	  induction	  of	  
an	   immune	   response	   against	   the	   administered	   T-­‐cells.	   Multiple	   CAR	   constructs	   use	  
scFv	   derived	   from	   mouse-­‐anti	   human	   antibodies.	   The	   presence	   of	   mouse	   elements	  
within	  the	  expressed	  construct	  can	  elicit	  an	  immune	  response	  against	  the	  CAR.	  Lamers	  
et	  al.	   treated	  patients	  with	  metastatic	  RCC	  with	  CAIX	  re-­‐targeted	  T-­‐cells.	  The	  binding	  
moiety	  of	   the	  CAR	  used	   consisted	  of	   an	   scFv	  of	   the	  anti-­‐CAIX	  mouse	  mAb	  G250.	  No	  
objective	  clinical	  response	  was	  seen	  in	  the	  patients,	  however	  ‘on-­‐target’	  hepatotoxicity	  
was	   observed	   (described	   in	   paragraph	   1.4.2.2),	   suggesting	   functionality	   of	   the	  
transfused	  T-­‐cells	  in	  vivo	  (242,	  366).	  A	  human	  antibody	  response	  to	  G250	  (human	  anti-­‐
CAR	   antibodies;	   HACA)	   became	   detectable	   after	   the	   second	   CAR+	   T-­‐cell	   treatment	  
cycle.	   In	  vitro,	  HACA	  was	  shown	  to	  inhibit	  CAR-­‐mediated	  cytolysis	   in	  a	  concentration-­‐
dependent	   manner	   (242).	   	   In	   addition	   to	   an	   antibody-­‐mediated	   response,	   a	   cell-­‐
mediated	  immune	  response	  against	  CAR+	  T-­‐cells	  was	  also	  detected.	  The	  cell-­‐mediated	  
response	   was	   also	   initiated	   after	   the	   second	   treatment,	   but	   occurred	   before	  
detectable	   HACA	   levels	   could	   be	   measured	   (242).	   Whether	   an	   immune	   response	   is	  
elicited	   against	   the	   mouse	   scFv	   domain	   used	   in	   the	   CAR	   is	   dependent	   its	  
immunogenicity.	  In	  keeping	  with	  this,	  Till	  et	  al.	  used	  a	  mouse	  anti-­‐human	  CD20	  scFv	  as	  
a	  binding	  moiety	  and	  no	   immune	  response	  against	  the	  CAR	  was	  detected	  (327,	  478).	  
However,	  mouse	   scFv	   is	  not	   the	  only	  element	   that	   can	   induce	  an	   immune	   response.	  
Lamers	   et	   al.	   also	   reported	   on	   the	   induction	   of	   an	   immune	   response	   against	   viral-­‐
vector	  immunogenic	  epitopes	  in	  two	  of	  their	  patients	  (242).	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1.4.2 Toxicity	  –	  Common	  to	  Serious	  Adverse	  Events	  
The	   severity	   of	   adverse	   events	   recorded	   in	   Phase-­‐I	   clinical	   trials	   is	   generally	   graded	  
using	   a	   scale	   developed	   by	   the	   National	   Cancer	   Institute	   (NCI).	   The	   ‘common	  
terminology	  for	  adverse	  events’	  (CTCAE)(481)	  distinguishes	  5	  grades	  of	  toxicity.	  Table	  
1-­‐5	  gives	  a	  brief	  definition	  of	  each	  grade	  as	  summarized	  by	  the	  NCI	  (481).	  
	  
Table	  1-­‐5	  Severity	  grades	  for	  adverse	  events	  as	  described	  in	  CTCAE	  version	  4.03	  
Grade	  1	   Mild;	   asymptomatic	  or	  mild	   symptoms;	   clinical	  or	  diagnostic	  observations	  
only;	  intervention	  not	  indicated.	  
Grade	  2	   Moderate;	   minimal,	   local	   or	   non-­‐invasive	   intervention	   indicated;	   limiting	  
age-­‐appropriate	  instrumental	  ADL.	  
Grade	  3	   Severe	   or	   medically	   significant	   but	   not	   immediately	   life-­‐threatening;	  
hospitalization	   or	   prolongation	   of	   hospitalization	   indicated;	   disabling;	  
limiting	  self	  care	  ADL.	  
Grade	  4	   Life-­‐threatening	  consequences;	  urgent	  intervention	  indicated.	  
Grade	  5	   Death	  related	  to	  adverse	  event.	  
A	  semi-­‐colon	  indicates	  ‘or’	  within	  the	  description	  of	  the	  grade.	  ADL	  =	  Activities	  of	  Daily	  Living	  
	  
1.4.2.1 Common	  Adverse	  Events	  
The	   most	   common	   adverse	   events	   reported	   in	   CAR-­‐mediated	   Phase-­‐I	   clinical	   trials	  
include	  fatigue,	  nausea,	  hypotension,	  rigors,	  diarrhoea,	  fevers,	  injection	  site	  reactions,	  
mental	  status	  changes,	  hepatic	  toxicity,	  renal	  failure	  and	  respiratory	  distress	  (304,	  322,	  
327,	  394,	  478,	  479).	  The	  severity	  of	  adverse	  effects	  can	  range	  from	  grade	  1-­‐4.	  In	  CAR-­‐
based	  trials	  in	  which	  IL-­‐2	  was	  also	  administered,	  most	  side	  effects	  resolved	  once	  the	  IL-­‐
2	  treatment	  was	  stopped	  (304,	  327,	  478).	  When	  caused	  by	  T-­‐cell	   transfusion,	  steroid	  
treatment	  could	  ameliorate	  most	  symptoms	  (317).	  In	  several	  cases,	  no	  treatment	  was	  
required	  and	  side-­‐effects	  resolved	  spontaneously	  overnight	  (327).	  	  
	   Hypogammaglobulinemia	   and	   cytopenia	   are	   common	   side	   effects	   due	   to	  
lymphodepleting	   chemotherapy	   and	   CD19	   or	   CD20	   targeting	   treatments	   (311,	   319,	  
322,	   394).	   The	   occurrence	   of	   these	   adverse	   events	   required	   Immunoglobulin	  
replacement	   therapy.	   The	   occurrence	   of	   bacteremia	   and	   pneumonitis	   has	   also	   been	  
reported	  in	  patients	  suffering	  from	  cytopenia	  (394).	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1.4.2.2 ‘On-­‐target	  ’-­‐Toxicity	  
‘On-­‐target’-­‐toxicity	   occurs	   when	   the	   target	   antigen	   expressed	   on	   healthy	   tissue	  
activates	   redirected	   T-­‐cells.	   Lamers	   et	   al.	   reported	   the	   occurrence	   of	   ‘on-­‐target’-­‐
toxicity	  in	  a	  Phase-­‐I	  clinical	  trial	  in	  which	  patients	  with	  metastatic	  renal	  cell	  carcinoma	  
were	   treated	  with	   T-­‐cells	   retargeted	   against	   CAIX.	   Immunohistochemistry	   showed	  T-­‐
cell	   infiltration	   around	  CAIX+	   bile	   duct	   epithelial	   cells,	   suggesting	   a	   specific	   attack	  by	  
CAR+	  cells	  which	  resulted	  in	  clinical	  grade	  3-­‐4	  hepatotoxicity	  (366).	  	  To	  mitigate	  against	  
this	  toxicity,	   low-­‐dose	  anti-­‐CAIX	  mAb	  cG250	  (chimeric	  G250;	  humanized	  mouse	  G250	  
in	  which	  the	  constant	  regions	  of	  the	  heavy	  and	  light	  chains	  have	  been	  substituted	  by	  
their	  human	  analogues)	  treatment	  was	  administered	  prior	  to	  infusion	  of	  the	  T-­‐cells.	  By	  
this	  means,	  it	  was	  possible	  to	  avert	  the	  occurrence	  of	  high-­‐grade	  liver	  toxicity.	  At	  a	  low	  
dose,	  cG250	  blocks	  CAIX	  in	  the	  liver	  cells	  but	  leaves	  it	  accessible	  at	  RCC	  tumour	  sites,	  
owing	  to	  higher	  expression	  at	  the	  tumour	  site	  (242).	  This	  ‘on-­‐target’-­‐toxicity	  does	  not	  
always	  occur	  when	   targeting	   antigens	   that	   are	   also	   expressed	  on	  healthy	   tissue.	   For	  
example,	  Park	  et	  al.	  reported	  no	  toxicity	  against	  L1-­‐CAM	  expressing	  healthy	  tissues	  in	  a	  
CAR	  study	  targeting	  neuroblastoma	  with	  a	  first-­‐generation	  CAR,	  despite	  the	  expression	  
of	  L1-­‐CAM	  on	  healthy	  tissue	  including	  the	  central	  nervous	  system,	  adrenal	  medulla	  and	  
sympathetic	  ganglia	  (394).	  
	  
1.4.2.3 Cytokine	  Release	  Syndrome	  
An	   important	   side	   effect	   that	   may	   complicate	   immune-­‐modulating	   therapies	   is	   the	  
occurrence	   of	   cytokine	   release	   syndrome	   (CRS).	   Clinical	   symptoms	   of	   CRS	   include	  
hypothermia	   or	   fevers,	   rigors,	   hypotension,	   rash,	   dyspnea	   and	   occasionally	  
bronchospasm,	  rash,	  nausea	  and	  diarrhoea.	  More	  severe	  symptoms	  include	  pulmonary	  
oedema,	   hepatitis	   and	  multi-­‐organ	   failure	   (482).	   Severe	   CRS	   is	   also	   referred	   to	   as	   a	  
cytokine	  storm,	  cytokine	  cascade	  or	  hypercytokinemia.	  For	  a	  more	  detailed	  description	  
of	  the	  kinetics	  of	  a	  cytokine	  storm,	  please	  refer	  to	  Chapter	  4.1.	  The	  most	  common	  side	  
effects	  registered	  in	  CAR-­‐mediated	  therapy	  are	  consistent	  with	  the	  occurrence	  of	  CRS.	  
Cytokines	  most	  commonly	  upregulated	  include	  TNF,	  IFNγ,	  IL-­‐6	  and	  IL-­‐10	  (319,	  320,	  327,	  
445).	   The	   increases	   in	   serum	   cytokine	   levels	   have	   been	   connected	   to	   both	   the	  
occurrence	   of	   adverse	   events	   as	   well	   as	   anti-­‐tumour	   efficacy.	   Kochenderfer	   et	   al.	  
showed	   that	  an	  elevation	   in	   serum	   IFNγ	  and	  TNF	   levels	   correlated	  with	  more	   severe	  
toxicity	   (319).	   	   The	   severity	   of	   toxicity	   was	  measured	   over	   a	   period	   of	   10	   days	   and	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quantified	  with	  the	  ‘sequential	  organ	  failure	  assessment’	  (SOFA)	  score.	  The	  SOFA	  score	  
is	  based	  on	  the	  measurements	  of	  blood	  pressure,	  respiratory	  function,	  renal	  function,	  
and	  the	  blood	  platelet	  count	   (483,	  484).	  Patients	  with	  elevated	  cytokine	   levels	  had	  a	  
significantly	  higher	  SOFA	  score	  (mean	  105.0)	  compared	  to	  patients	  without	  an	  increase	  
in	  cytokine	  levels	  (mean	  61.5)	  (319).	  The	  SOFA	  score	  for	  each	  patient	  was	  correlated	  to	  
the	   level	   of	   IFNγ	   and	   TNF	  measured	   over	   time	   (319).	   The	   increased	   cytokine	   levels	  
were	   probably	   not	   caused	   by	   exogenous	   IL-­‐2,	   because	   new	   elevations	   and	   severe	  
toxicity	  also	  occurred	  several	  days	  after	  the	  last	  IL-­‐2	  administration	  (319).	  
	   The	   relationship	   between	   T-­‐cell	   induced	   cytokine	   production,	   toxicity	   and	  
efficacy,	  is	  illustrated	  in	  a	  case	  report	  by	  Porter	  et	  al.	  (445).	  A	  patient	  with	  CLL	  received	  
a	   dose	   of	   3	   x	   108	   total	   T-­‐cells	   (5%	   transduced)	   after	   lymphodepletion	   without	   any	  
additional	  cytokine	  administration.	  Side	  effects	  started	  fourteen	  days	  after	  transfusion	  
and	  progressed	  during	   the	   following	  week.	  Tumour	   lysis	   syndrome	  was	  diagnosed	  at	  
day	   22.	   At	   the	   same	   time,	   the	   peak	   level	   	   (20%)	   of	   CAR+	   T-­‐cells	   in	   the	   blood	   were	  
measured	  as	  well	  as	  peak	  levels	  of	  IFNγ	  and	  IL-­‐6	  (160	  fold	  higher	  than	  base	  level).	  At	  
day	   23,	   there	   was	   no	   detectable	   CLL	   found	   in	   the	   bone	   marrow	   and	   no	  
lymphadenopathy	   evident	   on	   the	   CT	   scan	   at	   day	   31.	   At	   the	   time	   of	   publication,	   the	  
patient	   has	   sustained	   remission	   for	   10	   months	   (445).	   	   This	   relationship	   between	  
efficacy	  and	  CRS	  was	  confirmed	  in	  three	  additional	  patients	  (320).	  There	   is	  a	  delicate	  
balance	  between	  efficacy	  and	  toxicity	  related	  to	  cytokine	  production	  as	   illustrated	  by	  
the	  serious	  adverse	  events	  described	  in	  paragraph	  1.4.2.4.	  Timely	  treatment	  to	  reduce	  
the	   toxicity	   induced	   by	   a	   cytokine	   storm	   is	   required.	   Grupp	   et	   al.	   described	   rapid	  
effects	   after	   anti-­‐cytokine	   therapy	   in	   a	   7-­‐year	   old	   patient	   with	   acute	   lymphoblastic	  
leukaemia.	   The	   patient	   developed	   severe	   CRS	   five	   days	   after	   T-­‐cell	   transfusion,	  
including	   elevated	   levels	   of	   IFNγ	   and	   IL-­‐6.	   The	   patient	   developed	   severe	   respiratory	  
and	  cardiovascular	  compromise.	  Within	  hours	  after	  anticytokine	  therapy,	  consisting	  of	  
Etanercept	  (a	  TNF	  inhibitor)	  and	  Tocilizumab	  (anti-­‐IL-­‐6Rα	  mAb),	  the	  fever	  lowered	  and	  
the	  acute	  respiratory	  distress	  syndrome	  was	  resolved	  (477).	  
	   Brentjens	  et	  al.	  reported	  a	  positive	  correlation	  between	  tumour	  burden	  at	  the	  
time	  of	  T-­‐cell	  administration	  and	  the	  level	  of	  cytokine	  production.	  Additionally,	  tumour	  
burden	  was	  also	  correlated	  to	  the	  amount	  of	  circulating	  CAR+	  T-­‐cells	  and	  the	  expansion	  
of	   CAR+	   T-­‐cells	   (317).	   Patients	   received	   steroid	   treatment	   to	   ameliorate	   cytokine	  
toxicities,	  however	  this	  also	  led	  to	  a	  reduction	  of	  CAR+	  T-­‐cells	  (317).	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1.4.2.4 Serious	  Adverse	  Events	  
To	  date,	  the	  occurrence	  of	  two	  serious	  adverse	  events	  (SAE)	  in	  Phase-­‐I	  trials	  of	  CAR	  T-­‐
cells	   have	   been	   reported.	   Brentjens	   et	   al.	   reported	   an	   SAE	   in	   their	   trial	   treating	   CLL	  
with	   a	   CD19-­‐targeting	   second	   generation	   CAR	   (containing	   CD28	   and	   CD3ζ	   signalling	  
domains)	   (450).	   The	   patient	   underwent	   lymphodepleting	   chemotherapy	   and	   was	  
subsequently	  treated	  with	  a	  dose	  of	  1.2-­‐3.0	  x	  107	  CAR+	  T-­‐cells/kg.	  Three	  prior	  patients	  
had	  been	   treated	  with	   the	  same	  CAR+	  T-­‐cell	  dose,	  without	  prior	   lymphodepletion.	   In	  
these	  patients,	  toxicity	  was	  limited	  to	  rigors,	  chills	  and	  a	  transient	  fever	  within	  the	  first	  
24	   hours	   after	   T-­‐cell	   injection.	  However,	   in	   the	   first	   patient	  who	   received	   additional	  
lymphodepletion,	  the	  fever	  persisted	  and	  was	  associated	  with	  hypotension,	  as	  well	  as	  
respiratory	   distress.	   Additionally,	   the	   patient	   suffered	   from	   acute	   renal	   failure	   and	  
eventually	   died	   44	   hours	   after	   T-­‐cell	   infusion.	   Despite	   the	   occurrence	   of	   this	   SAE	  
shortly	  after	  T-­‐cell	  infusion,	  it	  is	  suggested	  that	  CAR+	  T-­‐cells	  were	  not	  the	  cause	  of	  this	  
toxicity.	   Post-­‐mortem	   pathology	   did	   not	   show	   any	   signs	   of	   tumour-­‐lysis	   syndrome.	  
Serum	   cytokine	   levels	   (IL-­‐2,	   IL-­‐7,	   IL-­‐15	   and	   IL-­‐12)	   were	   increased	   after	  
lymphodepletion,	   TNF	   and	   IFNγ	   levels	   remained	   unchanged	   prior	   to	   and	   after	   T-­‐cell	  
infusion.	   These	   data	   suggest	   that	   the	   patient	   developed	   a	   sepsis-­‐like	   syndrome	  
induced	  by	  a	  prior	  sub-­‐acute	  infection,	  which	  was	  aggravated	  by	  the	  lymphodepletion.	  
In	  response	  to	  the	  SAE,	  the	  administered	  T-­‐cell	  dose	  was	  lowered	  and	  administered	  in	  
split	   infusions	   over	   three	   days.	   Patients	   treated	   with	   the	  modified	   protocol	   did	   not	  
show	  any	  signs	  of	  a	   ‘cytokine	  storm’	   in	  response	  to	   lymphodepletion,	  or	  any	  notable	  
toxicity	  after	  T-­‐cell	  treatment	  (450,	  479).	  
	   The	   second	   SAE	   was	   reported	   by	   Morgan	   et	   al.	   who	   treated	   a	   patient	   with	  
metastatic	   colon	   cancer	   with	   an	   ErbB2-­‐targeted	   third	   generation	   CAR	   (containing	  
CD28,	  4-­‐1BB	  and	  CD3ζ	  signalling	  domains)	  (240).	  The	  patient	  was	  treated	  with	  a	  dose	  
of	   1	   x	   1010	   cells	   (79%	   CAR+)	   after	   administration	   of	   a	   lymphodepleting	   regimen	  
(cyclophosphamide	  and	  flurodarabine).	  Within	  15	  minutes	  after	  T-­‐cell	  administration,	  
the	  patient	  developed	  respiratory	  distress	  caused	  by	  pulmonary	  oedema.	  The	  patient	  
then	   developed	   hypotension	   and	   underwent	   two	   cardiac	   arrests.	   Five	   days	   after	  
treatment,	   progressive	   hypotension,	   bradycardia	   and	   gastrointestinal	   bleeding	  
resulted	  in	  a	  final	  cardiac	  arrest.	  Post-­‐mortem	  pathology	  revealed	  that	  the	  patient	  had	  
multiple	  organ	  failure	  secondary	  to	  systemic	  microangiopathic	  injury.	  Transduced	  cells	  
were	  detected	  predominantly	  in	  the	  lung	  and	  abdominal/mediastinal	  lymph	  nodes	  but	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had	  not	  homed	  to	  tumour	  sites.	  Serum	  cytokine	  levels	  showed	  a	  rapid	  increase	  in	  IFNγ,	  
GM-­‐CSF,	  TNF,	  IL-­‐6	  and	  IL-­‐10.	  All	  cytokines	  except	  IL-­‐10	  peaked	  at	  4	  hours	  after	  infusion	  
and	  decreased	  over	   the	   following	  3	  days.	   Interleukin-­‐10	   levels	   remained	  high	   for	   the	  
entire	  study	  duration.	  An	  increase	  in	  IL-­‐2	  levels	  was	  also	  detected	  at	  4	  hours,	  however	  
this	  was	  likely	  to	  be	  the	  result	  of	  the	  IL-­‐2	  present	  in	  the	  T-­‐cell	  infusion	  product.	  Morgan	  
et	  al.	  postulated	  that	  the	  highly-­‐active	  anti-­‐ErbB2	  redirected	  T-­‐cells	  recognized	  ErbB2	  
expressed	  by	  healthy	  lung	  tissue,	  inducing	  the	  release	  of	  inflammatory	  cytokines.	  This	  
resulted	   in	   pulmonary	   toxicity	   and	   oedema,	   followed	   by	   a	   cascading	   cytokine	   storm	  
and	  resulting	  in	  multiple	  organ	  failure	  (240).	  
	   The	   results	  achieved	   in	  Phase-­‐I	   clinical	   trials	  have	  shown	  the	  potency	  of	  CAR-­‐
mediated	   adoptive	   T-­‐cell	   therapy	   against	   a	   range	   of	   target	   antigen	   and	   tumours.	  
However,	   the	   occurrence	   of	   high-­‐grade	   toxicity	   has	   also	   indicated	   limitations	   to	   the	  
application	   of	   this	   therapy.	   More	   detailed	   investigation	   into	   the	   parameters	  
influencing	   both	   efficacy	   and	   toxicity	   of	   CAR-­‐mediated	   therapy	   is	   essential	   for	   the	  
progression	  and	  wider	  application	  of	  this	  therapy.	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1.5 Aims	  of	  this	  Thesis	  
	  
The	  work	   performed	   by	   Dr	   DM	  Davies	   prior	   to	   the	   commencement	   of	   this	   PhD	   has	  
detailed	  the	  functionality,	  specificity	  and	  efficacy	  of	  T28ζ	  and	  T4,	  both	   in	  vitro	  and	   in	  
vivo	   (299).	   The	   work	   performed	   in	   this	   PhD	   aims	   to	   determine	   the	   safety	   of	   T4	  
immunotherapy,	  in	  pre-­‐clinical	  in	  vitro	  and	  in	  vivo	  models,	  as	  well	  as	  prepare	  for	  first-­‐
in-­‐man	  toxicity	  testing	  in	  a	  phase-­‐I	  clinical	  trial.	  
	  
The	  specific	  aims	  of	  this	  PhD	  project	  include:	  
1. Determine	   the	   suitability	   of	   a	   SCID/Beige	   immunodeficient	  mouse	  model	   for	  
pre-­‐clinical	  toxicity	  testing.	  
2. Determine	   the	   longevity	   and	   migration	   pattern	   of	   human	   transduced	   T-­‐cells	  
after	  intravenous	  and	  subcutaneous	  injection.	  
3. Determine	  the	  risk	  of	  ‘on-­‐target’-­‐toxicity	  in	  vitro	  and	  in	  vivo.	  
4. Determine	   the	   risk	   of	   cytokine	   release	   syndrome	   in	   response	   to	   T4	  
immunotherapy.	  
5. Determine	   the	   functionality	   of	   T4	   immunotherapy	   through	   intra-­‐tumoural	  
administration.	  
6. Development	  of	  a	  GMP-­‐compliant	  production	  process	  for	  a	  phase-­‐I	  clinical	  trial.	  
	  
CHAPTER	  3	  details	  the	  experiments	  investigating	  the	  suitability	  of	  the	  SCID/Beige	  pre-­‐
clinical	  model	  and	  the	  experiment	  undertaken	  to	  investigate	  the	  risk	  of	  ‘on-­‐target	  off-­‐
target’-­‐toxicity.	  CHAPTER	  4	  details	  the	  investigation	  into	  the	  onset	  of	  cytokine	  release	  
syndrome	   after	   intra-­‐peritoneal	   T4	   immunotherapy	   administrations	   and	   the	   factors	  
influential	  to	  the	  onset	  of	  this.	  	  The	  use	  of	  a	  GMP-­‐compliant	  production	  process	  for	  the	  
application	  in	  a	  phase-­‐I	  clinical	  trial	  of	  T4	  immunotherapy	  is	  described	  in	  CHAPTER	  5.	  




CHAPTER	  2 	  
MATERIALS	  AND	  METHODS	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2.1 Molecular	  Biology	  Techniques	  
	  
2.1.1 Generation	  of	  CAR	  Constructs	  
	  
	  
Figure	  2-­‐1	  Schematic	  overview	  of	  the	  ErbB-­‐	  and	  PSMA-­‐targeting	  CARs	  
IL-­‐4Rα:	  Interleukin-­‐4	  Receptor	  α;	  IL-­‐2/15Rβ:	  Interleukin-­‐2/15	  Receptorβ;	  γc:	  common	  γ-­‐chain.	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2.1.1.1 T28ζ	  
The	  ErbB-­‐targeting	  T28ζ	  chimeric	  antigen	  receptor	  (CAR,	  Figure	  2-­‐1)	  was	  produced	  and	  
cloned	   into	   SFG	   prior	   to	   the	   commencement	   of	   this	   PhD	   (299).	   The	   construct	  
comprises	   a	   human	   fusion	   gene	   encoding	   the	  macrophage	   colony	   stimulating	   factor	  
receptor	   (FMS)	   leader	   sequence,	   the	   T1E	   peptide	   (for	   a	   detailed	   description	   please	  
refer	   to	  paragraph	  1.3.11.1)	   (451,	  457),	   the	  partial	  extracellular,	   transmembrane	  and	  
intracellular	   domain	   of	   CD28	   (from	   amino	   acid	   114	   to	   220)	   and	   the	   intracellular	  
domain	   of	   the	   CD3	   zeta	   (CD3ζ)	   chain	   (amino	   acids	   52-­‐164).	   The	   T1E	   peptide	   is	   a	  
chimeric	   fusion	   protein	   composed	   of	   the	   entire	   processed	   human	   EGF	   protein,	  
excluding	   the	   five	   most	   N-­‐terminal	   amino	   acids,	   which	   have	   been	   replaced	   by	   the	  
seven	  most	  N-­‐terminal	  amino	  aids	  of	  the	  mature	  human	  TGF-­‐α	  protein.	  The	  cDNA	  was	  
cloned	  as	  an	  NcoI/XhoI	  fragment	  into	  pre-­‐digested	  SFG-­‐P28ζ	  (403).	  The	  SFG	  retroviral	  
vector	   backbone	   (a	   kind	   gift	   from	   Dr	  M.	   Sadelain,	  Memorial	   Sloan-­‐Kettering	   Cancer	  
Center,	   New	   York)	   contains	   a	   5’	   long	   terminal	   repeat	   (LTR)	   as	   a	   promoter	   and	   a	  




The	  prostate	  specific	  membrane	  antigen	  (PSMA)-­‐targeting	  P28ζ	  CAR	  (see	  Figure	  2-­‐1)	  is	  
a	   second-­‐generation	   CAR	   that	   was	   constructed	   by	   Dr	   J.	   Maher	   prior	   to	   the	  
commencement	   of	   this	   PhD	   (403).	   The	   CAR	   was	   expressed	   using	   the	   SFG	   retroviral	  
expression	  vector.	  The	  binding	  moiety	  of	  P28ζ	  comprises	  of	  an	  scFv	  derived	  from	  the	  
J591	  hybridoma	  (485),	  joining	  the	  VH	  and	  VL	  fragments	  through	  a	  serine/glycine	  linker.	  
The	   transmembrane	   and	   intracellular	   domain	   of	   P28ζ	   comprises	   of	   CD28	   and	   CD3ζ	  
fragments,	  as	  described	  in	  paragraph	  2.1.1.1	  for	  T28ζ.	  Adequate	  expression	  on	  the	  cell	  
membrane	  is	  enabled	  through	  the	  addition	  of	  the	  CD8α	  leader	  sequence	  upstream	  of	  
the	  P28ζ	  sequence	  (in	  contrast	  to	  the	  FMS	  leader	  sequence	  which	  is	  used	  in	  T28ζ).	  
	  
2.1.1.3 4αβ	  
The	   chimeric	   cytokine	   receptor	   4αβ	   (see	   Figure	   2-­‐1)	   is	   a	   fusion	   of	   the	   IL-­‐4Rα	  
ectodomain	   (amino	   acids	   1-­‐233)	   to	   the	   shared	   IL-­‐2/15Rβ	   transmembrane	   and	  
endodomain	  (amino	  acids	  241-­‐551)	  (391).	  The	  construct	  was	  design	  by	  Dr	  SE	  Papa	  and	  
Dr	  S	  Wilkie	  prior	  to	  the	  commencement	  of	  this	  PhD.	  The	  4αβ	  sequence	  was	  designed	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as	  a	  NcoI/NcoI	   fragment	  to	  allow	  for	  cloning	  upstream	  of	  any	  selected	  CAR.	  The	  4αβ	  
sequence	   was	   followed	   by	   an	   optimised	   furin	   cleavage	   site	   (RRKR)(486),	   a	   serine	  
glycine	   linker,	   and	   a	   T2A	   sequence	   (detailed	   in	   paragraph	   2.1.1.4).	   The	   stop	   codon	  
form	   the	   4αβ	   gene	   sequence	   is	   omitted	   prior	   to	   the	   T2A	   sequence	   to	   ensure	   full	  
expression	  of	  the	  3’	  gene.	  
	  
2.1.1.4 T4	  
The	   T4	   (T28ζ	   +	   4αβ)	   vector	   construct	   (see	   Figure	   2-­‐1)	   was	   produced	   prior	   to	   the	  
commencement	   of	   this	   PhD	   by	   Dr	   Davies	   (299).	   The	   construct	   is	   defined	   by	   the	   co-­‐
expression	   of	   the	   T28ζ	   CAR	   with	   the	   chimeric	   cytokine	   receptor	   4αβ	   (391).	   Dual	  
expression	  of	  both	  proteins	  using	  the	  same	  promoter	  was	  achieved	  by	  the	  inclusion	  of	  
a	   self-­‐cleaving	   2A	  peptide	   sequence	   between	   the	   4αβ	   and	   T28ζ	   coding	   regions.	   This	  
peptide,	  derived	  from	  the	  insect	  virus	  Thosea	  asigna	  (and	  therefore	  referred	  as	  a	  T2A	  
sequence	   (487,	   488)	   permits	   dual	   polypeptide	   expression	   from	   the	   same	   mRNA	  
molecule	   by	   inducing	   a	   ribosomal	   ‘skip’,	   in	   which	   a	   peptide	   bond	   between	   the	   two	  
constructs	  is	  ‘missed’	  (489).	  To	  ensure	  full	  expression,	  the	  stop	  codon	  at	  the	  3’	  end	  of	  
the	  4αβ	  sequence	  has	  been	  removed.	  Furthermore,	  to	  reduce	  the	  inclusion	  of	  the	  T2A	  
sequence	   at	   the	   C-­‐terminal	   end	   of	   the	   4αβ	   construct,	   a	   furin	   cleavage	   site	   was	  
introduced	  5’	   of	   the	   T2A	   sequence	   (see	   Figure	  2-­‐2)	   Construction	  of	   T4	   into	   SFG	  was	  
achieved	  through	  the	  insertion	  of	  the	  NcoI-­‐flanked	  4αβ	  and	  T2A	  sequence	  at	  the	  NcoI	  
site	  upstream	  of	  T28ζ.	  
	  
2.1.1.5 P4	  
The	  P4	  (P28ζ	  and	  4αβ)	  vector	  construct	  (see	  Figure	  2-­‐1)	  was	  produced	  by	  Dr	  Papa	  prior	  
to	   the	   commencement	   of	   this	   PhD.	   The	   P28ζ	   CAR	   has	   a	   naturally	   occurring	   NcoI	  
restriction	  site	  within	  the	  J591	  scFV,	  making	  it	   impractical	  to	  insert	  the	  4αβ-­‐furin-­‐T2A	  
cassette	  upstream	  of	  P28ζ	  as	  an	  NcoI	   fragment.	  Consequently,	  an	  alternative	  cloning	  
strategy	  was	  devised.	  Both	  the	  HOX	  (a	  Muc-­‐1	  targeting	  third	  generation	  receptor)(305)	  
CAR	  and	  P28ζ	  have	  a	  CD8α	  leader	  sequence	  at	  their	  5’	  end.	  There	  is	  an	  SphI	  restriction	  
site	  within	  the	  CD8α	  leader,	  which	  is	  not	  replicated	  in	  either	  SFG-­‐P28ζ	  or	  H4	  (HOX	  co-­‐
expressed	  with	  4αβ)	   (391).	  Consequently,	   SFG-­‐P28ζ	  was	  digested	  with	  SphI/XhoI	  and	  
the	   smaller	   (CAR-­‐encoding)	   cDNA	   fragment	   was	   substituted	   for	   the	   corresponding	  
sequence	  in	  SFG-­‐H4,	  thereby	  generating	  SFG-­‐P4	  (see	  Figure	  2-­‐2).	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Figure	  2-­‐2	  Schematic	  representation	  of	  P4	  and	  T4	  within	  SFG	  
Within	   the	   P4	   and	   T4	   combinations,	   the	   coding	   sequences	   are	   separated	  by	   the	   T2A	  peptide	  derived	  
from	   the	  Thosea	   asigna	   plant	   virus,	  which	   induces	   a	   ribosomal	   ‘skip’	   and	   therefore	  misses	   a	   peptide	  
bond	  between	  the	  flucine	  and	  proline	  (as	  indicated	  by	  the	  right	  scissors).	  Expression	  of	  the	  T2A	  peptide	  
sequence	  at	  the	  C-­‐terminus	  of	  the	  mature	  4αβ	  protein	  is	  prevented	  by	  the	  presence	  of	  a	  furin	  cleavage	  
site	  (as	   indicated	  by	  the	   left	  scissors).	  The	  Furin	  cleavage	  site	   is	   linked	  to	  the	  T2A	  peptide	  by	  a	  serine-­‐
glycine	   linker.	  LTR:	   long	  terminal	   repeat;	  SD:	  splice	  donor;	  ψ:	  packaging	  signal;	  SA:	  splice	  acceptor;	  ★:	  
FMS	   leader	   sequence;	  :	   CD8α	   leader	   sequence.	  Note:	   size	  of	   the	  blocks	   is	   not	   representative	  of	   the	  
sizes	  of	  the	  individual	  elements.	  
	  
2.1.1.6 T4luc	  
The	  T4luc	  (T28ζ	  +	  4αβ	  +	  fireflyLuciferase)	  construct	  is	  defined	  by	  the	  co-­‐expression	  of	  
the	   T4	   construct	   with	   the	   gene	   encoding	   for	   the	   firefly	   Luciferase	   (ffLuc)	   enzyme.	  
Expression	  of	  all	  three	  elements	  is	  achieved	  with	  the	  insertion	  of	  a	  second	  T2A	  peptide	  
and	   furin	  cleavage	  site,	   separating	   the	  T28ζ	  protein	   from	  the	   ffLuc	  enzyme.	  To	  avoid	  
the	   introduction	  of	  a	   large	  direct	   repeat,	   that	  would	  promote	  proviral	   instability,	   the	  
DNA	  sequence	  of	  the	  second	  T2A	  sequence	  was	  made	  as	  different	  as	  possible	  from	  the	  
first	  T2A	  sequence.	  The	  ffLuc	  sequence	  was	  cloned	  into	  the	  SFG-­‐T4	  retroviral	  vector	  by	  
means	  of	  a	  four-­‐piece	  ligation	  (see	  Figure	  2-­‐3).	  	  The	  SFG-­‐T4	  plasmid	  was	  digested	  with	  
NotI/XhoI	   to	   isolate	   the	   SFG	   backbone	   and	   the	   majority	   of	   the	   T4	   sequence.	   The	  
pBabe-­‐puro-­‐ffLuc	   plasmid	  was	   digested	  with	  NcoI/AgeI,	   isolating	   the	  majority	   of	   the	  
ffLuc	   sequence	   (base	   53-­‐1186).	   Two	   linker	   peptides	  were	   designed	   by	   Dr	   Papa,	   and	  
synthesized	  by	  GenScript	  (Piscataway,	  New	  Jersey)	  to	  replace	  the	  removed	  bases	  from	  
T4	   and	   ffLuc.	   The	   pUC47-­‐ffLuc	   plasmid	   was	   digested	   with	   two	   separate	   digestions,	  
NotI/NcoI	  and	  AgeI/XhoI,	  isolating	  the	  two	  linker-­‐peptides.	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Figure	  2-­‐3	  Schematic	  representation	  of	  cloning	  strategy	  of	  SFG-­‐T4luc	  
The	   T4luc	   construct	  was	   cloned	   by	  means	   of	   a	   four-­‐piece	   ligation.	   (1)	   The	   partial	   T28ζ	   sequence	  was	  
removed	   from	  the	  SFG-­‐T4	  vector	   through	  NotI/XhoI	  digestion.	   (2)	  The	   removed	  partial	  T28ζ	   sequence	  
combined	  with	  a	  second	  T2A	  sequence	  and	  furine	  cleavage	  site,	  flanked	  by	  NotI/NcoI	  was	  generated	  by	  
GenScript	  as	  well	  as	  a	  3’	  sequence	  element	  of	  ffLuc,	  flanked	  by	  AgeI/XhoI.	  (3)	  The	  partial	  ffLuc	  sequence	  
was	  removed	  from	  pUC47-­‐ffLuc	  by	  means	  of	  NcoI/AgeI	  digestion.	  (4)	  The	  four	  elements	  resulting	  from	  
the	  digestions	  performed	   in	  1-­‐3	  are	   ligated	  together	   to	   form	  SFG-­‐T4luc.	  Note:	  size	  of	   the	  blocks	   is	  not	  
representative	  of	  the	  sizes	  of	  the	  individual	  elements.	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2.1.2 Production	  of	  New	  Vectors	  and	  Constructs	  using	  Restriction	  Enzyme	  Digestion	  
The	   production	   of	   the	   CAR	   constructs	   required	   DNA	   digestion	   with	   restriction	  
enzymes.	   Additionally,	   restriction	   patterns	   were	   used	   to	   accurately	   verify	   plasmid	  
inserts.	   Digestion	   was	   performed	   in	   the	   presence	   of	   buffers	   designed	   to	   optimize	  
enzyme	  efficiency.	  
	  
2.1.2.1 Materials,	  Reagents	  and	  Equipment	  
  Restriction	  enzymes	   New	  England	  Biolabs	  (NEB)	  
  10x	  Enzyme	  buffer	   NEB	  
  100x	  Bovine	  Serum	  Albumin	  (BSA)	  where	  
required	  
NEB	  
  Nuclease	  Free	  H2O	   BioLine	  
  DNA	  Template	   	  
  Eppendorf	  Mastercycler	  Gradient	  PCR	  Machine	   Eppendorf	  
  Ice	   	  
 
2.1.2.2 Protocol	  
1. A	  20μL	  reaction	  mixture,	  as	  detailed	  below	  for	  a	  double	  digest,	  was	  produced.	  All	  
components	  were	  kept	  at	  4°C	  throughout	  
 XμL	  (0.5-­‐1.0μg)	  DNA	  Template	  a.
 XμL	  Nuclease	  Free	  H2O	  b.
 2μL	  NEB	  Buffer	  c.
 10-­‐20U	  Enzyme	  1	  d.
 10-­‐20U	  Enzyme	  2	  e.
 1μL	  1	  in	  10	  diluted	  BSA	  f.
NOTE:	   in	   reactions	   requiring	   a	   single	   enzyme,	   the	   20μL	   reaction	   volume	   was	  
achieved	  using	  additional	  ultrapure	  water.	  For	  sequential	  digests,	  a	  20μL	  reaction	  
containing	   the	   first	   enzyme	   only	  was	   produced.	   The	   second	   enzyme	   (1.2μL)	   and	  
buffer	  (3μL)	  were	  added	  after	  completion	  of	  the	  first	  incubation.	  When	  performing	  
these	   sequential	  digests,	   the	  enzyme	   requiring	   the	  buffer	   containing	  a	   lower	   salt	  
concentration	  was	   used	   in	   the	   first	   reaction.	   For	   very	   dilute	   DNA	   samples,	   50μL	  
reaction	   volumes	   were	   used,	   with	   the	   volume	   of	   individual	   components	   altered	  
accordingly.	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2. Reaction	   mixtures	   were	   incubated	   for	   one	   hour	   in	   a	   PCR	   machine	   at	   the	  
temperature	   required	   for	   optimal	   enzyme	   activity.	   For	   sequential	   digests	   using	  
enzymes	  with	  differing	  optimal	  temperatures,	  the	  reaction	  mixture	  was	  cooled	  on	  
ice	  prior	  to	  incubation	  at	  the	  second	  temperature.	  
3. Once	  completed,	  an	  18μL	  aliquot	  of	  each	  reaction	  was	  mixed	  with	  3μL	  DNA	  loading	  
buffer	   (Buffers	  and	  solutions	  paragraph	  2.1.3.1)	  and	  separated	  by	  electrophoresis	  
on	  an	  agarose	  gel	  (please	  refer	  to	  paragraph	  2.1.3).	  
	  
2.1.3 Isolation	  of	  DNA	  Fragments	  using	  Agarose	  Gel	  Electrophoresis	  
Separation	   of	   DNA	   fragments	   was	   achieved	   using	   agarose	   gel	   electrophoresis.	   The	  
constant	  mass	  to	  charge	  ratio	  of	  DNA	  molecules	  means	  that	  separation	  is	  determined	  
by	  fragment	  size.	  Migration	  rates	  are	  therefore	  influenced	  by	  the	  pore	  size	  of	  the	  gel,	  
which	   in	   turn	   is	   determined	   by	   the	   agarose	   concentration	   (see	   Table	   2-­‐1).	  
Consequently,	   careful	   selection	   of	   the	   percentage	   of	   agarose	   used	   ensured	   optimal	  
resolution	  of	  the	  fragments	  of	  interest.	  
	  
Table	   2-­‐1	   Agarose	   concentrations	   required	   to	   achieve	   separation	   of	   specific	   DNA	  
fragments	  
Agarose	  (%	  w/v)	   Range	  of	  Separation	  (kb)	  
0.5	   0.7-­‐25	  
0.8	   0.5-­‐15	  
1.0	   0.25-­‐12	  
1.2	   0.15-­‐6	  
1.5	   0.08-­‐4	  
Adapted	  from	  Table	  5-­‐2,	  page	  5.6	  reference	  (490).	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2.1.3.1 Materials,	  Reagents	  and	  Equipment	  
  Electrophoresis	  grade	  Agarose	   MP	  Biomedicals	  
  TBE	  Buffer	   (please	  see	  below)	  
  Ethidium	  Bromide	   Sigma-­‐Aldrich	  
  DNA	  Loading	  Buffer	   (please	  see	  below)	  
  1kb	  DNA	  Ladder	   Invitrogen	  
  Gel	  Mould	   Biorad	  
  Gel	  Comb	   Biorad	  
  Balance	   Mettler	  Toledo	  
  Gel	  Tank	   Life	  Technologies	  
  Power	  Pack	   Kingshill	  
  Microwave	  Oven	   Proline	  
  UV	  Transilluminator	   UVI	  Tech	  
  TV	  Zoom	  Lens	   Avenir	  
  P90	  Thermal	  Monochrome	  Printer	   Mitsubishi	  
	  
Buffers	  and	  solutions:	  
10x	  TBE	  =	  108g	  Tris-­‐base,	  55g	  boric	  acid,	  9.3g	  EDTA	  in	  1L	  deionised	  water	  
6x	  DNA	  Loading	  Buffer	  =	  Distilled	  water,	  40%	  (w/v)	  sucrose,	  0.25%	  (w/v)	  bromophenol	  
blue,	  0.25%	  (w/v)	  xylene	  cyanol.	  
	  
2.1.3.2 Protocol	  
NOTE:	  The	  protocol	  described	  below	  is	  for	  the	  production	  of	  a	  1%	  100mL	  agarose	  gel.	  
The	  weight	  of	  agarose	  used	  and	  the	  volume	  of	  TBE	  into	  which	  it	  was	  dissolved	  differed	  
depending	  upon	  the	  size	  and	  percentage	  of	  the	  gel	  required.	  
	  
1. One	  gram	  of	   agarose	  was	  mixed	  with	   100mL	  1x	   TBE	   and	  heated	   in	   a	  microwave	  
oven	  (with	  regular	  agitation)	  until	  completely	  dissolved.	  
2. After	  cooling	  under	  cold	  running	  water	  to	  37°C,	  0.30μg/mL	  ethidium	  bromide	  was	  
added	  and	  the	  mixture	  swirled	  vigorously	  to	  ensure	  even	  distribution	  without	  the	  
introduction	  of	  air	  bubbles.	  
3. The	  gel	  was	  poured	  into	  a	  pre-­‐cast	  mould,	  a	  comb	  inserted	  and	  left	  to	  set	  at	  room	  
temperature.	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4. Prior	  to	  loading,	  samples	  were	  mixed	  5:1	  with	  6x	  DNA	  loading	  buffer.	  In	  addition	  to	  
the	   samples,	   a	   1kb	   DNA	   ladder	   was	   loaded	   to	   allow	   the	   size	   of	   migrating	   DNA	  
fragments	  to	  be	  estimated.	  
5. Once	  loaded,	  the	  gel	  was	  run	  at	  5-­‐8V/cm	  until	  sufficient	  migration	  (as	  visualized	  by	  
the	  loading	  dye)	  had	  occurred.	  
6. The	  DNA	  was	  visualized	  with	  UV	  light	  at	  154nm	  using	  a	  UV	  transilluminator.	  Images	  
were	  taken	  using	  a	  TV	  zoom	  lens	  and	  thermal	  monochrome	  printer.	  
 
NOTE:	  In	  instances	  when	  the	  DNA	  was	  required	  for	  further	  manipulation,	  the	  level	  of	  
UV	  exposure	  was	  minimized	  to	  reduce	  the	  risk	  of	  mutagenesis.	  
	  
2.1.4 Retrieval	  of	  DNA	  from	  Agarose	  Gel	  
DNA	   fragments	   are	   isolated	   from	   agarose	   gel	   to	   enable	   their	   insertion	   into	   a	   viral	  
vector.	   Isolation	   of	   the	   DNA	   relies	   its	   ability	   to	   bind	   the	   silica	   membrane	   of	   a	  
purification	  column	  in	  the	  presence	  of	  chaotropic	  salt.	  The	  DNA	  is	  subsequently	  eluted	  
following	  the	  replenishment	  of	  the	  hydration	  gell	  upon	  the	  addition	  of	  water.	  
	  
2.1.4.1 Materials,	  Reagents	  and	  Equipment	  
  Wizard	  SV	  Gel	  and	  PCR	  CleanUp	  System	   Promega	  
  Water	  Bath	   	  
  Eppendorf	  5415R	  Microcentrifuge	   Eppendorf	  
  1.5mL	  Eppendorfs	   Greiner	  Bio-­‐One	  
  Vortex	   Rotormixer	  
  Scalpel	   Swann	  Morton	  Ltd	  
  Balance	   Mettler	  Toledo	  
  UV	  Transilluminator	   UVI	  Tech	  
	  
Buffers	  and	  Solutions:	  
Membrane	  Binding	  Solution	  (MBS)	  =	  4.5M	  guanidine	   isothiocyanate,	  0.5M	  potassium	  
acetate	  (pH	  5.0)	  
Membrane	  Wash	  Solution	   (MWS)	  =	  10mM	  potassium	  acetate	   (pH	  5.0),	  80%	  ethanol,	  
16.7μM	  EDTA	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2.1.4.2 Protocol	  
1. The	  location	  of	  the	  required	  DNA	  fragment	  was	  visualised	  with	  UV	  light	  at	  254nm	  
using	  a	  UV	  transilluminator.	  
2. The	  required	  DNA	  band	  was	  excised	  from	  the	  gel	  using	  a	  sterile	  scalpel	  and	  placed	  
into	  a	  nuclease-­‐free	  1.5mL	  Eppendorf	  tube.	  
3. The	   gel	   fragment	   was	   weighed	   and	   submerged	   in	   the	   required	   volume	   of	  
membrane	   binding	   solution	   (MBS,	   v/w	   1μL/1mg)	   and	   incubated	   at	   54°C	   with	  
frequent	  vortexing	  until	  the	  gel	  had	  completely	  melted.	  
4. The	   resulting	   mixture	   was	   added	   to	   the	   silica	   membrane	   within	   a	   purification	  
column	  and	  centrifuged	  at	  10.700g	  for	  one	  minute	  in	  a	  microcentrifuge.	  
5. The	   eluate	   was	   discarded	   and	   the	   column	   washed	   with	   700μL	   membrane	   wash	  
solution	  prior	  to	  centrifugation	  for	  one	  minute	  at	  10,700g.	  
6. The	   eluate	   was	   discarded,	   the	   column	   washed	   with	   500μL	   membrane	   wash	  
solution	  and	  subsequently	  centrifuged	  for	  five	  minutes	  at	  10,700g.	  
7. Following	  an	  additional	  dry	  centrifugation	  step,	  the	  DNA	  bound	  to	  the	  membrane	  
was	  eluted	  by	  the	  addition	  of	  nuclease-­‐free	  water	  and	  centrifugation	  at	  10,7000g.	  
A	   one-­‐minute	   incubation	   step	   at	   room	   temperature	   was	   performed	   prior	   to	  
centrifugation	  to	  ensure	  complete	  dissociation	  of	  the	  DNA	  from	  the	  membrane.	  
	  
2.1.5 Calf	  Intestinal	  Alkaline	  Phosphatase	  Treatment	  
Calf	   Instestinal	   Alkaline	   Phosphatase	   (CIP)	   catalyzes	   the	   removal	   of	   5´	   phosphate	  
groups	   from	   DNA,	   RNA,	   ribo-­‐	   and	   deoxyribonucleoside	   triphosphates.	   Since	   CIP-­‐
treated	  fragments	  lack	  the	  5´phosphoryl	  termini	  required	  by	  ligases,	  they	  cannot	  self-­‐
ligate.	   This	   property	   can	   be	   used	   to	   decrease	   the	   vector	   background	   in	   cloning	  
strategies	  (490).	  
	  
2.1.5.1 Materials,	  Reagents	  and	  Equipment	  
  CIP	  (10,000U/mL)	   NEB	  
  DNA	  template	   NEB	  
  Nuclease	  Free	  H2O	   BioLine	  
  Ice	  	   	  
  Techne	  Dri-­‐block	  DB2A	   Techne	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2.1.5.2 Protocol	  
NOTE:	  All	  steps	  of	  the	  procedure	  (except	  for	  the	  incubations)	  were	  performed	  on	  ice	  
1. The	  CIP	  was	  diluted	  1/30	  in	  nuclease	  free	  H2O	  to	  a	  final	  concentration	  of	  0.3U/μL	  
2. For	   each	   1μg	   of	   DNA	   template	   (from	   a	   previously	   performed	   restriction	   digest),	  
0.5U	  CIP	  were	  added.	  
3. The	  mixture	  was	  incubated	  at	  37°C	  for	  45	  minutes.	  
4. Optional:	   CIP	   was	   incompletely	   inactivated	   by	   incubating	   the	   sample	   for	   30	  
minutes	   at	   65°C.	   	   Because	   CIP	   cannot	   be	   completely	   heat	   inactivated,	   further	  
processing	  of	  the	  sample	  was	  required	  immediately.	  
5. The	  appropriate	  amount	  of	  6x	   loading	  buffer	  was	  added	  and	  the	  sample	  was	  run	  
on	  an	  agarose	  gel.	  
	  
2.1.6 Fragment	  Insertion	  using	  DNA	  Ligation	  
New	  DNA	  fragments	  were	   inserted	   into	  a	   linearised	  vector	  backbone	  using	  a	   ligation	  
reaction.	  
	  
2.1.6.1 Materials,	  Reagents	  and	  Equipment	  
  T4	  DNA	  Ligase	   NEB	  
  10x	  T4	  DNA	  Ligase	  Buffer	   NEB	  
  Nuclease-­‐Free	  Water	   Promega	  
  Eppendorf	  mastercycler	  Gradient	  PCR	  Machine	   Eppendorf	  
  0.5mL	  Eppendorfs	   Greiner	  Bio-­‐One	  
	  
2.1.6.2 Protocol	  
1. A	   20μL	   ligation	  mixture,	   as	   detailed	   below,	  was	   produced.	   The	   example	   given	   is	  
representative	  of	  a	  three-­‐piece	  ligation.	  
a. Xμg	  DNA	  Backbone	  
b. Xμg	  Fragment	  1	  
c. Xμg	  Fragment	  2	  
d. 2μL	  10x	  DNA	  Ligase	  Buffer	  
e. 2μL	  (4000	  cohesive	  end	  units)	  DNA	  Ligase	  
f. XμL	  Nuclease	  free	  water	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NOTE:	   For	   reactions	   requiring	   ligation	   of	   fewer	   or	   more	   fragments,	   the	   volume	   of	  
nuclease	  free	  water	  was	  altered	  to	  ensure	  a	  final	  reaction	  volume	  of	  20μL.	  
	  
2. The	   reaction	   was	   incubated	   overnight	   at	   15°C	   in	   the	   Eppendorf	   mastercycler	  
Gradient	  PCR	  Machine.	  	  
	  
2.1.7 Analysis	  of	  DNA	  Concentration	  
The	   concentration	   of	   DNA	  was	  measured	   using	   the	  Nanodrop	  ND-­‐1000	   system.	   The	  
Nanodrop	   is	   a	   full-­‐spectrum	   (220-­‐750nm)	   spectrophotometer	   that	   can	   assay	   1μL	  
samples.	   The	   sample	   is	   pipetted	   onto	   the	   end	   of	   a	   fibre	   optic	   cable	   (the	   receiving	  
fibre).	  A	  second	   fibre	  optic	  cable	   (the	  source	   fibre)	   is	   then	  brought	   into	  contact	  with	  
the	   liquid	   sample	   causing	   the	   liquid	   to	  bridge	   the	  gap	  between	   the	   fibre	  optic	   ends.	  
The	   gap	   is	   controlled	   to	   both	   1mm	   and	   0.2mm	   paths.	   A	   pulsed	   xenon	   flash	   lamp	  
provides	   the	   light	   source	   and	   a	   spectrometer	   utilizing	   a	   linear	   CCD	   array	   is	   used	   to	  
analyse	  the	  light	  after	  passing	  through	  the	  sample.	  
	  
2.1.7.1 Materials,	  Reagents	  and	  Equipment	  
 	  Nuclease	  Free	  H2O	   BioLine	  
 	  Elution	  Buffer	   Qiagen	  
 	  Nanodrop	  ND-­‐1000	   Thermo	  Scientific	  
	  
2.1.7.2 Protocol	  
1. The	  Nanodrop	  is	  equilibrated	  using	  1μL	  nuclease	  free	  H2O.	  
2. Blank	  measurement	  is	  made	  using	  1μL	  of	  elution	  buffer.	  
3. 1μL	  of	  DNA	  is	  added	  to	  the	  Nanodrop.	  
4. The	  DNA	  concentration	  is	  directly	  calculated	  by	  the	  Nanodrop	  software	  and	  given	  
in	  ng/μL,	  using	  the	  measured	  absorbance	  and	  the	  Beer-­‐Lambert	  equation.	  
a. Absorbance	  	  =	  -­‐log(intensitysample/intensityblank)	  
b. The	  Beer-­‐Lambert	  equation	   is	  used	  to	  correlate	  the	  calculated	  absorbance	  
with	  concentration:	  
A	  =	  E	  *	  b	  *	  c	  
A	  =	  the	  absorbance	  represented	  in	  absorbance	  units	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E	  =	   the	  wavelength-­‐dependent	  molar	  absorptivity	  coefficient	  with	  units	  of	  
litre/mol-­‐cm	  
b	  =	  path	  length	  in	  cm	  
c	  =	  analyte	  concentration	  in	  moles/litre	  or	  molarity	  
	  
2.1.8 Production	  of	  Chemically	  Competent	  Escherichia	  Coli	  TOP10F’	  
Competent	   Escherichia	   Coli	   (E.	   Coli)	   TOP10F’	   are	   required	   for	   the	   replenishment	   of	  
plasmid	  stocks	  and	  selection	  of	  newly	  produced	  vectors.	  
	  
2.1.8.1 Materials,	  Reagents	  and	  Equipment	  
 	  TOP10F’	  E.	  Coli	   Invitrogen	  
 	  Agar	   Fisher	  Scientific	  
 	  Luria-­‐Broth	  (L.Broth)	   Fisher	  Scientific	  
 	  100%	  Ethanol	  (EtOH)	   Fisher	  Scientific	  
 	  0.3M	  Potassium	  Acetate	  (CH3CO2K)	   Sigma	  Aldrich	  
 	  1M	  Rubidium	  Chloride	  (RbCl)	   Sigma	  Aldrich	  
 	  0.1M	  Calcium	  Chloride	  (CaCl2)	   Sigma	  Aldrich	  
 	  0.5M	  Manganese	  Chloride	  (MnCl2)	   Sigma	  Aldrich	  
 	  0.2M	  Acetic	  Acid	  (C2H4O2)	   Sigma	  Aldrich	  
 	  1M	   3-­‐(N-­‐Morpholino)-­‐propanesulfonic	   acid	  	  
(MOPS)	  
Sigma	  Aldrich	  
 	  0.75M	  Calcium	  Chloride	  (CaCl2)	   Sigma	  Aldrich	  
 	  Potassium	  Hydroxide	  (KOH)	   Sigma	  Aldrich	  
 	  Distilled	  water	   	  
 	  Glycerol	   Fisher	  Scientific	  
 	  Oven	  set	  at	  37°C	   GenLab	  Ltd	  
 	  Bunsen	  burner	   	  
 	  Sorvall	  RC	  6+	  centrifuge	   Thermo	  Scientific	  
 	  14mL	  snap-­‐cap	  tubes	   BD	  Pharmingen	  
 	  Excella	  E25	  shake	  incubator	   New	  Brunswick	  Scientific	  
 	  Spectrophotometer	  UVI	  mini	  1240	   Shimadzu	  
 	  0.22μM	  vacuum	  filtration	  system	   TPP	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 	  Corex	  tubes	   Kendro	  Laboratory	  Products	  
 	  Ice	   	  
 	  Dry	  ice	   	  
	  
2.1.8.2 Protocol	  
NOTE:	  amounts	  mentioned	  are	  for	  1	  picked	  colony	  
1. Frozen	  TOP10F’	  E.	  Coli	  were	  streaked	  onto	  an	  agar	  plate	  in	  a	  zig-­‐zag	  pattern	  and	  
incubated	  overnight	  at	  37°C.	  
2. A	  single	  colony	  was	  picked	  and	  inoculated	  in	  5mL	  L.Broth	  and	  cultured	  overnight	  at	  
37°C	  at	  225rpm	  (Excella	  E25	  shake	  incubator).	  
3. The	  5mL	  L.Broth	  culture	  was	  transferred	  to	  100mL	  L.Broth	  and	  cultured	  at	  37°C,	  
225rpm	  for	  1-­‐2	  hours.	  The	  bacteria	  were	  allowed	  to	  grow	  to	  OD550	  =	  0.4-­‐0.6	  
(preferably	  around	  0.48)	  
4. Cells	  were	  chilled	  on	  ice	  for	  5	  minutes.	  
5. Cells	  were	  pelleted	  by	  centrifugation	  at	  6000g	  for	  5min	  at	  4°C	  in	  pre-­‐chilled	  corex	  
tubes.	  
6. The	  pelleted	  cells	  were	  resuspended	  in	  40mL	  TbfI	  buffer:	  
 TbfI	  buffer:	  a.
 30mM	  potassium	  acetate	  
 100mM	  rubidium	  chloride	  
 10mM	  calcium	  chloride	  
 50mM	  manganese	  chloride	  
• pH	  was	  adjusted	  to	  5.8	  using	  0.2M	  acetic	  acid	  
• Volume	  was	  made	  up	  to	  85mL	  using	  distilled	  water	  
 Buffer	  was	  filtered	  sterile	  prior	  to	  addition	  of	  15mL	  sterile	  glycerol	  
7. Cells	  were	  chilled	  on	  ice	  for	  15	  minutes.	  
8. Cells	  were	  pelleted	  at	  6000g	  for	  5min	  at	  4°C.	  
9. Cells	  were	  resuspended	  in	  4mL	  TbFII	  buffer	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 TbfII	  buffer:	  b.
 10mM	  MOPS	  
 75mM	  calcium	  chloride	   	   	  
 10mM	  rubidium	  chloride	  
• pH	  was	  adjusted	  to	  6.5	  using	  KOH	  
• Volume	  was	  made	  up	  to	  85mL	  using	  distilled	  water	  
 Buffer	  was	  filtered	  sterile	  prior	  to	  addition	  of	  15mL	  sterile	  glycerol	  
10. Cells	  were	  left	  on	  ice	  for	  15	  minutes.	  
11. Aliquots	  of	  100μL	  were	  snap	  frozen	  on	  dry	  ice	  and	  stored	  at	  -­‐80°C	  until	  further	  use.	  	  
	  
2.1.9 Transformation	  of	  Escherichia	  Coli	  TOP10F’	  
Replenishment	   of	   plasmid	   stocks	   and	   selection	   of	   newly	   produced	   vectors	   was	  
achieved	   by	   introducing	   the	   plasmid	   into	   chemically	   competent	   E.	   Coli.	   All	   steps	  
followed	   common	   microbiological	   practice,	   using	   a	   Bunsen	   burner	   to	   provide	   the	  
sterile	  vacuum.	  
	  
2.1.9.1 Materials,	  Reagents	  and	  Equipment	  
 	  TOP10F’	  E.	  Coli	   	  
 	  Plasmid	  DNA	   	  
 	  Agar	  Plates	   	  
 	  Super	  Optimal	  broth	  with	  Catabolite	  repression	  (SOC)	  media	   Invitrogen	  
 	  Glucose	   BDH	  
 	  Water	  Bath	   	  
 	  Ice	   	  
 	  Oven	  set	  at	  37°C	   Genlab	  Ltd	  
 	  Bunsen	  Burner	   	  
 	  Excella	  E-­‐25	  shake	  incubator	   	  
 	  Eppendorf	  5415R	  refrigerated	  Microcentrifuge	   Eppendorf	  
 	  Glass	  spreaders	   	  
 	  100%	  Ethanol	   Fisher	  Scientific	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Buffers	  and	  solutions:	  
1L	   SOC	  Media	  =	  20g	  bacto	   tryptone,	   5g	  bacto	   yeast	   extract,	   10mM	  Sodium	  Chloride	  
(NaCl),	   2.5mM	  potassium	  Chloride	   (KCl),	   10mM	  Magnesium	  Chloride	   (MgCl2),	   10mM	  
Magnesium	  Sulphate	  (MgSO4),	  20mM	  Glucose.	  
	  
2.1.9.2 Protocol	  
1. One	  vial	  of	  E.	  Coli	  was	  thawed	  on	  ice.	  
2. 1μg	  Plasmid	  DNA	  was	  added	  to	  the	  E.	  Coli	  and	  incubated	  for	  30	  minutes	  on	  ice.	  
3. Bacteria	  were	  heat	  shocked	  at	  42°C	  for	  90	  seconds	  and	  subsequently	  incubated	  on	  
ice	  for	  5	  minutes.	  
4. Following	  addition	  of	  300μL	  SOC	  media,	  samples	  were	  shaken	  at	  160rpm	  for	  one	  
hour	  at	  37°C.	  	  
5. Simultaneously,	   agar	   plates	   containing	   the	   required	   antibiotic	   were	   dried	   in	   an	  
oven	   at	   37°C	   (The	   antibiotic	   required	   was	   dependent	   upon	   the	   plasmid	   being	  
amplified).	  
6. The	  E.	  Coli	  were	  subsequently	  centrifuged	  at	  15,700g	  for	  3	  minutes	  and	  150μL	  of	  
supernatant	  removed.	  
7. Once	  resuspended	  in	  the	  remaining	  150μL	  SOC	  media,	  bacteria	  were	  spread	  onto	  
the	  pre-­‐dried	  plate	  and	  incubated	  either	  at	  37°C	  overnight,	  or	  at	  room	  temperature	  
for	  72	  hours.	  
	  
2.1.10 Production	  of	  Agar	  Plates	  
	  
2.1.10.1 Materials,	  Reagents	  and	  Equipment	  
 	  LB-­‐Agar	   Novagen	  
 	  Ampicillin	   Sigma	  
 	  Kanamycin	   Sigma	  
 	  Microwave	  Oven	   	  
 	  Non-­‐tissue	  culture	  treated	  10cm	  petri-­‐dishes	   Falcon	  
 	  Bunsen	  burner	   	  
	  
Buffers	  and	  solutions:	  
Agar	  =	  5g	  yeast	  extract,	  10g	  peptone	  from	  casein,	  10g	  NaCl	  in	  1L	  deionised	  water	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2.1.10.2 Protocol	  
1. 500mL	  agar	  was	  melted	  in	  a	  microwave	  oven	  for	  20min	  at	  40%	  maximum	  power	  to	  
obtain	  a	  molten	  solution	  
2. After	  cooling	  down,	  a	  selective	  antibiotic	  (50mg	  ampicillin	  or	  50μg	  kanamycin)	  was	  
added	  and	  mixed	  thoroughly	  
3. The	  solution	  was	  distributed	  evenly	  over	  20	  petri	  dishes	  and	  left	  to	  solidify	  at	  room	  
temperature.	  
4. Petri	  dishes	  were	  stored	  at	  4°C	  
	  
2.1.11 Selection	  of	  Bacterial	  Clones	  
	  
2.1.11.1 Materials,	  Reagents	  and	  Equipment	  
 	  L-­‐Broth	   	  
 	  Antibiotic	  of	  choice	   	  
 	  14mL	  Polystyrene	  round-­‐bottom	  tubes	   	  
 	  20μL	  pipette	  tips	   Star	  Lab	  
 	  Excella	  E-­‐25	  shake	  incubator	   	  
	  
Buffers	  and	  solutions:	  
L-­‐broth:	  10g	  tryptone,	  5g	  yeast	  extract,	  0.5g	  NaCl	  
	  
2.1.11.2 Protocol	  
1. 3mL	  of	  L-­‐broth,	  containing	  150ng	  -­‐	  150μg	  of	  the	  selected	  antibiotic	  was	  aliquotted	  
into	  14mL	  round-­‐bottom	  tubes.	  
2. Single	  bacterial	  colonies	  were	  selected	  using	  a	  pipette	  tip	  and	  submerged	  in	  the	  L-­‐
broth.	  
3. The	  tubes	  were	  shaken	  at	  160rpm	  for	  16	  hours	  at	  37°C	  prior	  to	  being	  centrifuged	  at	  
1500g	  for	  10	  minutes	  to	  pellet	  the	  bacteria.	  The	  supernatant	  was	  discarded	  and	  the	  
pellet	  subjected	  to	  plasmid	  isolation.	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2.1.12 Isolation	  of	  Plasmid	  DNA	  –	  Miniprep	  
Retrieval	   of	   plasmid	   DNA	   was	   achieved	   using	   a	   QIAprep	   Spin	   Miniprep	   kit.	   This	  
procedure	  is	  based	  on	  the	  rapid	  alkaline	  lysis	  procedure	  reported	  by	  Birnboim	  and	  Doly	  
(491),	  in	  which	  bacterial	  lysis	  was	  achieved	  using	  sodium	  dodecyl	  sulphate	  (SDS)	  in	  the	  
presence	  of	  200mM	  sodium	  hydroxide	  (NaOH).	  The	  resulting	  denaturation	  of	  proteins	  
and	  chromosomal	  DNA	  caused	  by	  the	  strongly	  alkaline	  environment	  ensured	  their	  co-­‐
precipitation	  with	  SDS	  upon	  neutralization	  of	  the	  solution	  and	  the	  conversion	  to	  high	  
salt	  conditions	  by	  the	  addition	  of	  potassium	  acetate.	  The	  supercoiled	  conformation	  of	  
the	   plasmid	  DNA	  prevented	   separation	   of	   the	  DNA	   strands,	   thereby	   ensuring	   that	   it	  
remained	  in	  solution.	  Contaminating	  RNA	  was	  removed	  by	  both	  the	  addition	  of	  RNAse	  
A	  to	  the	  intial	  resuspension	  buffer	  and	  precipitation	  in	  the	  high	  salt	  environment	  of	  the	  
neutralization	   buffer.	   Removal	   of	   any	   remaining	   impurities	  was	   achieved	   by	   running	  
the	  aqueous	  phase	  through	  a	  column	  containing	  a	  silica	  membrane.	  The	  presence	  of	  
the	   chaotropic	   salt,	   guanidine	   hydrochloride,	   in	   the	   neutralization	   buffer	   induced	  
dehydration	  of	   the	  plasmid	  DNA,	  allowing	   it	   to	  bind	   strongly	   to	   the	   silica	  membrane	  
(492),	  whilst	  other	  contaminating	  factors	  were	  removed	  in	  the	  flow-­‐through.	  Following	  
to	  further	  wash	  steps	  with	  chaotropic	  salt	  and	  ethanol-­‐containing	  buffers,	  the	  purified	  
plasmid	  DNA	  was	  eluted	  from	  the	  column	  using	  a	  low	  salt	  buffer.	  
	  
2.1.12.1 Materials,	  Reagents	  and	  Equipment	  
 	  QIAprep	  spin	  Miniprep	  kit	   Qiagen	  
 	  Pelleted	  TOP10F’	  E.	  Coli	   	  
 	  1.5mL	  Eppendorfs	   	  
 	  Eppendorf	  5415R	  refrigerated	  Microcentrifuge	   Eppendorf	  
	  
Buffers	  and	  solutions:	  
Buffer	  P1	  =	  50mM	  Tris-­‐Cl,	  1mM	  EDTA,	  100μg/mL	  RNAse	  A	  
Buffer	  P2	  =	  200mM	  NaOH,	  1%	  SDS	  
Buffer	  EB	  =	  10mM	  Tris-­‐Cl	  (pH	  8.5)	  
	  
NOTE:	   Qiagen	   does	   not	   publish	   the	   full	   composition	   of	   the	   neutralizing	   N3	   buffer,	  
buffer	  PB	  or	  buffer	  PE.	  Buffer	  N3	  is	  known	  to	  contain	  guanidine	  hydrochloride	  (as	  the	  
source	  of	  chaotropic	  salt)	  and	  acetic	  acid	  (probably	  in	  the	  form	  of	  potassium	  acetate)	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to	  neutralize	  the	  alkaline	  environment	  caused	  by	  the	  NaOH	  in	  buffer	  P2.	  Buffer	  PB	  also	  
contains	   guanidine	   hydrochloride,	   along	   with	   isopropanol.	   No	   details	   regarding	   the	  
composition	  of	  buffer	  PE	  have	  been	  released.	  
	  
2.1.12.2 Protocol	  
1. Pelleted	  bacteria	  were	  resuspened	  in	  250μL	  buffer	  P1.	  
2. An	   equal	   volume	   of	   buffer	   P2	   was	   added	   and	   the	   sample	   was	   gently	   inverted	  
approximately	  10	  times	  to	  ensure	  complete	  mixing.	  
3. After	  a	  five-­‐minute	  incubation	  at	  room	  temperature,	  350μL	  buffer	  N3	  was	  added	  to	  
each	  sample.	  Complete	  mixing	  was	  achieved	  through	  gentle	  inversion.	  
4. Centrifugation	  at	  15,700g	  pelleted	  the	  white	  precipitate	  in	  each	  sample.	  
5. The	   aqueous	   phase	  was	   carefully	   transferred	   to	   a	   QIAprep	   spin	   column	   and	   the	  
white	  precipitate	  discarded.	  
6. Following	   centrifugation	  at	  15,700g,	   each	   column	  was	  washed	  with	  500μL	  buffer	  
PB	  and	  centrifuged	  at	  15,700g,	  before	  discarding	  the	  eluate.	  
7. Each	  column	  was	  washed	  with	  750μL	  buffer	  PE	  and	  centrifuged	  at	  15,700g	  and	  the	  
eluate	  was	  again	  discarded.	  
8. After	  an	  additional	  centrifugation	  at	  15,700g	  to	  remove	  any	  residual	  ethanol,	   the	  
DNA	  was	  eluted	  in	  50μL	  buffer	  EB	  through	  centrifugation	  at	  15,700g.	  
9. The	  concentration	  of	  the	  isolated	  DNA	  was	  determined	  and	  stored	  at	  -­‐20°C.	  
	  
2.1.13 Isolation	  of	  Plasmid	  DNA	  –	  Maxiprep	  
Maxipreps	  were	  used	  for	  the	  production	  of	  higher	  concentrated	  DNA	  preparations	  As	  
with	  minipreps,	  the	  E.	  Coli	  were	   lysed	  under	  strong	  alkaline	  conditions,	  with	  proteins	  
and	  chromosomal	  DNA	  removed	  by	  precipitation	  upon	  neutralization	  and	  conversion	  
to	   a	   high	   salt	   environment.	   As	   before,	   RNA	   impurities	   were	   removed	   through	   the	  
addition	   of	   RNAse	   A	   in	   the	   initial	   resuspension	   buffer.	   Once	   insoluble	   contaminants	  
had	  been	  removed	  via	  filtration,	  the	  eluate	  (containing	  the	  plasmid	  DNA	  was	  subjected	  
to	   anion-­‐exchanged	   chromatography.	   Plasmid	   DNA	   is	   able	   to	   bind	   strongly	   to	   the	  
positively	  charged	  diethylaminoethyl	  (DEAE)	  resin	  beads,	  until	  eluted	  using	  a	  high-­‐salt	  
containing	  buffer.	   Intermediate	  washes	  with	  buffers	  of	   increasing	  salt	  concentrations	  
ensured	   the	   removal	   of	   remaining	   contaminants.	   Once	   eluted,	   the	   DNA	   was	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precipitated	  and	  desalted	  using	  a	  series	  of	  alcohol	  washes	  before	  being	  dissolved	  in	  EB	  
buffer.	  
	  
2.1.13.1 Materials,	  Reagents	  and	  Equipment	  
• 	  500mL	  TOP10F’	  E.	  Coli	  containing	  plasmid	  of	  interest	   	  
• 	  QIAgen	  Plasmid	  Maxi	  Kit	   Qiagen	  
• 	  50mL	  Falcon	  tubes	   SLS	  
• 	  1.5mL	  Eppendorfs	   	  
• 	  Oak	  ridge	  polypropylene	  copolymer	  centrifuge	  tubes	   Nalgene	  
• 	  Sorvall	  RC	  +6	  Centrifuge	   Sorvall	  
• 	  Vacuum	  filtration	  system	  0.22μM	  PES	  membrane	   TPP	  
• 	  70%	  Ethanol	   Fisher	  Scientific	  
• 	  Isopropanol	   Fisher	  Scientific	  
• 	  Excella	  E-­‐25	  shake	  incubator	   	  
	  
Buffers	  and	  solutions:	  
Buffer	   P1	   =	   50mM	   Tris-­‐Cl	   (pH	   8.0),	   10mM	   EDTA,	   100μg/mL	   RNAse	   A,	   lyse	   blue	  
(optional)	  
Buffer	  P2	  =	  200mM	  NaOH,	  1%	  (w/v)	  SDS	  
Buffer	  P3	  =	  3M	  Potassium	  Acetate	  
Buffer	   QBT	   =	   750mM	   NaCl,	   50mM	   3-­‐(N-­‐Morpholino)-­‐propanesulfonic	   acid	   (MOPS),	  
15%	  (v/v)	  isopropanol,	  0.15%	  (v/v)	  Triton	  X-­‐100	  
Buffer	  QC	  =	  1M	  NaCl,	  50mM	  MOPS,	  15%	  (v/v)	  isopropanol	  
Buffer	  QF	  =	  1.25M	  NaCl,	  50mM	  Tris-­‐Cl	  (pH	  8.5),	  15%	  (v/v)	  isopropanol	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2.1.13.2 Protocol	  




i. The	  provided	  RNase	  A	  and	  Lyse	  Blue	  were	  added	  to	  buffer	  P1.	  
ii. Buffer	   P2	  was	   checked	   for	   SDS	  precipitation	  due	   to	   low	   storage	   temperatures.	   If	  
necessary,	  the	  SDS	  was	  dissolved	  by	  warming	  to	  37°C.	  
iii. Buffer	  P3	  was	  pre-­‐chilled	  to	  4°C.	  
	  
1. A	  single	  colony	  was	  picked	  from	  a	  freshly	  streaked	  selective	  plate	  and	  inoculated	  of	  
a	   starter	   culture	   of	   2-­‐5mL	   L-­‐Broth	   media	   containing	   the	   appropriate	   selective	  
antibiotic.	  
2. The	  culture	  was	  incubated	  for	  8	  hours	  at	  37°C	  with	  vigorous	  shaking	  (300rpm).	  
3. The	   started	   culture	   was	   diluted	   1/1000	   into	   selective	   L-­‐Broth	  medium.	   For	   low-­‐
copy	  plasmids,	  500μL	  of	  starter	  culture	  was	  added	  to	  500mL	  L-­‐Broth	  medium	  and	  
incubated	  overnight	  at	  37°C	  with	  vigorous	  shaking	  (300rpm).	  
4. The	  bacteria	  were	  pelleted	  through	  centrifugation	  at	  3500g	  for	  10	  minutes	  at	  4°C.	  
5. The	  bacterial	  cell	  pellet	  was	  resuspended	  vigorously	  in	  10mL	  buffer	  P1	  until	  no	  cell	  
clumps	  remained.	  
6. An	  equal	  volume	  of	  buffer	  P2	  was	  added,	  and	  the	  sealed	  tube	   inverted	  4-­‐6	  times	  
and	  incubated	  at	  room	  temperature	  for	  5	  minutes.	  Complete	  lysis	  of	  the	  bacterial	  
pellet	  is	  confirmed	  by	  the	  cell	  suspension	  turning	  blue.	  
7. An	  equal	  volume	  of	  buffer	  P3	  is	  added	  and	  the	  suspension	  was	  mixed	  vigorously	  by	  
inverting	  the	  sealed	  tube	  4-­‐6	  times	  and	  incubated	  on	  ice	  for	  20	  minutes.	  Complete	  
protein	  precipitation	  is	  confirmed	  by	  the	  suspension	  becoming	  colourless.	  
8. The	  suspension	  is	  filtered	  through	  a	  0.22μM	  PES	  membrane	  vacuum	  filter.	  
9. During	   filtration	  of	   the	   suspension,	  a	  QIAgen-­‐tip	  500	  was	  equilibrated	  with	  10mL	  
buffer	  QBT.	  The	  column	  was	  allowed	  to	  empty	  by	  gravity	  flow.	  
10. The	  eluate	  from	  step	  8	  was	  added	  to	  the	  QIAgen-­‐tip	  and	  allowed	  to	  enter	  the	  resin	  
by	  gravity	  flow.	  
11. The	  tip	  was	  washed	  twice	  using	  30mL	  buffer	  QC	  before	  the	  plasmid	  was	  eluted	  into	  
a	  polypropylene	  copolymer	  centrifuge	  tube	  using	  15mL	  buffer	  QF.	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12. The	   DNA	   was	   precipitated	   by	   adding	   10.5mL	   isopropanol	   and	   pelleted	   by	  
centrifugation	  for	  30	  minutes	  at	  15,000g	  and	  4°C.	  
13. The	  pellet	  was	  washed	  with	  5mL	  70%	  ethanol	  to	  remove	  the	  salt	  and	  the	  DNA	  was	  
again	  pelleted	  by	  centrifugation	  at	  15,000g	  for	  10	  minutes.	  
14. After	   removal	   of	   the	   supernatant	   the	   DNA	   pellet	   was	   air-­‐dried	   at	   room	  
temperature	  for	  15	  minutes	  and	  resuspended	  in	  200μL	  of	  EB	  buffer.	  
15. The	  concentration	  of	   the	  DNA	  was	  determined	  using	   the	  Nanodrop	  ND-­‐1000	  and	  
was	  stored	  at	  -­‐20°C.	  
	  
2.1.14 Analysis	  of	  DNA	  Sequences	  
The	  ability	  to	  quickly	  and	  precisely	  determine	  DNA	  sequences	  has	  been	  an	  invaluable	  
tool	   to	   verify	   the	   correct	   production	   of	   new	   constructs	   and	   investigate	   successful	  
insertion	  of	  sequences	  into	  plasmids	  and	  viral	  vectors.	  The	  technique	  used	  was	  based	  
on	   the	   chain	   termination	   method	   originally	   described	   by	   Sanger	   et	   al.	   (493)	   and	  
utilised	  Big	  Dye	  Terminator	  chemistry.	  In	  this	  method,	  the	  dideoxynucleotides	  (ddNTP)	  
responsible	   for	   chain	   termination	   are	   fluorescently	   labelled	   with	   a	   different	  
fluorophore	   for	   each	  base,	   thereby	   enabling	   their	   incorporation	   into	  DNA	   fragments	  
that	  can	  easily	  be	  distinguished.	  Sequencing	  of	   the	  DNA	  was	  achieved	  using	  capillary	  
zone	   electrophoresis	   and	   was	   kindly	   performed	   by	   Cancer	   Research	   UK	   (London	  
Research	   Institute,	   Lincoln’s	   Inn	   Fields),	   using	   an	   Applied	   Biosystems	   3730	   DNA	  
Analyzer.	  
	  
2.1.14.1 Materials,	  Reagents	  and	  Equipment	  
• 	  Primers	  (see	  Appendix	  1)	   	  
• 	  DNA	  Template	   	  
• 	  Big	  Dye	  Terminator	  (BDT)	  reaction	  mix	   Applied	  Biosystems	  
• 	  Distilled	  water	   	  
• 	  Eppendorf	  Mastercycler	  Gradient	  PCR	  Machine	   Eppendorf	  
• 	  DyeEx	  2.0	  spin	  kit	   Qiagen	  
• 	  PCR	  tubes	   Bio-­‐Rad	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2.1.14.2 Protocol	  
1. A	  reaction	  mixture	  as	  detailed	  below	  was	  produced:	  
a. 8μL	  BDT	  
b. 1.5μL	  Template	  DNA	  
c. 1μL	  (3.2pmol)	  Primer	  
d. 9.5μL	  dH2O	  
2. Samples	  were	  incubated	  using	  the	  following	  PCR	  program:	  
a. Denaturation	   96°C	   	   1	  minute	  
b. Denaturation	   96°C	   	   10	  seconds	  *	  
c. Annealing	   	   58°C	   	   5	  seconds	  *	   	   *	  =	  25	  cycles	  
d. Elongation	  	   60°C	   	   4	  minutes	  *	  
e. Hold	   	   6°C	   	   HOLD	  
3. Excess	   unbound	   nucleotides	   were	   removed	   by	   running	   the	   reaction	   mixture	  
through	   a	   size	   exclusion	   column	   (DyeEx	   2.0	   spin	   kit)	   according	   to	   the	  
manufacturer’s	  protocol.	  
4. The	   resulting	   eluate	   was	   sent	   for	   sequence	   analysis	   via	   capillary	   zone	  
electrophoresis	  (CRUK	  London	  Research	  Institute,	  Lincoln’s	  Inn	  Fields).	  
5. Obtained	   sequences	   were	   analysed	   using	   4Peaks	   1.7.1	   and	   Serial	   Cloner	   2.5.0,	  
allowing	  for	  rapid	  identification	  of	  restriction	  sites	  and	  open	  reading	  frames.	  
	   109	  
2.2 Cell	  Culture	  
	  
All	  cells	  were	  incubated	  at	  37°C,	  97%	  O2	  /	  5%	  CO2	  
	  
2.2.1 Media	  and	  Common	  Solutions	  
	  
2.2.1.1 Media	  
D10	   =	   500mL	  Dulbecco’s	  Modified	  Eagle	  Medium	  
(DMEM)	  +	  4.5g/L	  glucose	  




125μg	  Amphotericin	  B	  
	  







D5	   =	   500mL	  Dulbecco’s	  Modified	  Eagle	  Medium	  
(DMEM)	  +	  4.5g/L	  glucose	  




125μg	  Amphotericin	  B	  
	  
	  
	   	  
	  
R10	   =	   500mL	  Roswell	  Park	  Memorial	  Institute	  
(RPMI)	  1640	  Medium	  without	  L-­‐Glutamine	   	  
50mL	  Human	  Male	  AB	  Serum	  	  
200mM	  GlutaMAX	   	   	   	  
50,000U	  Penicillin	   	   	   	   	  
50mg	  Streptomycin	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2.2.1.2 Common	  Solutions	  
	  
2.2.2 Primary	  Cells	  and	  Cell	  Lines	  
Primary	  cell	  lines	  were	  used	  for	  in	  vitro	  examination	  of	  the	  targetability	  of	  human	  and	  
mouse	  ErbB+	  healthy	  tissue	  by	  T4+	  T-­‐cells.	  
	  
2.2.2.1 Materials,	  Reagents	  and	  Equipment	  
 	  D10	  media	   Please	  refer	  to	  paragraph	  2.2.1.1	  
 	  D5	  media	   Please	  refer	  to	  paragraph	  2.2.1.1	  
 	  R10	  media	   Please	  refer	  to	  paragraph	  2.2.1.1	  
 	  Endothelial	  Cell	  Basal	  Medium	  MV	   PromoCell	  




 	  Myocyte	  Basal	  Medium	   PromoCell	  






500mL	  Roswell	  Park	  Memorial	  Institute	  
(RPMI)	  1640	  Medium	  without	  L-­‐Glutamine	   	  
50mL	  Foetal	  Bovine	  Serum	   	  
200mM	  GlutaMAX	   	   	   	  
50,000U	  Penicillin	   	   	   	   	  
50mg	  Streptomycin	   	   	   	  
125μg	  Amphotericin	  B	  








Trypsin	   =	   0.25%	  Trypsin-­‐EDTA	  
	  
Gibco	  
CDB	   =	   Cell	  Dissociation	  Buffer	  
Enzyme	   free	   aqueous	   formulation	   of	   salts,	  
chelating	  agents,	  and	  cell-­‐conditioning	  agents	  
in	  either	  Ca2+	  and	  Mg2+	  free	  PBS	  
	  
Invitrogen	  Life	  Tech	  
PBS	   =	   Phosphate	  Buffered	  Saline	   Biochrom	  AG	  
	   111	  
 	  Mouse	  Endothelial	  Cell	  Medium	   CellBiologics	  
 	  Mouse	  Endothelial	  Cell	  Medium	  
Supplement	  Kit	  
CellBiologics	  
 	  Gelatin-­‐based	  coating	  solution	   CellBiologics	  
 	  Interleukin-­‐2	  (IL-­‐2,	  Aldesleukin)	  (rhIL-­‐2)	   Novartis	  
 	  Recombinant	  human	  Interleukin-­‐4	  (rhIL-­‐4)	   Gentaur	  
 	  Tetracycline	   Calbiochem	  
 	  Puromycin	   Merck	  
 	  6-­‐well	  tissue	  culture-­‐treated	  plates	   Greiner	  Bio-­‐one	  
 	  T25	  tissue	  culture	  flasks	   NUNC	  
 	  T75	  tissue	  culture	  flasks	   NUNC	  
 	  T175	  tissue	  culture	  flasks	   NUNC	  
	  
2.2.2.2 Human	  T-­‐cells	  
Human	   T-­‐cells	   were	   cultured	   in	   R10	   media	   supplemented	   with	   100U/mL	   IL-­‐2	   (or	  
30ng/mL	  hIL-­‐4	  for	  T4+	  T-­‐cells).	  Fresh	  media	  and	  cytokine	  were	  supplied	  when	  required.	  
	  
2.2.2.3 Primary	  Cell	  (Lines)	  
Primary	   Human	   Pulmonary	   Microvascular	   Endothelial	   Cells	   (HPMEC)	   and	   Human	  
Cardiac	   Myocytes	   (HCM)	   were	   obtained	   from	   Promocell	   (Heidelberg,	   Germany).	  
Primary	   Balb/C	   mouse	   Pulmonary	   Microvascular	   Endothelial	   Cells	   (MPMEC)	   were	  
obtained	  from	  CellBiologics	  (Chicago,	  Illinois,	  USA).	  
The	   HPMEC	   originate	   from	   the	   capillary	   walls	   and	   were	   cyropreserved	   at	  
passage	   2.	   The	   cells	   were	   cultured	   at	   a	   density	   of	   10,000-­‐20,000	   cells/cm2	   in	   the	  
Endothelial	  Cell	  Growth	  Medium	  MV2	  (494).	  The	  HCM	  are	  derived	  from	  normal	  human	  
ventricular	  tissue	  of	  the	  adult	  heart.	  The	  cells	  were	  cyropreserved	  at	  passage	  2	  (495).	  
The	  cells	  were	  cultured	  at	  a	  density	  of	  10,000-­‐15,000	  cells/cm2	  in	  the	  Myocyte	  Growth	  
Medium.	  The	  MPMEC	  are	  isolated	  from	  tissue	  of	  pathogen-­‐free	  laboratory	  mice.	  Cells	  
are	   cultured	   in	   T25	   flasks	   pre-­‐coated	   with	   a	   gelatin-­‐based	   coating	   solution	   for	   30	  
minutes.	  Medium	  was	  changed	  when	  cell	  density	  >60%,	  cells	  were	  passaged	  1:2	  when	  
cells	  reached	  100%	  confluency	  (496).	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2.2.2.4 Tumour	  Cell	  Lines	  
Immortalized	  tumour	  cell	  lines	  were	  acquired	  from	  multiple	  sources	  (see	  Table	  2-­‐2).	  All	  
tumour	  cell	  lines	  were	  grown	  as	  serially	  diluted	  cultures	  in	  D10	  media	  and	  monolayers	  
were	   passaged	   when	   appropriate.	   The	   HN3luc	   cell	   line	   was	   produced	   prior	   to	   the	  
commencement	   of	   this	   PhD	   by	   transducing	   HNSCC	   HN3	   cells	   with	   the	   pBabe	   puro	  
retroviral	  vector	  (497)(please	  refer	  to	  paragraph	  2.2.3.2)	  containing	  the	  gene	  for	  firefly	  
luciferase	   (ffLuc).	  The	  cell	   line	  PLP	  was	  produced	  prior	   to	  the	  commencement	  of	   this	  
PhD	  by	  the	  transduction	  of	  the	  prostate	  cancer	  cell	  line	  PC3-­‐LN3	  with	  the	  pBabe	  puro	  
retroviral	   vector	   containing	   prostate-­‐specific	  membrane	   antigen	   (PSMA).	   In	   order	   to	  
ensure	  retention	  of	  the	  luciferase	  or	  PSMA	  gene,	  the	  cell	  lines	  were	  periodically	  grown	  
in	  the	  presence	  of	  1.5mg/mL	  Puromycin.	  	  
	  
Table	  2-­‐2	  Sources	  of	  acquired	  tumour	  cell	  lines	  
Tumour	  Cell	  Line	   Origin	   Source	  
HN3	  (HN3luc)	   Human	  (HNSCC)	   Dr	  Sue	  Eccles,	  Institute	  for	  Cancer	  Research,	  
Sutton,	  UK	  
SKOV3luc	   Human	  (Ovarian)	   Caliper	  Lifesciences	  
PC3-­‐LN3	  (PLP)	   Human	  (Prostate)	   Dr	  Sue	  Eccles,	  Institute	  for	  Cancer	  Research,	  
Sutton,	  UK	  
MDA-­‐MB-­‐435	   Human	  (Breast)	   Cancer	  Research	  UK	  
B7E3	   Mouse	  (HNSCC)	   Dr	   Carter	   van	   Waes,	   National	   Institute	   of	  
Health,	  Bethesda,	  Maryland,	  USA	  
	  
2.2.2.5 Retroviral	  Packaging	  Cell	  Lines	  
The	   majority	   of	   gene	   transfer	   undertaken	   during	   this	   PhD	   was	   achieved	   using	  
engineered	  retroviruses.	  The	  genome	  of	  every	  retrovirus	  (a	  dimer	  of	  two	  RNA	  copies)	  
encodes	  at	  least	  four	  specific	  genes	  (498),	  all	  of	  which	  are	  crucial	  for	  completion	  of	  the	  
retroviral	   life	   cycle	   (see	   Figure	   2-­‐4).	   The	   binding	   of	   a	  mature	   retroviral	   particle	   to	   a	  
target	   cell	   is	  mediated	   by	   interactions	   between	   glycoproteins	   expressed	   in	   the	   viral	  
envelope	   and	   a	   specific	   receptor	   or	  molecule	   on	   the	   surface	   of	   the	   host	   cell.	   These	  
glycoproteins	  are	  encoded	  by	  the	  retroviral	  env	  gene	  and	  are	  therefore	  responsible	  for	  
the	   tropism	   of	   the	   viruses	   (i.e.	   the	   target	   cells	   with	   which	   it	   can	   interact)	   (498).	  
Following	   fusion	   of	   the	   retroviral	   envelope	   with	   the	   host	   cell	   membrane,	   the	   RNA	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genome	   is	   extruded	   into	   the	   cytoplasm	   of	   the	   host	   cell,	   where	   it	   is	   converted	   to	   a	  
double	   stranded	  DNA	   copy	   by	   reverse	   transcriptase.	   This	   is	   subsequently	   integrated	  
into	  the	  host	  cell	  genome	  by	  an	  integrase	  enzyme,	  to	  give	  a	  ‘provirus’	  (498,	  499).	  Both	  
of	   these	   enzymes	   are	   encoded	   by	   the	   pol	   gene	   in	   the	   retroviral	   genome	   and	   are	  
contained	   within	   the	   packaged	   virus,	   before	   being	   released	   into	   the	   host	   cell	  
cytoplasm	  upon	  viral	   fusion.	  The	  transcription	  and	  translation	  of	  the	  viral	  genome	  by	  
the	  host	  cell	  RNA	  polymerase	  results	  in	  production	  of	  the	  proteins	  encoded	  by	  the	  gag	  
gene,	  as	  well	  as	   the	  production	  of	  new	  reverse	  transcriptase	  and	   integrase	  enzymes.	  
Although	  expressed	  as	  a	  single	  polypeptide	  until	   the	   late	  stages	  of	  viral	  budding,	   the	  
gag	   gene	   codes	   for	   a	   number	   of	   separate	   proteins.	   Taking	   the	   Moloney	   murine	  
leukaemia	  virus	  (MoMLV)	  as	  an	  example,	  the	  matrix	  (MA,	  p15),	  p12,	  capsid	  (CA,	  p30)	  
and	   nucleocapsid	   (NC,	   p10)	   structural	   proteins	   are	   all	   present	   within	   the	   gag	  
polypeptide	  (498).	  The	  N-­‐terminal	  end	  of	  the	  polypeptide	  (the	  N-­‐terminus	  of	  the	  MA	  
protein)	   is	  myristylated,	   thus	  anchoring	   it	   in	   the	  host	  cell	  membrane	  and	  providing	  a	  
focal	   point	   at	   which	   a	   new	   viral	   particle	   can	   be	   formed.	   Indeed,	   inhibition	   of	  
myristylation	  can	  interfere	  with	  viral	  assembly	  (500).	  At	  the	  C-­‐terminal	  end	  of	  the	  gag-­‐
encoded	  polypeptide,	  the	  NC	  protein	  interacts	  with	  the	  viral	  genome	  an	  is	  responsible	  
for	   ensuring	   its	   packaging	   into	   the	   new	   retroviral	   particle	   (501).	   The	   reverse	  
transcriptase	  and	  integrase	  enzymes	  are	  incorporated	  into	  the	  new	  viral	  particle,	  along	  
with	  a	  viral	  protease,	  which	  is	  the	  product	  of	  the	  pro	  gene	  found	  between	  the	  gag	  and	  
the	  pol	   genes.	  During	  and	   following	  budding	   this	  protease	   is	   responsible	   for	  cleaving	  
the	  gag-­‐encoded	  polypeptide	  into	  its	  four	  constituent	  proteins.	  The	  importance	  of	  this	  
polypeptide	  processing	   is	   highlighted	  by	   the	   fact	   that	  mutations	   in	   the	   cleavage	   site	  
between	  the	  p12	  and	  CA	  proteins	  are	  sufficient	  to	   inhibit	  the	  formation	  of	   infectious	  
MoMLV	   viral	   particles	   (502).	   This	   cleavage	   event	   is	   part	   of	   the	  maturation	   process,	  
during	  which	  retroviruses	  gain	  the	  ability	  to	  infect	  target	  cells	  and	  begin	  another	  round	  
of	  replication.	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Figure	  2-­‐4	  Retroviral	  Life	  Cycle	  
Image	  is	  adapted	  from	  Figure	  6-­‐39,	  Essential	  Cell	  Biology,	  3rd	  Edition	  (503).	  Following	  fusion	  of	  the	  viral	  
particle	   with	   the	   target	   cell	   (step	   1),	   the	   envelope	   and	   capsid	   are	   disassembled,	   releasing	   the	   viral	  
genome	  and	  proteins	  into	  the	  cytoplasm.	  The	  reverse	  transcriptase	  from	  the	  disassembled	  viral	  particle	  
binds	  to	  a	  transfer	  RNA	  (tRNA)	  primer	  bound	  the	  LTR	  at	  the	  5’	  end	  of	  the	  viral	  genome	  and	  synthesises	  a	  
complementary	  DNA	  strand	  (step	  2).	  The	  degradation	  of	  the	  RNA	  strand	  by	  the	  RNase	  H	  subunit	  of	  the	  
reverse	  transcriptase	  enzyme	  enables	  synthesis	  of	  a	  second	  DNA	  strand	  (step	  3).	  The	  double	  stranded	  
DNA	  (dsDNA)	  is	  integrated	  into	  the	  host	  genome	  by	  the	  viral	  integrase	  enzyme	  (step	  4).	  Amplification	  of	  
the	   viral	   genome	   by	   the	   host	   RNA	   polymerase	   produces	   large	   quantities	   of	   the	   viral	   RNA	   (step	   5).	  
Following	   export	   from	   the	   nucleus,	   the	   majority	   of	   this	   is	   transcribed	   to	   give	   the	   gag,	   pol,	   and	   env	  
proteins	  (step	  6).	  These	  proteins,	  along	  with	  two	  copies	  of	  untranslated	  viral	  RNA	  are	  incorporated	  into	  
a	  new	  viral	  particle	  (step	  7),	  which	  subsequently	  buds	  from	  the	  target	  cell	  (step	  8).	  
	  
The	  ability	  of	  retroviruses	  to	  integrate	  their	  genome	  into	  that	  of	  a	  host	  cell	  provides	  an	  
attractive	  way	  of	  achieving	  stable	  expression	  of	  a	  transgene	  within	  a	  specific	  target	  cell	  
population.	   In	   the	  majority	  of	   cases,	   however,	   the	   continued	   replication	  of	   the	   virus	  
following	  infection	  of	  the	  target	  cell	  population	  is	  undesirable.	  One	  way	  of	  preventing	  
the	   production	   of	   so-­‐called	   replication-­‐competent	   retrovirus	   (RCR)	  within	   the	   target	  
cell	  is	  to	  replace	  the	  gag,	  pro,	  pol	  and	  env	  genes	  with	  that	  of	  the	  transgene	  of	  interest.	  
However,	  as	  detailed	  above,	  the	  proteins	  encoded	  by	  these	  four	  genes	  are	  essential	  for	  
the	  production	  and	  function	  of	  viable	  virions.	  The	  use	  of	  retroviral	  packaging	  cell	  lines	  
offers	  a	  way	  of	  producing	  viable	  viral	  particles	   that	  are	  unable	   to	   replicate	   following	  
infection	   of	   the	   target	   cell,	   and	   of	   the	   required	   proteins	   are	   available	   for	   viral	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assembly.	   The	   retroviral	   genomic	   sequence	   (containing	   the	   desired	   gene)	   is	  
subsequently	   packaged	   into	   these	   viruses,	   which	   are	   then	   capable	   of	   infecting	   the	  
target	   cell	   of	   choice.	   However,	   as	   these	   viruses	   do	   not	   contain	   any	   of	   the	   genes	  
required	  for	   the	   formation	  of	   fresh	  viral	  particles,	   further	  replication	   is	  prevented.	   In	  
order	  to	  minimize	  the	  risk	  of	  producing	  RCR,	  the	  gag-­‐pol	  and	  env	  genes	  are	  expressed	  
on	   separate	   plasmids	   within	   the	   packaging	   cells.	   Consequently,	   three	   separate	  
recombination	   events	   would	   need	   to	   occur	   before	   all	   of	   these	   genes	   could	   be	  
expressed	  in	  cis.	  The	  pol	  gene	  is	  always	  expressed	  on	  the	  same	  plasmid	  as	  gag	  due	  to	  
the	   fact	   that	   the	  gag-­‐pro-­‐pol	   genes	  are	   transcribed	  as	  a	   single	  mRNA	   transcript.	   The	  
presence	  of	  a	  stop	  codon	  at	  the	  end	  of	  the	  gag	  coding	  sequence	  means	  that,	  in	  95%	  of	  
cases,	   translation	   results	   in	   expression	   of	   the	   gag	   polypeptide	   alone.	   Occasionally,	  
however,	   translational	   readthrough	   (caused	   by	   the	   misreading	   of	   the	   stop	   codon)	  
results	  in	  the	  production	  of	  a	  gag-­‐pro-­‐pol	  polypeptide	  (504).	  
	  
Two	  different	   types	  of	   retroviral	  packaging	  cell	   lines	  were	  used	   throughout	   this	  PhD,	  
depending	  on	  the	  required	  type	  of	  transfection.	  
	  
2.2.2.5.1 H29D	  
The	   H29D	   retroviral	   packaging	   cell	   line	   (293GPG	   in	   (505))	   is	   based	   on	   the	   human	  
embryonic	   kidney	   adenoviral	   5-­‐transformed	   cell	   line	   (HEK293,	   ref	   (506)).	   This	  
packaging	   cell	   line	   expresses	   the	   MoMLV	   gag-­‐pol	   genes	   under	   the	   control	   of	   the	  
cytomegalovirus	   (CMV)	   immediately	   early	   (IE)(505).	   Expression	   of	   the	   vesicular	  
stomatitis	   virus-­‐G	   (VSV-­‐G)	   env	   proteins	   results	   in	   the	   production	   of	   viral	   particles	  
displaying	   a	   brad	   tropism	   (‘pantropic’).	   As	   constitutive	   expression	   of	   the	   VSV-­‐G	  
envelope	   protein	   is	   toxic,	   controlled	   expression	   was	   achieved	   by	   placing	   the	   VSV-­‐G	  
coding	   sequence	   under	   the	   control	   of	   a	   tetracycline-­‐repressed	   promoter	   (505).	  
Originally	  described	  by	  Gossen	  and	  Bujard	   (507),	  activation	  of	   transcription	   from	  this	  
promoter	  is	  depedent	  upon	  the	  binding	  of	  a	  tetracycline-­‐transactivator	  (tTa)	  molecule.	  
In	   the	   presence	   of	   tetracycline,	   however,	   the	   binding	   of	   the	   tTa	   molecule	   to	   the	  
promoter	   is	   inhibited	   and	   thereby	   prevents	   subsequent	   gene	   expression.	  
Consequently,	  to	  prevent	  constitutive	  expression	  of	  the	  VSV-­‐G	  env	  protein,	  these	  cells	  
were	  maintained	   in	  D10	  media	  supplemented	  with	  2μg/mL	  tetracycline.	  Fresh	  media	  
and	   tetracycline	  were	   provided	   every	   three	   days	   and	   the	   cells	  were	   passaged	  when	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confluent.	  As	  detailed	   in	  paragraph	  2.2.5.2,	   removal	  of	   the	   tetracycline	  was	   required	  
for	  the	  production	  of	  VSV-­‐pseudotyped	  virus	  and	  the	  toxicity	  of	  this	  envelope	  protein	  




The	  PG13	  retroviral	  packaging	  cell	   line	   is	  derived	  from	  the	  NIH	  3T3	  murine	  fibroblast	  
cell	   line	   (508).	   As	   with	   H29D	   cell,	   PG13	   cells	   express	   the	  MoMLV	   gag-­‐pol	   genes.	   In	  
contrast,	   however,	   PG13	   viral	   particles	   are	   pseudotyped	   with	   the	   gibbon-­‐ape	  
leukaemia	   virus	   (GaLV)	   envelope	   protein.	   As	  with	   the	   VSV-­‐G	   psuedotyped	   virus,	   the	  
PG13	  GaLV	  pseudotyped	  viral	  particles	  are	  capable	  of	  infecting	  human	  cells.	  However,	  
as	   the	  GaLV	   is	  not	  toxic	   to	  the	  PG13	  cells,	  stably	  expressing	  clones	  can	  be	  produced.	  
The	   PG13	   packaging	   cells	   were	   grown	   in	   D10	  media	   in	   serially	   diluted	   cultures	   and	  
were	  passaged	  when	  confluent.	  
	  
2.2.3 Retroviral	  Vectors	  
Retroviral	   vectors	   constitute	   the	  backbone	  of	   the	   virus	   an	   tend	   to	   include	  necessary	  
elements,	   such	   as	   the	   promoter	   regions	   required	   for	   transcription	   of	   the	   inserted	  
gene(s)	   and	   the	   packaging	   signal	   (Ψ)	   required	   for	   packaging	   of	   the	  mRNA	   transcript	  
into	  new	  viral	  particles.	  Two	  different	  retroviral	  vectors	  were	  used	  during	  this	  study.	  
	  
2.2.3.1 SFG	  
The	  SFG	  retroviral	  vector	  is	  based	  on	  the	  MFG	  vector	  (509),	  in	  which	  gene	  expression	  is	  
driven	   by	   the	  MoMLV	   long	   terminal	   repeats	   (LTRs).	   The	   presence	   of	   the	  MoMLV	  Ψ	  
packaging	  signal	  ensures	  efficient	  packaging	  of	  the	  RNA	  into	  the	  virus.	  The	  presence	  of	  
the	  splice	  donor	  and	  splice	  acceptor	  sites	  allow	  the	  production	  of	  the	  subgenomic	  RNA	  
transcripts	   usually	   required	   for	   the	   translation	   of	   the	   env	   gene	   (504).	   The	   gene	   of	  
interest	  is	  inserted	  at	  a	  naturally	  occurring	  NcoI	  site,	  ensuring	  that	  its	  start	  codon	  is	  in	  
the	  precise	  location	  previously	  occupied	  by	  the	  deleted	  env	  gene.	  This	  vector	  does	  not	  
contain	   a	   eukaryotic	   cell-­‐compatible	   selectable	   marker	   gene.	   It	   does	   contain	   an	  
ampicillin	   resistance	   gene	   for	   selection	   following	   transformation	   of	   competent	  
bacteria.	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2.2.3.2 pBabe	  puro	  
The	  pBabe	  puro	  retroviral	  vector	  uses	  the	  LTRs	  of	  the	  murine	  leukaemia	  virus	  (MLV)	  to	  
drive	  transcription	  of	   the	  transgene.	  An	   improved	  vector,	  as	  described	  by	  Zhao	  et	  al.	  
(510),	  was	  used	  in	  which	  a	  constitutive	  transport	  element	  (CTE)	  from	  the	  Mason-­‐Pfizer	  
monkey	  virus	  (MPMV)	  is	  included	  to	  increase	  titre,	  by	  increasing	  nuclear	  export	  of	  the	  
RNA.	   This	   vector	   also	   has	   an	   improved	   safety	   profile	   as	   the	   partial	  gag	   gene	   in	   the	  
parental	   vector	   has	   been	   removed	   to	   reduce	   potential	   areas	   of	   homology	   that	  may	  
favour	   recombination.	   Prior	   to	   the	   commencement	  of	   this	   PhD,	   the	   firefly	   luciferase	  
(ffLuc)	  was	  cloned	  into	  pBabe	  puro	  using	  a	  BamHI,	  BglII	  digest	  from	  the	  commercially	  
available	  pGL3-­‐Basic	  Vector	  (Promega).	  Antibiotic	  selection	  of	  pBabe	  puro	  transduced	  
cells	  is	  possible	  due	  to	  the	  presence	  of	  the	  puromycin	  resistance	  gene.	  
	  
2.2.4 PBMC	  Isolation	  and	  Activation	  
Peripheral	   blood	   mononuclear	   cells	   (PBMCs)	   were	   isolated	   from	   healthy	   donor	   or	  
patient	   blood	   samples	   using	   Ficoll-­‐Paque	   gradient.	   Recruitment	   of	   healthy	   volunteer	  
donors	   for	   this	   purpose	   was	   approved	   by	   the	   Guy’s	   Hospital	   Research	   Ethics	  
Committee	   (09/H0804/92;	  Use	  of	  Donor	  Blood	  Samples	   for	  Pre-­‐Clinical	  Development	  
of	  Active	  and	  Passive	  Immunotherapy	  for	  Cancer).	  Recruitment	  of	  patient	  donors	  was	  
approved	   by	   the	   Guy’s	   Hospital	   Research	   Ethics	   Committee	   (09/H0707/086;	  
Generation	  of	  clinical	  grade	  T-­‐cells	  for	  adoptive	  cell	  therapy)	  
	  
2.2.4.1 Materials,	  Reagents	  and	  Equipment	  
 	  Fresh	  Blood	   	  
 	  Citrate-­‐Dextrose	  solution	  (ACD)	   Sigma	  
 	  50mL	  Syringe	   BD	  Biosciences	  
 	  21G	  Butterfly	  Needle	   Greiner	  Bio-­‐One	  
 	  50mL	  Falcon	  tubes	   SLS	  
 	  Ficoll-­‐Paque	  Plus	   GE	  Healthcare	  
 	  Eppendorf	  5804	  Centrifuge	   Eppendorf	  
 	  Pasteur	  Pipettes	   SLS	  
 	  Phytohaemagglutinin/Leucoagglutinin	  (L-­‐PHA)	   Sigma-­‐Aldrich	  
 	  Anti-­‐CD3/Anti-­‐CD28	  Dynabeads	   Invitrogen	  
 	  R10	  Medium	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2.2.4.2 Protocol	  
Note:	  All	   steps	  of	   the	  procedure	   and	  all	   reagents	  used	  are	   at	   room	   temperature	   for	  
optimal	  cell	  recovery.	  
1. 15mL	  Ficoll-­‐Paque	  was	  aliquotted	  into	  two	  separate	  50mL	  Falcon	  tubes.	  
2. Fresh	  Blood	  (25mL)	  (anticoagulated	  with	  1x	  citrate-­‐dextrose	  solution)	  was	  slowly	  
layered	  onto	  the	  Ficoll-­‐Paque	  and	  were	  centrifuged	  at	  1150g	  for	  25	  minutes	  
(acceleration	  =	  0,	  deceleration	  =	  0).	  
3. The	  PBMC	  layer,	  present	  at	  the	  interface	  between	  the	  Ficoll-­‐Paque	  and	  the	  plasma,	  
was	  transferred	  into	  fresh	  50mL	  Falcon	  tubes	  using	  a	  Pasteur	  pipette	  and	  diluted	  to	  
a	  final	  volume	  of	  50mL	  in	  pre-­‐warmed	  PBS	  and	  centrifuged	  for	  15	  minutes	  at	  550g.	  
4. The	  cell	  pellet	  was	  re-­‐suspended	  in	  50mL	  pre-­‐warmed	  PBS	  and	  centrifuged	  for	  10	  
minutes	  at	  400g.	  
5. Following	  aspiration	  of	  the	  supernatant,	  the	  cell	  pellet	  was	  resuspended	  in	  10mL	  
R10	  media	  and	  cells	  were	  counted.	  
6. Cells	  were	  resuspended	  in	  R10	  media	  at	  a	  concentration	  of	  3	  x	  106	  cells/mL	  and	  
activated	  with	  5μg/mL	  phytohaemagglutinin	  (PHA)	  or	  with	  anti-­‐CD3,	  anti-­‐CD28	  
paramagnetic	  Dynabeads	  at	  a	  1:1	  cell:bead	  ratio.	  
	  
2.2.5 Production	  of	  retroviral	  packaging	  cell	  lines	  
For	  the	  transduction	  of	  human	  T-­‐cells	  stable	  PG13-­‐retroviral	  packaging	  cell	  lines	  were	  
produced	  using	  H29D	  viral	  supernatant	  as	  an	  intermediate	  for	  PG13	  transduction.	  
	  
2.2.5.1 Materials,	  Reagents	  and	  Equipment	  
 	  CalPhos	  mammalian	  transfection	  kit	   CloneTech	  
 	  Vortex	   	  
 	  Polyethylenimine	  (PEI)	   Sigma-­‐Aldrich	  
 	  Plasmid	  DNA	   	  
 	  H29D	  cells	   	  
 	  PG13	  cells	   	  
 	  H29D	  retroviral	  supernatant	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Components	  of	  the	  CalPhos	  Calcium	  Phosphate	  transfection	  kit:	  
 2M	  Calcium	  Solution	  (CaCl2)	  
 2x	  HEPES-­‐buffered	  saline	  (HBS)	   	  
 Sterile	  H2O	  
	  
2.2.5.2 Calcium-­‐Phosphate	  transfection	  (H29D)	  
Preparation	  of	  H29D	  cells	  
1. H29D	  cells	  were	  transduced	  in	  6-­‐well	  culture	  plates.	  
2. Cells	  were	   split	   at	   least	  2	  days	  prior	   to	   transfection	  day	   so	   they	  would	   reach	  80-­‐
90%	  confluence	  on	  the	  day	  of	  transfection	   in	  3mL	  D10	  media	  supplemented	  with	  
tetracycline.	  
3. The	  tetracycline	  was	  removed	  from	  the	  H29D	  cells	  a	  minimum	  of	  2	  hours	  prior	  to	  
transfection	  by	  replacing	  the	  tetracycline-­‐containing	  D10	  with	  fresh	  D10	  only.	  
	  
Preparation	  of	  Transfection	  Mixture	  
1. Solution	  A	  was	  prepared	  and	  left	  to	  incubate	  at	  room	  temperature	  for	  5	  minutes;	  
Solution	  A:	  
 12.4μL	  2M	  Calcium	  Solution	  (CaCl2)	  
 1-­‐3μg	  retroviral	  vector	  
 Sterile	  H2O	  to	  a	  final	  volume	  of	  100μL	  
2. Solution	  A	  was	  added	  dropwise	  to	  100μL	  2X	  HBS	  whilst	  vortexing.	  
3. The	   mixture	   was	   incubated	   at	   room	   temperature	   for	   20	   minutes	   to	   ensure	   the	  
formation	  of	  precipitate,	  before	  being	  added	  dropwise	  to	  the	  target	  cells.	  
4. After	  gentle	  rocking	  ensured	  complete	  mixing	  of	  the	  transfection	  mixture,	  the	  cells	  
were	  incubated	  for	  24	  hours	  after	  which	  the	  media	  was	  replaced.	  
5. Supernatants	  were	  harvested	  daily	  from	  day	  3-­‐7	  post	  transfection	  and	  directly	  used	  
for	  infection	  of	  target	  cells	  (PG13).	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2.2.5.3 PEI-­‐mediated	  transfection	  (H29D)	  
1. H29D	  packaging	  cell	  lines	  were	  prepared	  as	  described	  in	  paragraph	  2.2.5.2.	  
2. Transfection	  mixture	  was	  prepared	  and	   left	   to	   incubate	  at	   room	  temperature	   for	  
20	  minutes.	  
 400μL	  serum	  free	  DMEM	  
 5μg	  plasmid	  DNA	  
 1μl	  1mM	  PEI	  
3. Transfection	  mixture	  was	  dropwise	  added	  to	  the	  target	  cells.	  
4. The	   cells	  were	   incubated	   for	  3-­‐4	  hours	   after	  which	   the	  media	  was	   replaced	  with	  
fresh	  D10	  media.	  
5. Media	   was	   again	   refreshed	   24	   hours	   prior	   to	   the	   (first)	   harvest	   of	   retroviral	  
supernatant.	  
6. Supernatants	  were	  harvested	  daily	  from	  day	  3-­‐7	  post	  transfection	  and	  directly	  used	  
for	  target	  cell	  infection	  (PG13).	  
	  
2.2.5.4 PG13	  Transduction	  
1. The	  media	  was	  removed	  from	  empty	  PG13	  packaging	  cells	  and	  replaced	  with	  3mL	  
H29D	  supernatant	  containing	  the	  VSV-­‐pseudotyped	  virions.	  
2. 8μg/mL	  polybrene	  was	  added	  and	  mixed	  thoroughly	  to	  facilitate	  retroviral	  uptake.	  
3. The	  PG13	  were	  subsequently	  incubated	  for	  72	  hours	  prior	  to	  analysis	  for	  transgene	  
expression	  using	  flow	  cytometry.	  
4. PG13	  population	   in	  which	  >90%	  of	   the	  cells	  were	  expressing	   the	  virus	  of	   interest	  
were	  used	  as	  stable	  packaging	  cell	  lines.	  
	  
2.2.6 Production	  of	  RetroNectin	  coated	  plates/bags	  
In	  order	   to	   improve	  T-­‐cell	   transduction	   rates,	   the	  plates	  used	  were	  pre-­‐treated	  with	  
RetroNectin	   (RN).	   RetroNectin	   is	   a	   fragment	   of	   the	   extracellular	   matrix	   protein	  
fibronectin	   that	   binds	   the	   target	   T-­‐cell	   through	   a	   CS-­‐1	   domain	   and	   a	   cell-­‐binding	  
domain	   (CBD),	   which	   interacts	   with	   the	   VLA-­‐4	   and	   VLA-­‐5	   integrin	   receptors	  
respectively.	   Attachment	   of	   the	   virus	   to	   the	   heparin	   binding	   domain	   present	   in	   RN	  
between	  the	  CS-­‐1	  and	  CBD	  causes	  co-­‐localisation	  of	  the	  target	  cell	  and	  the	  virus,	  thus	  
greatly	   improving	   gene	   transfer	   efficiency	   (511,	   512).	   Amounts	   less	   than	  20	   x	   106	   T-­‐
cells	   were	   transduced	   in	   6-­‐well	   plates;	   quantities	   larger	   than	   20	   x	   106	   T-­‐cells	   were	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transduced	  in	  197-­‐adherent	  culture	  (AC)	  VueLife	  fluorinated	  ethylene	  propylene	  (FEP)	  
bags.	  
	  
2.2.6.1 Materials,	  Reagents	  and	  Equipment	  
 	  RetroNectin	   TaKaRa	  
 	  Non-­‐tissue	  culture	  treated	  6-­‐well	  plates	   Falcon	  
 	  197-­‐AC	  VueLife	  FEP	  bags	   American	  Fluoroseal	  Corporation	  
 	  PBS	   	  
 	  Pasteur	  pipettes	   	  
 	  50mL	  syringe	   	  
	  
2.2.6.2 Protocol	  –	  6	  well	  plates	  
1. 200μg	  of	  RN	  was	  resuspended	  in	  12mL	  PBS/plate	  
2. 2mL	  of	  the	  resulting	  solution	  was	  transferred	  using	  a	  Pasteur	  pipette	  into	  each	  well	  
of	   a	   non-­‐tissue	   culture	   treated	   6-­‐well	   plate,	   thereby	   giving	   coverage	   of	  
approximately	  3.5μg/cm2	  
3. Plates	  were	  incubated	  for	  a	  minimum	  of	  2	  hours	  at	  room	  temperature	  or	  24	  hours	  
at	  4°C	  prior	  to	  use.	  
4. When	  the	  plate	  was	  to	  be	  used,	  unbound	  RN	  was	  transferred	  to	  a	  new	  plate	  using	  
a	  Pasteur	  pipette.	  Retronectin	  was	  used	  for	  a	  maximum	  of	  two	  transductions.	  
	  
2.2.6.3 Protocol	  –	  197-­‐AC	  VueLife	  FEP	  Bags	  
1. One	   vial	   (2.5mg)	   of	   RN	  was	   diluted	   in	   150mL	   PBS	   and	   transferred	   into	   a	   197-­‐AC	  
VueLife	  FEP	  bag,	  using	  a	  50mL	  syringe,	  to	  give	  coverage	  of	  approximately	  6μg/cm2.	  
2. The	  bag	  was	  incubated	  at	  4°C	  overnight.	  
3. When	   the	  bag	  was	   to	  be	  used,	   the	  unbound	  RN	  was	   removed	  prior	   to	   retroviral	  
supernatant	  and	  transferred	  into	  non-­‐tissue	  culture	  plates	  or	  a	  197-­‐AC	  VueLife	  FEP	  
bag.	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2.2.7 Retroviral-­‐Mediated	  Human	  T-­‐cell	  Transduction	  
To	   introduce	   the	   CAR	   constructs	   into	   T-­‐cells,	   they	   were	   subjected	   to	   retroviral-­‐
mediated	  transduction.	  This	  ensured	   integration	  of	   the	   inserted	  coding	  DNA	   into	   the	  
host	  T-­‐cell	  genome,	  thereby	  permitting	  stable	  CAR	  expression.	  
	  
2.2.7.1 Materials,	  Reagents	  and	  Equipment	  
 	  Activated	  T-­‐cells	   	  
 	  Retroviral	  packaging	  cell	  lines	   	  
 	  Centrifuge	   	  
 	  Retronectin-­‐coated	  plate/bag	   	  
 	  Pasteur	  pipettes	   	  
 	  Interleukin-­‐2	  (Aldesleukin)	   Novartis	  
	  
2.2.7.2 Protocol	  –	  6	  well	  plate	  
1. After	   the	   unbound	   RN	   had	   been	   transferred	   to	   a	   fresh	   plate	   using	   a	   Pasteur	  
pipette,	  each	  well	  was	  coated	  with	  3mL	  of	  retrovirus-­‐containing	  supernatant	  from	  
the	  desired	  packaging	  cell	  line.	  
2. Activated	  T-­‐cells	  were	  counted	  using	  trypan-­‐blue	  exclusion	  and	  1	  x	  106	  viable	  cells	  
added	  to	  each	  well.	  
3. Each	  well	  was	  supplemented	  with	  100U/mL	  of	  IL-­‐2.	  
4. Plates	  were	  centrifuged	  for	  one	  hour	  at	  50g,	  at	  room	  temperature.	  
5. Cells	  were	  subsequently	  incubated	  for	  96	  hours,	  after	  which	  the	  transduction	  rate	  
was	  determined	  using	  flow	  cytometry.	  
	  
2.2.7.3 Protocol	  –	  197-­‐AC	  VueLife	  FEP	  bag	  
1. The	  unbound	  retronectin	  was	  removed	  from	  the	  FEP	  bag	  and	  coated	  with	  60mL	  of	  
retrovirus-­‐containing	  supernatant	  from	  the	  desired	  packaging	  cell	  line.	  
2. Activated	  T-­‐cells	  were	  counted	  using	  trypan-­‐blue	  exclusion	  and	  20-­‐40	  x	  106	  viable	  
cells	  were	  added.	  
3. The	  bag	  was	  supplemented	  with	  100U/mL	  of	  IL-­‐2.	  
4. Cells	   were	   incubated	   for	   96	   hours,	   after	   which	   the	   transduction	   rate	   was	  
determined	  using	  flow	  cytometry.	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2.2.8 Determination	  of	  the	  Anti-­‐Tumour	  Potential	  of	  CAR+	  T-­‐cells	  
In	   order	   to	   demonstrate	   the	   ability	   of	   CAR+	   T-­‐cells	   to	   recognise	   and	   destroy	   ErbB-­‐
expressing	   targets,	   they	  were	  co-­‐cultured	  with	  a	  variety	  of	  human	  and	  murine	  ErbB+	  
tumour	   cell	   lines.	   Target	   recognition	  was	  monitored	   by	  measuring	   cytokine	   release,	  
whilst	  anti-­‐tumour	  activity	  was	  quantitated	  using	  an	  MTT	  (3-­‐[4,5-­‐dimethylthiazol-­‐2-­‐yl]-­‐
2,5-­‐	   diphenyltetrazolium	   bromide;	   thiazolyl	   blue)	   assay	   (please	   refer	   to	   paragraph	  
2.2.9)	  and	  visualized	  with	  crystal	  violet	  staining	  (please	  refer	  to	  paragraph	  2.2.10).	  
	  
2.2.8.1 Materials,	  Reagents	  and	  Equipment	  
 	  Transduced	  T-­‐cells	   	  
 	  Tumour	  cells	   	  
 	  R10	  media	   	  
 	  Interleukin-­‐2	  (Aldesleukin)	   	  
 	  rhIL-­‐4	   Gentaur	  
 	  24-­‐well	  cell	  culture	  plate	   	  
	  
2.2.8.2 Protocol	  
1. Tumour	   cells	  were	   seeded	   into	   a	   24-­‐well	   cell	   culture	   plate	   and	   allowed	   to	   reach	  
confluence.	  
2. T-­‐cells	  were	  counted	  using	  trypan-­‐blue	  exclusion	  and	  re-­‐suspended	  in	  R10	  media	  at	  
a	   concentration	   of	   1	   x	   106	   cells/mL	   and	   gently	   pipetted	   onto	   the	   surface	   of	   the	  
confluent	  tumour	  monolayer.	  
3. After	   24	   hours	   of	   incubation,	   500μL	   supernatant	   was	   removed	   for	   analysis	   of	  
cytokine	  (IL-­‐2	  and	  IFNγ)	  secretion.	  
4. T-­‐cells	  were	  supplied	  with	  fresh	  R10	  media	  containing	  100U/mL	  rhIL-­‐2	  or	  30ng/mL	  
IL-­‐4	  at	  2-­‐3	  day	  intervals	  until	  the	  desired	  monolayer	  destruction	  was	  achieved.	  	  
	  
2.2.9 Quantification	  of	  Tumour-­‐Cell	  Destruction	  
Anti-­‐tumour	   activity	   of	   CAR+	   T-­‐cells	   was	   quantified	   using	   an	   MTT	   (3-­‐[4,5-­‐
dimethylthiazol-­‐2-­‐yl]-­‐2,5-­‐	  diphenyltetrazolium	  bromide;	  thiazolyl	  blue)	  assay.	  MTT	  is	  a	  
water	  soluble	  tetrazolium	  salt	  yielding	  a	  yellowing	  solution	  when	  prepared	  in	  media	  or	  
salt	  solutions	  lacking	  phenol	  red.	  Mitochondrial	  dehydrogenases	  of	  viable	  cells	  cleave	  
the	   tetrazolium	   ring	   in	   dissolved	   MTT,	   yielding	   purple	   formazan	   crystals	   which	   are	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insoluble	  in	  aqueous	  solutions.	  The	  crystals	  are	  dissolved	  in	  acidified	  isopropanol.	  The	  
resulting	   purple	   solution	   is	   detected	   optimally	   at	   a	   wavelength	   of	   570nm	   using	   a	  
spectrophotometer.	  Dead	   cells	  do	  not	   cause	   this	   change.	  An	   increase	  or	  decrease	   in	  
viable	  cell	  number	  results	  in	  a	  concomitant	  change	  in	  the	  amount	  of	  formazan	  formed,	  
indicating	  the	  degree	  of	  cytotoxicity	  caused	  (513).	  
	  
2.2.9.1 Materials,	  Reagents	  and	  Equipment	  
 	  MTT	   Sigma	  
 	  MTT	  solubilisation	  solution	   Sigma	  
 	  PBS	   	  
 	  DMSO	   VWR	  
 	  FLUOstar	  Omega	   BMT	  Labtech	  
 	  Omega	  Software	  (version	  1.20)	   BMT	  Labtech	  
 	  MARS	  data	  analysis	  software	  (version	  1.20	  R2)	   BMT	  Labtech	  
MTT	  Solubilisation	  Solution:	  10%	  Triton	  X-­‐100	  plus	  0.1	  N	  HCl	  anhydrous	  isopropanol	  
	   	  
2.2.9.2 Protocol	  
1. MTT	  assays	  were	  performed	  in	  24-­‐well	  cell	  culture	  treated	  plates.	  
2. MTT	   stock	   solution	   was	   reconstituted	   at	   a	   concentration	   of	   5mg/mL	   in	   MTT	  
solubilisation	  solution.	  Stock	  solution	  is	  stored	  at	  -­‐20°C.	  
3. Medium	  was	  aspirated	  from	  the	  co-­‐culture	  and	  wells	  were	  washed	  with	  500μL	  PBS	  
to	  remove	  residual	  T-­‐cells.	  
4. MTT	   stock	   solution	   was	   diluted	   1/10	   (to	   a	   concentration	   of	   500μg/mL)	   in	   D10	  
media	  and	  500μL	  (250μg)	  was	  added	  to	  each	  well.	  
5. Cell	  cultures	  were	  incubated	  for	  2-­‐4	  hours	  at	  37°C	  and	  5%	  CO2.	  
6. The	   supernatant	   was	   aspirated	   and	   the	   formed	   formazan	   crystals	   were	  
resuspended	  in	  300μL	  DMSO.	  
7. Absorbance	  was	  measured	  spectrophotometrically	  at	  570nm.	  
8. Relative	  cell	  viability	  was	  calculated	  using	  the	  following	  equation:	  
Viability	   =	   (absorbance	   of	   test	   well/	   average	   absorbance	   of	   untreated	   tumour	  
monolayer)x100	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2.2.10 Visualisation	  of	  Tumour	  Cells	  using	  Crystal	  Violet	  Staining	  
Visualisation	  of	   tumour-­‐cell	  destruction	  by	  CAR-­‐transduced	  T-­‐cells	  may	  be	  effectively	  
achieved	   by	   staining	   the	   remaining	   target	   cells	   with	   crystal	   violet.	   Crystal	   violet	   is	  
commonly	   used	   as	   a	   stain	   for	   identifying	  Gram-­‐positive	   bacteria	   due	   to	   it	   becoming	  
trapped	   within	   the	   peptidoglycan	   layer	   upon	   ethanol-­‐induced	   dehydration.	   When	  
supplied	  with	  a	  mordant	  (methanol),	  it	  is	  also	  capable	  of	  staining	  human	  cells.	  
	  
2.2.10.1 Materials,	  Reagents	  and	  Equipment	  
 	  Crystal	  Violet	   Sigma-­‐Aldrich	  
 	  PBS	   	  
 	  Methanol	   Fisher	  Scientific	  
 	  Inverted	  light	  microscope	   Nikon	  TMS	  
 	  AxioVision	  HR	  camera	   AxioVision	  
 	  Axiovert	  S100	  software	   AxioVision	  
	  
2.2.10.2 Protocol	  
1. Media	  was	  carefully	  aspirated	  from	  the	  plate	  of	  interest.	  
2. The	  wells	  were	  gently	  washed	  with	  500μL	  PBS	  before	  being	  treated	  with	  500μL	  of	  
ice-­‐cold	  methanol	  and	  fixed	  at	  -­‐20°C	  for	  a	  minimum	  of	  ten	  minutes.	  
3. After	  aspiration	  of	  the	  methanol,	  each	  well	  was	  submerged	  in	  crystal	  violet	  dye	  and	  
incubated	  at	  room	  temperature	  for	  five	  minutes.	  
4. Following	   removal	   of	   the	   crystal	   violet,	   the	   plates	   were	   washed	   by	   gentle	  
submersion	  in	  water	  to	  remove	  excess	  dye.	  
5. Plates	  were	  dried	  at	  room	  temperature	  overnight.	  
6. Images	  were	  captured	  under	   light	  microscopy	  on	  an	   inverted	  microscope	  with	  an	  
AxioVision	   HR	   camera.	   Images	   were	   analysed	   and	   scale	   determined	   using	   Zeiss	  
Axiovert	  S100	  software.	  
	  
2.2.11 Analysis	  of	  firefly	  Luciferase	  Expression	  
Bioluminescent	  imaging	  (BLI)	  was	  used	  to	  monitor	  tumour	  growth	  and	  T-­‐cell	  migration	  
and	   longevity	   in	   vivo.	   This	   was	   achieved	   by	   expression	   of	   a	   firefly	   luciferase	   (ffLuc)	  
enzyme	  within	   the	   transplanted	   cells.	   Stable	   expression	   of	   the	   luciferase	   enzyme	  by	  
the	   various	   tumour	   cell	   lines	   was	   achieved	   using	   the	   retroviral	   vector	   pBabe	   puro	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(details	  of	  this	  vector	  are	  given	  in	  paragraph	  2.2.3.2).	  Expression	  of	  the	  firefly	  enzyme	  
in	  T-­‐cells	  was	  achieved	  using	  the	  retroviral	  vector	  SFG,	  containing	  4αβ,	  T28ζ	  and	  ffLuc	  
(details	  of	  the	  vector	  are	  given	  in	  paragraph	  2.1.1.6).	  	  Prior	  to	  transfer	  of	  the	  luciferase-­‐
tagged	   cells	   in	   vivo,	   it	   was	   important	   to	   ensure	   the	   continued	   expression	   and	  
functionality	  of	  the	  enzyme.	  Firefly	  luciferase	  catalyses	  the	  conversion	  of	  a	  molecule	  of	  
D-­‐luciferin	  to	  an	  electronically	  ‘excited’	  molecule	  of	  oxyluciferin	  when	  in	  the	  presence	  
of	   magnesium,	   ATP	   and	   oxygen.	   The	   subsequent	   relaxation	   of	   this	   oxyluciferin	  
molecule	  to	  a	  lower	  energy	  state	  results	  in	  the	  release	  of	  a	  single	  photon,	  which	  can	  be	  
detected	   by	   a	   super-­‐cooled	   ‘charged-­‐coupled	   device’	   (CCD)	   and	   a	   camera	   or	  
luminometer	  (514-­‐516).	  
	  
2.2.11.1 Materials,	  Reagents	  and	  Equipment	  
 	  Luciferase	  assay	  substrate	   Promega	  
 	  Luciferase	  assay	  buffer	   Promega	  
 	  5x	  Reporter	  Lysis	  buffer	   Promega	  
 	  Cell	  Lysate	   	  
 	  White	  96-­‐well	  plate	   Nunc	  
 	  FLUOstar	  Omega	  Plate	  Reader	   BMT	  Labtech	  
 	  Omega	  Software	  (version	  1.20)	   BMT	  Labtech	  
 	  MARS	  data	  analysis	  software	  (version	  1.20	  R2)	   BMT	  Labtech	  
	  
2.2.11.2 Protocol	  
1. The	  5x	  Reporter	  Lysis	  buffer	  was	  diluted	  in	  dH2O	  to	  give	  a	  1x	  solution,	  which	  was	  
equilibrated	  to	  room	  temperature	  prior	  to	  use.	  
2. Viable	  cells	  were	  counted	  based	  on	  trypan-­‐blue	  based	  exclusion	  and	  0.5	  x	  106	  cells	  
were	  resuspended	  in	  500μL	  1x	  Reporter	  Lysis	  buffer.	  
3. Lysed	  Cells	  were	  transferred	  into	  a	  1.5mL	  Eppendorf	  and	  snap-­‐frozen	  on	  dry	  ice.	  
4. Cell	  lysate	  was	  centrifuged	  for	  15	  seconds	  at	  10,400g.	  
5. 20μL	  of	  cell	  lysate	  was	  mixed	  with	  100μL	  luciferase	  assay	  substrate	  in	  one	  well	  of	  a	  
white	  96-­‐well	  plate.	  
6. The	  luminescence	  was	  read	  using	  the	  FLUOstar	  Omega	  luminometer.	  
7. Luminescence	   values	   were	   compared	   with	   negative	   control	   lysates	   gained	   from	  
matched	  luciferase-­‐negative	  cells.	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2.3 In	  vivo	  models	  
All	   in	   vivo	   experiments	   were	   performed	   strictly	   adhering	   to	   the	   UK	   Home	   Office	  
guidelines	   as	   stated	   in	   the	   project	   license	   (license	   number	   70/7603)	   and	   personal	  
license	  (license	  number	  70/23089)	  that	  governed	  this	  work.	  
	  
2.3.1 Tumour	  Inoculation	  
Tumour	   cells	   were	   inoculated	   by	   either	   subcutaneous	   (SC)	   or	   intra-­‐peritoneal	   (IP)	  
injection.	  	  
	  
2.3.1.1 Materials,	  Reagents	  and	  Equipment	  
 	  1mL	  Syringe	   BD	  Plastipak	  
 	  25	  G	  Needle	   BD	  Biosciences	  
 	  BD	  Matrigel	  Basement	  Membrane	  Matrix	  
Growth	  Factor	  Reduced,	  Phenol	  Red-­‐free	  
	  
BD	  Biosciences	  
 	  PBS	   	  
	  
2.3.1.2 Protocol	  
The	  amount	  of	  tumour	  cells	  and	  injection	  volumes	  used	  are	  specified	  in	  the	  individual	  
experiments.	  
	  
Intra-­‐peritoneal	  	  (IP)	  tumour	  inoculation	  
1. Mice	  were	  randomised	  into	  the	  required	  number	  of	  groups.	  
2. The	  specified	  number	  of	  tumour	  cells	  were	  resuspended	  in	  400μL	  PBS	  and	  injected	  
into	  the	  intra-­‐peritoneal	  cavity	  using	  a	  25G	  needle	  connected	  to	  a	  1mL	  syringe.	  
3. Tumour	  growth	  was	  monitored	  using	  BLI	  (please	  refer	  to	  paragraph	  2.3.4).	  
	  
Subcutaneous	  (SC)	  tumour	  inoculation	  
1. Mice	  were	  randomised	  into	  the	  required	  number	  of	  groups.	  
2. Mice	  were	  anaesthethised	  with	  3-­‐4%	  gaseous	  isofluorane.	  	  
3. The	  specified	  number	  of	  tumour	  cells	  were	  resuspended	  in	  200μL	  PBS	  or	  Matrigel	  
and	  injected	  subcutaneously	  into	  the	  left	  flank	  using	  a	  25G	  needle	  connected	  to	  a	  
1mL	  syringe.	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4. Tumour	   growth	   was	   monitored	   using	   BLI	   (please	   refer	   to	   paragraph	   2.3.4)	   and	  
caliper	  measurements	  (please	  refer	  to	  paragraph	  2.3.5)	  where	  appropriate.	  
	  
2.3.2 T-­‐cell	  Administration	  
To	  determine	  in	  vivo	  efficacy	  and	  toxicity	  of	  T-­‐cell	  immunotherapy,	  mice	  were	  treated	  
with	   different	   doses	   of	   CAR+	   or	   control	   T-­‐cells,	   administered	   using	   the	   SC,	   IP	   or	  
intravenous	  (IV)	  routes	  of	  injection.	  
	  
2.3.2.1 Materials,	  Reagents	  and	  Equipment	  
 	  1mL	  insulin	  syringes	  (29G)	   Terumo	  
 	  PBS	   	  
	  
2.3.2.2 Protocol	  
The	  amount	  of	   T-­‐cells	   and	   route	  of	   administration	  used	   is	   specified	   in	   the	   individual	  
experiment	  descriptions	  in	  the	  results	  chapters.	  
	  
Intra-­‐peritoneal	  T-­‐cell	  injection	  
1. The	  required	  number	  of	  T-­‐cells	  was	  resuspended	  in	  500μL	  PBS	  and	  injected	  intra-­‐
peritoneally	  using	  a	  1mL	  insulin	  syringe.	  
	  
Intra-­‐tumoural	  (IT)/	  peri-­‐tumoural	  (PT)	  T-­‐cell	  injection	  
1. The	  mice	  were	  anaesthethised	  with	  3-­‐4%	  gaseous	  isofluorane.	  
2. The	  required	  amount	  of	  T-­‐cells	  were	  resuspended	  in	  50μL	  PBS	  and	  injected	  into	  the	  
subcutaneous	  tumour	  using	  a	  1mL	  insulin	  syringe.	  
3. If	  SC	  tumours	  were	  too	  small	  to	  allow	  for	  IT	  injection,	  T-­‐cells	  were	  injected	  PT.	  
	  
Intravenous	  T-­‐cell	  injection	  
1. Mice	  were	  restrained	  and	  better	  visualization	  of	  the	  tail	  vein	  was	  achieved	  using	  a	  
heat	  lamp.	  
2. The	  required	  number	  of	  T-­‐cells	  were	  resuspended	  in	  200μL	  PBS	  and	  injected	  into	  
the	  tail	  vein	  using	  a	  Terumo	  1mL	  insulin	  syringe.	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2.3.3 Body	  Weight	  Measurement	  
One	  of	  the	  hallmarks	  by	  which	  toxicity	  can	  be	  quantified	  is	  the	  change	  in	  body	  weight	  
of	  the	  mouse.	  Body	  weights	  were	  measured	  at	  regular	  intervals	  during	  the	  studies	  
	  
2.3.3.1 Materials,	  Reagents	  and	  Equipment	  
 	  Balance	   Mettler	  Toledo	  
	  
2.3.3.2 Protocol	  
1. Mice	  were	  individually	  transferred	  from	  their	  cage	  to	  the	  balance	  
2. Weight	  was	  monitored	  at	  regular	  timepoints	  during	  the	  study	  
	  
2.3.4 Bioluminescent	  Imaging	  
Bioluminescent	  Imaging	  (BLI)	  is	  a	  sensitive,	  non-­‐invasive	  technique,	  which	  allows	  semi-­‐
quantitative	   monitoring	   of	   tumour	   growth	   and	   T-­‐cell	   migration	   in	   vivo.	   After	  
administration	  of	  the	  D-­‐luciferin	  substrate,	  the	  luciferase-­‐tagged	  cells	  can	  be	  visualized	  
in	  situ	  whilst	  the	  mice	  are	  under	  anaesthetic.	  
	  
2.3.4.1 Materials,	  Reagents	  and	  Equipment	  
 	  D-­‐Luciferin	   Caliper	  Lifesciences	  
 	  Isofluorane	   Baxter	  
 	  IVIS	  Lumina	  II	  imaging	  platform	   Caliper	  Lifesciences	  
 	  1mL	  insulin	  syringes	  (29G)	   	  
	  
2.3.4.2 Protocol	  
1. Mice	  were	  injected	  with	  3mg	  (400μL)	  D-­‐luciferin	  intra-­‐peritoneally	  and	  placed	  back	  
into	  the	  cage	  for	  five	  minutes	  
2. Mice	  were	   anaesthethised	  with	   3-­‐4%	   gaseous	   isofluorane	   and	   transferred	   to	   the	  
IVIS	  Lumina	  II	  imaging	  platform	  
3. A	  total	  of	  nine	   images	  of	   increasing	  duration	   (1s,	  2s,	  5s,	  10s,	  30s,	  45s,	  60s,	  120s,	  
180s)	   were	   taken	   using	   small	   (for	   tumours)	   or	   large	   (for	   T-­‐cells)	   binning.	  
Throughout	  the	  imaging	  the	  mice	  were	  kept	  under	  1.5%	  isofluorane	  anaesthesia.	  
4. After	   completion	   of	   the	   imaging,	   the	   mice	   were	   returned	   to	   their	   cages	   and	  
monitored	  until	  they	  regained	  consciousness.	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2.3.5 Caliper	  Measurements	  
Caliper	   measurements	   are	   a	   non-­‐invasive	   way	   to	   monitor	   subcutaneous	   tumour	  
growth.	   The	   length	   and	   width	   of	   a	   subcutaneous	   tumour	   is	   measured	   using	   an	  
electronic	   caliper,	   which	   allows	   the	   calculation	   of	   the	   tumour	   volume	   using	   the	  
formula	  indicated	  below.	  
 
2.3.5.1 Materials,	  Reagents	  and	  Equipment	  
  Golden	  A5	  animal	  clipper	   Oster	  
  Electronic	  Caliper	   SiTE	  
 
2.3.5.2 Protocol	  
1. The	  area	  of	  the	  subcutaneous	  is	  shaved	  using	  an	  electronic	  shaver	  
2. The	  length	  and	  width	  of	  the	  tumour	  is	  measured	  using	  an	  electronic	  caliper	  
3. The	  volume	  of	  the	  tumour	  is	  calculated	  using	  the	  formula:	  	  
Volume	  =	  (length	  x	  width2)/2	  
	  
2.3.6 Blood	  Sampling	  from	  Tail	  Vein	  
To	   determine	   serum	   cytokine	   levels	   after	   T-­‐cell	   administration,	   blood	   samples	  were	  
taken	  from	  the	  tail	  vein	  at	  suitable	  time-­‐points	  during	  the	  study.	  
	  
2.3.6.1 Materials,	  Reagents	  and	  Equipment	  
 	  Isofluorane	   Baxter	  
 	  Scissors	   	  
 	  Microvette	  CB300	  tubes	   Sarstedt	  
 	  1.5mL	  Eppendorf	  tubes	   Eppendorf	  
	  
2.3.6.2 Protocol	  
1. Prior	   to	   the	   first	   blood	   sample,	   mice	   were	   anaesthetised	   with	   3-­‐4%	   gaseous	  
isofluorane.	  
2. The	   tip	   of	   the	   tail	   vein	   is	   clipped	   off	   and	   100μL	   of	   blood	   is	   collected	   in	   the	  
Microvette	  CB300	  tube.	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3. Blood	   samples	   are	   taken	   at	   multiple	   timepoints	   after	   T-­‐cell	   injection	   during	   the	  
study:	  
a. 4	  hours	  	  
b. 24	  hours	  
c. 48	  hours	  
4. To	  isolate	  the	  serum,	  blood	  was	  allowed	  to	  clot	  within	  the	  Microvette	  CB300	  tubes	  
and	   were	   centrifuged	   for	   5	   minutes	   at	   10,000g.	   The	   serum	   was	   transferred	   to	  
1.5mL	  Eppendorf	  tubes	  and	  stored	  at	  -­‐20°C.	  
	  
2.3.7 Liposomal	  Clodronate	  and	  Liposomal	  PBS	  treatment	  
Liposomal	   Clodronate	   (LC)	   and	   Liposomal	   PBS	   (LP)	   were	   obtained	   from	   Dr	   N.	   van	  
Rooijen,	  Foundation	  Clodronate	  Liposomes,	  Haarlem,	  the	  Netherlands.	  Mice	  received	  
two	  doses	  of	  LC/LP,	  one	  four	  days	  prior	  to	  T-­‐cell	  administration,	  and	  a	  second	  one	  day	  
prior	  to	  T-­‐cell	  administration.	  
	  
2.3.7.1 Materials,	  Reagents	  and	  Equipment	  
 	  Liposomal	  Clodronate	  (10mg/mL)	   Foundation	  Clodronate	  Liposomes	  
 	  Liposomal	  PBS	  (10mg/mL)	   Foundation	  Clodronate	  Liposomes	  
 	  1mL	  syringe	   	  
 	  23G	  Needle	   BD	  
 	  Balance	   	  
	  
2.3.7.2 Protocol	  
1. Mice	  were	  transferred	  individually	  from	  the	  cage	  to	  the	  balance	  
2. Weight	  of	  the	  mice	  was	  recorded	  
3. Mice	  were	  injected	  ip	  with	  the	  required	  dose	  of	  LC/LP	  
a. Dose	  1:	  1mg/10g	  body	  weight	  
b. Dose	  2:	  0.5mg/10g	  body	  weight	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2.3.8 Peritoneal	  Lavage	  
To	  determine	  the	  content	  of	  macrophages	  in	  the	  peritoneal	  cavity	  after	  treatment	  with	  
LC	   or	   LP,	   ip	   lavages	   were	   performed	   to	   remove	   all	   cell-­‐content	   and	   macrophage	  
content	  was	  determined	  by	  flow	  cytometry.	  
	  
2.3.8.1 Materials,	  Reagents	  and	  Equipment	  
 	  Ice-­‐cold	  PBS	   	  
 	  5mL	  syringe	   BD	  Plastipak	  
 	  19	  G	  Needle	   BD	  
 	  50mL	  Falcon	  tube	   BD	  
 	  Scissors	   	  
 	  Tweezers	   	  
 	  Ice	   	  
	  
2.3.8.2 Protocol	  
1. Prior	  to	  ip	  lavage,	  mice	  were	  culled	  by	  dislocation	  of	  the	  neck	  
2. 5mL	  ice-­‐cold	  PBS	  was	  injected	  into	  the	  intra-­‐peritoneal	  cavity.	  
3. The	  body	  of	  the	  mouse	  was	  massaged	  to	  ensure	  optimal	  distribution	  of	  the	  PBS	  
4. The	  skin	  was	  opened,	  leaving	  the	  peritoneum	  in	  tact.	  
5. A	  small	  hole	  was	  made	  in	  the	  peritoneum,	  allowing	  the	  PBS	  to	  flow	  out	  into	  a	  
50mL	  falcon	  tube	  that	  was	  placed	  on	  ice.	  
6. The	  macrophage	   content	  was	   determined	   by	   flow	   cytometry	   (please	   refer	   to	  
paragraph	  2.4.1.10).	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2.3.9 Homogenisation	  of	  Mouse	  Organs	  
Organs	   were	   harvested	   from	   untreated	   healthy	   SCID/Beige	   mice	   to	   analyse	   ErbB	  
expression	  using	  flow	  cytometry.	  
	  
2.3.9.1 Materials,	  Reagents	  and	  Equipment	  
 	  Organs	  from	  SCID/Beige	  mice	   	  
 	  2mL	  syringe	   BD	  Plastipak	  
 	  100μM	  Nylon	  filter	   BD	  
 	  Red	  Blood	  Cell	  Lysis	  buffer	   Miltenyi	  
 	  PBS	   	  
 	  mR10	   Please	  refer	  to	  paragraph	  2.2.1.1	  
	  
2.3.9.2 Protocol	  
1. Organs	  were	  harvested	  and	  directly	  submerged	  into	  sterile	  PBS.	  
2. Single	  organs	  were	  passed	  through	  a	  100μm	  nylon	  filter	  with	  the	  aid	  of	  the	  plunger	  
of	  a	  2mL	  syringe.	  
3. Cells	  were	  washed	  in	  mR10	  and	  red	  blood	  cells	  were	  lysed	  using	  red	  blood	  cell	  lysis	  
buffer.	  
4. For	   flow	   cytometry	   analysis:	   cells	   were	   washed	   in	   excess	   mR10	   after	   which	   the	  
pellet	   was	   resuspended	   in	   1-­‐10mL	   mR10	   (depending	   on	   the	   organ	   size)	   and	  
immediately	  used	  for	  flow	  cytometry	  analysis.	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2.4 Flow	  Cytometry	  
Flow	  cytometry	  was	  used	  to	  probe	  for	  protein	  expression	  either	  at	  the	  cell	  surface	  or	  
intracellularly.	  Determination	  of	  protein	  expression	  at	   the	  cell	   surface	  was	   important	  
for	  showing	  the	  expression	  of	  the	  CAR	  by	  the	  T-­‐cells	  and	  packaging	  cell	  lines	  as	  well	  as	  
for	  investigation	  of	  the	  levels	  of	  ErbB	  expression	  on	  tumour	  cells	  and	  healthy	  tissue.	  	  
	  
2.4.1 Cell	  Surface	  Staining	  
	  
2.4.1.1 Materials,	  Reagents	  and	  Equipment	  
Antibodies	   (please	  see	  below)	  
FACS	  Calibur	  Flow	  Cytometer	   Becton	  Dickinson	  
5mL	  polystyrene	  round-­‐bottom	  flow	  cytometry	  tubes	   BD	  Falcon	  
Normal	  Rabbit	  Serum	   DAKO	  
Cell	  Dissociation	  Buffer	   Gibco	  
Ice	   	  
Methanol	   Fisher	  Chemical	  
Trypsin/EDTA	   Gibco	  
Intracellular	  (IC)	  staining	  buffer	   (please	  see	  below)	  
38%	  Paraformaldehyde	   Fisher	  Scientific	  
	  
Buffers	  and	  common	  solutions:	  
IC	  staining	  buffer	  =	  4	  parts	  D10	  +	  6	  parts	  PBS	  
	  
2.4.1.2 Antibodies	  
Staining	  for	  T28ζ	  
Mouse	  IgG1	  anti-­‐human	  EGF	  (clone	  10825)	   R&D	  Systems	  
Polyclonal	  F(ab’)2	  Goat	  anti-­‐mouse	  PE-­‐conjugated	   DAKO	  
Affinity	  purified	  Goat	  IgG	  hEGF	  biotinylated	   R&D	  Systems	  
Streptavidin	  PE-­‐conjugated	   Invitrogen	  
	  
Staining	  for	  P28ζ	  
Goat	  anti-­‐mouse	  IgG	  PE-­‐conjugated	   DAKO	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Staining	  for	  4αβ	  
Mouse	  IgG1	  anti-­‐human	  CD124	  PE-­‐conjugated	   BD	  Pharmingen	  
	  
Staining	  for	  CD4	  and	  CD8	  
Mouse	  IgG	  PC5-­‐conjugated	   Beckman	  Coulter	  
Mouse	  IgG	  anti-­‐human	  CD8	  PC5-­‐conjugated	   Beckman	  Coulter	  
Mouse	  IgG	  FITC-­‐conjugated	   MACS	  
Mouse	  IgG	  anti-­‐human	  CD4	  FITC-­‐conjugated	   MACS	  
	  
Staining	  for	  human	  ErbBs	  
Rat	  anti-­‐human	  ErbB1	  (ICR62)	   ICR	  
Purified	  rat	  monoclonal	  IgG2A	  (clone	  54447)	   R&D	  Systems	  
Rat	  anti-­‐human	  ErbB2	  (ICR12)	   ICR	  
Purified	  rat	  monoclonal	  IgG2B	  (clone	  441045)	   R&D	  Systems	  
Mouse	  anti-­‐human	  ErbB3	  (clone	  H3.105.5)	   Neomarkers	  
Mouse	  anti-­‐human	  ErbB4	  (clone	  H4.77.16)	   Neomarkers	  
Goat	  anti-­‐rat	  IgG	  PE-­‐conjugated	   Invitrogen	  
Goat	  anti-­‐mouse	  IgG	  PE-­‐conjugated	   DAKO	  
Rat	  IgG2A	  anti-­‐human	  ErbB1	  FITC-­‐conjugated	   R&D	  Systems	  
Mouse	  IgG2B	  anti-­‐human	  ErbB2	  APC-­‐conjugated	   R&D	  Systems	  
Mouse	  IgG1	  anti-­‐human	  ErbB3	  PerCP-­‐conjugated	   R&D	  Systems	  
Mouse	  IgG2A	  anti-­‐human	  ErbB4	  APC-­‐conjugated	   R&D	  Systems	  
Rat	  IgG2A	  FITC-­‐conjugated	   R&D	  Systems	  
Mouse	  IgG1	  APC-­‐conjugated	   R&D	  Systems	  
Mouse	  IgG1	  PerCP-­‐conjugated	   R&D	  Systems	  
	  
Staining	  for	  murine	  ErbBs	  
Polyclonal	  Rabbit	  IgG	  anti-­‐EGFR	  (1005,	  sc-­‐03)	   SantaCruz	  Biotech	  
Polyclonal	  Rabbit	  IgG	  anti-­‐Neu	  (c-­‐18)	   SantaCruz	  Biotech	  
Polyclonal	  Rabbit	  IgG	  anti-­‐ErbB3	  (c-­‐17)	   SantaCruz	  Biotech	  
Polyclonal	  Rabbit	  IgG	  anti-­‐ErbB4	  (c-­‐18)	   SantaCruz	  Biotech	  
Swine	  F(ab’)2	  anti-­‐rabbit	  IgG	  FITC-­‐conjugated	  	   DAKO	  
	  
	   136	  
Staining	  for	  PSMA	  
Mouse	  anti-­‐human	  PSMA	  (clone	  K0142-­‐3)	   MBL	  International	  
Goat	  anti-­‐mouse	  IgG	  PE-­‐conjugated	   DAKO	  
	  
Staining	  for	  mouse	  macrophages	  
Anti-­‐mouse	  CD16/CD32	  (Fc	  receptor	  block)	   eBioscience	  
Anti-­‐mouse	  CD45	  PerCP-­‐Cy5.5-­‐conjugated	   eBioscience	  
Anti-­‐mouse	  IgG	  PerCP-­‐Cy5.5-­‐conjugated	   eBioscience	  
Anti-­‐mouse	  F4/80	  FITC-­‐conjugated	   eBioscience	  
Anti-­‐mouse	  IgG	  FITC-­‐conjugated	   eBioscience	  
	  
2.4.1.3 Analysis	  of	  T28ζ	  Expression	  
1. A	   pre-­‐determined	   number	   of	   T-­‐cells	   (1	   x	   105	   –	   1	   x	   106)	   were	   placed	   in	   a	   flow-­‐
cytometry	  tube	  and	  incubated	  with	  400ng	  primary	  antibody	  for	  30	  minutes	  on	  ice.	  
2. Samples	  were	  washed	   using	   2mL	   PBS,	   and	   each	   sample	  was	   incubated	  with	   3μg	  
secondary	  antibody	  for	  30	  minutes	  on	  ice	  in	  the	  dark.	  
3. Samples	  were	  again	  washed	  with	  PBS,	  centrifuged	  and	  subsequently	  resuspended	  
in	  200μL	  PBS	  immediately	  prior	  to	  analysis.	  Samples	  were	  kept	  in	  the	  dark	  and	  on	  
ice	  until	  analysed.	  
4. Results	   were	   compared	   against	   untransduced	   T-­‐cells	   stained	   using	   the	   same	  
protocol.	  
	  
2.4.1.4 Analysis	  of	  P28ζ	  Expression	  
1. A	   pre-­‐determined	   number	   of	   T-­‐cells	   (1	   x	   105	   –	   1	   x	   106)	   were	   placed	   in	   a	   flow-­‐
cytometry	  tube	  and	  incubated	  with	  400ng	  antibody	  for	  30	  minutes	  on	  ice	  
2. Samples	  were	  washed	  using	  2mL	  PBS,	  and	  resuspended	  in	  200μL	  PBS	  immediately	  
prior	  to	  analysis.	  Samples	  were	  kept	  in	  the	  dark	  and	  on	  ice	  until	  analysed.	  
3. Results	   were	   compared	   against	   untransduced	   T-­‐cells	   stained	   using	   the	   same	  
protocol.	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2.4.1.5 Analysis	  of	  4αβ	  Expression	  
NOTE:	   4αβ+	   T-­‐cells	   were	   transferred	   to	  media	   supplemented	  with	   rhIL-­‐2	   at	   least	   24	  
hours	  prior	  to	  analysis	  of	  4αβ	  expression.	  
	  
1. A	   pre-­‐determined	   number	   of	   T-­‐cells	   (1	   x	   105	   –	   1	   x	   106)	   were	   placed	   in	   a	   flow-­‐
cytometry	  tube	  and	  incubated	  with	  400ng	  of	  the	  directly-­‐conjugated	  antibody	  for	  
20	  minutes	  at	  room	  temperature	  in	  the	  dark.	  
2. Samples	   were	   washed	   with	   PBS,	   centrifuged	   and	   subsequently	   resuspended	   in	  
200μL	  PBS	  immediately	  prior	  to	  analysis.	  Samples	  were	  kept	  in	  the	  dark	  and	  on	  ice	  
until	  analysed.	  
3. Results	  were	  compared	  to	  untransduced	  cells	  stained	  using	  the	  same	  protocol.	  
	  
2.4.1.6 Analysis	  of	  CD4	  and	  CD8	  content	  
CD4	   and	   CD8	   content	   in	   the	   total	   population	   was	   determined,	   not	   on	   the	   CAR+	  
population	  specifically.	  
	  
1. A	   pre-­‐determined	   number	   of	   T-­‐cells	   (1	   x	   105	   –	   1	   x	   106)	   were	   placed	   in	   a	   flow-­‐
cytometry	  tube	  and	  incubated	  with	  400ng	  of	  the	  directly-­‐conjugated	  antibody	  for	  
20	  minutes	  at	  room	  temperature	  in	  the	  dark.	  
2. Samples	   were	   washed	   with	   PBS,	   centrifuged	   and	   subsequently	   resuspended	   in	  
200μL	  PBS	  immediately	  prior	  to	  analysis.	  Samples	  were	  kept	  in	  the	  dark	  and	  on	  ice	  
until	  analysed.	  
3. Results	  were	  compared	  to	  untransduced	  cells	  stained	  using	  the	  same	  protocol.	  
	  
2.4.1.7 Analysis	  of	  Receptor	  Expression	  on	  Viral	  Packaging	  Cells	  
In	  order	  to	  determine	  the	  quality	  of	  the	  retroviral	  packaging	  cells,	  cells	  were	  regularly	  
tested	  for	  CAR	  expression.	  
1. Viral	   packaging	   cells	  were	   removed	  using	  Cell	  Dissociation	  buffer	   and	  washed	   in	  
PBS	  
2. Cells	  were	  stained	  using	  the	  same	  protocol	  of	  step	  1-­‐4	  of	  paragraphs	  0	  -­‐	  2.4.1.5.	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2.4.1.8 	  Extracellular	  ErbB	  Receptor	  Detection	  
Expression	   of	   ErbB	   receptors	   was	   analysed	   using	   either	   unconjugated	   antibodies	   or	  
directly-­‐conjugated	  antibodies.	  
	  
1. Adherent	  cells	  were	  harvested	  using	  Cell	  Dissociation	  Buffer	  and	  a	  pre-­‐determined	  
number	  (1	  x	  105-­‐1	  x	  106)	  was	  transferred	  to	  a	  flow-­‐cytometry	  tube.	  
2. Prior	  to	  staining	  cells	  were	  washed	  in	  2mL	  PBS	  and	  the	  cell	  pellet	  was	  resuspended	  
in	  the	  remainder	  of	  the	  PBS	  at	  the	  bottom	  of	  the	  tube.	  
	  
Directly	  conjugated	  antibodies	  
3. 500ng	  of	  the	  directly	  conjugated	  antibody	  was	  added	  and	  the	  cells	  were	  incubated	  
for	  20	  minutes	  in	  the	  dark,	  at	  room	  temperature.	  
4. Cells	  were	  washed	  and	  resuspended	  in	  200μL	  PBS	  prior	  to	  analysis.	  
5. Results	  were	  compared	  to	  cells	  stained	  with	  the	  appropriate	  isotype	  control.	  
	  
Unconjugated	  antibodies	  
3. 400ng	  of	  the	  primary	  antibody	  was	  added	  to	  the	  cells	  and	  were	   incubated	  for	  30	  
minutes	  on	  ice.	  
4. Cells	   were	   washed	   in	   2mL	   PBS	   and	   subsequently	   incubated	   with	   3-­‐7μg	   of	   the	  
appropriate	  secondary	  antibody.	  Cells	  were	  incubated	  for	  30	  minutes	  on	  ice,	  in	  the	  
dark.	  
5. Cells	  were	  washed	  and	  resuspended	  in	  200μL	  PBS	  prior	  to	  analysis.	  
6. Results	  were	   compared	   to	   cells	   stained	  with	   the	   secondary	   conjugated	   antibody	  
alone.	  
	  
NOTE:	  Staining	  for	  PSMA	  was	  performed	  using	  the	  same	  protocol	  as	  staining	  for	  ErbB	  
receptors	  using	  unconjugated	  antibodies.	  
	  
2.4.1.9 Intracellular	  ErbB	  Receptor	  Detection	  
1. Adherent	  cells	  were	  trypsinised	  to	  harvest	  and	  a	  pre-­‐determined	  number	  (1	  x	  105-­‐1	  
x	  106)	  was	  transferred	  to	  a	  flow-­‐cytometry	  tube.	  
2. Cells	  were	  washed	  in	  D10	  and	  resuspended	  in	  1mL	  D10	  with	  addition	  of	  52μL	  38%	  
paraformaldehyde	  and	  fixed	  at	  37°C	  for	  10	  minutes.	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3. For	  permeabilisation,	  2mL	  ice-­‐cold	  methanol	  was	  added	  and	  cells	  were	   incubated	  
on	  ice	  for	  at	  least	  30	  minutes.	  
4. Cells	  were	  centrifuged	  for	  5	  minutes	  at	  200g	  and	  subsequently	  washed	   in	  2mL	   IC	  
staining	  buffer.	  
5. The	   supernatant	  was	   removed	   and	   30μL	   of	   a	   1/50	   dilution	   of	   rabbit	   serum	  was	  
added,	  as	  well	  as	  5μL	  (1μg)	  of	  the	  primary	  antibody.	  Cells	  were	  incubated	  at	  room	  
temperature	  for	  20	  minutes	  and	  washed	  again	  in	  2mL	  IC	  staining	  buffer.	  
6. 	  500ng	   of	   secondary	   antibody	   was	   added	   and	   the	   cells	   were	   incubated	   for	   20	  
minutes	  at	  room	  temperature,	  in	  the	  dark.	  
7. After	  a	   final	  wash	   in	  2mL	   IC	  staining	  buffer,	   the	  cells	  were	   resuspended	   in	  200μL	  
PBS	  and	  analysed.	  
8. Results	   were	   compared	   to	   cells	   stained	   with	   rabbit	   serum	   and	   the	   secondary	  
conjugated	  antibody	  alone.	  
	  
2.4.1.10 Staining	  for	  Mouse	  Macrophages	  
To	  determine	   the	  macrophage	   content	   in	   the	   intra-­‐peritoneal	   cavity	  of	  mice	   treated	  
with	  LC	  or	  LP	  cells	  were	  stained	  using	  anti-­‐mouse	  CD45	  and	  anti-­‐mouse	  F4/80.	  
	  
1. IP	  lavage	  content	  was	  washed	  and	  resuspended	  in	  3mL	  red	  blood	  cell	  lysis	  buffer	  
2. Cells	  were	  incubated	  on	  ice	  for	  10	  minutes	  
3. Cells	  were	  washed	  and	  resuspended	  in	  2mL	  PBS	  
4. Total	  cell	  count	  was	  enumerated	  using	  trypan-­‐blue	  exclusion	  
5. A	  pre-­‐determined	  number	  of	  cells	  (approximately	  1	  x	  105)	  cells	  were	  transferred	  to	  
a	  flow-­‐cytometry	  tube	  
6. 1μL	  of	  Fc	  receptor	  block	  was	  added	  and	  cells	  were	  incubated	  for	  30’	   in	  the	  dark,	  
on	  ice.	  
7. Cells	  were	  washed	  in	  PBS	  and	  resuspended	  in	  200μL	  PBS.	  
8. 500ng	  of	  both	  anti-­‐mouse	  CD45	  and	  anti-­‐mouse	  F4/80	  were	  added,	  and	  cells	  were	  
incubated	  for	  30’,	  in	  the	  dark,	  on	  ice.	  
9. Cells	  were	  washed,	  resuspended	  in	  200μL	  PBS	  and	  analysed.	  
10. Results	  were	  compared	  to	  cells	  stained	  with	  the	  appropriate	  isotype	  control.	  
	  
	   140	  
2.4.1.11 Gating	  strategy	  for	  FACS	  analysis	  
To	  determine	  the	   level	  of	  expression	  of	  the	  receptor	  of	   interest,	   fluorescence	  on	  the	  
stained	  cells	  of	  interest	  was	  compared	  to	  the	  level	  of	  fluorescence	  on	  the	  appropriate	  
control	   population.	   Figure	   2-­‐5	   shows	   the	   gating	   strategy	   for	   the	   analysis	   of	   ErbB1	  
expression	  on	  HN3	  cells.	  	  
	  
1. Live	  cells	  were	  gated	  based	  on	  their	  position	  in	  the	  forward/side	  scatter	  plot.	  Live	  
gate	   was	   adjusted	   to	   the	   appropriate	   location	   for	   each	   separate	   analysis	   (see	  
Figure	  2-­‐5	  1).	  
2. A	  total	  of	  100,000	  cells	  were	  recorded.	  
3. Fluorescence	   of	   cells	   within	   the	   live	   gate	   was	   visualised	   in	   dot	   plots	   and	  
histograms	  of	  the	  right	  FL	  channel	  (see	  Figure	  2-­‐5	  2	  and	  3).	  
4. Gates	   and	  markers	  were	   set	   to	   indicate	   negative	   or	   background	   staining.	   Gates	  
and	  markers	  remained	  in	  the	  same	  position	  between	  each	  control	  and	  test	  sample	  
pair	  (see	  Figure	  2-­‐5	  2	  and	  3).	  
5. MFI	  indicates	  the	  mean	  fluorescence	  intensity	  of	  the	  entire	  population	  within	  the	  
live	  gate.	  
6. Percentage	   of	   cells	   (within	   the	   live	   gate)	   positive	   for	   the	   receptor	   of	   interest	   is	  
calculated	  based	  on:	  
%	  test	  population	  within	  M1	  -­‐	  %	  control	  population	  within	  M1	  	  =	  %	  test	  population	  
expressing	  the	  receptor	  of	  interest.	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Figure	  2-­‐5	  FACS	  gating	  strategy	  
Analysis	   of	   ErbB1	   expression	   on	   HN3	   cells.	   HN3	   cells	   are	   stained	  with	   rat	   IgG2A	   and	   goat-­‐anti-­‐rat	   PE-­‐
conjugated	   (control	   population)	   or	   rat	   anti-­‐human	   ErbB1	   and	   goat-­‐anti-­‐rat	   IgG	   PE-­‐conjugated	   (test	  
population)	  (1)	  Live	  gate	  R1	  is	  set	  to	  analysis	  only	  the	  live	  cell	  population,	  based	  on	  their	  location	  within	  
the	  forward/side	  scatter	  plot.	  Percentage	  indicates	  amount	  of	  cells	  within	  the	  live	  gate.	  (2)	  Fluorescence	  
of	  the	  live	  cell	  population	  within	  the	  channel	  of	   interest	  (in	  this	  case	  FL2)	  and	  quadrants	  are	  placed	  to	  
indicate	  level	  of	  background	  signal	  on	  control	  population.	  Percentage	  indicates	  the	  percentage	  of	  cells	  
within	  the	  upper	  left	  quadrant.	  (3)	  Histograms	  indicating	  the	  fluorescence	  of	  the	  live	  cell	  population	  in	  
the	   channel	   of	   interest.	  Marker	   is	   set	   to	   indicate	   level	   of	   background	   fluorescence	   based	   on	   control	  
population.	   Value	   in	   the	   upper	   left	   corner	   indicates	   MFI,	   value	   in	   upper	   right	   corner	   indicates	   the	  
amount	  of	  cells	  within	  M1.	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2.5 Detection	  of	  Cytokine	  Release	  
	  
2.5.1 Enzyme-­‐Linked	  Immunosorbent	  Assay	  (ELISA)	  
Cytokine	   release	   in	   cell	   culture	   supernatants	  was	  detected	  using	  a	   sandwich	  Enzyme	  
Linked	  Immunosorbent	  Assay	  (ELISA),	  tailored	  to	  the	  cytokine	  of	   interest	  (human	  IL-­‐2	  
or	  human	  IFNγ).	  Measuring	  the	  release	  of	  specific	  cytokines	  by	  CAR-­‐transduced	  T-­‐cells,	  
during	  co-­‐culture	  with	  targets	  provided	  a	  quantitative	  technique	  for	  investigating	  T-­‐cell	  
activation.	  Plates	  were	  pre-­‐coated	  with	  a	  ‘capture’	  antibody	  specific	  for	  the	  cytokine	  of	  
interest	   thereby	   immobilizing	   cytokine	   present	   within	   the	   samples.	   Bound	   cytokine	  
was	   detected	   using	   a	   biotin-­‐labelled	   antibody	   and	   subsequently	  with	   avidin-­‐labelled	  
horseradish	   peroxidase	   (HRP).	   Visualisation	   was	   achieved	   using	   a	   3,5,3’,5’-­‐
tetramethylbenzadine	   (TMB)/hydrogen	  peroxide	  solution.	  Oxidation	  of	   the	  colourless	  
TMB	   reagent	   to	  a	  blue	   solution	   (an	  equilibrium	  between	   the	  TMB	  cation	   radical	  and	  
the	   diamine-­‐diimine	   charge	   transfer	   complex	   (517))	   highlighted	   assay	   progression.	  
Following	   a	   reasonable	   development	   time	   (as	   determined	   by	   development	   of	   the	  
standard	  curve),	   the	   reaction	  was	   stopped	  using	  1M	  sulphuric	  acid.	  The	   reduction	   in	  
pH	   induced	   by	   the	   addition	   of	   sulphuric	   acid	   results	   in	   the	   formation	   of	   the	   yellow	  
diimine	   product	   and	   prevented	   further	   development	   by	   denaturation	   of	   the	   HRP.	  
Plates	  were	  subsequently	  read	  at	  450nm	  and	  the	  concentrations	  of	  each	  sample	  were	  
calculated	  with	  respect	  to	  the	  known	  concentrations	  of	  the	  standard	  curve.	  
	  
2.5.1.1 Materials,	  Reagents	  and	  Equipment	  
 	  Human	  IFNγ	  Ready-­‐SET-­‐Go!	  ELISA	   eBioscience	  
 	  Human	  IL-­‐2	  Ready-­‐SET-­‐Go!	  ELISA	   eBioscience	  
 	  Mouse	  IL-­‐6	  Ready-­‐SET-­‐Go!	  ELISA	   eBioscience	  
 	  Corning	  Costar	  9018	  96-­‐well	  flat-­‐bottom	  plates	   Costar	  
 	  FLUOstar	  Omega	  plate	  reader	   BMT	  Labtech	  
 	  Omega	  Software	  (version	  1.20)	   BMT	  Labtech	  
 	  MARS	  data	  analysis	  software	  (version	  1.20	  R2)	   BMT	  Labtech	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Contents	  of	  Ready-­‐SET-­‐Go!	  ELISA	  kits:	  
o Capture	  antibody	  
o Detection	  antibody	  
o Standard	  
o 10x	  Coating	  buffer	  
o 5x	  Assay	  diluent	  
o Avidin-­‐HRP	  
o Substrate	  solution	  
	  
Buffers	  and	  solutions:	  
Wash	  buffer	  =	  PBS	  +	  0.05%	  Tween-­‐20	  
	  
2.5.1.2 Protocol	  
1. The	   capture	   antibody	  was	   diluted	   1/250	   in	   coating	   buffer.	   Subsequently	   the	   96-­‐
well	  ELISA	  plate	  was	  coated	  with	  100μl/well	  of	  capture	  antibody.	  
2. Plates	  were	  covered	  and	  incubated	  overnight	  at	  4°C	  
3. All	  the	  wells	  were	  aspirated	  and	  washed	  5	  times	  with	  >250μL/well	  wash	  buffer.	  The	  
wash	   buffer	   was	   allowed	   to	   soak	   for	   1	   minute	   during	   each	   step	   for	   increased	  
effectiveness	  of	  the	  washes.	  
4. One	  part	  5x	  concentrated	  assay	  diluent	  was	  diluted	  in	  4	  parts	  distilled	  water.	  
5. All	  wells	  were	   blocked	  with	   200μL/well	   of	   1x	   assay	   diluent	   for	   the	   duration	   of	   1	  
hour	  at	  room	  temperature.	  
6. Plates	  were	  washed	  as	  described	  in	  step	  3.	  
7. Standard	   curve	   samples	   were	   serially	   diluted	   two-­‐fold	   in	   assay	   diluent	   to	   give	   a	  
seven	  point	   standard	   curve	   ranging	   from	  an	   initial	   concentration	  of	  500pg/mL	   to	  
3.9pg/mL	  and	  were	  plated	  in	  duplicate.	  Background	  absorbance	  was	  measured	  by	  
plating	   assay	   diluent	   alone.	   Samples	   of	   co-­‐cultivation	   were	   diluted	   between	   1:2	  
and	  1:20	  in	  assay	  diluent	  prior	  to	  plating	  in	  triplicate.	  Serum	  samples	  were	  diluted	  
1:20	  and	  plated	  single.	  
8. Plates	  were	  covered	  and	  incubated	  overnight	  at	  4°C	  
9. Plates	  were	  washed	  as	  described	  in	  step	  3.	  
10. Detection	   antibodies	   were	   diluted	   1/250	   in	   assay	   diluent,	   and	   100μL/well	   was	  
added.	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11. Plates	  were	  covered	  and	  incubated	  for	  1	  hour	  at	  room	  temperature	  
12. Plates	  were	  washed	  as	  described	  in	  step	  3.	  
13. Avidin-­‐HRP	  was	  diluted	  1/250	  in	  assay	  diluent,	  and	  100μL/well	  was	  added.	  
14. Plates	  were	  covered	  and	  incubated	  for	  30	  minutes	  at	  room	  temperature.	  
15. Plates	  were	  washed	  as	  described	  in	  step	  3.	  On	  this	  occasion,	  plates	  were	  washed	  a	  
total	  of	  7,	  allowing	  1-­‐2	  minutes	  of	  soaking	  between	  washings.	  
16. 100μL/well	  of	  TMB	  substrate	  solution	  was	  added	  to	  each	  well.	  
17. Plates	  were	  incubated	  for	  15	  minutes	  at	  room	  temperature.	  
18. 50μL	  of	  stop	  solution	  (1M	  H2SO4)	  was	  added	  to	  each	  well.	  
19. Absorbance	   was	   read	   at	   450nm	   using	   the	   FLUOStar	   Omega	   plate	   reader	   and	  
Omega	  Software	  (version	  1.20).	  
20. Standard	  curves	  and	  cytokine	  concentrations	  were	  calculated	  using	  the	  MARS	  data	  
analysis	  software	  (version	  1.20	  R2).	  
	  
2.5.2 BD	  Cytometric	  Bead	  Array	  (CBA)	  
To	   deterime	   the	   cytokine	   levels	   in	  murine	   blood	   serum	   samples,	   the	   BD	   Cytometric	  
Bead	   Array	   was	   used.	   The	   BD	   CBA	   assays	   provide	   a	   method	   of	   capturing	   a	   soluble	  
analyte	   or	   set	   of	   analytes	   using	   beads	   of	   known	   size	   and	   fluorescence,	   making	   it	  
possible	   to	  detect	  analytes	  using	   flow	  cytometry.	  Each	  capture	  bead	   in	  a	  BD	  CBA	  kit	  
has	  been	  conjugated	  with	  a	  specific	  antibody.	  The	  detection	  reagent	  provided	  in	  the	  kit	  
is	  a	  mixture	  of	  phycoerythrin	  (PE)-­‐conjugated	  antibodies,	  which	  provides	  a	  fluorescent	  
signal	   in	   proportion	   of	   the	   amount	   of	   bound	   analyte.	  When	   the	   capture	   beads	   and	  
detector	   reagent	   are	   incubated	   with	   an	   unknown	   sample	   containing	   recognized	  
analytes,	   sandwich	   complexes	   (capture	   bead	   +	   analyte	   +	   detection	   reagent)	   are	  
formed.	  These	  complexes	  can	  be	  measured	  using	  flow	  cytometry	  to	   identify	  particles	  
with	  fluorescence	  characteristics	  of	  both	  the	  bead	  and	  the	  detector.	  
The	  Human	  Th1/Th2/Th17	  Cytokine	  Kit	  can	  be	  used	  to	  measure	  IL-­‐2,	  IL-­‐4,	  IL-­‐6,	  
IL-­‐10,	  TNF,	  IFNγ,	  and	  IL-­‐17A	  protein	  levels	  in	  a	  single	  sample.	  The	  mouse	  Th1/Th2/Th17	  
Cytokine	  Kit	  measures	   the	  equivalent	  mouse	  cytokines.	  Seven	  bead	  populations	  with	  
distinct	  fluorescence	  intensities	  have	  been	  coated	  with	  capture	  antibodies	  specific	  for	  
one	  of	  each	  of	  the	  cytokines.	  The	  seven	  bead	  populations	  are	  mixed	  together	  to	  form	  
the	  bead	  array,	  which	  is	  resolved	  in	  a	  red	  channel	  of	  a	  flow	  cytometer.	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2.5.2.1 Materials,	  Reagents	  and	  Equipment	  
 	  BD	  Cytometric	  Bead	  Array	  (CBA)	  	  
Human	  Th1/Th2/Th17	  Cytokine	  Kit	  
	  
BD	  Biosciences	  
 	  BD	  Cytometric	  Bead	  Array	  (CBA)	  
Mouse	  Th1/Th2/Th17	  Cytokine	  Kit	  
	  
BD	  Biosciences	  
 	  FACS	  Calibur	  Flow	  Cytometer	   Becton	  Dickinson	  
 	  FCS	  Filter	  Software	   Soft	  Flow	  Inc	  
 	  FCAP	  Array	  Software	   BD	  Biosciences	  
	  
2.5.2.2 Protocol	  
1. The	   number	   of	   assay	   tubes	   (including	   standards	   and	   controls)	   required	   for	   the	  
experiment	  was	  determined.	  
2. Each	  Capture	  Bead	  suspension	  was	  vigorously	  vortexed	  for	  3	  to	  5	  seconds	  before	  
mixing.	  
3. For	  each	  assay	  and	  standard	  tube	  to	  be	  analysed,	  a	  10μL	  aliquot	  of	  each	  Capture	  
Bead	  was	  added	  to	  a	  single	  tube	  labelled	  ‘mixed	  Capture	  Beads’.	  
4. The	  bead	  mixture	  was	  mixed	  thoroughly	  and	  centrifuged	  for	  5	  minutes	  at	  200g.	  
5. Supernatant	  was	  carefully	  aspirated	  and	  discarded.	  
6. The	  mixed	  Capture	  Beads	   pellet	  was	   resuspended	   in	   Serum	  Enhancement	  Buffer	  
(an	  equal	  volume	  as	  was	  removed	  in	  step	  5)	  and	  vortexed	  thoroughly.	  
7. The	   mixed	   Capture	   Beads	   were	   incubated	   for	   30	   minutes	   at	   room	   temperatre,	  
protected	  from	  light.	  
8. Serum	  samples	  were	  diluted	  1:5	  using	  the	  appropriate	  volume	  of	  Assay	  Diluent	  and	  
samples	  were	  mixed	  thoroughly.	  
9. One	   vial	   of	   lyophilized	  Human	   (or	  Mouse)	   Th1/Th2/Th17	   Standards	  was	   opened.	  
The	  spheres	  were	  transferred	  to	  a	  15mL	  conical,	  polypropylene	  tube,	  creating	  the	  
Top	  Standard.	  
10. Standards	  were	   reconstituted	  using	   2mL	  of	  Assay	  Diluent	   and	  equilibrated	   for	   at	  
least	  15	  minutes	  at	  room	  temperature.	  
11. Reconstituted	  protein	  was	  gently	  mixed	  by	  pipetting.	  
12. The	  Top	  Standard	  was	  serially	  diluted	  to	  create	  an	  8-­‐point	  standard	  curve,	  ranging	  
from	  5,000pg/mL	  to	  20pg/mL.	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13. One	   tube	   containing	   only	   Assay	   Diluent	   was	   prepared	   to	   serve	   as	   the	   0pg/mL	  
negative	  control.	  
14. The	  mixed	  Capture	  Beads	  were	  vortexed,	  and	  50μL	  was	  added	  to	  all	  assay	  tubes	  as	  
well	  as	  the	  standard	  curve	  tubes.	  
15. 50μL	   of	   each	   unknown	   sample	   or	   standard	   curve	   sample	   was	   added	   to	   the	  
appropriately	  labelled	  tube.	  
16. 50μL	  of	  the	  Human	  (or	  Mouse)	  Th1/Th2/Th17	  PE	  Detection	  Reagent	  was	  added	  to	  
all	  tubes.	  
17. The	  tubes	  were	  incubated	  for	  3	  hours	  at	  room	  temperature,	  protected	  from	  light.	  
18. 1mL	  of	  Wash	  Buffer	  was	  added	  to	  each	  assay	  tube	  and	  centrifuged	  at	  200g	  for	  5	  
minutes.	  
19. The	  supernatant	  was	  carefully	  aspirated	  and	  discarded	  from	  each	  tube.	  
20. The	  bead	  pellet	  was	  resuspended	  in	  300μL	  of	  Wash	  Buffer.	  
	  
The	  FACS	  Calibur	  Flow	  Cytometer	  was	  set	  up	  as	  follows:	  
21. 50μL	   of	   Cytometer	   Setup	   Beads	   were	   added	   to	   three	   cytometer	   setup	   tubes	  
labelled	  A,	  B,	  and	  C.	  
22. 50μL	  of	  FITC	  Positive	  Control	  Detector	  was	  added	  to	  tube	  B.	  
23. 50μL	  of	  PE	  Positive	  Control	  Detector	  was	  added	  to	  tube	  C.	  
24. Tubes	  A,	  B,	  and	  C	  were	  incubated	  at	  room	  temperature	  for	  30	  minutes,	  protected	  
from	  light.	  
25. 450μL	  of	  Wash	  Buffer	  was	  added	  to	  tube	  A,	  and	  400μL	  of	  Wash	  Buffer	  was	  added	  
to	  tubes	  B	  and	  C.	  
26. Tubes	   A,	   B	   and	   C	   were	   used	   to	   set	   up	   the	   instrument	   settings	   on	   the	   flow	  
cytometer	  to	  allow	  for	  optimal	  detection.	  
	  
Cytokine	  Content	  in	  serum	  samples	  was	  determined	  as	  follows:	  
27. All	  samples	  were	  analysed	  using	  the	  optimised	  instrument	  settings.	  
28. The	   raw	   data	   acquired	   with	   BD	   CellQuest	   could	   not	   be	   analysed	   directly	   by	   the	  
FCAP	  software	  due	  to	  debris,	  which	  is	  detected	  by	  the	  system	  and	  disturbs	  the	  data	  
analysis.	  For	  this	  reason,	  data	  had	  to	  be	  “cleaned”	  by	  FCS	  Filter	  Software	  prior	  to	  
analysis.	  
29. Cleaned	  data	  is	  analysed	  using	  FCAP	  Array	  Software.	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2.6 Statistical	  Analysis	  
To	  investigate	  statistical	  significance,	  values	  were	  subjected	  to	  a	  student’s	  t-­‐test,	  equal	  
variances	  assumed.	  p-­‐values	  <	  0.05	  were	  taken	  as	  significant.	  Data	  was	  analysed	  using	  
GraphPad	  Prism	  software	  (version	  5.0d),	  and	  Microsoft	  Excel	  (version	  14.3.5).	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3.1 Introduction	  
‘On-­‐target’-­‐toxicity	   is	   the	   toxicity	   induced	   by	   recognition	   of	   the	   target	   antigen	   on	  
healthy	  tissue.	  The	  ErbB-­‐receptor	  family	   is	  overexpressed	  on	  tumour	  cells,	  but	   is	  also	  
expressed	  on	  healthy	  tissue.	  Therefore,	  ErbB-­‐targeted	  therapies	  have	  been	  associated	  
with	   ‘on-­‐target’-­‐toxicities.	   Here,	   the	   risks	   of	   ‘on-­‐target’-­‐toxicity	   in	   response	   to	   the	  
targeting	  of	  the	  extended	  ErbB-­‐family	  with	  T4	  immunotherapy	  are	  described.	  
	  
3.1.1 T4	  Immunotherapy	  
T4	   immunotherapy	  uses	   ErbB	   re-­‐targeted	  T-­‐cells	   to	   induce	   cytotoxicity	   against	   ErbB+	  
tumour	   cells.	   T-­‐cells	   are	   transduced	   to	  express	   two	   transgenes,	   the	   chimeric	  antigen	  
receptor	   T28ζ	   and	   the	   chimeric	   cytokine	   receptor	   4αβ.	   The	   composition	   and	  
functionality	   of	   both	   receptor	   and	   the	   combined	   expression	   is	   detailed	   in	   chapter	  
1.3.11.	  
	   T28ζ	  is	  a	  second	  generation	  CAR	  (see	  Figure	  3-­‐1).	  The	  binding	  moiety	  consists	  of	  
the	  chimeric	  T1E	  peptide,	  which	  is	  coupled	  to	  the	  CD28	  hinge,	  transmembrane	  domain	  
and	  partial	  intracellular	  domain.	  In	  turn,	  CD28	  is	  coupled	  to	  the	  intracellular	  domain	  of	  
CD3ζ	   (299).	  The	  T1E	  peptide	   is	  a	  chimeric	  peptide	   resulting	   from	  the	   replacement	  of	  
the	   first	   five	  amino	  acids	  of	  EGF	  with	  the	   first	  seven	  amino	  acids	  of	  TGFα.	  Epidermal	  
growth	   factor	   and	   TGFα	   are	   both	   exclusive	   ligands	   for	   ErbB1.	   However,	   the	  
combination	   of	   the	   His4	   and	   Phe5	   residues	   of	   TGFα	   with	   the	   Leu28	   residue	   in	   EGF	  
enables	  the	  T1E	  peptide	  to	  also	  bind	  the	  ErbB2/3	  heterodimer	  with	  high	  affinity	  (451,	  
457).	  The	  use	  of	  the	  T1E	  peptide	  as	  the	  binding	  moiety,	  allows	  for	  the	  targeting	  of	  the	  
extended	   ErbB-­‐receptor	   family.	   Targeting	   of	   multiple	   ErbB	   receptors	   may	   reduce	  
tumour	  resistance	  and	  increase	  tumour	  control	  compared	  to	  the	  targeting	  of	  a	  single	  
ErbB	  receptor.	  In	  vitro,	  T28ζ+	  T-­‐cell	  activation	  can	  be	  achieved	  by	  all	  ErbB1-­‐containing	  
homo-­‐	  and	  heterodimers,	  as	  well	  as	  the	  ErbB2/3	  heterodimer,	  but	  not	  ErbB2	  or	  ErbB3	  
alone	  (299).	  Additionally,	  weak	  activation	  can	  be	  induced	  by	  ErbB4	  containing	  dimers.	  
In	  vivo,	  T28ζ+	  cells	  were	  shown	  to	  be	  able	   to	  control	   tumour	  growth	  of	   the	  ErbB1/2+	  
HN3	   xenograft	  model,	   the	   ErbB2/3+	  MDA-­‐MB-­‐435-­‐ErbB2	   xenograft	  model	   (299)	   and	  
the	  SKOV-­‐3	  ovarian	  tumour	  xenograft	  (358).	  
	   4αβ	   is	   a	   chimeric	   cytokine	   receptor,	  which	   consists	  of	   the	   IL4-­‐Rα	  ectodomain	  
coupled	  to	  the	  shared	  IL-­‐2/-­‐15Rβ	  endodomain	  (see	  Figure	  3-­‐1).	  Upon	  binding	  of	  IL-­‐4	  to	  
the	  receptor,	   it	  dimerizes	  with	  the	  common	  γ-­‐chain	  and	  an	  IL-­‐2	  like	  signal	   is	   induced.	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Co-­‐expression	  of	  4αβ	  with	  any	  CAR	  allows	  for	  the	  selective	  expansion	  of	  the	  transgene+	  
T-­‐cell	  population	  through	  the	  culture	  in	  media	  supplemented	  with	  IL-­‐4	  rather	  than	  IL-­‐2.	  
Culture	  in	  IL-­‐4	  induces	  both	  IL-­‐4	  and	  IL-­‐2	  like	  signalling.	  However,	  cells	  do	  not	  polarize	  
towards	  a	  Th2	  phenotype	  (391).	  
	   The	  combined	  expression	  of	  T28ζ	  and	  4αβ	  is	  referred	  to	  as	  ‘T4’.	  The	  expression	  
of	   two	  transgenes	  using	  one	  retroviral	  vector	   is	  achieved	  with	   the	   insertion	  of	  a	  T2A	  
peptide	  sequence.	  The	  T2A	  peptide	  induces	  a	  ribosomal	  ‘skip’	  in	  which	  a	  peptide	  bond	  
between	  the	   two	  constructs	   is	   ‘missed’	   (488,	  489).	  To	  enable	   this,	   the	  stop	  codon	  at	  
the	   3’	   end	   of	   4αβ	   has	   been	   removed.	   A	   furin	   cleavage	   sequence	   was	   introduced	  
upstream	   of	   the	   T2A-­‐sequence	   to	   ensure	   that	   most	   of	   the	   residual	   T2A	   peptide	   is	  
removed	  from	  the	  C-­‐terminus	  of	  4αβ.	  	  
In	   vivo,	   T4+	   T-­‐cells	   showed	   functionality	   against	   the	   HN3	   and	   MDA-­‐MB-­‐435-­‐
ErbB2	  xenograft	  models	  as	  well	  as	  the	  SKOV3	  xenograft	  model.	  In	  the	  SKOV3	  model	  it	  
was	   shown	   that	   repeated	   T-­‐cell	   administration	   resulted	   in	   better	   tumour	   control	  
compared	   to	   a	   single	   treatment	   dose.	   Additionally,	   combined	   treatment	   with	  
carboplatin	  further	  increased	  the	  anti-­‐tumour	  activity	  (358).	  
	  
Figure	  3-­‐1	  Schematic	  representation	  of	  T4	  
The	  combined	  expression	  of	  the	  T28ζ	  chimeric	  antigen	  receptor	  and	  the	  4αβ	  chimeric	  cytokine	  receptor	  
is	  referred	  to	  as	  ‘T4’.	  T28ζ	  comprises	  of	  the	  T1E	  peptide	  (shown	  in	  green/turquoise)	  as	  a	  binding	  moiety,	  
the	  CD28	  hinge	  and	  transmembrane	  domain	   (shown	   in	  red),	  coupled	  to	  the	  CD3ζ	   intracellular	  domain	  
(shown	  in	  dark	  blue).	  The	  receptor	  is	  expressed	  on	  the	  cell	  surface	  as	  a	  dimer,	  coupled	  by	  a	  disulphide	  
bond.	   4αβ	   comprises	   of	   the	   IL-­‐4Rα	   ectodomain	   (shown	   in	   lined	   yellow)	   coupled	   to	   the	   IL-­‐2/15Rβ	  
endodomain	  (shown	  in	  lined	  blue).	  Upon	  binding	  with	  IL-­‐4	  the	  receptor	  dimerizes	  with	  the	  common	  γ-­‐
chain	  (γc)(shown	  in	  lined	  red).	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3.1.2 ‘On-­‐Target’-­‐Toxicities	  in	  ErbB	  Targeted	  Therapies	  
Members	   of	   the	   ErbB-­‐receptor	   family	   are	   commonly	   upregulated	   on	   tumour	   cells.	  
However,	  ErbB	  expression	  is	  not	  exclusive	  to	  tumour	  cells.	  Healthy	  tissues	  expressing	  
ErbB	   receptors	   are	   also	   at	   risk	   of	   being	   affected	   by	   ErbB-­‐targeted	   treatment.	   The	  
occurrence	  of	  such	  ‘on-­‐target’-­‐toxicities	  have	  been	  reported	  in	  the	  treatment	  with	  the	  
ErbB-­‐targeting	  monoclonal	  antibodies	  Cetuximab	  and	  Herceptin.	  
	   Cetuximab	   is	   a	   monoclonal	   antibody	   targeted	   against	   ErbB1.	   It	   is	   a	   receptor	  
antagonist,	   which	   prevents	   downstream	   signalling	   and	   nuclear	   translocation	   upon	  
receptor	   binding.	   Additionally	   it	   induces	   antibody-­‐dependent	   cellular	   cytotoxicity	  
(ADCC)	  as	  well	  as	  downregulation	  of	  receptor	  expression	  (135-­‐137).	  The	  most	  common	  
toxicities	  reported	  are	  skin	  toxicities	  such	  as	  acneiform	  rash	  (152-­‐155).	  	  However,	  the	  
occurrence	   of	   Cetuximab-­‐induced	   skin	   toxicities	   (Cet-­‐ST)	   has	   been	   correlated	   to	  
treatment	  outcome,	  and	  can	  be	  used	  as	  an	  early	  indicator	  for	  treatment	  efficacy	  (156).	  
Skin	  toxicities	  are	  not	  exclusive	  to	  Cetuximab,	  similar	  results	  have	  been	  obtained	  with	  
the	   use	   of	   Erlotinib	   and	   Gefitinib	   (small	   tyrosine	   kinase	   inhibitors)	   (157-­‐159).	   More	  
severe	  side	  effects	  were	  seen	  in	  a	  trial	  in	  which	  Cetuximab	  was	  combined	  with	  chemo-­‐
radiotherapy.	   Side	   effects	   included	   two	   deaths	   (one	   myocardial	   infarction	   and	   one	  
unknown	  cause).	  However,	   these	  side	  effects	  could	  not	  conclusively	  be	  attributed	   to	  
Cetuximab	  (162).	  
	   Herceptin	   is	   a	   monoclonal	   antibody	   targeted	   against	   ErbB2.	   Similar	   to	  
Cetuximab,	   Herceptin	   is	   a	   receptor	   antagonist.	   Upon	   binding	   to	   the	   receptor,	  
Herceptin	   induces	   cell	   cycle	   arrest,	   thereby	   reducing	   cell	   proliferation	   (518).	  
Additionally,	   it	   can	   also	   induce	   ADCC	   and	   it	   has	   been	   indicated	   to	   have	   an	   anti-­‐
angiogenic	  effect	  (519).	  One	  major	  side	  effect	  of	  Herceptin	  is	  cardiac	  toxicity,	  including	  
congestive	   heart	   failure	   and	   a	   lower	   left	   ventricular	   ejection	   fraction	   (520,	   521).	  
Alcohol	   intake	   during	   treatment	   (≥10	   drinks	   per	   week)	   and	   the	   ErbB2	   Ile/Val	   single	  
nucleotide	  polymorphism	  are	  associated	  with	  a	  significantly	  higher	  risk	  of	  developing	  
cardiac	  toxicity	  (522,	  523).	  However,	  the	  cardiac	  toxicity	   induced	  by	  Herceptin	  seems	  
to	  be	  reversible	  (524).	  Patients	  recovered	  after	  drug	  withdrawal	  (525,	  526).	  Recently,	  a	  
case	   report	   on	   the	   occurrence	   of	   severe	   neutropenia	   (grade	   3)	   and	   oral	   stomatitis	  
(grade	  4)	  has	  been	  described	  in	  the	  treatment	  of	  breast	  cancer	  with	  Herceptin	  (527).	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3.1.3 ‘On-­‐Target’-­‐Toxicities	  in	  CAR-­‐mediated	  Adoptive	  Cell	  Therapies	  
Three	  reports	  of	   ‘on-­‐target’-­‐toxicity	  have	  been	  published	  so	  far	  due	  to	  CAR-­‐mediated	  
ACT.	   First,	   Lamers	   et	   al.	   reported	   ‘on-­‐target’-­‐hepatotoxicity	   in	   a	   trial	   using	   CAIX	   re-­‐
targeted	   T-­‐cells	   to	   treat	   metastatic	   renal	   cell	   carcinoma	   (242,	   366).	   Carbonic	  
Anhydrase	  IX	  is	  overexpressed	  in	  RCC,	  however	  most	  healthy	  tissues	  also	  express	  low	  
levels	  of	  CAIX	  (528).	  A	  total	  of	  eleven	  patients	  were	  treated,	  with	  and	  inpatient	  dose-­‐
escalation	   scheme	   ranging	   from	   2	   x	   107	   to	   2	   x	   109	   cells	   IV	   in	   combination	   with	  
subcutaneous	   IL-­‐2	   administration.	   Four	   patients	   developed	   grade	   3-­‐4	   hepatotoxicity,	  
leading	   to	   cessation	   of	   the	   treatment	   (366).	   A	   liver	   biopsy	   of	   one	   of	   the	   patients	  
revealed	  discrete	  cholangitis	  with	  T-­‐cell	  infiltration	  around	  the	  bile	  ducts.	  Expression	  of	  
CAIX	  on	  the	  bile	  duct	  epithelial	  cells	  was	  also	  detected.	  Although	  CAR	  expression	  in	  the	  
infiltrated	  T-­‐cells	  could	  not	  be	  verified,	   these	  data	  suggest	   that	   the	  toxicity	  seen	  was	  
caused	  by	  a	   specific	   cytotoxicity	  of	  CAR+	  T-­‐cells	   against	   the	  CAIX+	  bile	  duct	  epithelial	  
cells	  (366).	  The	  occurrence	  of	  this	  toxicity	   in	  subsequent	  patients	  could	  be	  prevented	  
by	  pre-­‐treatment	  with	  a	  low	  dose	  (5mg)	  of	  the	  anti-­‐CAIX	  antibody	  cG250.	  A	  single	  low	  
dose	  results	  in	  a	  saturated	  uptake	  by	  the	  liver	  cells,	  protecting	  them	  from	  CAR+	  T-­‐cells.	  
However,	   it	   leaves	   the	   CAIX	   expressed	   on	   tumour	   cells	   available	   for	   CAR-­‐mediated	  
cytotoxicity	  (529,	  530).	  Three	  patients	  who	  received	  this	  pre-­‐treatment	  with	  cG250	  did	  
not	  develop	  hepatotoxicity	  after	  T-­‐cell	  treatment	  (242).	  
	   Second,	   Morgan	   et	   al.	   reported	   a	   severe	   adverse	   event	   in	   response	   to	  
treatment	  with	  ErbB2	  re-­‐targeted	  T-­‐cells.	  A	  patient	  with	  metastatic	  colon	  cancer	  was	  
treated	   with	   a	   single	   dose	   of	   1	   x	   1010	   cells	   (79%	   CAR+)	   IV,	   after	   lymphodepletion.	  
Within	   15	   minutes	   after	   T-­‐cell	   administration	   the	   patient	   developed	   respiratory	  
distress.	  Chest	  X-­‐ray	  revealed	  pulmonary	  oedema.	  The	  patients	  received	  vasopressors	  
and	  ventilator	  support	  but	  eventually	  succumbed	  to	  a	  cardiac	  arrest.	  At	  post	  mortem	  
examination,	   high	   levels	   of	   CAR+	   T-­‐cells	   were	   detected	   in	   the	   lung	   and	  
abdominal/mediastinal	  lymph	  nodes.	  It	  was	  suggested	  that	  the	  CAR+	  T-­‐cells	  recognized	  
ErbB2	  expressed	  by	  healthy	  lung	  tissue/	  endothelium,	  inducing	  cytokine	  release,	  which	  
resulted	  in	  a	  fatal	  cytokine	  storm	  (240).	  In	  vitro,	  IFNγ	  production	  by	  CAR+	  T-­‐cells	  could	  
be	  induced	  by	  a	  wide	  range	  of	  healthy	  human	  cells,	  including	  fibroblasts,	  umbilical	  vein	  
endothelial	  cells	  (HUVEC),	  bronchial/tracheal	  epithelial	  cells	  (NHBE),	  prostate	  epithelial	  
cells	   (PrEC),	   skeletal	   muscle	   myoblasts	   (HSMM),	   keratinocytes,	   mammary	   epithelial	  
cells	  (HMEC)	  and	  renal	  epithelial	  cells	  (HRE).	  However,	  these	  in	  vitro	  analyses	  were	  not	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performed	  until	  after	  the	  occurrence	  of	  the	  SAE.	  Prior	  to	  the	  start	  of	  the	  trial,	  safety	  
considerations	  were	  based	  on	  the	  use	  of	  Herceptin,	  the	  lack	  of	  toxicity	  seen	  in	  studies	  
immunizing	  against	  epitopes	  of	  ErbB2	  as	  well	  as	  the	  lack	  of	  toxicity	  seen	  in	  the	  use	  of	  
autologous	  anti-­‐ErbB2	  T-­‐cell	  clones	  in	  breast	  cancer	  treatment	  (240).	  
	   Finally,	  ‘on-­‐target’-­‐toxicity	  is	  common	  with	  the	  use	  of	  CD19	  re-­‐targeted	  T-­‐cells.	  
Normal	   human	   plasma	   cells	   also	   express	   CD19,	   and	   antigen-­‐specific	   eradication	   of	  
normal	  B-­‐cells	  has	  been	  reported	  in	  several	  trials	  (311,	  317,	  319,	  320,	  445,	  477,	  479).	  
Eradication	  of	  the	  B-­‐cell	  lineage	  has	  been	  reported	  to	  last	  up	  to	  7	  months	  (latest	  time-­‐
point	  of	  follow-­‐up)	  (319).	  This	  eradication	  results	  in	  decreased	  serum	  immunoglobulin	  
levels	  (320).	  Hypogammaglobulinemia	  can	  be	  treated	  with	  IV	  infusions	  of	  IgGs,	  making	  
B-­‐cell	  depletion	  a	  manageable	  form	  of	  ‘on-­‐target’-­‐toxicity	  (319).	  Recovery	  of	  normal	  B-­‐
cell	   clones	   and	   normal	   B-­‐cell	   lymphophoiesis	   have	   been	   reported,	   alongside	  
restoration	  of	  normal	  hematopoiesis	  (317).	  Restoration	  of	  normal	  B-­‐cell	  clones	  without	  
recurrence	  of	  disease	  is	  thought	  to	  be	  due	  to	  waning	  persistence	  of	  CAR+	  T-­‐cells	  (317).	  
	  
3.1.4 Risk	  of	  ‘On-­‐Target’	  Toxicity	  of	  T4	  Immunotherapy	  
The	   previously	   discussed	   toxicities	   which	   have	   been	   reported	   in	   response	   to	   ErbB-­‐
targeted	   and	   CAR-­‐mediated	   therapies	   raise	   the	   concern	   of	  which	   toxicities	   could	   be	  
induced	  by	  T4	  immunotherapy.	  The	  combination	  of	  two	  circumstances	  is	  required	  for	  
organs	  to	  be	  at	  risk	  of	  T4-­‐mediated	  toxicity.	  First,	  T4+	  T-­‐cells	  need	  to	  migrate	  into	  the	  
organ,	  and	  second,	  the	  organ	  in	  question	  must	  express	  one	  or	  more	  ErbB	  receptors	  at	  
levels	  that	  are	  amenable	  to	  recognition	  by	  the	  T28ζ	  chimeric	  antigen	  receptor.	  All	  four	  
ErbB	   receptors	   are	   widely	   expressed	   in	   several	   major	   organs	   (531-­‐536).	   After	  
intravenous	   (IV)	   injection,	   T4+	   T-­‐cell	   can	  migrate	   throughout	   the	  whole	   body	   via	   the	  
circulation.	   Imaging	   studies	   have	   shown	   that	   IV	   injected	   T-­‐cells	   initially	   reside	   in	   the	  
lungs	  and	  then	  migrate	  to	  the	   liver,	  spleen	  and	  lymph	  nodes,	  gaining	  access	  to	  these	  
sites	  within	  the	  first	  24	  hours	  after	   injection	  (460).	  Lung	  and	   liver	  are	  sites	  that	  have	  
previously	   been	   affected	   by	   profound	   toxicity	   in	   studies	   of	   CAR-­‐mediated	  
immunotherapy	   (240,	   242).	   The	   experience	   with	   ErbB2	   re-­‐targeted	   T-­‐cells	   also	  
emphasized	   the	   importance	  of	  adequate	  pre-­‐clinical	   safety	   testing	   in	  order	   to	  assess	  
the	   level	   of	   potential	   side	   effects.	   In	   this	   chapter,	   experiments	   investigating	   the	  
potential	   occurrence	   of	   ‘on-­‐target’-­‐toxicity	   in	   response	   to	   T4	   immunotherapy	   are	  
described.	   The	   toxicity	   is	   assessed	   using	   a	   SCID/Beige	  mouse	  model.	   There	   are	   four	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reasons	  as	  to	  why	  this	  model	  was	  chosen	  for	  pre-­‐clinical	  toxicity	  assessment.	  First,	  the	  
regulatory	   authorities	   require	   safety	   testing	   of	   the	   therapeutic	   product	   (in	   this	   case	  
human	  T4+	  T-­‐cells).	  Second,	  it	  is	  anticipated	  that	  the	  T28ζ	  CAR	  will	  be	  able	  to	  activate	  
human	  T-­‐cells	  upon	  engagement	  with	  mouse	  ErbB	  receptors.	  Third,	  activated	  human	  
T-­‐cells	  are	  able	  to	  elicit	  severe	  toxicity	  in	  mice	  (537).	  Finally,	  trafficking	  of	  T-­‐cells	  after	  
IV	  administration	  is	  similar	  in	  mouse	  and	  man	  (460).	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3.2 Results	  
	  
3.2.1 Functionality	  of	  the	  T4	  construct	  
Expression	  of	  T4	  in	  T-­‐cells	  is	  achieved	  by	  transduction	  using	  the	  SFG	  retroviral	  vector,	  
which	   is	   derived	   from	   the	  MFG	   vector.	   Gene	   expression	   is	   driven	   by	   the	   promoter	  
activity	   of	   the	  Moloney	  murine	   leukaemia	   virus	   (MoMLV)	   long	   terminal	   repeat	   (LTR)	  
(Figure	   3-­‐1).	   Efficient	   packaging	   of	   SFG-­‐based	   T4	   viral	   particles	   is	   ensured	   by	   the	  
presence	  of	  the	  MoMLV	  packaging	  signal.	  	  
	  
	  
Figure	   3-­‐2	   Schematic	   representation	   of	   the	   SFG	   retroviral	   vector	   containing	   the	   T4	  
construct	  
Schematic	   representation	  of	   the	  T4	  construct	   in	  SFG.	  Co-­‐expression	  of	  both	  4αβ	  and	  T28ζ	   transgenes	  
under	   the	   control	   of	   the	   long	   terminal	   repeat	   (LTR)	   promoter	   is	   achieved	   using	   an	   intervening	   T2A	  
peptide	  sequence,	  which	   induces	  a	  ribosomal	   ‘skip’	  and	  therefore	  misses	  a	  peptide	  bond	  between	  the	  
glycine	  and	  proline	  (as	  indicated	  by	  the	  right	  scissors).	  Expression	  of	  the	  T2A	  peptide	  sequence	  at	  the	  C-­‐
terminus	  of	  the	  mature	  4αβ	  protein	  is	  prevented	  by	  the	  presence	  of	  a	  furin	  cleavage	  site	  (as	  indicated	  by	  
the	  left	  scissors).	  SD	  =	  splice	  donor	  site;	  Ψ	  =	  packaging	  signal;	  SA	  =	  splice	  acceptor	  site;	  ★	  =	  macrophage	  
colony	  stimulating	  factor	  receptor	  (FMS)	  leader	  sequence.	  Note:	  size	  of	  the	  blocks	  is	  not	  representative	  
of	  the	  sizes	  of	  the	  individual	  elements.	  
	  
Retroviral	  transduction	  of	  primary	  human	  T-­‐cells	  was	  achieved	  using	  virus	  produced	  by	  
the	   packaging	   cell	   line,	   PG13.	   Expression	   of	   both	   transgenes	   was	   detected	   on	   the	  
surface	  of	  PG13	  cells	  by	   flow	  cytometry,	   indicating	  stable	  gene	   insertion	  and	  protein	  
expression	   (Figure	   3-­‐3).	   Following	   retroviral-­‐mediated	   gene	   transfer,	   T-­‐cells	   were	  
cultured	  in	  media	  supplemented	  with	  30ng/mL	  IL-­‐4	  to	  allow	  for	  selective	  expansion	  of	  
the	  transduced	  population,	  acting	  through	  the	  cytokine	  receptor	  4αβ	  (391).	  As	  shown	  
in	   Figure	   3-­‐3	   B,	   selective	   IL-­‐4-­‐driven	   expansion	   of	   transduced	   T-­‐cells	   resulted	   in	   the	  
enrichment	   of	   an	   initially	   small	   CAR+	   population	   (day	   7)	   so	   that	   it	   later	   became	  
dominant	  within	  the	  culture	  (day	  14).	  Expression	  of	  both	  transgenes	  was	  detected	  on	  
the	  T-­‐cell	  surface	  by	  flow	  cytometry	  (Figure	  3-­‐3	  B	  and	  C).	  A	  decrease	  in	  the	  level	  of	  CAR	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expression	   was	   observed	   over	   time	   (as	   indicated	   by	   a	   decrease	   in	   MFI).	   The	   LTR	  
promotor	  within	  SFG	  exhibits	  a	  low	  basal	  transcriptional	  activity	  in	  unstimulated	  cells.	  
During	  the	  in	  vitro	  expansion,	  cells	  are	  not	  stimulated,	  and	  therefore	  a	  downregulation	  
of	   transgene	   expression	   is	   observed.	   Besides	   enrichment	   of	   the	   transduced	   cell	  
population,	  expansion	  of	  the	  total	  cell	  population	  was	  also	  recorded	  (see	  Figure	  3-­‐3	  D).	  




Figure	  3-­‐3	  T4	  expression	  in	  PG13	  packaging	  cells	  and	  T-­‐cells	  
A:	   Expression	   of	   T28ζ	   (open	   red	   histogram)	   and	   4αβ	   (open	   green	   histogram)	   was	   detected	   on	   the	  
surface	  of	  PG13	  packaging	  cells	  using	  flow	  cytometry	  Filled	  histograms	  show	  untransduced	  PG13	  stained	  
with	   the	   same	   protocol.	   Light	   grey	   number	   represents	   MFI	   background	   staining,	   coloured	   number	  
represents	  MFI	   receptor	  stained	  population.	  B:	  Expression	  of	  T28ζ	  was	  detected	  on	  the	  surface	  of	  T4-­‐
transduced	  primary	  human	  T-­‐cells	  using	  flow	  cytometry	   (open	  red	  histograms).	  Cells	  were	  analysed	  at	  
multiple	   days	   after	   transduction	   to	   determine	   enrichment	   of	   the	   transduced	   population	   in	   cultured	  
media	   supplemented	   with	   IL-­‐4.	   Filled	   histograms	   show	   untransduced	   T-­‐cells	   stained	   with	   the	   same	  
protocol.	   Light	   grey	   number	   represents	   MFI	   background	   staining,	   red	   number	   represents	   MFI	   T28ζ	  
stained	  population,	  black	  number	   indicates	  percentage	  T28ζ	  positive	  cells.	  C:	  Expression	  of	  4αβ	   (open	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green	  histogram)	  on	  T-­‐cells	   transduced	  with	  T4.	  To	  determine	  expression	  of	  4αβ	  on	  day	  14	  cells	  were	  
cultured	   in	   media	   supplemented	   with	   IL-­‐2	   24	   hours	   prior	   to	   analysis.	   Filled	   histogram	   shows	  
untransduced	   T-­‐cells	   stained	   with	   the	   same	   protocol.	   Light	   grey	   number	   represents	  MFI	   background	  
staining,	   red	  number	   represents	  MFI	   4αβ	   stained	  population,	   black	  number	   indicates	  percentage	  4αβ	  
positive	  cells.	  D:	  Expansion	  of	  total	  cell	  population,	   live	  cells	  were	  counted	  on	  day	  4,	  10	  and	  14	  during	  
cultured	   based	   on	   trypan	   blue	   exclusion	   of	   dead	   cells.	   E:	   Viability	   of	   cells	   during	   culture	   based	   on	  
live/dead	  gating	  on	  day	  4,	  10	  and	  14.	  Data	  show	  one	  of	  three	  similar	  experiments.	  	  	  
	  
Functionality	  of	  T4+	  T-­‐cells	  was	  investigated	  by	  co-­‐cultivation	  of	  1	  x	  106	  transduced	  T-­‐
cells	  with	  a	  confluent	  monolayer	  of	  the	  human	  head	  and	  neck	  cancer	  cell	  line	  HN3(luc).	  
HN3	  cells	  express	  high	   levels	  of	  both	  ErbB1	  as	  well	  as	  ErbB2,	  with	   low	  expression	  of	  
ErbB3	  and	  ErbB4	  (Figure	  3-­‐4	  A),	  making	  it	  a	  theoretically	  suitable	  target	  for	  recognition	  
by	  the	  T28ζ	  CAR.	  Additionally	  T4+	  was	  co-­‐cultivated	  with	  confluent	  monolayers	  of	  the	  
ErbBLO	   human	   breast	   cancer	   cell	   line	   MDA-­‐MB-­‐435	   (hereafter	   referred	   to	   as	   435),	  
which	   expresses	   low	   levels	   of	   ErbB2	   and	   ErbB3	   but	   is	   negative	   for	   ErbB1	   and	   ErbB4	  
(see	  Figure	  3-­‐4	  A).	  Both	  cell	   lines	  were	  also	  co-­‐cultivated	  with	  1	  x	  106	  P4+	  (the	  PSMA	  
targeting	  CAR	  P28ζ	   (403)	  combined	  with	  4αβ)	  T-­‐cells,	  or	  untransduced	  (UT)	  T-­‐cells	   to	  
determine	  whether	  tumour	  monolayer	  destruction	  was	  specific	  for	  T28ζ-­‐expressing	  T-­‐
cells.	  Expression	  of	  P4	  on	  PG13	  packaging	  cells	  as	  well	  as	  expression	  and	  expansion	  of	  
P4	  on	  T-­‐cells	   is	   shown	   in	  Supplementary	  Figure	  1	   in	  Appendix	  2.	  The	  HN3	  cell	   line	   is	  
negative	   for	   PSMA	   and	   435	   expressed	   very	   low	   levels	   of	   PSMA	   (see	   Supplementary	  
Figure	  2	  in	  Appendix	  2),	  allowing	  for	  P4+	  T-­‐cells	  to	  function	  as	  a	  negative	  control	  for	  T4+	  
T-­‐cells.	   Functionality	   of	   P4+	   T-­‐cells	   was	   confirmed	   by	   co-­‐cultivation	   with	   the	   PSMA+	  
human	  prostate	  cancer	  cell	  line	  PLP	  (see	  Supplementary	  Figure	  3	  in	  Appendix	  2).	  
After	  24	  hours	  of	  co-­‐cultivation,	  monolayer	  destruction	  was	  quantified	  using	  an	  
MTT	   assay	   (see	   Figure	   3-­‐4	   B).	   Alternatively,	   residual	   tumour	   cells	  were	   visualised	   by	  
staining	   with	   crystal	   violet	   (see	   Figure	   3-­‐4	   C).	   This	   showed	   that	   tumour	   monolayer	  
destruction	  was	  specific	   for	   the	  combination	  of	  T28ζ+	  T-­‐cells	  co-­‐cultivated	  with	  ErbB+	  
tumour	   monolayer.	   Levels	   of	   IL-­‐2	   and	   IFNγ	   in	   the	   supernatant	   were	   also	   measured	  
after	   24	   hours	   co-­‐cultivation.	   The	   presence	   of	   increased	   levels	   of	   these	   cytokines	  
confirm	  that	  the	  interaction	  between	  T28ζ	  and	  ErbB	  receptors	  caused	  T-­‐cell	  activation.	  
This	   finding	   is	   consistent	  with	   the	   results	  of	  monolayer	  destruction	  assay	   (see	  Figure	  
3-­‐4	  D).	  Low	  levels	  of	  IFNγ	  production	  in	  response	  to	  co-­‐cultivation	  with	  ErbBLO	  tumour	  
cell	   line	  435	   is	  most	   likely	  due	  to	  recognition	  of	   low	  expression	   levels	  of	  the	  ErbB2/3	  
heterodimer.	  Production	  of	  IFNγ	  was	  also	  detected	  in	  co-­‐cultivations	  of	  P4+	  T-­‐cells	  with	  
435,	  which	  can	  be	  attributed	  to	  the	  low	  level	  of	  target	  (PSMA)	  expression.	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Figure	  3-­‐4	  T-­‐cell	  activation	  through	  interaction	  of	  T28ζ	  and	  ErbB	  receptors	  
A:	  ErbB	  expression	  on	  HN3	  and	  MDA-­‐MB-­‐435	  tumour	  cell	  as	  determined	  by	  flow	  cytometry.	  Cells	  were	  
stained	  using	   ICR12	   (ErbB1),	   ICR62	   (ErbB2)	   followed	  by	  anti-­‐rat-­‐PE,	  ErbB3-­‐PerCP	   (ErbB3)	  or	  ErbB4-­‐APC	  
(ErbB4)	  (open	  coloured	  histograms)	  MFI	  indicated	  by	  coloured	  number.	  Expression	  levels	  are	  compared	  
to	  isotype	  control	  stained	  cells	  (filled	  histograms)	  MFI	  indicated	  by	  grey	  umber.	  B:	  MTT	  assay	  performed	  
after	  24	  hours	  of	  co-­‐cultivation	  of	  1	  x	  106	  T4+	  (red	  bar),	  P4+	  (blue	  bar)	  or	  UT	  (yellow	  bar)	  T-­‐cells.	  Values	  
were	  corrected	   for	  background	   level	  of	  T-­‐cell	   cultured	  without	  a	   target	  monolayer,	  %	  viable	  cells	  was	  
calculated	  in	  comparison	  to	  a	  confluent	  monolayer,	  which	  had	  not	  been	  co-­‐cultivated	  with	  T-­‐cells.	  **	  =	  
p<0.01	  n=3	  data	  show	  mean	  ±	  SD.	  C:	  Crystal	  violet	  staining	  of	  remaining	  monolayers	  after	  24	  hour	  co-­‐
cultivation	  of	  the	  indicated	  tumour	  monolayer	  and	  T-­‐cell	  population	  as	  described	  in	  B.	  D:	  IFNγ	  and	  IL-­‐2	  
production	  by	  1	  x	  106	  T4+	  T-­‐cells	   (red	  bars),	  P4+	  T-­‐cells	   (blue	  bars)	  or	  UT	  T-­‐cells	   (yellow	  bars)	  after	  24	  
hours	  co-­‐cultivation	  with	  HN3	  or	  435	  confluent	  tumour	  monolayers	  or	  without	  a	  target	  monolayer.	  **	  =	  
p<0.01	  n=6	  data	  show	  mean	  ±	  SD	  one	  of	  3	  similar	  experiments	  
	  
	   160	  
3.2.2 Evaluation	  of	  Toxicity	  Risk	  on	  Healthy	  Primary	  Cells	  
Primary	   human	   cardiac	  myocytes	   (HCM)	   and	   primary	   human	   pulmonary	   endothelial	  
cells	   (HPMEC)	   were	   examined	   for	   expression	   of	   the	   four	   ErbB	   receptors	   using	   flow	  
cytometry.	   Both	   the	  HCM	  and	  HPMEC	   showed	   clear	   expression	  of	   ErbB1	  and	  ErbB2,	  
low	  expression	  of	  ErbB3	  and	  no	  expression	  of	  ErbB4	  (see	  Figure	  3-­‐5	  A).	  
Based	  on	   the	   ErbB	   expression	  profiles	   of	   both	  of	   these	   cultured	   cell	   types,	   it	  
was	   expected	   that	   T4+	   T-­‐cells	  would	   be	   capable	   of	   targeting	   these	   cells.	   To	   confirm	  
this,	  HCM	  and	  HPMEC	  were	  co-­‐cultivated	  with	  1	  x	  106	  T4+	  or	  1	  x	  106	  UT	  T-­‐cells.	  Crystal	  
violet	  staining	  (see	  Figure	  3-­‐5	  B)	  showed	  that	  both	  HCM	  and	  HPMEC	  were	  destroyed	  
by	  T4+	  T-­‐cells,	  whereas	  there	  was	  no	  monolayer	  destruction	  when	  target	  cells	  were	  co-­‐
cultivated	  with	  UT	  T-­‐cells.	  These	  results	  suggest	  that	  T4+	  T-­‐cells	  were	  activated	  through	  
CAR-­‐target	   interaction,	  unlike	  UT	  T-­‐cells.	  Activation	  of	  T4+	  T-­‐cells	   in	  these	  co-­‐cultures	  
was	   confirmed	   by	   measurement	   of	   IL-­‐2	   and	   IFNγ	   in	   supernatant	   collected	   after	   24	  
hours	   of	   co-­‐cultivation	   (see	   Figure	   3-­‐5	   C).	   Remarkable	   is	   the	   higher	   level	   of	   IL-­‐2	  
production	   by	   T4+	   T-­‐cells	   in	   response	   to	   co-­‐cultivation	   with	   healthy	   primary	   cells	  
compared	   to	   tumour	   cell	   lines.	   Various	   reasons	   could	   attribute	   to	   this.	   First,	   ErbB	  
expression	   levels	   are	   not	   static	   and	   can	   change	   during	   prolonged	   culture.	  
Downregulation	  of	  ErbB	  receptors	  by	  HN3	  has	  been	  observed	  during	  prolonged	  culture	  
(data	   not	   shown),	   this	   downregulation	   can	   affect	   the	   level	   of	   T-­‐cell	   activation	   and	  
cytokine	  production.	  Second,	  the	  affinity	  of	  the	  T28ζ	  CAR	  is	  dependent	  of	  the	  formed	  
ErbB	   dimers.	   Dimerisation	   patterns	   have	   not	   been	   determined	   in	   the	   cell	   lines,	   but	  
differences	   in	   the	   expression	   of	   ErbB1	   homo-­‐	   and	   heterodimers	   and	   the	   ErbB2/3	  
heterodimer	   can	   contribute	   to	   the	   level	   of	   T-­‐cell	   activation.	   Third,	   endothelial	   cells	  
have	  been	   reported	   to	   support	   the	   induction	  of	  mitogen-­‐induced	  T-­‐cell	   activation	   in	  
vitro	   (538).	   Expression	  of	   accessory	  molecules	  on	  HPMEC	   could	  have	   attributed	   to	   a	  
stronger	  T-­‐cell	  activation.	  
The	  ErbB	  expression	   levels	  detected	  on	  healthy	  primary	  cells	  (Figure	  3-­‐5	  A),	   is	  
lower	  than	  the	  expression	  levels	  on	  the	  tumour	  cell	  line	  HN3luc	  (Figure	  3-­‐4	  A).	  Higher	  
ErbB	  expression	   levels	  on	  tumour	  tissue	  could	  give	  the	  T4+	  T-­‐cells	  a	  higher	  activation	  
stimulus,	  and	  increase	  affinity	  for	  tumour	  tissue	  compared	  to	  healthy	  tissue.	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Figure	  3-­‐5	  T4+	  T-­‐cell	  activation	  by	  HCM	  and	  HPMEC	  
A:	  ErbB	  expression	  (open	  coloured	  histograms,	  MFI	  indicated	  by	  coloured	  number)	  by	  HCM	  and	  HPMEC	  
was	   determined	   using	   flow	   cytometry.	   Expression	   is	   compared	   to	   cells	   stained	   with	   isotype	   control	  
(closed	  grey	  histograms,	  MFI	  indicated	  by	  grey	  number).	  Cells	  were	  stained	  as	  described	  in	  Figure	  3-­‐4	  A.	  	  
B:	  A	  confluent	  monolayer	  of	  the	  indicated	  cell	  lines	  (24	  well	  dish)	  were	  co-­‐cultivated	  for	  24	  hours	  with	  1	  
x	  106	  T4+	  T-­‐cells,	  a	  similar	  number	  of	  UT	  T-­‐cells	  or	  without	  T-­‐cells	  as	  control.	  Medium	  and	  non-­‐adherent	  
cells	  were	  then	  removed	  and	  residual	  monolayers	  fixed	  and	  stained	  using	  crystal	  violet.	  C:	  IFNγ	  and	  IL-­‐2	  
production	  by	  1	  x	  106	  T4+	  (red	  bars)	  or	  UT	  (yellow	  bars)	  T-­‐cells	  after	  co-­‐cultivation	  as	  described	  in	  B.	  Data	  
shows	  mean	  ±	  SD	  of	  3	  replicates.	  *	  =	  p<0.001	  compared	  to	  T-­‐cells	  without	  a	  target	  and	  compared	  to	  UT	  
T-­‐cells	  on	  the	  same	  target	  (HPMEC).	  
	  
3.2.3 In	  Vivo	  Subcutaneous	  Growth	  of	  HN3luc	  
In	   order	   to	   develop	   an	   in	   vivo	   model	   to	   test	   T4	   immunotherapy,	   the	   ability	   of	   the	  
human	   tumour	   cell	   line	   HN3luc	   to	   grow	   subcutaneously	   in	   SCID	   Beige	   mice	   was	  
determined.	   Subcutaneous	   tumour	   growth	   would	   allow	   for	   testing	   of	   efficacy	   and	  
safety	  of	  T4	  immunotherapy,	  delivered	  using	  the	  intra-­‐tumoural	  or	  alternative	  routes.	  	  
	   Animals	  were	  injected	  with	  5	  x	  106	  HN3luc	  tumour	  cells	   in	  Matrigel	   in	  the	  left	  
flank.	  Matrigel	   is	   a	   reconstituted	   basement	  membrane	   extract,	  which	   is	   reported	   to	  
enhance	  tumour	  growth	  	  (539,	  540).	  Tumours	  were	  grown	  over	  a	  period	  of	  56	  days	  and	  
size	  was	  measured	  at	   regular	   intervals.	  Additionally,	   the	  weight	  and	  clinical	   status	  of	  
the	   animals	   was	   monitored	   to	   eliminate	   the	   possibility	   that	   tumour	   progression	  
resulted	  in	  significant	  distress	  to	  the	  animals.	  As	  shown	  in	  Figure	  3-­‐6	  A,	  the	  weight	  of	  
the	   animals	   remained	   stable	   throughout	   the	   entire	   study,	   suggesting	   that	  
subcutaneous	   tumour	   growth	   is	   not	   detrimental	   to	   overall	   health	   over	   this	   time	  
period.	  Tumour	  growth	  was	  monitored	  using	  caliper	  measurements	  (Figure	  3-­‐6	  B)	  and	  
BLI	   (Figure	   3-­‐6	   C).	   Tumours	   showed	   exponential	   growth	   over	   time.	   However,	  
substantial	  variability	  between	  animals	  was	  observed.	  
	   To	   determine	   whether	   HN3luc	   cells	   retain	   their	   ErbB	   expression	   during	  
subcutaneous	   growth,	   tumours	   were	   harvested	   and	   homogenised.	   ErbB	   expression	  
was	   analysed	   using	   flow	   cytometry	   (Figure	   3-­‐6	   D).	   Cells	   were	   stained	   using	   ICR12	  
(ErbB1),	   ICR62	   (ErbB2)	   followed	   by	   anti-­‐rat-­‐PE,	   ErbB3-­‐PerCP	   (ErbB3)	   or	   ErbB4-­‐APC	  
(ErbB4).	   Expression	   levels	   were	   compared	   to	   isotype	   control	   stained	   cells.	   Tumours	  
retained	   expression	   of	   ErbB	   receptors	   when	   grown	   as	   subcutaneous	   xenografts.	  
Expression	   of	   ErbB1	   and	   ErbB2	   was	   still	   present,	   although	   levels	   were	   decreased	  
compared	   to	   in	   vitro	   culture.	   ErbB3	   expression	   remained	   negative	   and	   ErbB4	  
expression	  remained	  low.	  The	  demonstration	  that	  HN3luc	  cells	  exhibit	   in	  vivo	  growth	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with	   retention	  of	  ErbB	  expression	   suggested	   that	   subcutaneous	  HN3luc	   tumours	   can	  
be	  used	  to	  test	  intra-­‐tumoural	  T4	  immunotherapy	  treatment	  in	  mice.	  	  
	  
	  
Figure	  3-­‐6	  HN3luc	  growth	  subcutaneous	  in	  SCID/Beige	  mice	  
Animals	   were	   injected	   subcutaneously	   in	   the	   left	   flank	   with	   5	   x	   106	   HN3luc	   tumour	   cells	   in	   200μL	  
matrigel.	   A:	   Sequential	   weight	   measurements	   over	   the	   duration	   of	   in	   vivo	   tumour	   growth.	   Weight	  
change	   is	   expressed	   as	   relative	   change	   compared	   to	   start	   of	   the	   study	   (start	  weight	   equals	   100%)	  B:	  
Tumour	  volume	  based	  on	   sequential	   caliper	  measurements.	  Volume	   is	   calculated	  based	  on:	  volume	  =	  
(length	  x	  width2)/2.	  C:	  Tumour	  growth	  based	  on	  sequential	  bioluminescent	  imaging	  (total	  flux).	  Data	  in	  
panels	  A	  to	  C	  show	  mean	  ±	  SD	  of	  10	  mice.	  D:	  ErbB	  expression	  (open	  coloured	  histograms,	  MFI	  indicated	  
by	   coloured	   number)	   as	   determined	   by	   flow	   cytometry	   of	   resected	   subcutaneous	   tumour.	   Filled	  
histograms	  show	  isotype	  control	  stained	  cells,	  MFI	  indicated	  by	  grey	  number.	  Samples	  were	  stained	  as	  
described	  in	  Figure	  3-­‐4.	  Data	  are	  representative	  of	  three	  separate	  tumours,	  all	  of	  which	  yielded	  similar	  
results.	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3.2.4 Activation	  of	  T4+	  T-­‐cells	  by	  Mouse	  ErbB	  Receptors	  
The	  results	  shown	  in	  Figure	  3-­‐5	  raise	  concerns	  that	  cardiac-­‐	  and	  pulmonary	  endothelial	  
toxicity	   may	   be	   elicited	   by	   T4	   immunotherapy.	   However,	   there	   are	   substantial	  
differences	  between	  the	  conditions	   in	  vitro	  and	   in	  vivo.	  This	  possible	  toxicity	  can	  only	  
be	  induced	  if	  the	  T-­‐cells	  migrate	  into	  these	  organs	  to	  interact	  with	  the	  ErbB	  receptors	  
expressed	  on	  the	  cell	  surface.	  An	  animal	  model	  is	  required	  to	  determine	  whether	  this	  
migration	  and	  interaction	  occurs.	  To	  decide	  whether	  a	  mouse	  model	  would	  be	  suitable	  
for	   this	  purpose,	   it	  has	   to	  be	  shown	  that	  human	  T-­‐cells	  expressing	  human	  T4	  can	  be	  
activated	   by	  mouse	   ErbB	   receptors.	   To	   test	   this,	   the	  mouse	  HNSCC	   tumour	   cell	   line	  
B7E3	   was	   selected.	   The	   ErbB	   expression	   profile	   of	   B7E3	   was	   tested	   using	   flow	  
cytometry	   (Figure	   3-­‐7).	   B7E3	   showed	   intermediate	   expression	   of	   ErbB1,	   no	   ErbB2	  
expression	   and	   low	  expression	  of	   ErbB3	   and	  4	   (see	   Figure	   3-­‐7).	   If	   the	   human	  T-­‐cells	  
expressing	  human	  T28ζ	  can	  be	  activated	  by	  mouse	  ErbB	  receptors,	  exposure	  of	  human	  
T4+	  T-­‐cells	  to	  these	  mouse	  tumour	  cell	  lines	  should	  induce	  T-­‐cell	  activation,	  tumour	  cell	  
destruction	  and	  cytokine	  production.	  
To	  allow	  for	  a	  comparison	  of	  the	  ErbB	  expression	  levels	  on	  mouse	  tumours	  with	  
the	  human	  tumour	  cell	  line	  HN3,	  HN3	  was	  stained	  using	  the	  same	  intracellular	  staining	  
protocol.	   The	   levels	   of	   ErbB1,	   ErbB2	   and	   ErbB3	   expression	   are	   higher	   on	   HN3	  
compared	   to	   B7E3,	   both	   in	   regard	   to	   the	   increase	   in	   measured	   MFI	   compared	   to	  
control	  stained	  cells,	  as	  well	  as	  the	  proportion	  of	  cells	  positive	  for	  the	  receptors.	  The	  
level	   of	   ErbB4	   expression	   is	   higher	   on	   B7E3.	   However,	   because	   T28ζ	   has	   very	   low	  
affinity	   for	  ErbB4,	  differences	   in	  expression	   level	  of	   this	   receptor	  are	  very	  unlikely	   to	  
contribute	  to	  differences	  in	  efficacy	  (Figure	  3-­‐7).	  Both	  cell	  lines	  are	  negative	  for	  PSMA	  
(Supplementary	  Figure	  2	  in	  Appendix	  2).	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Figure	  3-­‐7	  ErbB	  expression	  profiles	  mouse	  and	  human	  tumour	  cell	  lines	  
ErbB	   expression	   on	   the	   mouse	   tumour	   cell	   line	   B7E3	   and	   the	   human	   tumour	   cell	   line	   HN3luc,	   was	  
detected	   by	   flow	   cytometry	   after	   intracellular	   staining	   using	   the	   same	   rabbit	   polyclonal	   ErbB-­‐specific	  
antibodies	  followed	  by	  sheep	  anti-­‐rabbit-­‐FITC	  (coloured	  open	  histograms),	  MFI	  represented	  in	  coloured	  
number.	   Grey	   solid	   histograms	   represent	   background	   staining	   (rabbit	   serum	   followed	   by	   sheep	   anti-­‐
rabbit-­‐FITC)	  MFI	  represented	  in	  grey	  number.	  Black	  number	  indicates	  percentage	  of	  cells	  positive	  for	  the	  
ErbB	   receptor	   of	   interest.	   Data	   are	   representative	   of	   n=5	   (B7E3)	   and	   n=2	   (HN3)	   independent	  
experiments.	  
	  
Co-­‐cultivation	   of	   1	   x	   106	   human	   T4+,	   P4+	   or	   UT	   T-­‐cells	   with	   confluent	   B7E3	  
monolayers	  resulted	   in	  T28ζ-­‐specific	  monolayer	  destruction	   (see	  Figure	  3-­‐8	  A	  and	  B).	  
Consistent	  with	  monolayer	  destruction,	  cytokine	  production	  (IL-­‐2	  and	  IFNγ)	  were	  also	  
only	  produced	  in	  co-­‐cultivation	  of	  T4+	  T-­‐cells	  with	  B7E3	  (see	  Figure	  3-­‐8	  C).	  The	  level	  of	  
IL-­‐2	  produced	   in	   response	   to	  B7E3	   is	   similar	   as	   to	   the	   level	  produced	   in	   response	   to	  
exposure	  to	  HN3	  (see	  Figure	  3-­‐4	  D).	  However,	  the	  level	  of	  IFNγ	  produced	  is	  significantly	  
higher	   (p<0.001)	   in	   response	   to	   HN3	   compared	   to	   B7E3.	   This	   lower	   level	   of	   IFNγ	  
production	   could	   indicate	   a	   lower	   level	   of	   activation	   in	   response	   to	   mouse	   ErbB	  
receptors	  compared	  to	  human	  ErbB	  receptors,	  perhaps	  because	  the	  T1E	  peptide	  has	  a	  
higher	   affinity	   for	   the	   human	   ErbB	   receptors	   than	   the	   mouse	   ErbB	   receptors.	  
Alternatively	  this	  may	  reflect	  differences	  in	  interactions	  between	  accessory	  molecules	  
on	  human	  T-­‐cells,	  interacting	  with	  human	  compared	  to	  mouse	  target	  cells.	  
	   166	  
	  
	  
Figure	  3-­‐8	  Activation	  of	  human	  T4+	  T-­‐cells	  by	  mouse	  HNSCC	  tumour	  cell	  line	  B7E3	  
T4+,	  P4+	  or	  UT	  T-­‐cells	  (1	  x	  106)	  were	  co-­‐cultivated	  with	  a	  confluent	  monolayer	  of	  B7E3	  tumour	  cells	  (24	  
well	  plate)	   for	  24	  hours.	  A:	  The	  degree	  of	   tumour	  monolayer	  destruction	  was	  quantified	  with	  an	  MTT	  
assay.	  Results	  are	  expressed	  as	  %	  viable	  cells	  compared	  to	  a	  confluent	  monolayer	  without	  T-­‐cells.	  Data	  
represents	  mean	   ±	   SD	   (n=6).	   **	   =	   p<0.001	  B:	   Residual	   tumour	  monolayers	  were	   fixed	   and	   visualised	  
using	   crystal	   violet	   after	   24	   hours	   of	   co-­‐culture	   with	   indicated	   T-­‐cell	   population	   C:	   IL-­‐2	   and	   IFNγ	  
production	  were	  measured	  in	  the	  supernatant	  after	  24	  hours	  of	  co-­‐cultivation.	  Data	  shown	  mean	  ±	  SD	  
(n=9).	  **	  =	  p<0.001.	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3.2.5 ErbB	  Expression	  in	  Healthy	  Mouse	  Organ	  Tissue	  
As	  described	   in	  paragraph	  3.2.2,	  cardiac	  and	  endothelial	   tissue	  could	  be	  at	  risk	  to	  be	  
targeted	  by	  T4+	  T-­‐cells.	  To	  determine	  which	  specific	  organs	  might	  be	  susceptible	  to	  T4-­‐
mediated	  toxicity	  in	  vivo,	  mouse	  organs	  were	  harvested	  and	  tested	  for	  ErbB	  expression	  
using	   flow	  cytometry	   (see	  Figure	  3-­‐9).	  Organs	  were	  harvested	   from	  healthy,	   tumour-­‐
free	  SCID/Beige	  mice	  and	  homogenized.	  The	  level	  of	  ErbB	  expression	  was	  determined	  
by	   intracellular	   staining	   with	   rabbit	   serum	   and	   the	   appropriate	   polyclonal	   anti-­‐
ErbB1/2/3/4	   rabbit	   IgG,	   followed	   by	   Sheep	   anti-­‐Rabbit	   FITC-­‐conjugated	   secondary	  
antibody.	   Expression	   levels	  were	   compared	   to	   cells	   stained	  with	   rabbit	   serum	   alone	  
followed	   by	   the	   Sheep	   anti-­‐Rabbit	   FITC-­‐conjugated	   secondary	   antibody.	   ErbB	  
expression	  was	  only	  determined	  within	  the	  live	  cell	  population,	  based	  on	  their	  position	  
within	  the	  FFSC/SSC	  scatter	  plot.	  The	  organs	  tested	  for	  ErbB	  expression	  include	  brain,	  
heart,	  kidney,	  liver,	  lung	  and	  intestines.	  	  	  
	   The	  strongest	  T-­‐cell	  activation	  through	  T28ζ	  can	  be	  elicited	  by	  ErbB1-­‐containing	  
dimers	   and	   the	   ErbB2/3	   heterodimer.	   Therefore,	   high	   expression	   levels	   of	   all	   these	  
three	  receptors	  would	  place	  an	  organ	  at	  risk	  for	  potential	   ‘on-­‐target’	  toxicity.	   	  Heart,	  
Kidney	  and	   Lung	   tissue	  all	   show	  expression	  of	   ErbB1,	  2	   and	  3	   in	  which	  expression	   is	  
most	  pronounced	  in	  Heart	  tissue	  (see	  Figure	  3-­‐9).	  Intestinal	  tissue	  shows	  expression	  of	  
ErbB1	   and	   2	   but	   is	   negative	   for	   ErbB3	   expression.	   Brain	   and	   Liver	   show	   low	   to	   no	  
expression	  of	  ErbB	  1,	  2	  and	  3,	  placing	  them	  at	  a	  reduced	  risk	  for	  toxicity	  compared	  to	  
the	  other	  organs.	  Expression	  of	  ErbB4	   is	  detected	   in	  all	  organ	  tissue,	  except	   for	  Liver	  
tissue.	   However,	   because	   T28ζ	   has	   a	   low	   affinity	   for	   ErbB4	   it	   is	   unlikely	   to	   be	   of	  
significant	  influence	  to	  the	  risk	  of	  toxicity.	  Due	  to	  different	  antibody	  staining	  protocols,	  
a	   reliable	   comparison	   between	   ErbB	   expression	   on	   mouse	   organ	   tissue	   and	   their	  
human	  equivalents	  (Figure	  3-­‐5)	  cannot	  be	  made.	  





Figure	  3-­‐9	  ErbB	  expression	  in	  mouse	  organs	  
Organs	   were	   harvested	   and	   homogenised	   using	   a	   cell	   strainer	   or	   electronic	   homogenizer.	   ErbB	  
expression	   profile	  was	   tested	   using	   intracellular	   staining	   and	   flow	   cytometry	   analysis.	   Coloured	   open	  
histograms	  represent	  ErbB	  expression	  (rabbit	  serum	  +	  polyclonal	  anti-­‐ErbB1/2/3/4	  rabbit	   IgG	  followed	  
by	  sheep	  anti-­‐rabbit-­‐FITC).	  Grey	  solid	  histograms	  represent	  background	  staining	  (rabbit	  serum	  followed	  
by	  sheep	  anti-­‐rabbit-­‐FITC).	  Grey	  numbers	   indicate	  background	  MFI,	  coloured	  numbers	   indicate	  MFI	  or	  
receptor	  of	  interest.	  Percentage	  of	  positive	  cells	  is	  indicated	  in	  top	  right	  corner.	  Data	  show	  one	  of	  four	  
similar	  experiments	  (except	  intestine	  where	  n=1).	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3.2.6 Activation	  of	  Human	  T4+	  T-­‐cells	  by	  Primary	  Mouse	  Pulmonary	  Endothelial	  Cells	  
To	  determine	  whether	  the	  ErbB	  expression	   levels	  on	  mouse	  primary	  healthy	  tissue	   is	  
also	  sufficient	  to	  induce	  activation	  of	  human	  T4+	  T-­‐cells,	  1	  x	  106	  T4+	  (or	  control	  T-­‐cells)	  
were	   co-­‐cultivated	   with	   confluent	   monolayers	   of	   primary	   mouse	   pulmonary	  
endothelial	   cells	   (MPMEC).	   The	   MPMEC	   express	   intermediate	   levels	   of	   ErbB1	   and	  
ErbB2,	  low	  levels	  of	  ErbB3	  and	  high	  levels	  of	  ErbB4	  (see	  Figure	  3-­‐10	  A).	  This	  expression	  
pattern	   is	   similar	   to	   that	   detected	   in	   fresh	  mouse	   lung	   tissue	   (see	   Figure	   3-­‐9).	   ErbB	  
expression	  levels	  are	  also	  similar	  as	  on	  HPMEC,	  except	  for	  the	  high	  expression	  of	  ErbB4	  
on	  MPMEC	   compared	   to	   no	   expression	   of	   ErbB4	   on	   HPMEC	   (see	   Figure	   3-­‐5	   A).	   Co-­‐
cultivation	  of	  confluent	  MPMEC	  monolayers	  with	  1	  x	  106	  T4+,	  P4+	  or	  UT	  T-­‐cells	  resulted	  
in	  T28ζ-­‐dependent	  monolayer	  destruction	  (see	  Figure	  3-­‐10	  B)	  and	  cytokine	  production	  
(see	  Figure	  3-­‐10	  C).	  	  
These	  results	  indicate	  that	  the	  human	  T1E	  peptide	  can	  cross	  the	  species	  barrier	  
and	  consequently	   that	  human	  T4+	  T-­‐cells	   can	  be	  activated	  by	  mouse	  ErbB	   receptors.	  
These	  data	  support	  the	  use	  of	  a	  mouse	  model	  to	  determine	  the	   in	  vivo	   toxicity	  of	  T4	  
immunotherapy,	  satisfying	  the	  requirement	  of	  the	  Medicines	  and	  Healthcare	  products	  
Regulatory	  Agency	  (MHRA)	  for	  direct	  testing	  of	  the	  therapeutic	  product.	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Figure	   3-­‐10	   Human	   T4+	   T-­‐cell	   activation	   by	   mouse	   pulmonary	   microvascular	  
endothelial	  cells	  
A:	   ErbB	   expression	   in	   the	  mouse	   pulmonary	  microvascular	   endothelial	   cells	   was	   determined	   by	   flow	  
cytometry	   (as	  described	   in	  Figure	  3-­‐7)	  Open	  coloured	  histograms	  represent	  ErbB	  expression,	  coloured	  
number	   represent	   MFI	   stained	   population,	   filled	   histograms	   represent	   isotype	   control	   staining,	   grey	  
number	  represents	  MFI	   isotype	  control	  population.	  B:	  1	  x	  106	  T4+,	  P4+	  or	  UT	  T-­‐cells	  were	  co-­‐cultivated	  
with	  confluent	  MPMEC	  monolayers.	  After	  24	  hours	  monolayer	  destruction	  was	  quantified	  using	  an	  MTT	  
assay.	   %	   viable	   cells	   were	   calculated	   compared	   to	   a	   confluent	   monolayer	   without	   T-­‐cells.	   Data	  
represents	  mean	  ±	  SD	  (n=3).	  *=p<0.001.	  C:	  IFNγ	  levels	  in	  the	  supernatant	  after	  24	  hours	  of	  co-­‐cultivation	  
as	  described	  in	  B.	  Data	  represents	  mean	  ±	  SD	  (n=6).	  *	  =	  p<0.001.	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3.2.7 Functionality	  of	  T4luc	  
Toxicity	  due	  to	  the	  expression	  of	  ErbB	  receptors	  by	  healthy	  tissue	  (so-­‐called	  ‘on-­‐target	  
toxicity)	  is	  a	  risk	  for	  as	  long	  as	  viable	  T4+	  T-­‐cells	  remain	  in	  the	  body.	  For	  this	  reason,	  the	  
MHRA	   directed	   that	   in	   vivo	   toxicity	   testing	   of	   the	   proposed	   therapeutic	   product	   (eg	  
human	  T4+	  T-­‐cells)	  should	  be	  performed	  at	  the	  time-­‐point	  when	  viable	  T4+	  T-­‐cells	  could	  
no	   longer	   be	   detected	   in	   vivo.	   	   The	   rationale	   behind	   this	   time-­‐point	   for	   toxicity	  
assessment	  is	  that	  toxicity	  can	  only	  occur	  as	  long	  as	  the	  medicinal	  product	  (in	  this	  case	  
the	   T4+	   T-­‐cells)	   is	   present	   in	   the	   body,	   and	   therefore	   the	   experiment	   can	   only	   be	  
terminated	   when	   there	   are	   no	   viable	   T4+	   T-­‐cells	   present	   anymore.	   However,	  
assessment	   of	   the	   toxicity	   at	   this	   single	   timepoint	   also	   assumes	   that	   any	   toxicity	  
occurring	   prior	   to	   that	   endpoint	   will	   still	   be	   detectable	   at	   the	   pre-­‐determined	  
endpoint.	  Any	  mild,	  reversible,	  clinically	  undetectable	  toxicity	  will	  not	  be	  detected	  with	  
this	  methodology.	  If	  any	  clinically	  visible	  toxicity	  were	  to	  occur	  prior	  to	  the	  endpoint,	  
the	  experiment	  would	  be	  terminated	  for	  human	  reasons.	  	  
	   To	  determine	  the	  longevity	  of	  human	  T4+	  T-­‐cells	  in	  a	  SCID/Beige	  mouse	  model,	  
a	  long-­‐term	  imaging	  study	  was	  required.	  To	  perform	  this	  study,	  a	  new	  construct	  named	  
T4luc	  was	  designed	  (see	  Figure	  3-­‐11).	  In	  this	  construct,	  T4	  is	  co-­‐expressed	  with	  firefly	  
luciferase,	   allowing	   for	   in	   vivo	   T-­‐cell	   tracking	   using	   bioluminescent	   imaging.	   It	   was	  
assumed	   that	   when	   no	   luciferase	   activity	   could	   be	   detected,	   significant	   numbers	   of	  
viable	   T4luc+	   T-­‐cells	  were	   no	   longer	   present.	   Consequently,	   toxicity	   testing	   could	   be	  
performed	   shortly	   after	   this	   time	   point,	   in	   compliance	   with	   MHRA	   directions.	   In	  
addition	   to	   determining	   the	   longevity	   of	   the	   engrafted	   cells,	   BLI	   also	   allows	   the	  
investigator	   to	  monitor	   the	  migration	   pattern	   of	   the	   cells.	  Migration	   patterns	   could	  
indicate	  which	   organs	   are	   at	   risk	   for	   toxicity	   following	   T-­‐cell	   delivery	   using	   different	  
routes	  of	  administration.	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Figure	   3-­‐11	   Schematic	   representation	   of	   the	   SFG	   γ-­‐retroviral	   vector	   containing	   the	  
T4luc	  construct	  
All	  three	  transgenes	  are	  expressed	  under	  the	  control	  of	  the	  long	  terminal	  repeat	  (LTR)	  promoter.	  This	  is	  
achieved	   using	   two	   intervening	   T2A	   peptide	   sequences	   (each	   placed	   downstream	   of	   a	   furin	   cleavage	  
site).	  Though	  encoding	  an	   identical	  protein	  sequence,	   the	  DNA	  sequence	  of	   the	  second	   furin	  cleavage	  
and	  T2A	  peptide	  (✜)	  has	  been	  maximally	  altered	  from	  the	  first	  through	  codon	  “wobbling”,	   in	  order	  to	  
minimise	  the	  risk	  of	  vector	  instability.	  SD:	  splice	  donor	  site;	  Ψ:	  packaging	  signal;	  SA:	  splice	  acceptor	  site;	  
★:	   macrophage	   colony	   stimulating	   factor	   receptor	   (FMS)	   leader	   sequence;	   ✜:	   altered	   T2A	   peptide	  
sequence.	  Note:	  size	  of	  the	  blocks	  is	  not	  representative	  of	  the	  sizes	  of	  the	  separate	  elements.	  
	  
The	  T4luc	  construct	  was	  cloned	  into	  the	  SFG	  γ-­‐retroviral	  vector.	  The	  expression	  
of	   three	   separate	   transgenes	   under	   the	   control	   of	   a	   single	   promoter	  was	   facilitated	  
through	   the	   incorporation	   of	   two	   intervening	   T2A	   sequences/	   furin	   cleavage	   sites	  
(Figure	   3-­‐11).	   T-­‐cells	  were	   transduced	   using	   GALV-­‐enveloped	   virions	   produced	   using	  
the	   packaging	   cell	   line	   PG13.	   Validation	   of	   PG13	   packaging	   cells	   prior	   to	   T-­‐cell	  
transduction	  was	  determined	  by	  analysis	  of	  transgene	  expression.	  Expression	  of	  both	  
T28ζ	  and	  4αβ	  was	  demonstrated	  by	  flow	  cytometry,	  while	  firefly	  luciferase	  expression	  
was	   confirmed	   using	   an	   in	   vitro	   luciferase	   assay	   (Figure	   3-­‐12	   A	   and	   D).	   Following	  
transduction	  with	  the	  T4luc	  vector,	  T-­‐cells	  were	  cultured	  in	  media	  supplemented	  with	  
IL-­‐4.	  By	  this	  means,	  the	  T28ζ+	  population	  could	  be	  increased	  from	  4.01%	  to	  47.5%	  over	  
8	  days,	  thereby	  confirming	  the	  function	  of	  T4luc-­‐encoded	  4αβ (Figure	  3-­‐12	  B).	  At	  the	  
end	  of	  the	  14	  day	  culture	  period,	  CD4+	  and	  CD8+	  T-­‐cells	  both	  contributed	  to	  about	  half	  
of	   the	   total	   population	   (Figure	   3-­‐10	   C).	   Transduced	   cells	   did	   not	   only	   expand	   in	  
proportion	   within	   the	   entire	   population,	   but	   total	   cell	   count	   also	   increased	   during	  
culture	   (Figure	   3-­‐10	   E).	   Cell	   viability	   decreased	   between	   day	   10	   and	   14	   of	   culture	  
(Figure	  3-­‐10	  F)	   this	   is	  most	   likely	  due	  to	  the	  selective	  pressure	  of	  culture	   in	   IL-­‐4.	  The	  
large	   proportion	   of	   dead	   cells	   is	   most	   likely	   untransduced	   T-­‐cells.	   Firefly	   luciferase	  
function	   in	   T4luc-­‐transduced	   T-­‐cells	  was	   confirmed	   using	   an	   in	   vitro	   luciferase	   assay	  
(Figure	  3-­‐10	  D).	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Figure	  3-­‐12	  T4luc	  expression	  in	  PG13	  and	  T-­‐cells	  
A:	   Expression	   of	   T28ζ	   (open	   red	   histogram,	   MFI	   indicated	   by	   red	   number)	   and	   4αβ	   (open	   green	  
histogram,	   MFI	   indicated	   by	   green	   number)	   on	   the	   cell	   surface	   of	   PG13	   packaging	   cells	   using	   flow	  
cytometry.	  Expression	  is	  compared	  to	  untransduced	  PG13	  stained	  with	  the	  same	  protocol	  (closed	  grey	  
histograms,	  MFI	  indicated	  by	  grey	  number)	  B:	  Expression	  of	  T28ζ	  (open	  red	  histograms,	  MFI	  indicated	  by	  
red	  number)	  on	  the	  cell	  surface	  of	  primary	  human	  T-­‐cells	  using	  flow	  cytometry.	  Expression	  is	  compared	  
to	   untransduced	   cells	   stained	  with	   the	   same	   protocol	   (closed	   grey	   histograms,	  MFI	   indicated	   by	   grey	  
number).	   Cells	   were	   analysed	   at	   multiple	   days	   after	   transduction	   to	   test	   for	   enrichment	   of	   the	  
transduced	   population	   in	   media	   supplemented	   with	   IL-­‐4.	   Proportion	   of	   CAR+	   cells	   indicated	   by	  
percentage	   in	   upper	   right	   corner	   C:	   Proportion	   of	   CD4+	   and	   CD8+	   T-­‐cells	   within	   the	   entire	   T-­‐cell	  
population	   on	   day	   14	   of	   culture.	   D:	   Activity	   of	   firefly	   luciferase	   was	   determined	   using	   an	   in	   vitro	  
luciferase	  assay.	  A	  total	  of	  0.5	  x	  106	  cells	  (T4luc	  transduced	  or	  untransduced	  cells	  as	  control)	  were	  lysed	  
and	  luciferase	  activity	  was	  determined	  using	  the	  FLUOStar	  Omega	  plate	  reader	  (mean	  ±	  SD	  of	  n=3).	  *	  =	  
p<	  0.05	  of	   T4luc	   transduced	   cells	   compared	   to	  matched	  untransduced	   cells.	  E:	   Expansion	  of	   total	   cell	  
population,	  live	  cells	  were	  counted	  on	  day	  4,	  10	  and	  14	  during	  cultured	  based	  on	  trypan	  blue	  exclusion	  
of	  dead	  cells.	  F:	  Viability	  of	  cells	  during	  culture	  based	  on	  live/dead	  gating	  on	  day	  4,	  10	  and	  14.	  
	  
Functionality	  of	  T28ζ	  in	  T4luc	  was	  confirmed	  by	  co-­‐cultivation	  of	  1	  x	  106	  T4luc+	  
T-­‐cells	  with	  human	  (HN3	  and	  435)	  and	  mouse	  (B7E3)	  tumour	  monolayers.	  Monolayer	  
destruction	   and	   cytokine	   production	   were	   both	   monitored.	   T4luc+	   T-­‐cells	   destroyed	  
both	   ErbB+	   human	   (HN3)	   and	   ErbB+	   mouse	   (B7E3)	   monolayers,	   but	   left	   the	   ErbBLO	  
human	  monolayer	  435	   intact	   (see	  Figure	  3-­‐13	  A).	  Untransduced	  T-­‐cells	  did	  not	  affect	  
any	   of	   the	   monolayers,	   as	   predicted.	   Cytokine	   production	   (see	   Figure	   3-­‐13	   B)	   by	  
activated	   T4luc+	   T-­‐cells	   was	   consistently	   low.	   Interleukin-­‐2	   production	   was	   not	  
significantly	  higher	  in	  co-­‐cultivations	  of	  T4luc+	  T-­‐cells	  with	  ErbB+	  monolayers	  compared	  
to	  any	  of	  the	  controls.	  Interferon-­‐γ	  levels	  were	  significantly	  higher	  in	  co-­‐cultivations	  of	  
T4luc+	  T-­‐cells	  with	  HN3	  compared	  to	  co-­‐cultivation	  with	  other	  targets	  (see	  Figure	  3-­‐13	  
B).	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Figure	  3-­‐13	  T4luc	  functionality	  in	  vitro	  
A:	  1	  x	  106	  T4luc+	  T-­‐cells	  or	  UT	  T-­‐cells	  were	  co-­‐cultivated	  with	  confluent	  monolayers	  of	  the	  ErbB+	  human	  
tumour	  cell	   line	  HN3luc,	   the	  ErbB+	  mouse	  tumour	  cell	   line	  B7E3	  or	   the	  ErbBLO	  human	  tumour	  cell	   line	  
435	   for	  24	  hours.	  Residual	   tumour	  monolayer	  was	  visualised	  using	  crystal	  violet	   staining.),	  B:	   IL-­‐2	  and	  
IFNγ	   was	   measured	   in	   supernatants	   collected	   from	   the	   indicated	   T-­‐cell	   /	   tumour	   cell	   monolayer	   co-­‐
cultivations	   after	   24	   hours	   of	   co-­‐cultivation.	   Data	   shows	   mean	   ±	   SD	   (n=3)	   from	   one	   of	   two	   similar	  
experiments.	  *	  =	  p<0.05.	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Collectively,	   these	   in	   vitro	   data	   confirm	   the	   functionality	   of	   all	   three	   transgenes	  
encoded	   by	   T4luc.	   However,	   transduction	   efficiency,	   rates	   of	   CAR	   positivity,	   IL-­‐4-­‐
mediated	  enrichment	  of	  the	  CAR+	  population	  and	  CAR	  functionality	  were	  consistently	  
lower	  in	  cells	  transduced	  with	  T4luc	  compared	  to	  T4.	  Expression	  of	  all	  three	  transgenes	  
by	  a	  single	  LTR	  driven	  promoter	  is	  likely	  to	  account	  for	  the	  decrease	  in	  expression	  level	  
and	  functionality	  of	  each	  of	  the	  transgenes.	  However,	  the	  main	  purpose	  of	  the	  T4luc	  
construct	  was	   to	  permit	   serial	   in	  vivo	   imaging	  of	  T-­‐cells	   that	  co-­‐express	   the	  T28ζ	  and	  
4αβ	  transgenes.	  Consequently,	  such	  experiments	  were	  undertaken	  in	  tumour-­‐bearing	  
mice.	  
	  
3.2.8 In	  Vivo	  Imaging	  of	  T4luc+	  T-­‐cells	  in	  Mice	  bearing	  HN3	  Tumour	  Xenografts	  
To	   determine	   the	   longevity	   of	   transduced	   human	   T-­‐cells	   in	   vivo,	   SCID/Beige	   mice	  
bearing	   subcutaneous	   HN3	   head	   and	   neck	   tumours	   were	   treated	   with	   T4luc	  
transduced	  T-­‐cells.	  Tumours	  were	   included	  in	  the	  experimental	  design	  to	  account	  for	  
the	   possible	   effect	   of	   ErbB-­‐T28ζ	   interaction	   on	   T-­‐cell	   proliferation	   as	   well	   as	   to	  
determine	  whether	  the	  T-­‐cells	  migrated	  towards	  the	  tumour.	  An	  imaging	  gene	  was	  not	  
included	  in	  HN3	  cells	  since	  the	  resultant	  tumours	  could	  be	  visualised	  directly,	  allowing	  
for	  imaging	  of	  T4luc+	  T-­‐cells	  using	  BLI.	  Both	  male	  and	  female	  mice	  were	  included	  in	  the	  
experiment	  to	  account	  for	  possible	  gender	  differences.	  
T-­‐cells	   were	   activated	   using	   CD3/CD28-­‐coated	   paramagnetic	   beads	   and,	  
following	  transduction,	  were	  expanded	  in	  IL-­‐4	  for	  a	  period	  of	  11	  days.	  Expanded	  T4luc+	  
T-­‐cells	  were	  administered	  using	  either	  the	  intravenous	  or	  peri-­‐tumoural	  (PT)	  routes	  (in	  
proximity	  to	  the	  tumour	  site),	  as	  summarised	  in	  Table	  3-­‐1.	  Control	  mice	  received	  no	  T-­‐
cells.	  Thereafter,	  animals	  were	  analysed	  by	  BLI	  on	  days	  1,	  2,	  5,	  7,	  9	  and	  12	  in	  order	  to	  
monitor	  T-­‐cell	  distribution	  and	  longevity	  in	  vivo.	  
	  
Table	  3-­‐1	  Design	  of	  ‘T4luc	  in	  vivo	  imaging	  study’	  
Number	  Mice	   HN3	  Tumour	  cells	  SC	   T4luc+	  T-­‐cells	  IV	   T4luc+	  T-­‐cells	  PT	  
2	  male	  
1	  female	  
-­‐	   -­‐	   -­‐	  
2	  male	  
1	  female	  
5	  x	  106	   -­‐	   -­‐	  
3	  male	  
3	  female	  
5	  x	  106	   20	  x	  106	   -­‐	  
3	  male	  
3	  female	  
5	  x	  106	   -­‐	   20	  x	  106	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Figure	   3-­‐14	   A	   and	   B	   show	   serial	   images	   obtained	   from	   one	   representative	  
animal	  of	  each	  gender,	  following	  IV	  or	  PT	  administration	  of	  T4luc+	  T-­‐cells.	  Pooled	  data	  
from	   all	   animals	   are	   shown	   in	   Figure	   3-­‐14	   C.	   These	   data	   demonstrate	   that	   infused	  
T4luc+	  T-­‐cells	  became	  undetectable	  after	  day	  5,	  with	  no	  secondary	  rebound	  observed	  
over	   the	   ensuing	   7	   days.	   The	   small	   residual	   signal	   seen	   in	   animals	   following	   IV	  
treatment	   was	   similar	   to	   that	   seen	   in	   untreated	   animals,	   indicating	   that	   it	   is	   non-­‐
specific	  in	  nature	  (Figure	  3-­‐14	  C).	  	  
When	   looking	   at	   the	   T-­‐cell	  migration	   patterns,	   clear	   differences	   can	   be	   seen	  
between	  the	  two	  injection	  routes.	  Directly	  after	  IV	  injection	  (Figure	  3-­‐14	  A),	  T-­‐cells	  can	  
be	  detected	  throughout	  the	  entire	  body,	  with	  the	  highest	  signal	  detected	  in	  the	  area	  of	  
the	  lungs.	  After	  24	  hours	  (day	  1)	  the	  signal	  has	  clearly	  decreased,	  and	  focuses	  on	  the	  
liver/intestine	  area	  and	  around	  the	  site	  of	  injection	  in	  the	  tail	  vein.	  After	  48	  hours	  (day	  
2)	   the	   detectable	   signal	   and	   pattern	   have	   reduced	   similar	   to	   the	   signal	   detected	   in	  
untreated	  animals.	  No	  clear	  homing	  towards	  the	  SC	  tumour	  site	  could	  be	  detected.	  No	  
difference	  was	  seen	  between	  male	  and	  female	  animals.	  
	   Animals	   treated	   PT	   (Figure	   3-­‐14	   B)	   show	   a	   completely	   different	   migration	  
pattern	  compared	  to	  the	  IV	  treated	  animals.	  T-­‐cells	  were	  injected	  SC	  in	  close	  proximity	  
to	   the	   tumour	   site,	   and	   imaged	   at	   the	   same	   time-­‐points	   as	   the	   IV	   treated	   animals.	  
Imaging	  revealed	  that	  the	  PT	  injected	  T4luc+	  T-­‐cells	  resided	  at	  the	  site	  of	  injection	  and	  
did	   not	  migrate	   throughout	   the	   rest	   of	   the	   body.	   Similarly	   as	   seen	   in	   the	   IV	   treated	  
animals,	  the	  signal	  decreased	  over	  time	  and	  had	  reduced	  to	  background	  level	  five	  days	  
after	  T-­‐cell	  injection.	  
The	  weight	  of	  the	  animals	  was	  monitored	  throughout	  the	  entire	  duration	  of	  the	  
experiment	   (Figure	   3-­‐14	   D).	   Animals	   in	   all	   groups	   showed	   no	   changes	   in	   weight	   in	  
response	  to	  tumour	  inoculation,	  nor	  in	  response	  to	  T-­‐cell	  injection.	  
The	   T-­‐cell	   migration	   patterns	   seen	   with	   the	   bioluminescence	   imaging	  
correspond	  with	   results	   previously	   reported	   by	   our	   group	   using	   111-­‐indium-­‐labelled	  
T4+	   T-­‐cells,	  which	  were	   imaged	   using	   single	   photon	   emission	   computed	   tomography	  
(SPECT)-­‐CT	  (460).	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Figure	  3-­‐14	  In	  vivo	  bioluminescence	  imaging	  of	  T4luc+	  T-­‐cells	  
Animals	  received	  5	  x	  106	  HN3	  tumour	  cells	  SC	  in	  200μL	  PBS	  and	  tumours	  were	  allowed	  to	  grow	  over	  a	  
time	  period	  of	  two	  weeks	  prior	  to	  T-­‐cell	  administration.	  A:	  Bioluminescent	  imaging	  of	  20	  x	  106	  T4luc+	  T-­‐
cells	  after	  IV	  administration.	  One	  representative	  animal	  of	  three	  per	  gender	  is	  shown.	  (exposure	  time	  =	  
3min,	   field	   of	   view	   =	   20,	   binning	   =	   4)	   B:	   BLI	   imaging	   of	   20	   x	   106	   T4luc+	   T-­‐cells	   injected	   PT.	   One	  
representative	  animal	  of	  three	  per	  gender	  is	  shown.	  (exposure	  time	  =	  3min,	  field	  of	  view	  =	  20,	  binning	  =	  
4)	  C:	  Quantification	  of	  BLI	  signal,	  black	  dotted	  line	  represents	  background	  (BG)	  seen	  in	  untreated	  animal.	  
Data	   shown	  mean	   ±	   SD	   for	   n=6	   (except	   for	   BG	  where	   n=3).	  D:	   weight	   as	  monitored	   over	   the	   entire	  
duration	  of	  the	  study,	  black	  arrow	  indicates	  the	  timepoint	  of	  T-­‐cell	  injection.	  Data	  shown	  mean	  ±	  SD	  for	  
n=6	  (except	  for	  HN3	  alone	  where	  n=3)	  
	  
3.2.9 Pre-­‐Clinical	  Toxicity	  Study	  (in	  vitro)	  
The	  MHRA	  required	  pre-­‐clinical	  toxicity	  assessment	  using	  the	  exact	  product	  described	  
in	   the	   investigational	  medicinal	  product	  dossier	   (IMPD).	  To	  address	   this,	  a	   study	  was	  
planned	  in	  which	  human	  T4+	  T-­‐cells	  were	  evaluated	  for	  safety	   in	  an	   immunodeficient	  
(SCID/Beige)	   mouse	   model.	   The	   use	   of	   an	   immunodeficient	   mouse	   model	   was	  
considered	  appropriate	  for	  three	  major	  reasons.	  First,	  human	  T-­‐cells	  are	  able	  to	  elicit	  
severe	   xenogeneic	   graft-­‐versus-­‐host	   toxicity	   in	   mice	   (537).	   Second,	   as	   previously	  
described,	   human	   T28ζ+	   T-­‐cells	   can	   engage	   with	  mouse	   ErbB	   receptors,	   resulting	   in	  
cytokine	   production	   and	   monolayer	   destruction.	   ErbB	   expression	   levels	   on	   both	  
healthy	  and	  tumour	  mouse	  tissue	  can	  elicit	  T-­‐cell	  activation	  (see	  Figure	  3-­‐8	  and	  Figure	  
3-­‐10).	   Third,	   after	   IV	   injection,	   human	  T-­‐cells	  migrate	   similarly	   in	  mouse	   and	   in	  man	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(460).	   The	   capacity	   of	   human	   T-­‐cells	   to	   traffic	   appropriately	   in	   SCID/Beige	   mice	  
provides	   reassurance	   concerning	   the	   validity	   of	   the	   model	   for	   pre-­‐clinical	   toxicity	  
testing.	   In	   particular,	   the	   capacity	   of	   the	   cells	   to	   accumulate	   in	   the	   lung	   and	   liver	   is	  
important	  because	  of	  previously	  reported	  toxicities	  in	  these	  areas	  (240,	  366,	  450).	  The	  
cells	  were	  transduced	  using	  the	  GMP-­‐grade	  vector	  produced	  by	  EUFETS	  GmbH	  (batch	  
VR-­‐0042-­‐R-­‐1711).	   Cells	   were	   transduced	   and	   cultured	   according	   to	   the	  most	   recent	  
clinical	   batch	   manufacturing	   protocol	   (as	   described	   in	   CHAPTER	   5)	   available.	   For	  
detailed	   information	   regarding	   the	   risk	   of	   toxicity,	   the	   MHRA	   required	   extensive	  
histological	   assessment	   of	   the	   major	   organs	   of	   the	   mice.	   The	   organs	   required	   for	  
testing	   were	   listed	   in	   Annex	   I	   of	   the	   EMA	   guideline	   of	   repeated	   dose	   toxicity	  
(CPMP/SWP/1042/99)	  (see	  Figure	  3-­‐15).	  	  
	   Imaging	  studies	  described	  in	  paragraphs	  3.2.7	  and	  3.2.8	  indicated	  that	  T4luc+	  T-­‐
cells	   persisted	   in	   vivo	   following	   IV	   or	   peri-­‐tumoural	   injection	   for	   a	  maximum	  of	   five	  
days.	  As	  indicated	  above,	  MHRA	  dictated	  that	  toxicity	  induced	  by	  T4+	  T-­‐cells	  should	  be	  
tested	   at	   the	   end	   of	   their	   lifespan	   in	   vivo.	   To	   accommodate	   for	   potential	   batch-­‐
variances	   and	   low	   sensitivity	   of	   the	   ffLuc	   imaging,	   it	   was	   decided	   to	   undertake	   this	  
safety	  study	  in	  organs	  harvested	  from	  mice	  seven	  days	  after	  T4+	  T-­‐cell	  injection.	  	  
In	   our	   planned	   Phase-­‐I	   clinical	   trial,	   we	   intend	   to	   inject	   T4	   immunotherapy	  
using	   the	   intra-­‐tumoural	   route.	   However,	   tumour	   sizes	   in	   the	   mouse	   model	   are	  
substantially	  smaller	  than	  in	  humans,	  making	  IT	  injections	  challenging.	  If	  an	  IT	  injection	  
was	  not	  feasible,	  T-­‐cells	  were	  injected	  in	  a	  peri-­‐tumoural	  (PT)	  distribution	  to	  mimic	  an	  
IT	   injection	   as	   closely	   as	   possible.	   Intravenous	   injections	   were	   also	   included	   in	   the	  
safety	  study	  to	  provide	  a	  worst-­‐case	  scenario	  of	  toxicity	  induced	  by	  T4+	  T-­‐cells	  
The	  T4+	  T-­‐cell	  dose	  level	  with	  which	  the	  animals	  were	  treated	  was	  20	  x	  106	  total	  
T-­‐cells	   (51%	   transduced),	   mimicking	   a	   dose	   level	   of	   5	   x	   109	   total	   cells	   (2.5	   x	   109	  
transduced)	  in	  humans	  (for	  calculation	  details	  please	  refer	  to	  Appendix	  3).	  This	  makes	  
the	   chosen	  dose	   for	   the	   toxicity	   study	   two	   fold	   higher	   than	   the	   dose	   that	  would	   be	  
administered	  to	  the	  patients	  within	  the	  highest	  dose	  cohort	  (1	  x	  109	  T4+	  T-­‐cells).	  
To	  determine	  the	  possible	   toxicity,	   the	  general	  behaviour	  and	  body	  weight	  of	  
the	  animals	  was	  monitored	   throughout	   the	   study.	  After	   termination	  of	   the	   study,	  all	  
organs	  were	  harvested	  for	  independent	  histopathological	  studies	  performed	  by	  Abbey	  
Vet	  Services	  (Newton	  Abbot,	  Devon,	  United	  Kingdom).	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To	  perform	  the	   toxicity	   study,	  blood	  was	  derived	   from	  a	  healthy	  volunteer	  donor.	  T-­‐
cells	   were	   activated	   using	   CD3/CD28	   beads	   and	   cultured	   over	   a	   period	   of	   72	   hours	  
prior	  to	  transduction.	  A	  total	  of	  80	  x	  106	  cells	  were	  transduced	  in	  a	  Retronectin-­‐coated	  
(5μg/cm2)	   197-­‐AC	  VueLife	   Bag,	   using	   clinical-­‐grade	   virus	   produced	   by	   EUFETS	   (Batch	  
VR-­‐0042-­‐R-­‐1711).	   After	   transduction,	   cultures	   were	   propagated	   based	   on	   the	   GMP-­‐
manufacturing	  process	  described	  in	  CHAPTER	  5.	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Figure	  3-­‐16	  T4+	  T-­‐cell	  enrichment	  and	  expansion	  
A:	  Enrichment	  of	  T4+	  population	  during	  culture	  in	  media	  supplemented	  with	  IL-­‐4,	  as	  determined	  by	  flow	  
cytometry.	   Day	   7	   equals	   three	   days	   after	   transduction	   (performed	   on	   day	   4).	   Open	   red	   histograms	  
shown	  T28ζ+	  cells,	  filled	  histograms	  represent	  untransduced	  cells	  stained	  with	  the	  same	  protocol.	  Grey	  
number	   indicates	   background	  MFI,	   red	   number	   indicates	  MFI	   of	   CAR-­‐stained	   population.	  B:	   CD4/CD8	  
content	  within	   the	  entire	  cell	  population	  on	  day	  15	  of	  culture.	  C:	  Expansion	  of	   total	  cell	  population	   in	  
media	  supplemented	  with	  IL-­‐4	  from	  the	  day	  of	  transduction	  (day	  4)	  to	  the	  final	  day	  of	  culture	  (day	  15)	  D:	  
Micrographs	  of	  T-­‐cell	  during	  first	  week	  of	  culture,	  prior	  to	  transduction	  (day	  2),	  at	  transduction	  (day	  4)	  
and	  after	  transduction	  (day	  5	  and	  day	  7).	  
	  
Over	  the	  14	  day	  culture	  period,	  the	  T4+	  T-­‐cell	  population	  enriched	  from	  26%	  to	  
~50%	   	   (Figure	  3-­‐16	  A)	  and	  total	  cell	  number	   increased	   from	  80	  x	  106	   to	  7	  x	  108.	  This	  
represents	  a	  greater	  than	  25	  fold	  expansion	  of	  T4+	  T-­‐cells	  (Figure	  3-­‐16	  C).	  At	  the	  end	  of	  
the	  15	  day	  culture	  period,	  CD4:CD8	  ratio	  was	  approximately	  1:2	  (Figure	  3-­‐16	  B).	  Figure	  
3-­‐16	   D	   shows	  micrographs	   of	   the	   T-­‐cells	   prior	   to	   transduction	   (day	   2),	   immediately	  
after	  transduction	  (day	  4)	  and	  on	  day	  5	  and	  day	  7	  of	  culture	  (the	  first	  and	  third	  day	  of	  
IL-­‐4	  feeding	  regimen).	  Cells	  looked	  healthy	  and	  activated	  throughout	  the	  entire	  culture	  
period.	  
To	   verify	   functionality	   of	   the	   T4+	   T-­‐cells	   prior	   to	   the	   in	   vivo	   study,	  monolayer	  
destruction	   and	   cytokine	   production	   were	   determined	   (see	   Figure	   3-­‐17).	   T4+	   T-­‐cells	  
were	  able	  to	  destroy	  HN3	  monolayers	  in	  vitro	  (Figure	  3-­‐17	  A).	  Increased	  levels	  of	  IFNγ	  
production	   were	   detected	   in	   co-­‐cultivations	   of	   T4+	   T-­‐cells	   with	   HN3	   compared	   to	  
untransduced	  T-­‐cells	  or	  T4+	  T-­‐cells	  alone	  (Figure	  3-­‐17	  B).	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Figure	  3-­‐17	  in	  vitro	  T4+	  T-­‐cell	  functionality	  
A:	  1	  x	  106	  T4+	  or	  UT	  T-­‐cells	  were	  co-­‐cultivated	  with	  a	  confluent	  HN3	  monolayer	  for	  24	  hours.	  Residual	  
monolayer	  was	  visualised	  using	  crystal	  violet	  staining.	  B:	  IFNγ	  production	  measured	  after	  24	  hours	  of	  co-­‐
cultivation	  as	  described	  in	  A.	  Data	  show	  mean	  ±	  SD	  of	  n=3,	  *	  =	  p<0.01.	  
	  
In	   the	   proposed	   clinical	   study	   in	   which	   T4	   immunotherapy	   will	   be	   tested	   in	  
patients	  with	   HNSCC	   (please	   refer	   to	   paragraph	   5.1),	   release	   of	   the	   therapeutic	   cell	  
product	   is	   dependent	   on	   satisfying	   several	   criteria	   (see	   Table	   3-­‐2).	   Consequently,	  
where	   possible,	   the	   cells	   used	   for	   toxicity	   testing	   were	   tested	   for	   compliance	   with	  
these	   release	   criteria.	   The	   final	   product	   passed	   all	   available	   release	   criteria	   and	  
therefore	  met	  the	  quality	  requirements	  necessary	  for	  pre-­‐clinical	  toxicity	  testing	  of	  the	  
cell	  product.	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Table	  3-­‐2	  Testing	  of	  T4+	  toxicity	  cell	  production	  against	  release	  specifications*	  
*	   Release	   specifications	  were	   defined	   in	   version	   2.1	   of	   the	   Investigational	  Medicinal	   Product	   Dossier	  
pertaining	   to	   first	   in	   man	   testing	   of	   T4	   immunotherapy	   in	   patients	   with	   HNSCC.	  	  
**	  For	  gating	  strategy	  please	  refer	  to	  Supplementary	  Figure	  4	  in	  Appendix	  2.	  
	  
3.2.10 Pre-­‐Clinical	  Toxicity	  Study	  (in	  vivo)	  
Mice	  with	  15	  day-­‐established	  subcutaneous	  tumours	  were	  treated	  with	  a	  total	  of	  20	  x	  
106	  T-­‐cells	  (of	  which	  approximately	  51%	  were	  T4+).	  Cells	  were	  administered	  either	  by	  
IV	   injection	  or	  by	  direct	  PT	  administration.	  For	  each	  route	  of	  administration,	  3	  males	  
and	  3	  females	  were	  treated,	  as	  specified	  in	  Table	  3-­‐3.	  	  
	  
Table	  3-­‐3	  Design	  of	  ‘T4	  toxicity	  study’	  
Number	  Mice	   HN3	  Tumour	  cells	  SC	  	   T4luc+	  T-­‐cells	  IV	   T4luc+	  T-­‐cells	  PT	  
3	  males	  
3	  females	  
7.5	  x	  106	   20	  x	  106	   -­‐	  
3	  males	  
3	  females	  
7.5	  x	  106	   -­‐	   20	  x	  106	  
	  
Test	   Test	  Method	   Test	  Limits	   T4	   toxicity	   cell	  
product	  
Comments	  
Viability	   Flow	  cytometry	  
(DAPI	  staining)	  
>70%	  viable	  cells	  
within	  the	  
lymphocyte	  gate	  
84%	   Based	  on	  live/dead	  
gating**	  
Cell	  number	   Flow	  cytometry	  
using	  Trucount	  
tube	  technology	  
>1	  x	  107	  cells.	  	  
	  
7	  x	  108	  cells	  -­‐	  Pass	   Trucount	  was	  not	  
yet	  available,	  
trypan	  blue	  count	  
used.	  




>	  10%	  T4+	  
transduced	  cells	  
40%	  -­‐	  Pass	   N/A	  
Transgene	  
function	  
Cell	  count	  on	  day	  
15	  divided	  by	  cell	  
count	  on	  day	  4.	  
At	  least	  doubling	  in	  
cell	  number	  
achieved	  in	  
response	  to	  culture	  
in	  IL-­‐4.	  
8.75	  fold	  increase	  -­‐	  
Pass	  
N/A	  
Sterility	   BacT-­‐ALERT	  &	  
direct	  inoculation	  
No	  growth	   Not	  performed	   Test	  method	  was	  
not	  yet	  in	  place.	  
Mycoplasma	  
Culture	  
Ph.	  Eur	  (2.6.7)	  	   No	  growth	   Not	  performed	   Test	  method	  was	  





Flow	  cytometry	   <333,000	  beads/mL	  
in	  final	  product	  
Not	  performed	   Beads	  were	  
removed,	  test	  
method	  was	  not	  
yet	  in	  place.	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Mice	   were	   monitored	   for	   clinical	   parameters	   of	   toxicity,	   e.g	   alterations	   in	  
behaviour,	   appearance	   or	   weight.	   No	   differences	   were	   seen	   between	   males	   and	  
females,	   therefore	   the	   data	   was	   pooled	   per	   route	   of	   T-­‐cell	   administration.	   No	  
significant	  changes	  in	  behaviour	  or	  appearance	  were	  observed	  and	  mice	  continued	  to	  
gain	  weight	  over	  the	  duration	  of	  the	  study	  (see	  Figure	  3-­‐18).	  These	  findings	  suggested	  
that	  no	  severe	  toxicity	  had	  occurred.	  
	  
	  
Figure	  3-­‐18	  Serial	  weight	  measurements	  of	  PT	  and	  IV	  T4+	  treated	  mice	  
The	  weight	  of	  the	  mice	  was	  monitored	  at	  regular	  intervals	  as	  a	  primary	  indicator	  for	  toxicity.	  Mice	  with	  
15	  day-­‐established	  tumours	  were	   treated	  with	  20	  x	  106	  T-­‐cells	   (as	   indicated	  by	  arrow),	  either	   through	  
peri-­‐tumoural	  (PT,	  red	  line)	  or	  intravenous	  (IV,	  blue	  line)	  administration.	  Data	  represent	  mean	  ±	  SD	  of	  6	  
mice	   (3	  male	  and	  3	   female).	  No	  difference	  was	   seen	  between	  males	  and	   females,	  data	  was	   therefore	  
pooled	  per	  injection	  route.	  
	  
Functionality	   of	   T4+	   T-­‐cells	   is	   elementary	   to	   the	   ability	   to	   detect	   possible	  
toxicity.	   To	  determine	   functionality	   in	   vivo,	   tumour	   size	  was	  monitored	  using	   caliper	  
measurements	  (data	  not	  shown)	  as	  well	  as	  bioluminescent	  imaging	  (see	  Figure	  3-­‐19).	  
Based	  on	  BLI	  data,	   in	  all	   animals	  a	   significant	  decrease	   in	   tumour	   size	  was	  detected,	  
independent	   of	   gender	   or	   route	   of	   injection,	   suggesting	   in	   vivo	   functionality	   of	   the	  
administrated	  T4+	  T-­‐cells.	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Figure	  3-­‐19	  Tumour	  size	  	  
Mice	  received	  7.5	  x	  106	  HN3luc	  tumour	  cells	  SC	  in	  200uL	  Matrigel.	  Mice	  were	  treated	  with	  20	  x	  106	  T4	  
transduced	  T-­‐cells	  14	  days	  after	  tumour	  inoculation.	  T-­‐cell	  administration	  was	  performed	  either	  via	  peri-­‐
tumoural	   (PT)	  or	   intravenous	   (IV)	   routes.	  A:	  Sequential	  BLI	  of	   tumour	   size	   (as	   total	   flux	   (p/s))	  prior	   to	  
(day	   7	   and	   day	   15)	   and	   after	   (day	   22)	   T-­‐cell	   administration.	   T-­‐cells	   were	   administered	   on	   day	   15	   as	  
indicated	  by	  the	  arrow.	  Data	  represent	  mean	  ±	  SD	  of	  n=6	  mice.	  *	  =	  p<0.05	  comparing	  BLI	  signal	  on	  day	  
22	  with	  day	  15	  after	   IV	  T-­‐cell	  administration	  B:	   Images	  of	  all	  animals	   indicating	  tumour	  size	  one	  week	  
prior	   to	  T-­‐cell	   injection	   (day	  7)	  on	  the	  day	  of	  T-­‐cell	   injection	   (day	  15)	  and	  a	  week	  after	  T-­‐cell	   injection	  
(day	  22),	  prior	  to	  histopathological	  analysis.	  
	  
As	  described	  in	  paragraph	  3.2.8,	  the	  goal	  was	  to	  analyse	  toxicity	  at	  a	  timepoint	  
at	   which	   there	   were	   no	   more	   viable	   T-­‐cells	   detectable	   in	   vivo.	   The	   organs	   were	  
harvested,	  embedded	  in	  10%	  paraformaldehyde	  and	  sent	  to	  Abbey	  Veterinary	  Services	  
for	   independent	   histopathological	   analysis.	   Results	   are	   summarised	   in	   Table	   3-­‐4,	   full	  
reports	  can	  be	  found	  in	  Appendix	  4.	  As	  shown	  in	  Table	  3-­‐4,	  no	  evidence	  of	  toxicity	  or	  
residual	  T-­‐cells	  was	  detected	  in	  any	  of	  the	  organs.	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Table	   3-­‐4	   Independent	   histopathological	   analysis	   of	   organs	   collected	   from	   mice	  
treated	  with	  T4	  immunotherapy	  
	   IV	   SC	  
	   Male	   Female	   Male	   Female	  
Cerebellum	   NAD*	   NAD	   NAD	   NAD	  
Cerebrum	   NAD	   NAD	   NAD	   NAD	  
Spinal	  cord	   NAD	   NAD	   NAD	   NAD	  
Bone	  marrow	   NAD	   NAD	   NAD	   NAD	  
Cortical	  bone	   NAD	   NAD	   NAD	   NAD	  
Vertebral	  muscle	   NAD	   NAD	   NAD	   NAD	  
Heart	   NAD	   NAD	   NAD	   NAD	  










within	  wall	  not	  in	  
alveolar	  spaces	  
Mild	  collapse	  
Oesophagus	   NAD	   NAD	   NAD	   -­‐	  
Ovary	   -­‐	   NAD	   -­‐	   NAD	  
Uterus	   -­‐	   NAD	   -­‐	   NAD	  
Salivary	  gland	   NAD	   NAD	   NAD	   NAD	  
Kidney	   NAD	   NAD	   NAD	   NAD	  
Liver	   NAD	   NAD	   NAD	   NAD	  
Pancreas	   NAD	   NAD	   NAD	   NAD	  
Small	  intestine	   NAD	   NAD	   NAD	   NAD	  
Large	  intestine	   NAD	   NAD	   NAD	   NAD	  
Spleen	   NAD	   NAD	   Depleted	  lymphoid	  
cells	  
NAD	  
Stomach	   NAD	   NAD	   NAD	   NAD	  





Bronchial	   lymph	  
node	  
-­‐	   NAD	   -­‐	   NAD	  
Lacrimal	  gland	   NAD	   -­‐	   -­‐	   -­‐	  
Eye	   NAD	   -­‐	   -­‐	   -­‐	  
Testis	   NAD	   -­‐	   NAD	   -­‐	  
Adrenal	   NAD	   -­‐	   -­‐	   -­‐	  
*	  NAD:	  No	  abnormality	  detected	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3.3 Discussion	  
T4	   immunotherapy	   is	  a	   form	  of	  adoptive	  cell	   therapy	   in	  which	  T-­‐cells	  are	  re-­‐targeted	  
against	   the	   extended	   ErbB-­‐receptor	   family	   using	   a	   chimeric	   antigen	   receptor.	   T4+	   T-­‐
cells	   have	   effectively	   controlled	   tumour	   growth	   in	   three	   separate	   xenograft	   tumour	  
models	  (299,	  358).	  However,	  ErbB	  receptor	  expression	  is	  not	  exclusive	  to	  tumour	  cells.	  
Low	   level	   expression	   on	   healthy	   tissue	   can	   lead	   to	   so-­‐called	   ‘on-­‐target’-­‐toxicity.	  
Toxicity	   induced	   by	   ErbB	   receptor	   recognition	   on	   healthy	   lung	   epithelial	   cells,	   and	  
cardiac	  myocytes	  has	  been	  reported	  in	  relation	  to	  ErbB	  targeted	  therapies	  (240,	  520,	  
521).	  A	  clinical	  trial	  using	  a	  third	  generation	  CAR	  re-­‐targeting	  T-­‐cells	  against	  ErbB2	  has	  
resulted	   in	   a	   serious	   adverse	   event,	   due	   to	   a	   cytokine	   storm	   induced	   by	   T-­‐cell	  
activation	   in	   response	   to	   ErbB2	   expression	   in	   the	   pulmonary	   microvasculature	   and	  
parenchyma	   (240).	   These	   results	   show	   the	   severity	   of	   the	  potential	   risks	   of	   ErbB	   re-­‐
targeted	   cell	   therapy	   and	   emphasize	   the	   need	   for	   extensive	   pre-­‐clinical	   toxicity	  
assessment.	   In	   this	   chapter	   the	   experiments	   performed	   to	   investigate	   potential	   ‘on-­‐
target’-­‐toxicity	  of	  T4	  immunotherapy	  have	  been	  described.	  	  
	   T4+	   T-­‐cells	   have	   been	   shown	   to	   be	   able	   to	   selectively	   enrich	   in	   culture	  
supplemented	  with	  IL-­‐4	  (see	  Figure	  3-­‐3),	  and	  have	  selective	  cytotoxicity	  towards	  ErbB+	  
tumour	   cells	   (HN3)	   and	  no	  activity	   against	   ErbBLO	   tumour	   cell	   lines	   (435)	   (see	   Figure	  
3-­‐4).	   These	   results	   are	   all	   in	   agreement	   with	   previously	   reported	   extensive	  
functionality	  assessment	  of	  T28ζ	  and	  T4	  by	  Dr	  Davies	  (299).	  Targeting	  of	  healthy	  tissue	  
was	   first	   determined	   in	   vitro.	   Expression	   of	   ErbB	   receptors	   by	   primary	   cardiac	  
monocytes	   (HCM)	   and	   primary	   human	   pulmonary	   microvascular	   endothelial	   cells	  
(HPMEC)	   was	   determined	   by	   flow	   cytometry.	   It	   has	   previously	   been	   reported	   that	  
ErbB3	  is	  no	  longer	  detectable	  in	  adult	  heart	  tissue,	  but	  ErbB1,	  2	  and	  4	  are	  expressed	  at	  
detectable	   levels	   (532).	   Additionally,	   ErbB2	   is	   reportedly	   not	   overexpressed	   in	  
cardiomyocytes	   (541).	  Flow	  cytometry	  analysis	  of	   the	  primary	  cell	   lines	  derived	   from	  
these	   tissues	  confirmed	   the	  expression	  of	  ErbB1	  and	  2	  and	   the	  absence	  of	  ErbB3	  on	  
HCM.	   In	   contrast	   to	   earlier	   results,	   expression	   of	   ErbB4	   was	   not	   detected	   by	   these	  
cells.	   Expression	   of	   ErbB2	   in	   the	   respiratory	   tract	   has	   also	   been	   previously	   reported	  
(536).	  Primary	  HPMEC	  showed	  low	  expression	  of	  ErbB1,	  2	  and	  3	  but	  no	  expression	  of	  
ErbB4.	   Co-­‐cultivation	   of	   T4+	   T-­‐cells	   with	   either	   primary	   cell	   type	   resulted	   in	   CAR-­‐
mediated	  monolayer	  destruction,	  T-­‐cell	  activation	  and	  cytokine	  production	  (see	  Figure	  
3-­‐5).	  These	  results	  suggest	  that	  T-­‐cells	  could	  be	  activated	  by	  ErbB	  receptors	  expressed	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in	   the	   pulmonary	   microvasculature,	   which	   could	   lead	   to	   destruction	   of	   the	  
microvascular	   epithelial	   cells	   or	   the	   induction	   of	   a	   cytokine	   storm.	  Additionally,	   if	   T-­‐
cells	  are	  able	  to	  migrate	  into	  the	  heart,	  cardiotoxicity	  could	  be	  induced.	  
	   Intra-­‐tumoural	   T-­‐cell	   administration	   could	   reduce	   the	   risk	   of	   pulmonary	   and	  
cardiac	  toxicity.	  We	  have	  previously	  reported	  that	   imaging	  studies	  showed	  that	  T-­‐cell	  
injected	  subcutaneously	  reside	  in	  the	  area	  of	  injection	  and	  do	  not	  migrate	  to	  the	  lungs	  
and	  liver	  as	  seen	  after	  intravenous	  injection	  (460).	  Therefore,	  we	  decided	  to	  design	  a	  
phase	  I	  clinical	  trial	  in	  which	  patients	  with	  locally	  recurrent	  HNSCC	  will	  be	  treated	  with	  
escalating	   doses	   of	   T4+	   T-­‐cells,	   delivered	   using	   the	   intra-­‐tumoural	   route.	   The	   risk	   of	  
‘on-­‐target’-­‐toxicity	  after	  intra-­‐tumoural	  T-­‐cell	  injection	  was	  determined	  in	  a	  pre-­‐clinical	  
mouse	  model.	  The	  human	  ErbB+	  HNSCC	  cell	  line	  HN3(luc)	  was	  shown	  to	  grow	  following	  
subcutaneous	   inoculation	   in	   SCID/Beige	   mice.	   The	   resultant	   tumours	   retained	   ErbB	  
expression	   in	   vivo	   (see	   Figure	   3-­‐6),	   providing	   a	   model	   to	   test	   intra-­‐tumoural	   T4	  
immunotherapy.	   However,	   toxicity	   against	   healthy	   tissue	   can	   only	   be	   determined	   in	  
mice	   if	  human	  T4+	  T-­‐cells	  can	  also	  be	  activated	  by	  mouse	  ErbB-­‐receptors.	  This	  cross-­‐
species	  recognition	  is	  expected	  to	  occur	  based	  on	  the	  fact	  that	  both	  human	  and	  mouse	  
EGF	   exert	   an	   equimolar	   capacity	   to	   promote	   eyelid	   opening	   in	   newborn	  mice	   (542),	  
augment	   cytokine	   production	  by	  mouse	   splenocytes	   (543),	   stimulate	   proliferation	  of	  
mouse	   Balb/C	   3T3	   cells	   and	   can	   inhibit	   the	   binding	   of	   radiolabelled	   mouse	   EGF	   to	  
mouse	   ErbB1	   (544).	   Additionally,	   human	   TGFα	   is	   highly	   active	   in	   promoting	   bone	  
resorption	  in	  mice	  (545)	  and	  is	  as	  active	  as	  mouse	  EGF	  in	  accelerating	  eyelid	  opening	  in	  
newborn	  mice	  (542).	  Third,	  human	  NRG-­‐1β	  exerts	  potent	  therapeutic	  activity	  in	  mouse	  
model	  of	  Parkinson’s	  disease	  and	  viral	  myocarditis	   (544,	  546).	  Finally,	  human	  CAR+	  T-­‐
cells	   can	   undergo	   equally	   efficient	   activation	   by	  mouse	   and	   human	   target	   cells	   that	  
express	  comparable	  levels	  of	  target	  antigen	  (403).	  To	  confirm	  whether	  the	  T1E	  peptide	  
can	   indeed	   cross	   the	   species	   border,	   human	   T4+	   T-­‐cells	   were	   co-­‐cultivated	  with	   the	  
mouse	  ErbB+	  HNSCC	   tumour	   cell	   line	  B7E3	   (see	  Figure	  3-­‐7).	  Co-­‐cultivation	   confirmed	  
monolayer	  destruction	  and	  T-­‐cell	   activation	   in	   response	   to	   interaction	  between	  T28ζ	  
and	  mouse	  ErbB	   receptors	   (see	  Figure	  3-­‐8).	  Analysis	  of	   the	  ErbB	  expression	   levels	   in	  
mouse	   healthy	   tissue	   confirmed	   expression	   in	   several	  major	   organs,	   including	   heart,	  
kidney,	  lung	  and	  intestines	  (see	  Figure	  3-­‐9).	  To	  determine	  whether	  the	  expression	  level	  
of	  ErbB	  receptors	  in	  healthy	  mouse	  tissue	  was	  also	  sufficient	  to	  elicit	  T-­‐cell	  activation,	  
T4+	   T-­‐cells	   were	   co-­‐cultivated	   with	   primary	   mouse	   pulmonary	   microvascular	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endothelial	  cells	   (MPMEC).	  Similar	  as	  seen	   in	  HPMEC	  co-­‐cultivations,	  T4+	  T-­‐cells	  were	  
activated	   and	   destroyed	   the	   ErbB+	   primary	   cells.	   These	   data	   suggest	   that	   the	  
SCID/Beige	  mouse	  model	  should	  be	  able	  to	  indicate	  whether	  ‘on-­‐target’-­‐toxicity	  can	  be	  
induced	  by	  T4	  immunotherapy.	  	  
	   The	   MHRA	   guidelines	   required	   extensive	   histopathological	   analysis	   for	   ‘on-­‐
target’-­‐toxicity	   at	   the	   timepoint	   at	   which	   no	   detectable	   levels	   of	   T4+	   T-­‐cells	   were	  
present.	   To	   determine	   the	   longevity	   and	   migration	   of	   human	   T4+	   T-­‐cells	   in	   vivo,	  
prolonged	   imaging	   is	   required.	   To	   enable	   this,	   T4	   was	   co-­‐expressed	   with	   firefly	  
Luciferase	   (T4luc)	   (see	   Figure	   3-­‐11).	   The	   expression	   of	   three	   transgenes	   within	   one	  
retroviral	   vector	   resulted	   in	   low	   expression	   of	   the	   three	   encoded	   proteins.	   T4luc+	  
expanded	  in	  vitro	  when	  cultured	  in	  IL-­‐4.	  However,	  expansion	  and	  enrichment	  of	  these	  
cells	  was	  substantially	  lower	  compared	  to	  T4+	  T-­‐cells.	  Cell	  surface	  expression	  levels	  of	  
T28ζ	   and	   4αβ	   were	   also	   low.	   T4luc+	   T-­‐cells	   were	   able	   to	   destroy	   both	   human	   and	  
mouse	  ErbB+	  monolayers.	  However	  T4luc+	  T-­‐cells	  were	  not	  as	  effectively	  as	  T4+	  T-­‐cells	  
in	  this	  regard	  and	  the	  levels	  of	  cytokine	  production	  were	  barely	  detectable	  (see	  Figure	  
3-­‐12	  and	  Figure	  3-­‐13).	  However,	  most	  importantly,	  T4luc+	  T-­‐cells	  had	  luciferase	  activity	  
in	   vitro	   and	   could	   be	   visualised	   in	   vivo	   by	   bioluminescent	   imaging	   (see	   Figure	   3-­‐14).	  
Migration	   and	   longevity	   of	   T4luc+	   T-­‐cells	   was	   determined	   in	   both	  males	   and	   female	  
mice	  after	  peri-­‐tumoural	  or	  intravenous	  administration.	  Trafficking	  patterns	  seen	  after	  
either	   route	   of	   administration	  were	   consistent	  with	   those	   previously	   reported	   using	  
SPECT-­‐CT	   imaging	   in	   mice	   and	   in	   humans	   (460,	   547-­‐550).	   Bioluminescent	   signals	  
reduced	   to	   background	   levels	   as	   soon	   as	   five	   days	   after	   T-­‐cell	   administration	   and	  
remained	  low	  for	  the	  consecutive	  week.	  No	  differences	  could	  be	  seen	  between	  males	  
and	  females.	  Since	  the	  expression	  level	  of	  the	  receptors	  and	  the	  luciferase	  activity	  of	  
T4luc+	  T-­‐cells	  was	   low,	  the	  sensitivity	  of	  bioluminescent	   imaging	  of	  T4luc+	  T-­‐cells	  was	  
suboptimal	   and	   high	   binning	   was	   required	   for	   T-­‐cell	   visualisation.	   It	   has	   been	  
previously	  reported	  that	  the	  ffLuc	  signal	   is	   lower	  in	  human	  T-­‐cells	  compared	  to	  other	  
haematopoietic	   cells	   or	   tumour	   cells	   (551,	   552).	   Histopathological	   analysis	   of	   the	  
organs	  retrieved	  in	  the	  toxicity	  study	  revealed	  no	  changes	  in	  any	  of	  the	  healthy	  tissue	  
analysed,	   and	   no	   infiltrated	   T-­‐cells,	   regardless	   of	   gender	   or	   route	   of	   administration	  
(see	  Table	  3-­‐4).	  This	  suggests	  that	  despite	  the	  low	  expression	  of	  ffLuc	  by	  T4luc+	  T-­‐cells,	  
this	  was	  sufficient	  for	  adequate	  estimation	  of	   in	  vivo	   longevity.	  Additionally	  and	  most	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importantly,	  these	  results	  show	  that	  T4	  immunotherapy	  did	  not	  cause	  any	  ‘on-­‐target’-­‐
toxicity	  in	  the	  pre-­‐clinical	  model.	  
	   The	   absence	   of	   detectable	   ‘on-­‐target’-­‐toxicity	   attributable	   to	   T4	  
immunotherapy	  is	  remarkable	  considering	  the	  toxicities	  seen	  in	  response	  to	  ErbB2	  re-­‐
targeted	   T-­‐cells	   and	   both	   monoclonal	   antibodies	   and	   tyrosine	   kinase	   inhibitors	  
targeting	   the	   ErbB	   receptor	   family	   (154,	   157,	   159,	   521).	   	   Potential	   reasons	   for	   the	  
discrepancy	   between	   the	   toxicity	   seen	   with	   ErbB2	   re-­‐targeted	   T-­‐cells	   and	   T4	  
immunotherapy	   is	   the	  dose	  administered	  and	   the	  degree	  of	  T-­‐cell	   activation	   (a	   third	  
generation	   CAR	   versus	   a	   second	   generation	   CAR).	   In	   vitro,	   T4+	   T-­‐cells	   produced	  
approximately	   15	   fold	   higher	   cytokine	   levels	   in	   response	   to	   HPMEC	   compared	   to	  
MPMEC,	  suggesting	  more	  efficient	  T-­‐cell	  activation	  by	  the	  HPMEC.	  The	  dose	  of	  20	  x	  106	  
T-­‐cells	  administered	  in	  the	  pre-­‐clinical	  toxicity	  study	  is	  equivalent	  to	  a	  clinical	  dose	  of	  5	  
x	  109	  T-­‐cells	   (of	  which	  51%	  were	  CAR+)	   in	  man.	  This	   is	  half	   the	  dose	  (1	  x	  1010	  cells	  of	  
which	   79%	   CAR+)	   that	   was	   administered	   in	   the	   ErbB2	   re-­‐targeting	   trial	   (240).	   The	  
occurrence	  of	   toxicities	  has	  been	   related	   to	   the	  T-­‐cell	  dose,	  and	  delayed	   toxicity	  has	  
been	   observed	   after	   substantial	   expansion	   of	   the	   administered	   T-­‐cells	   in	   vivo	   (319).	  
This	  SCID/Beige	  pre-­‐clinical	  model	  does	  not	  support	  in	  vivo	  expansion	  of	  T4+	  T-­‐cells	  due	  
to	   the	   absence	   of	   appropriate	   cytokine	   stimulation.	   Therefore,	   it	   cannot	   be	  
determined	   whether	   T-­‐cell	   expansion	   could	   lead	   to	   toxicity	   at	   a	   later	   time-­‐point.	  
Additionally,	  prolonged	  in	  vivo	  longevity	  could	  result	  in	  more	  extensive	  T-­‐cell	  migration	  
and	  infiltration	  into	  organs,	  which	  cannot	  be	  determined	  in	  this	  model.	  
	  
In	   summary,	   the	   combination	   of	   the	   lack	   of	   T-­‐cell	   migration	   after	   intra-­‐tumoural	  
injection,	  the	  ability	  of	  T4+	  T-­‐cells	  to	  be	  activated	  by	  ErbB+	  healthy	  mouse	  tissues	  and	  
previous	  reports	  that	  toxicity	  can	  be	  induced	  by	  human	  T-­‐cells	  in	  a	  mouse	  model	  (537)	  
would	   suggest	   that	   local	   treatment	  with	  T4+	  T-­‐cells	   is	  not	  expected	   to	   induce	   severe	  
‘on-­‐target’-­‐toxicity	   in	   patients.	   However,	   due	   to	   previously	  mentioned	   limitations	   of	  
the	  used	  mouse	  model,	   this	  cannot	  be	  said	  with	  certainty.	  Prolonged	  T-­‐cell	   longevity	  
and/or	   altered	   T-­‐cell	   migration	   patterns	   could	   induce	   ‘on-­‐target’-­‐toxicity	   in	   patients	  	  
which	  was	  not	  detected	  in	  the	  pre-­‐clinical	  model.	  
	  
	  








CHAPTER	  4 	  
THE	  INDUCTION	  OF	  	  
CYTOKINE	  RELEASE	  SYNDROME	  	  
BY	  T4	  IMMUNOTHERAPY	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4.1 Introduction	  
In	   addition	   to	   'on-­‐target’	   chronic	   organ	   damage,	   a	   second	   major	   predicted	   risk	   of	  
immunotherapy	   is	   ‘cytokine	   release	   syndrome’.	   When	   clinically	   overwhelming,	  
cytokine	  release	  syndrome	  is	  often	  referred	  to	  as	  a	  cytokine	  storm,	  cytokine	  cascade	  or	  
hypercytokinemia.	   Cytokine	   storms	   have	   been	   reported	   to	   occur	   in	   response	   to	  
infectious	   diseases	   such	   as	   cytomegalovirus	   (553),	   Epstein-­‐Barr	   virus-­‐associated	  
hemophagocytic	  lymphohistiocytosis	  (554),	  severe	  acute	  respiratory	  syndrome	  (SARS)	  
coronavirus	  (555)	  and	  avian	  H5N1	  influenza	  virus	  infection	  (556).	  Additionally,	  cytokine	  
storms	   may	   be	   induced	   by	   several	   forms	   of	   immunotherapy,	   including	   the	  
administration	  of	   IL-­‐2	   (557),	   some	  monoclonal	   antibodies	   (558,	   559)	   as	  well	   as	   CAR-­‐
engineered	   T-­‐cells	   (240).	   To	   illustrate	   this,	   in	   approximately	   50%	  of	   patients	   treated	  
with	   Muromonab-­‐CD3	   (OKT3;	   an	   anti-­‐CD3	   monoclonal	   antibody	   used	   for	   the	  
treatment	  of	  renal	  allograft	  rejection)	  severe	  CRS	  occurs	  if	  patients	  are	  not	  pre-­‐treated	  
with	  high-­‐dose	  corticosteroids	  (560).	  High-­‐dose	  corticosteroids	  are	  routinely	  applied	  as	  
pre-­‐medication	  before	   the	   first	   administration	  of	  mAbs	   to	   reduce	   the	   effects	   of	   CRS	  
(561).	   In	   adoptive	   cell	   therapy,	   corticosteroids	   have	   been	   administered	   after	   T-­‐cell	  
administration	  to	  reduce	  the	  effects	  of	  CRS	  (240).	  Clinically	  significant	  cytokine	  release	  
syndrome	   carries	   a	   high	   morbidity	   and	   fatality	   rate	   (562,	   563).	   As	   described	   in	  
paragraph	  1.4.2.3,	  CRS	  has	  been	  implicated	  as	  the	  cause	  of	  a	  serious	  adverse	  event	  in	  a	  
patient	  treated	  with	  ErbB2	  re-­‐targeted	  T-­‐cells	   (240).	  However,	   the	  occurrence	  of	  CRS	  
has	   also	  been	   related	   to	   treatment	   efficacy.	   Porter	   et	   al.	   have	  described	  a	   temporal	  
relationship	   between	   the	   occurrence	   of	   CRS	   and	   in	   vivo	   expansion	   of	   CAR+	   T-­‐cells,	  
leading	   to	   the	   onset	   of	   tumour	   lysis	   syndrome	   (445).	   Additionally,	   Grupp	   et	   al.	   and	  
Brentjens	  et	  al.	  have	  reported	  clinical	  efficacy	  using	  CD19	  re-­‐targeted	  T-­‐cells	  which,	  in	  
both	  cases,	  was	  related	  to	  patients	  showing	  signs	  of	  severe	  CRS	  (317,	  321).	  
	  
4.1.1 Components	  and	  consequence	  of	  severe	  cytokine	  release	  syndrome	  
There	  is	  no	  definition	  as	  to	  what	  exactly	  constitutes	  severe	  cytokine	  release	  syndrome,	  
or	  a	  cytokine	  storm.	  Also,	  there	  remains	  a	  lack	  in	  knowledge	  concerning	  the	  molecular	  
events	  that	  precipitate	  a	  cytokine	  storm	  and	  what	  contribution	  a	  cytokine	  storm	  makes	  
to	  the	  pathogenesis	  of	  disease	  and	  functionality	  of	  treatments	  	  (564).	  A	  cytokine	  storm	  
is	   comparable	   to	   sepsis,	   in	  which	   a	   local	   inflammation	   ‘spills-­‐over’	   into	   the	   systemic	  
circulation,	   causing	   persistent	   hypotension,	   hyper-­‐	   or	   hypothermia,	   leucocytosis	   or	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leukopenia	   and	   often	   thrombocytopenia	   (565).	   Acute	   lung	   injury	   is	   a	   common	  
consequence	   of	   a	   cytokine	   storm	   in	   the	   lung	   alveolar	   environment,	   associated	  with	  
infections	  in	  the	  lungs	  and	  other	  organs.	  Acute	  lung	  injury	  is	  characterised	  by	  an	  acute	  
mononuclear	   and	   neutrophilic	   inflammatory	   response	   followed	   by	   a	   chronic	  
fibroproliferative	  phase	  marked	  by	  progressive	  collagen	  deposition	   in	   the	   lung	   (566).	  
Patients	   with	   severe	   sepsis	   resulting	   from	   pulmonary	   infections	   show	   characteristic	  
plasma	   cytokine	   profiles.	   Acute-­‐response	   cytokines	   including	   TNF,	   IL-­‐1β	   and	   the	  
chemotactic	   cytokines	   IL-­‐8	   and	   monocyte	   chemoattractant	   protein	   (MCP)-­‐1	   (CCL2)	  
appear	  in	  the	  early	  minutes	  to	  hours	  after	  infection,	  followed	  by	  a	  sustained	  increase	  
in	   IL-­‐6.	   Interleukin-­‐6	  production	   is	   stimulated	  by	  TNF	  and	   IL-­‐1β	  and	  can	  therefore	  be	  
used	  to	  assess	  the	  intensity	  of	  the	  cytokine	  response.	  The	  anti-­‐inflammatory	  cytokine	  
IL-­‐10	  can	  be	  detected	  later,	  as	  part	  of	  the	  counter-­‐inflammatory	  response,	  also	  known	  
as	  ‘immunoparalysis’.	  Patients	  who	  initially	  recover	  from	  a	  cytokine	  storm	  but	  die	  later	  
on	  may	  not	  have	  recovered	  from	  the	  ‘immunoparalysis’-­‐state,	  leading	  to	  uncontrolled	  
infection	   (567).	   The	   occurrence	   of	   a	   cytokine	   storm	   in	   response	   to	   a	   dengue	   virus	  
infection	   is	   associated	   with	   increased	   capillary	   permeability	   syndrome.	   Increased	  
capillary	  permeability	  syndrome	  occurs	  between	  day	  four	  and	  six	  of	  illness,	  at	  which	  IL-­‐
10	  and	  IFNγ	  are	  at	  their	  peak-­‐levels.	  T-­‐cells	  have	  been	  identified	  as	  potent	  contributors	  
to	  cytokinaemia,	  which	  contributes	  to	  vasodilation	  during	  this	  stage	  of	  illness	  (568).	  	  
	  
4.1.2 Unexpected	  severe	  CRS	  in	  TGN1412	  Phase-­‐I	  clinical	  trial	  
The	  significance	  of	  CRS	  as	  a	  key	  risk	  related	  to	  immunotherapy	  is	  strikingly	  illustrated	  
by	  the	  events	  that	  took	  place	  during	  phase-­‐I	  clinical	  testing	  of	  an	  immunotherapeutic	  
monoclonal	  antibody	  named	  TGN1412.	  TGN1412	  is	  a	  ‘superagonist’	  of	  CD28,	  bypassing	  
any	  required	  TCR-­‐stimulation	  as	  well	  as	  co-­‐stimulatory	  signals	  and	  resulting	  in	  direct	  T-­‐
cell	   activation	   upon	   binding	   to	   CD28	   (569).	   In	   pre-­‐clinical	   studies,	   TGN1412	   was	  
predicted	   to	   stimulate	   the	   release	   of	   anti-­‐inflammatory	   cytokines	   and	   expand	  
regulatory	   T-­‐cells	   (Tregs)	   giving	   it	   a	   potential	   therapeutic	   application	   in	   autoimmune	  
disease	   (569-­‐571).	   In	   March	   2006,	   six	   healthy,	   male	   volunteers	   were	   treated	   with	  
0.1mg/kg	  body	  weight	  of	  TGN1412	  by	  IV	  administration.	  Two	  additional	  healthy	  male	  
volunteers	  received	  a	  placebo	  control.	  Within	  60	  minutes	  after	  administration,	  all	   six	  
test-­‐volunteers	  were	   critically	   ill.	   Investigation	   at	   the	   time	   indicated	   the	  presence	  of	  
pulmonary	   infiltrates,	  acute	   lung	   injury,	  acute	   renal	   failure	   followed	  by	  disseminated	  
	   195	  
intravascular	   coagulation.	   All	   six	   required	   intensive	   care	   therapy	   including	  
cardiopulmonary	   support	   and	   dialysis.	   Two	   patients	   developed	   prolonged	  
cardiovascular	  shock	  and	  acute	  respiratory	  distress,	  requiring	  intensive	  organ	  support	  
for	  8-­‐16	  days	  (558).	  Analysis	  of	  circulating	  cytokine	  levels	  revealed	  a	  dramatic	  increase	  
in	   TNF	   levels	   within	   one	   hour	   after	   TGN1412	   administration.	   This	   was	   followed	   by	  
elevations	  of	  circulating	  IL-­‐2,	  IL-­‐6,	  IL-­‐10	  and	  IFNγ	  within	  the	  first	  four	  hours	  (558).	  The	  
disastrous	   results	   of	   this	   clinical	   trial	   prompted	   two	   important	   questions.	   First,	   how	  
was	  this	  cytokine	  storm	  induced	  and	  second,	  why	  had	  pre-­‐clinical	  toxicity	  studies	  failed	  
to	  predict	  the	  occurrence	  of	  these	  adverse	  events?	  
High	  levels	  of	  IL-­‐2	  production	  (in	  combination	  with	  TNF	  and	  IFNγ)	  were	  already	  
reported	   in	   response	   to	   administration	   of	   the	   first	   clinically	   available	   mAb,	   OKT3	  
(Muromonab-­‐CD3).	   These	   pro-­‐inflammatory	   mediators	   cause	   inter	   alia,	   capillary	  
leakage,	  leukocyte	  sequestration	  and	  flu-­‐like	  symptoms	  (572).	  TGN1412	  was	  shown	  to	  
induce	  a	  28.4-­‐fold	  higher	  level	  of	  IL-­‐2	  compared	  to	  OKT3.	  The	  difference	  in	  levels	  of	  IL-­‐
2	  production	  could	  be	  a	  driving	  force	  behind	  the	  severity	  of	  the	  induced	  CRS	  (573).	  This	  
was	   because	   high-­‐dose	   IL-­‐2	   administration	   for	   therapeutic	   purposes	   (eg	   in	   selected	  
cancers)	   can	   induce	   similar	   toxicity	   (574).	   Increased	   levels	   of	   the	   soluble	   forms	   of	  
adhesion	  molecules	   ICAM1,	  VCAM	  and	  E-­‐selectin	  are	   found	  after	   IL-­‐2	  administration.	  
These	   are	   suggested	   to	   play	   a	   role	   in	   the	   inflammatory	   reaction	   induced	   by	   IL-­‐2	   in	  
addition	   to	   promoting	   blood	   vessel	   inflammation,	   vascular	   damage,	   leakage	   and	  
hypotension	   (557).	   Increased	   circulating	   levels	   of	  metalloproteinases	   (MMP)	  2,	   3,	   10	  
and	   13	   have	   also	   been	   detected	   after	   IL-­‐2	   administration.	   This	   finding	   may	   be	  
responsible	  for	  the	  destruction	  of	  endothelial	  basement	  membranes,	  extravasation	  of	  
mononuclear	  cells	  and	  the	  accumulation	  of	  toxic	  by-­‐products	  in	  tissues	  (557).	  	  
	  
4.1.3 Role	  of	  Macrophages	  in	  CRS	  
T-­‐cells	  might	  not	  be	  the	  only	  source	  of	  cytokine	  release	  in	  CRS.	  Sandilands	  et	  al	  showed	  
that	  the	  high	  levels	  of	  TNF	  seen	  as	  early	  as	  two	  hours	  after	  TGN1412	  stimulation	  was	  
most	   likely	   produced	   by	   monocytes.	   Monocytes	   were	   the	   only	   cell	   population	   that	  
showed	   a	   significant	   upregulation	   of	   TNF	   mRNA,	   along	   with	   11	   other	   monocyte	  
cytokines,	   including	   IL-­‐1β,	   IL-­‐2R,	   IL-­‐6	   and	   IL-­‐17	   (575).	   Macrophages	   have	   also	   been	  
implicated	   in	   the	   induction	   of	   CRS	   in	   response	   to	   Blinatumomab	   treatment.	  
Blinatumomab	  is	  a	  CD19/CD3-­‐bispecific	  T	  cell	  receptor-­‐engaging	  (BiTE)	  antibody,	  which	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has	   shown	   efficacy	   in	   refractory	   B-­‐precursor	   acute	   lymphoblastic	   leukaemia	   (B-­‐ALL).	  
However,	   Blinatumomab	   has	   been	   associated	   with	   considerable	   but	   manageable	  
toxicity.	  Elevated	  circulating	   levels	  of	   IL-­‐6,	   IL-­‐10	  and	   IFNγ	  are	  detected	   in	  all	  patients	  
receiving	  Blinatumomab	  (576).	  Elevated	  levels	  of	  these	  three	  cytokines	  were	  also	  seen	  
in	  patients	  receiving	  CD19-­‐re-­‐targeted	  CAR	  T-­‐cells	  (317,	  321).	  Because	  these	  cytokines	  
are	  also	  elevated	  in	  ‘macrophage	  activation	  syndrome’,	  Teachey	  et	  al.	  suggested	  that	  
severe	  toxicity	  might	  be	  due	  to	  abnormal	  macrophage	  activation,	  which	  is	  triggered	  by	  
the	  release	  of	  cytokines	  by	  cytotoxic	  T-­‐cells	  (577).	  This	  theory	  is	  supported	  by	  the	  fact	  
that	  high	  levels	  of	  IL-­‐6	  and	  IL-­‐10	  would	  normally	  not	  be	  expected	  in	  a	  cytotoxic	  T-­‐cell	  
response	   alone.	   Interleukin-­‐6	   is	   principally	   released	   by	   macrophages	   and	   IL-­‐10	   is	   a	  
negative	   regulator	   of	   macrophage	   function.	   	   Additionally,	   treatment	   with	   the	   IL-­‐6R	  
blocking-­‐antibody	  Tocilizumab	  induces	  a	  rapid	  improvement	  in	  patients	  with	  clinically	  
severe	  CRS	   (317,	   321,	   577),	   suggesting	   that	   IL-­‐6	   and	  perhaps	  macrophage	   activation	  
plays	  an	  important	  role	  in	  CRS	  alongside	  cytotoxic	  T-­‐cells.	  
	  
4.1.4 Cytokine	  Release	  Syndrome	  in	  CAR-­‐mediated	  adoptive	  T-­‐cell	  therapy	  
Cases	   of	   cytokine	   storms	   in	   response	   to	   CAR-­‐mediated	   adoptive	   T-­‐cell	   therapy	   have	  
been	  reported	  (240).	  In	  one	  such	  case,	  1	  x	  1010	  T-­‐cells	  (79%	  gene-­‐modified	  with	  a	  third	  
generation	   ErbB2-­‐specific	   CAR)	  were	   administered	   IV	   after	   the	   patient	   had	   received	  
lymphodepleting	  chemotherapy.	  Within	  15	  minutes	  after	  T-­‐cell	  transfusion,	  the	  patient	  
developed	   respiratory	   distress	   and	   was	   transferred	   to	   intensive	   care.	   The	   patient	  
finally	  succumbed	  to	  a	  cardiac	  arrest	  five	  days	   later.	  Serum	  cytokine	  analysis	  showed	  
high	   levels	   of	   IFNγ,	   TNF,	   GM-­‐CSF	   and	   IL-­‐6,	   peaking	   at	   4	   hours	   after	   T-­‐cell	  
administration.	  Interleukin-­‐10	  levels	  also	  increased	  after	  infusion	  but	  remained	  stable	  
thereafter	  (240).	  This	  case	  illustrates	  the	  rapid	  onset	  and	  severity	  of	  CAR	  T-­‐cell	  induced	  
cytokine	   release	   syndrome.	   Cytokine	   storms	   have	   also	   been	   reported	   with	   delayed	  
onset	  in	  patients	  treated	  with	  CAR	  T-­‐cells.	  Porter	  et	  al.	  described	  a	  case	  in	  which	  peak	  
cytokine	   levels	  were	  not	   seen	  until	   22	  days	   after	   T-­‐cell	   transfusion.	  However,	   in	   this	  
case	  a	  lower	  CAR+	  T-­‐cell	  dose	  was	  given	  (1.46	  x	  105	  T-­‐cells/kg	  of	  which	  5%	  were	  CAR+),	  
separated	   over	   three	   days.	   The	   onset	   of	   the	   CRS	   coincided	   with	   the	   diagnosis	   of	  
tumour	   lysis	   syndrome,	   suggesting	   that	  CRS	  could	  also	  be	  an	   indicator	   for	   treatment	  
functionality	   (445).	   This	   suggestion	   is	   confirmed	   in	   two	   further	   clinical	   experiences	  
described	   by	   Grupp	   et	   al.	   and	   Brentjens	   et	   al.	   In	   both	   cases	   patients	   suffered	   from	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severe	  CRS,	  combined	  with	  treatment	  efficacy	  leading	  to	  complete	  remission	  in	  some	  
cases.	   In	   both	   trials,	   CRS	   was	   successfully	   treated	   with	   Tocilizumab	   administration,	  
implicating	  IL-­‐6	  mediated	  toxicity	  in	  this	  event	  (317,	  321).	  
	  
4.1.5 The	  importance	  of	  appropriate	  pre-­‐clinical	  safety	  testing	  
An	   important	   question	   is	   why	   in	   vivo	   and	   in	   vitro	   pre-­‐clinical	   studies	   had	   failed	   to	  
indicate	  the	  risk	  of	  CRS	  in	  response	  to	  Immunotherapies?	  In	  the	  case	  of	  TGN1412,	  pre-­‐
clinical	   toxicity	   studies	   using	   the	   rat-­‐equivalent	   of	   TGN1412,	   named	   JJ316,	   the	  
antibody	   was	   shown	   to	   be	   well	   tolerated	   and	   not	   accompanied	   by	   a	   toxic	   cytokine	  
storm.	   This	   was	   attributed	   to	   the	   release	   of	   counter-­‐regulatory	   anti-­‐inflammatory	  
cytokines	   such	   as	   IL-­‐10	   by	   regulatory	   T-­‐cells	   (569,	   578).	   In	   humans,	   this	  mechanism	  
failed	  most	  likely	  due	  to	  the	  fact	  that	  CD4+	  effector	  memory	  T-­‐cells	  (the	  main	  source	  of	  
cytokine	  production)	  are	  present	  in	  a	  higher	  abundance	  in	  adult	  humans	  compared	  to	  
young	  rodents	  (579).	  
Pre-­‐clinical	   testing	   using	   TGN1412	   itself	   was	   performed	   in	   cynomolgus	  
macaques.	  TGN1412	  binds	  to	  macaque	  CD28	  with	  the	  same	  affinity	  as	  to	  human	  CD28.	  
Pre-­‐clinical	   testing	   in	   cynomologus	  macaques,	   at	   doses	   of	   up	   to	   50mg/kg/week	  was	  
well	   tolerated	   with	   no	   signs	   of	   toxicity	   or	   systemic	   immune	   stimulation	   (579).	   The	  
absence	  of	  a	  cytokine	  storm	  in	  TGN1412-­‐treated	  cynomolgus	  macaques	  is	  most	  likely	  
due	   to	  a	   specific	   species	  difference.	  Whereas	  all	  human	  CD4+	  memory	  T-­‐cell	   subsets	  
express	  high	  levels	  of	  CD28,	  the	  CD4+	  memory	  T-­‐cell	  subsets	  of	  cynomolgus	  macaques	  
(as	   well	   as	   rhesus	   macaques)	   do	   not	   express	   CD28	   (579).	   The	   difference	   in	   the	  
distribution	  of	  CD28	  expression	  by	  human	  and	  macaque	  PBMCs	  is	  most	  likely	  to	  be	  the	  
reason	  why	  TGN1412	  did	  not	  induce	  a	  cytokine	  storm	  in	  cynomolgus	  macaques	  (580).	  
In	  vitro	   studies	  showed	  that	  human	  CD4+CD45RO+	  memory	  T-­‐cells	  are	  predominantly	  
responsible	   for	   the	   TNF,	   IFNγ	   and	   IL-­‐2	   production	   in	   response	   to	   stimulation	   with	  
immobilised	  TGN1412	  (579,	  581).	  The	  immobilisation	  of	  TGN1412	  in	  the	  in	  vitro	  assays	  
promoted	   the	   formation	   of	   an	   immunological	   synapse	   (582),	   similar	   to	   that	   formed	  
upon	   cell-­‐to-­‐cell	   contact.	   Aqueous-­‐phase	   TGN1412	   allows	   for	   CD28	   engagement	  
outside	  of	  the	  immunological	  synapse,	  which	  is	  known	  to	  impede	  T-­‐cell	  activation	  (583,	  
584).	   However,	   immobilised	   TGN1412	   fails	   to	   stimulate	   PBMCs	   from	   cynomolgus	  
macaques	   in	  vitro.	  Römer	  et	  al.	  reported	  that	  cell	  density	  is	  another	  important	  factor	  
contributing	  to	  the	  level	  of	  cytokine	  production	  in	  response	  to	  TGN1412.	  Pre-­‐culture	  of	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human	   PBMCs	   at	   ten-­‐fold	   higher	   densities	   showed	   increased	   cytokine	   response	   to	  
aqueous-­‐phase	   TGN1412,	   possibly	   due	   to	   the	   increased	   cellular	   interaction,	   in	  
response	   to	   which	   both	   monocytes	   and	   T-­‐cells	   upregulated	   functional	   activity	  
mediated	   (585,	   586).	   The	   experience	   with	   TGN1412	   emphasises	   the	   importance	   of	  
performing	  pre-­‐clinical	  toxicity	  studies	  using	  an	  appropriate	  model,	  which	  allow	  for	  the	  
detection	  of	  potential	  adverse	  events.	  
	  
This	   chapter	   discusses	   the	   risk	   of	   CRS	   in	   relation	   to	   T4	   immunotherapy.	   I	   have	  
investigated	   this	   question	   using	   an	   immunodeficient	   SCID/Beige	   mouse	   model.	   This	  
model	   should	   allow	   for	   detection	   of	   CRS	   in	   response	   to	   T4	   immunotherapy	   for	   two	  
reasons.	   First,	   as	   shown	   in	   paragraph	   3.2.4,	   T28ζ	   can	   induce	   T-­‐cell	   activation	   in	  
response	  to	  mouse	  ErbB	  receptors.	  Second,	  although	  SCID/Beige	  mice	  are	  deficient	  in	  
T-­‐cells,	  B-­‐cells	  and	  NK-­‐cells,	  they	  retain	  a	  normal	  macrophage	  population	  (587),	  which	  
is	  the	  major	  source	  of	  the	  key	  toxic	  cytokine,	  IL-­‐6.	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4.2 Results	  
	  
4.2.1 Transient	   Weight	   Loss	   Induced	   by	   T4+	   T-­‐cells	   in	   Ovarian	   Cancer	   Xenograft	  
Model	  
As	  described	  in	  paragraph	  3.2.10,	  no	  toxicity	  such	  as	  weight	  loss	  was	  observed	  in	  the	  IV	  
and	   PT	   HNSCC	   xenograft	   models,	   following	   treatment	   with	   T4	   immunotherapy.	   By	  
contrast,	   transient	  weight	   loss	  has	  been	  consistently	  reported	   in	   IP	  xenograft	  models	  
of	  ovarian	  cancer	  performed	  by	  Dr	  AC	  Parente-­‐Pereira	  and	  Dr	  LM	  Whilding	  following	  IP	  
administration	  of	  T4+	  T-­‐cells	  (Figure	  4-­‐1).	  In	  those	  studies,	  mice	  with	  18	  day	  established	  
firefly	  luciferase-­‐expressing	  SKOV3	  (SKOV3luc)	  tumours	  were	  treated	  with	  10	  x	  106	  T4+	  
T-­‐cells,	  making	   comparison	  with	   control	   P4+	   T-­‐cells	   or	   PBS.	  Mice	   treated	  with	   T4+	   T-­‐
cells	   consistently	   showed	   transient	  and	  mild	  weight	   loss,	   from	  which	   they	   recovered	  
over	  a	  14-­‐day	  period.	  No	  weight	  loss	  was	  seen	  in	  control	  mice.	  
	  
	  
Figure	   4-­‐1	   Transient	   weight	   loss	   in	   ovarian	   cancer	   xenograft	   model	   after	   T4	  
treatment	  
Serial	   weight	   measurement	   of	   SKOV3luc	   tumour-­‐bearing	   mice	   following	   T4+	   or	   P4+	   T-­‐cell,	   or	   PBS	  
treatment	   (mean	   ±	   SD;	   number	   of	   replicates	   indicated	   below).	   The	   y-­‐axis	   indicates	   weight	   change	  
normalised	   to	   that	   at	   the	   start	   of	   the	   study	   (e.g.	   weight	   at	   day	   0	   =	   100%).	   Mice	   were	   treated	   with	  
engineered	  T-­‐cells	  18	  days	  after	  tumour	  inoculation	  (as	  indicated	  by	  the	  arrow).	  Mice	  received	  10	  x	  106	  
T4+	  T-­‐cells,	  10	  x	  106	  P4+	  T-­‐cells	  or	  PBS	  as	  control.	  PBS,	  n=15;	  P4,	  n=5;	  T4,	  n=14.	  Data	  are	  derived	  from	  
three	  pooled	  experiments	  	  *	  =	  p<0.01	  comparing	  weight	  of	  T4	  treated	  mice	  on	  day	  25	  with	  the	  weight	  of	  
T4	  treated	  mice	  on	  day	  18.	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4.2.2 Serious	  Adverse	  Events	  in	  Ovarian	  Cancer	  Xenograft	  Model	  
In	  an	  additional	  experiment	  performed	  by	  Dr	  Parente-­‐Pereira	  and	  Dr	  Whilding,	  female	  
SCID/Beige	  mice	  with	  a	  high	   IP	  SKOV3luc-­‐tumour	  burden	  (34	  days	  established),	  were	  
treated	  with	  10	  x	  106	  T4+	  T-­‐cells	   IP,	  or	  PBS	  as	  a	   control.	  Within	  72	  hours	  after	  T-­‐cell	  
injection,	  11	  of	  12	  mice	  had	  died	  or	  had	   to	  be	   culled,	  whereas	  all	   control	  mice	   (PBS	  
treated)	   remained	   healthy.	   The	   single-­‐surviving	  mouse	   after	   T4	   treatment	   showed	   a	  
remarkable	  reduction	   in	  tumour	  burden.	  Control	  mice	  showed	  an	   increase	   in	  tumour	  
levels	  (see	  Figure	  4-­‐2).	  At	  post-­‐mortem	  examination	  of	  5	  of	  these	  T4	  treated	  mice,	  no	  
apparent	  cause	  of	  death	  could	  be	  determined	  and	  no	  residual	  tumour	  was	  detected.	  
Signs	  of	  inflammation	  were	  detected	  in	  the	  abdomen	  (see	  Appendix	  5).	  These	  finding	  
suggested	   that	   T4+	   T-­‐cells	   are	   able	   to	   induce	   severe	   toxicity	   of	   rapid	   onset	   when	  
injected	  IP	  in	  the	  presence	  of	  tumour.	  
	  
	  
Figure	  4-­‐2	  Severe	  Adverse	  Events	  in	  IP	  xenograft	  model	  of	  ovarian	  cancer	  
Twelve	  mice	  with	  advanced,	  34	  day-­‐established	  SKOV3luc	  tumours	  were	  treated	  with	  10	  x	  106	  T4+	  T-­‐cells	  
(n=12)	  IP,	  control	  mice	  received	  400μL	  PBS	  IP	  (n=9).	  A:	  	  Serial	  BLI	  indicating	  IP	  tumour	  growth	  (mean	  ±	  
SD,	  n=12	  for	  T4	  or	  9	  for	  PBS).	  Arrow	  indicates	  timepoint	  of	  T-­‐cell/PBS	  treatment.	  Lethal	  toxicity	  occurred	  
in	  11/12	  mice	   treated	  with	  T4	   immunotherapy	  within	  72	  hours	  after	  T-­‐cell	  administration.	  The	  day	  43	  
imaging	  in	  the	  T4	  group	  is	  the	  single	  surviving	  mouse	  from	  the	  original	  group	  of	  12	  B:	  BLI	  of	  the	  surviving	  
T4	   treated	   mouse	   compared	   to	   one	   representative	   PBS-­‐treated	   control.	   Day	   32	   represents	   tumour	  
burden	  2	  days	  prior	  to	  treatment,	  day	  43	  represent	  tumour	  burden	  9	  days	  after	  treatment.	  Images	  are	  
from	  the	  same	  mice,	  before	  and	  after	  treatment	  and	  shown	  on	  the	  same	  scale.	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4.2.3 Transient	  Weight	  Loss	  induced	  by	  T4+	  T-­‐cells	  in	  IP	  HNSCC	  Xenograft	  Model	  
The	  SKOV3luc	  xenograft	  model	  is	  a	  more	  aggressive	  and	  faster	  growing	  tumour	  model	  
than	   the	  HN3luc	  xenograft	  model.	   In	  order	   to	  determine	  whether	   the	   toxicities	   seen	  
were	  specifically	  related	  to	  the	  ovarian	  cancer	  model	  or	  a	  more	  general	  side	  effect	  of	  
T4	  immunotherapy,	  weight	  loss	  was	  measured	  in	  an	  IP	  model	  of	  HNSCC.	  Mice	  with	  14-­‐
day	  established	  HN3luc	  tumours	  were	  treated	  with	  either	  5	  x	  106	  or	  10	  x	  106	  T4+	  T-­‐cells	  
or	   10	   x	   106	  UT	   T-­‐cells	   as	   control	   (see	   Table	   4-­‐1).	   Due	   to	   the	   risk	   of	   inducing	   severe	  
toxicity,	   only	   2	   mice	   were	   included	   for	   ethical	   reasons	   (as	   specified	   in	   the	   Project	  
License	  governing	  this	  work).	  Additionally,	  non-­‐tumour	  bearing	  mice	  were	  treated	  with	  
either	   5	   x	   106	  or	   10	   x	   106	   T4+	   T-­‐cells	   to	  determine	  whether	   the	  presence	  of	   tumour	  
influenced	  the	  severity	  of	  toxicity.	  Functionality	  of	  in	  vivo	  administered	  T4+	  T-­‐cells	  was	  
confirmed	   by	   serial	   tumour	   burden	  measurement	   using	   BLI.	   A	   reduction	   of	   tumour	  
burden	  was	  seen	  using	  both	  5	  x	  106	  and	  10	  x	  106	  T4+	  treatment	  doses	  (see	  Figure	  4-­‐3).	  
	  
Table	  4-­‐1	  Design	  of	  ‘Efficacy	  of	  T4	  immunotherapy	  after	  IP	  administration’-­‐study	  
Number	  Mice	   HN3	  Tumour	  cells	  IP	   T-­‐cells	  IP	  
2	  male	   -­‐	   5	  x	  106	  T4	  
2	  male	   -­‐	   10	  x	  106	  T4	  
2	  male	   10	  x	  106	   5	  x	  106	  T4	  
2	  male	   10	  x	  106	   10	  x	  106	  T4	  
2	  male	   10	  x	  106	   10	  x	  106	  UT	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Figure	  4-­‐3	  Efficacy	  of	  T4	  immunotherapy	  after	  intra-­‐peritoneal	  T-­‐cell	  administration	  
Mice	  with	  14	  day-­‐established	  HN3luc	  tumours	  were	  treated	  IP	  with	  5	  x	  106	  or	  10	  x	  106	  T4+	  T-­‐cells	  (n=2).	  
Control	  mice	  were	  treated	  with	  10	  x	  106	  UT	  T-­‐cells	  (n=2).	  A:	  Serial	  BLI	  indicating	  tumour	  status	  directly	  
prior	  to	  T-­‐cell	  administration	  (0	  hours)	  and	  7	  days	  (168	  hours)	  after	  T-­‐cell	  administration	  (mean	  ±	  SD).	  B:	  
BLI	  images	  of	  all	  mice	  prior	  and	  after	  T-­‐cell	  administration.	  All	  mice	  are	  shown	  on	  the	  same	  scale.	  
	  
The	  weight	  of	  all	  mice	  was	  measured	  at	  regular	   intervals	  (0,	  4,	  24,	  48,	  72	  and	  
168	  hours	  after	  T-­‐cell	  administration).	  Minor	  weight	  loss	  was	  seen	  in	  mice	  treated	  with	  
10	   x	   106	   UT	   T-­‐cells	   in	   the	   first	   72	   hours	   after	   T-­‐cell	   administration	   (see	   Figure	   4-­‐4).	  
More	   pronounced	   weight	   loss	   was	   seen	   in	  mice	   treated	   with	   T4+	   T-­‐cells.	  Mice	   that	  
received	  10	  x	  106	  T4+	  T-­‐cells	  lost	  relatively	  more	  weight	  than	  mice	  treated	  with	  5	  x	  106	  
T4+	  T-­‐cells.	  The	  presence	  of	  tumour	  did	  not	  influence	  the	  degree	  of	  weight	  loss	  in	  both	  
treatment	  dose	   levels	   (see	  Figure	  4-­‐4).	  These	  results	  suggest	  that	  the	  adverse	  events	  
observed	   are	   dose-­‐dependent	   toxicities	   of	   T4	   immunotherapy,	   independent	   of	   the	  
tumour	  type	  treated.	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Figure	  4-­‐4	  Serial	  weight	  monitoring	  of	  mice	  following	  T4	  immunotherapy	  in	  absence	  
or	  presence	  of	  tumour	  burden	  
Serial	  weight	  measurements	   in	   tumour-­‐bearing	   (shown	   in	   green)	   or	   tumour-­‐free	   (shown	   in	   red)	  mice	  
treated	  with	  5	  x	  106	   (left	  graph)	  or	  10	  x	  106	   (right	  graph)	  T4+	  T-­‐cells	   (mean	  ±	  SD).	  Weight	   loss	   in	  both	  
graphs	   is	   compared	   to	   control	   tumour-­‐bearing	  mice	   that	   received	   10x106	   UT	   T-­‐cells	   (shown	   in	   blue).	  
(n=2).	  Weights	  of	  tumour-­‐bearing	  and	  tumour-­‐free	  mice	  following	  treatment	  with	  either	  dose	  of	  T4+	  T-­‐
cells	   are	  not	   significantly	  different.	  *	  =	  p<0.05;	  **	  =	  p<0.01	   comparing	  T4+	  T-­‐cells	  with	  UT	  T-­‐cells;	   #	  =	  
p<0.05	   comparing	   the	   effect	   of	   5	   x	   106	   with	   10	   x	   106	   T4+	   T-­‐cells	   in	   tumour-­‐free	   mice.	   The	   latter	  
difference	  is	  not	  significant	  in	  tumour-­‐bearing	  mice.	  	  
	  
	  
4.2.4 Induction	  of	  Cytokine	  Release	  Syndrome	  by	  T4	  immunotherapy	  in	  Tumour-­‐Free	  
Mice	  
The	   rapid	   onset	   of	   the	   toxicities	   recorded,	   and	   the	   absence	   of	   any	   major	   organ	  
pathology,	   suggested	   that	   a	   cytokine	   storm	   might	   be	   the	   cause	   for	   these	   adverse	  
events.	   As	   mentioned	   previously,	   complications	   due	   to	   cytokine	   release	   syndrome	  
(CRS)	   have	   been	   reported	   in	   clinical	   studies	   involving	   CAR-­‐engineered	   T-­‐cells.	   To	  
determine	  whether	   the	   toxicities	   seen	   in	   the	   SCID/Beige	   xenograft	  models	   could	   be	  
due	  to	  CRS,	  non-­‐tumour	  bearing	  mice	  were	  treated	  IP	  with	  escalating	  doses	  (3	  x	  106,	  
10	  x	  106	  and	  30	  x	  106)	  of	  T4+	  T-­‐cells	  or	  the	  same	  dose	  of	  P4+	  or	  UT	  T-­‐cells	  as	  a	  control	  
(see	  Table	  4-­‐2).	  Serial	  weight	  measurements	  performed	  in	  mice	  treated	  with	  T4+	  T-­‐cells	  
were	   consistent	   with	   a	   dose-­‐dependent	   induction	   of	   toxicity	   (see	   Figure	   4-­‐5).	   Mice	  
treated	  with	   the	   lowest	   dose	   (3	   x	   106	   T4+	   T-­‐cells)	   did	   not	   show	   any	  weight	   change.	  
Minor	  weight	  loss	  was	  recorded	  in	  mice	  treated	  with	  10	  x	  106	  T4+	  T-­‐cells.	  Mice	  treated	  
with	  30	  x	  106	  T4+	  T-­‐cells	  had	  significant	  weight	  loss	  within	  24	  hours	  and	  died	  within	  30	  
hours	  after	  T-­‐cell	  administration	  (see	  Figure	  4-­‐5).	  Mice	  treated	  with	  30	  x	  106	  T4+	  T-­‐cells	  
showed	  additional	  clinical	  signs	  including	  piloerection,	  subdued	  behaviour	  and	  reduced	  
mobility.	  Control	  mice	  treated	  with	  the	  same	  doses	  of	  P4+	  T-­‐cells	  or	  UT	  T-­‐cells	  did	  not	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have	   any	   significant	   weight	   loss	   in	   response	   to	   treatment,	   nor	   did	   they	   show	   any	  
clinical	   signs	   of	   toxicity	   (see	   Figure	   4-­‐6).	   The	   absence	   of	  weight	   loss	   in	  mice	   treated	  
with	  P4+	  T-­‐cells,	  suggest	  that	  the	  induced	  toxicity	  is	  specific	  for	  the	  ErbB-­‐targeting	  CAR	  
T28ζ,	  present	  within	  the	  T4	  combination.	  
	  
Table	  4-­‐2	  Design	  of	  ‘Cytokine	  Release	  Syndrome’-­‐study	  
Number	  Mice	   T4+	  T-­‐cells	  IP	   P4+	  T-­‐cells	  IP	   UT+	  T-­‐cells	  IP	  
2	  male	   3	  x	  106	   3	  x	  106	   3	  x	  106	  
2	  male	   10	  x	  106	   10	  x	  106	   10	  x	  106	  
2	  male	   30	  x	  106	   30	  x	  106	   30	  x	  106	  
	  
	  
Figure	   4-­‐5	   Weight	   loss	   induced	   in	   tumour-­‐free	   mice	   by	   intra-­‐peritoneal	   T4	  
immunotherapy	  
Serial	  weight	  measurement	  of	  tumour-­‐free	  mice	  treated	  with	  3	  x	  106	  (red;	  n=2),	  10	  x	  106	  (blue;	  n=4)	  or	  
30	   x	   106	   (green;	   n=4)	   T4+	   T-­‐cells	   (%	   mean	   ±	   SD).	   Results	   are	   a	   combination	   of	   two	   independent	  
experiments.	  All	  4	  mice	  treated	  with	  30	  x	  106	  T4+	  T-­‐cells	  died	  within	  30	  hours	  after	  T-­‐cell	  administration.	  
*	  =	  p<0.01	   comparing	  weight	  of	  mice	   treated	  with	  30	   x	  106	  T4+	  T-­‐cells	   after	  24	  hours	  with	   their	   start	  
weight	  (0	  hours).	  Weight	  changes	  in	  mice	  treated	  with	  3	  x	  106	  or	  10	  x	  106	  T4+	  T-­‐cells	  are	  not	  significant	  at	  
any	  stage.	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Figure	  4-­‐6	  Monitoring	  of	  weight	  in	  tumour-­‐free	  mice	  treated	  with	  P4+	  or	  UT	  T-­‐cells	  
Serial	  weight	  measurements	  were	  performed	   in	   tumour-­‐free	  mice	  treated	  with	  3	  x	  106	   (red),	  10	  x	  106	  
(blue)	  or	  30	  x	  106	  	  (green)	  P4+	  or	  UT	  T-­‐cells	  (n=2	  for	  all	  groups)	  (%	  mean	  ±	  SD).	  No	  significant	  weight	  loss	  
was	  detected	  at	  any	  point.	  
	  
To	   investigate	   whether	   this	   rapid,	   dose	   dependent	   weight	   loss	   could	   be	  
attributed	   to	   CRS,	   circulating	   cytokine	   levels	   were	  measured	   at	   several	   time-­‐points.	  
Blood	   samples	  were	   taken	   at	   4,	   24	   and	   48	   hours	   after	   T-­‐cell	   administration.	  Human	  
and	  mouse	  cytokine	  levels	  were	  measured	  using	  a	  cytometric	  bead	  assay	  (IL-­‐2,	  IL-­‐4,	  IL-­‐
6,	  IL-­‐10,	  IL-­‐17A,	  IFNγ),	  or	  ELISA	  (hIL-­‐2,	  hIFNγ,	  mIL-­‐6).	  Cytokine	  levels	  at	  4	  and	  24	  hours	  
after	  T4+	  T-­‐cell	  administration	  are	  shown	  here.	  Circulating	  cytokine	  levels	  at	  48	  hours	  
in	  mice	  treated	  with	  3	  x	  106	  or	  10	  x	  106	  T4+	  T-­‐cells	  were	  all	  below	  detection	  level	  (data	  
not	   shown).	   Additionally,	   circulating	   cytokine	   levels	   (hIL-­‐2,	   hIFNγ	   and	  mIL-­‐6)	   in	  mice	  
treated	  with	  P4+	  or	  UT	  T-­‐cells	  were	  all	  below	  detection	  level	  at	  all	  tested	  time	  points	  
(data	  not	  shown).	  
	   High	  levels	  of	  human	  IL-­‐2,	  human	  IFNγ	  and	  mouse	  IL-­‐6	  were	  detected	  in	  mice	  
treated	  with	  30	  x	  106	  T4+	  T-­‐cells	  (see	  Figure	  4-­‐7	  and	  Figure	  4-­‐8).	  	  Low	  levels	  of	  hIL-­‐17A	  
were	  detected	  amongst	  all	  treatment	  doses	  (see	  Figure	  4-­‐7).	  Low	  level	  of	  mIL-­‐10	  was	  
detected	  in	  one	  of	  the	  mice	  treated	  with	  30	  x	  106	  T4+	  T-­‐cells	  (see	  Figure	  4-­‐8).	  In	  man,	  
elevated	  levels	  of	  IL-­‐2,	  IL-­‐10,	  IFNγ,	  TNF	  and	  IL-­‐6	  have	  been	  reported	  in	  relation	  to	  T-­‐cell	  
therapy	   (240,	   317,	   319,	   320,	   327,	   445,	   450,	   477).	   Treatment	   with	   the	   anti-­‐IL-­‐6R	  
antibody	  Tocilizumab	  has	  achieved	  rapid	  relief	  of	  side	  effects	  in	  patients,	  suggesting	  a	  
key	   role	   for	   IL-­‐6	   in	   the	   CRS-­‐related	   toxicities.	   Blocking	   of	   mouse	   IL-­‐6	   in	   this	   model	  
would	   be	   useful	   to	   determine	  whether	  mIL-­‐6	   plays	   a	   similar	   role	   in	   this	   pre-­‐clinical	  
model.	   At	   the	   time	   of	   printing	   this	   thesis,	   the	   murine	   equivalent	   (MR16-­‐1	   (588))	   is	  
being	  acquired.	  In	  a	  mouse	  model	  of	  graft-­‐versus-­‐host	  disease	  (GvHD)	  after	  allogeneic	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bone	  marrow	   transplantation,	   treatment	  with	  MR16-­‐1	   resulted	   in	  a	   reduction	  of	   the	  
GvHD	  induced	  mortality,	  while	  preserving	  the	  graft-­‐versus-­‐tumour	  response	  (589).	  The	  
antibody	  would	   allow	   us	   to	   determine	  whether	   blocking	   IL-­‐6R	   is	   equally	   efficient	   in	  
relieving	  side	  effects	  in	  SCID/Beige	  mice	  as	  Tocilizumab	  is	  in	  man.	  	  
	   Interleukin-­‐6	   is	   principally	   produced	   by	   macrophages,	   which	   led	   to	   the	  
hypothesis	   that	   the	   high	   levels	   of	   IL-­‐2	   produced	   by	   the	   T4+	   T-­‐cells	   induced	   mIL-­‐6	  
production	  by	   the	  macrophages	   in	   the	   intra-­‐peritoneal	  cavity.	  To	  determine	  whether	  
macrophages	   are	   influential	   in	   this	   pre-­‐clinical	   model,	   further	   toxicity	   experiments	  
were	   conducted	   in	  mice	   in	  which	  macrophages	  were	   depleted	   first,	   using	   liposomal	  
clodronate.	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Figure	   4-­‐7	   Circulating	   human	   cytokine	   concentrations	   in	   mice	   following	   IP	  
administration	  of	  T4+	  T-­‐cells.	  
Human	   circulating	   cytokine	   levels	   were	   quantified	   at	   4	   (red)	   and	   24	   (yellow)	   hours	   after	   T-­‐cell	  
administration	   in	  mice	   treated	   with	   escalating	   doses	   of	   T4	   immunotherapy	   (n=4	   for	   human	   IL-­‐2	   and	  
IFNγ;	   n=2	   for	   all	   remaining	   cytokines)	   data	   show	   mean	   ±	   SD.	   Human	   IL-­‐2	   and	   IFNγ	   levels	   were	  
determined	  using	  cytometric	  bead	  array	  (n=2)	  or	  ELISA	  (n=2),	  all	  other	  cytokines	  were	  measured	  using	  
cytometric	  bead	  array.	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Figure	   4-­‐8	   Circulating	   mouse	   cytokine	   concentrations	   in	   mice	   following	   IP	  
administration	  of	  T4+	  T-­‐cells	  
Mouse	   circulating	   cytokine	   levels	   at	   4	   (red)	   and	   24	   (yellow)	   hours	   after	   T-­‐cell	   administration	   in	  mice	  
treated	  with	  escalating	  doses	  of	  T4	  immunotherapy	  (n=4	  for	  mouse	  IL-­‐6;	  n=2	  for	  all	  remaining	  cytokines)	  
data	  show	  mean	  ±	  SD.	  Mouse	   IL-­‐6	   levels	  were	  determined	  using	  cytometric	  bead	  array	   (n=2)	  or	  ELISA	  
(n=2).	  All	  other	  cytokines	  were	  measured	  with	  a	  cytometric	  bead	  array.	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4.2.5 Influence	  of	  Macrophages	  on	  Cytokine	  Release	  Syndrome	  
Liposomes	  are	  lipid	  vesicles	  consisting	  of	  concentric	  phospholipid	  bilayers	  and	  may	  be	  
used	   to	   encapsulate	   hydrophilic	   molecules,	   including	   clodronate.	   Clodronate	   is	   a	  
bisphosphonate,	  which	   is	   used	   in	   treatment	   of	   (secondary)	   bone	   cancer.	   Clodronate	  
has	  a	  short	  half-­‐life	   in	  circulation,	  but	  due	  to	  its	  hydrophilic	  nature,	   it	  does	  not	  easily	  
cross	  the	  phospholipid	  bilayer	  liposome	  or	  cell	  membrane.	  When	  macrophages	  take	  up	  
liposomal	  clodronate	  (LC)	  through	  phagocytosis,	  it	  accumulates	  within	  the	  cell	  until	  the	  
liposomes	   are	   digested	   and	   the	   clodronate	   is	   released.	   At	   certain	   intracellular	  
concentrations,	   clodronate	   induces	   the	   apoptosis	   of	   macrophages.	   Neither	   the	  
liposomes	   nor	   the	   clodronate	   is	   toxic	   to	   other	   cell	   types,	   allowing	   for	   specific	  
macrophage	  depletion	  (590-­‐592).	  	  
To	  ensure	  maximal	  macrophage	  depletion,	  mice	  were	  treated	  with	  two	  doses	  
of	   LC	   (or	   liposomal	   PBS	   (LP)	   as	   control)	   prior	   to	   T4+	   T-­‐cell	   administration	   (see	   Table	  
4-­‐3).	   Four	   days	   prior	   to	   T-­‐cell	   administration,	  mice	   received	   a	   dose	   of	   1mg	   LC/	   10g	  
body	  weight.	  Three	  days	  later	  (one	  day	  prior	  to	  T-­‐cell	  administration)	  mice	  received	  an	  
additional	   dose	   of	   0.5mg	   LC/	   10g	   body	   weight.	   To	   determine	   the	   efficacy	   of	  
macrophage	  depletion,	  the	  amount	  of	  CD45+	  F4/80+	  cells	  in	  the	  IP	  cavity	  of	  T4+	  treated	  
mice	   was	   determined	   using	   flow	   cytometry.	   Treatment	   with	   liposomal	   clodronate	  
resulted	  in	  a	  lower	  absolute	  number	  of	  CD45+	  F4/80+	  cells	  in	  the	  intra-­‐peritoneal	  cavity	  
compared	  to	  the	  content	  in	  control	  mice	  treated	  with	  LP	  (see	  Figure	  4-­‐9).	  	  
	  
Table	  4-­‐3	  Design	  of	  ‘Macrophage	  depletion’	  study	  
Number	  Mice	   LC	  (day	  -­‐4)	   LP	  (day	  -­‐1)	   T4+	  T-­‐cells	   P4+	  T-­‐cells	  
1	  male	   Dose	  1:	  1mg/10g	  
Dose	  2:	  0.5mg/10g	  
-­‐	   30	  x	  106	   -­‐	  
2	  male	   -­‐	   Dose	  1:	  1mg/10g	  
Dose	  2:	  0.5mg/10g	  
30	  x	  106	   -­‐	  
2	  male	   Dose	  1:	  1mg/10g	  
Dose	  2:	  0.5mg/10g	  
-­‐	   -­‐	   30	  x	  106	  
2	  male	   -­‐	   Dose	  1:	  1mg/10g	  
Dose	  2:	  0.5mg/10g	  
-­‐	   30	  x	  106	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Figure	  4-­‐9	  Peritoneal	  macrophage	  content	  in	  mice	  treated	  with	  liposomal	  clodronate.	  
Total	  macrophage	  content	  in	  IP	  cavity	  after	  liposomal	  PBS	  (LP)	  or	  liposomal	  clodronate	  (LC)	  treatment.	  	  
Total	  cells	  were	  counted	  and	  macrophage	  content	  was	  determined	  based	  on	  CD45+	  F4/80+	  content.	  LP,	  
n=1;	  LC,	  n=2.	  Data	  shown	  mean	  ±	  SD	  for	  LC.	  
	  
Mice	   received	   a	   dose	   of	   30	   x	   106	   T4+	   or	   P4+	   T-­‐cells,	   after	   which	   weight,	  
behaviour	   and	   circulating	   cytokines	   were	   monitored	   as	   described	   in	   the	   previous	  
experiment.	  Severe	  weight	  loss	  was	  seen	  in	  the	  mouse	  treated	  with	  30	  x	  106	  T4+	  T-­‐cells	  
without	  macrophage	  depletion,	  whereas	   no	  weight	   loss	  was	   seen	   in	  mice	   that	  were	  
macrophage	   depleted	   prior	   to	   T-­‐cell	   treatment	   (see	   Figure	   4-­‐10).	   Weight	   remained	  




Figure	   4-­‐10	   Weight	   loss	   induced	   by	   T4+	   T-­‐cells	   in	   tumour-­‐free	   mice	   with(out)	  
macrophage	  depletion	  
Mice	  were	  treated	  with	  liposomal	  PBS	  (LP)	  or	  liposomal	  clodronate	  (LC)	  prior	  to	  administration	  of	  30	  x	  
106	  T4+	  or	  P4+	  T-­‐cells.	  Weight	  was	  measured	  at	  0,	  4	  and	  24	  hours	  post	  T-­‐cell	  administration.	  LP	  +	  T4	  n=1;	  
all	  other	  conditions	  n=2.	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Blood	   samples	   were	   obtained	   at	   4	   and	   24	   hours	   after	   T-­‐cell	   injections.	  
Circulating	   levels	   of	  mouse	   IL-­‐6	   (mIL-­‐6)	   was	   determined	   by	   ELISA.	   High	  mIL-­‐6	   levels	  
were	  detected	  in	  the	  mouse	  treated	  with	  liposomal	  PBS	  (LP),	  at	  an	  equivalent	  level	  as	  
previously	   measured	   in	   non-­‐tumour	   bearing	   mice.	   In	   mice	   treated	   with	   liposomal	  
clodronate	  prior	  to	  T4+	  T-­‐cell	  administration	  (see	  Figure	  4-­‐11	  and	  Figure	  4-­‐8),	  low	  levels	  
of	  mIL-­‐6	   were	   detected	   4	   hours	   after	   T4+	   T-­‐cell	   administration,	   which	   decreased	   to	  
levels	  below	  the	  detection	  limit	  24	  hours	  after	  T4+	  T-­‐cell	  administration.	  No	  detectable	  
levels	  of	  mIL-­‐6	  were	  seen	  in	  any	  of	  the	  control	  mice	  treated	  with	  P4+	  T-­‐cells	  (see	  Figure	  
4-­‐11).	   These	   results	   suggest	   that	   measured	   mIL-­‐6	   levels	   are	   indeed	   produced	   by	  
macrophages,	   and	   that	   elimination	   of	   macrophages	   reduced	   mIL-­‐6	   production	   and	  
consequently	  reduces	  the	  toxicity	  related	  to	  CRS.	  
	  
Figure	   4-­‐11	   Circulating	  mouse	   Interleukin-­‐6	   following	   IP	   administration	  of	   30	   x	   106	  
T4/P4+	  T-­‐cells.	  
Prior	   to	   T-­‐cell	   administration,	   mice	   were	   treated	   with	   two	   doses	   liposomal	   PBS	   (LP)	   or	   liposomal	  
clodronate	  (LC).	  Mice	  received	  1μg/10g	  body	  weight	  4	  days	  prior	  to	  T-­‐cell	  administration	  and	  0.5μg/10g	  
body	  weight	  1	  day	  prior	  to	  T-­‐cell	  administration.	  Mice	  received	  30	  x	  106	  T4+/P4+	  T-­‐cells	  IP.	  Blood	  samples	  
were	  collected	  at	  4	  and	  24	  hours	  post	  T-­‐cell	  administration.	  LP+T4	  n=1,	  all	  other	  conditions	  n=2	  (mean	  +	  
SD).	  Cytokine	  levels	  were	  determined	  by	  ELISA.	  
	  
In	  mice	  bearing	  advanced	  SKOV3	  tumours,	  the	  lower	  dose	  of	  10	  x	  106	  T4+	  T-­‐cells	  
was	   able	   to	   induce	   severe	   toxicity,	   whereas	   in	   non-­‐tumour	   bearing	   animals	   severe	  
toxicity	  was	  only	  detected	  with	   the	  high	  dose	  of	   30	   x	   106	   T4+	   T-­‐cells.	   Toxicity	  of	   the	  
lower	  dose	  in	  mice	  with	  a	  high	  tumour	  burden	  could	  be	  due	  to	  an	  increased	  presence	  
of	   ErbB-­‐expressing	   cells.	   However,	   SKOV3	   tumours	   are	   associated	  with	   a	   substantial	  
influx	   of	   macrophages	   (see	   Figure	   4-­‐12).	   When	   comparing	   macrophage	   content	   in	  
SKOV3	   tumour	   bearing	   mice	   with	   the	   macrophage	   content	   in	   tumour-­‐free	   mice,	   a	  
significantly	   higher	   amount	   of	   macrophages	   is	   detected	   in	   SKOV3	   tumour-­‐bearing	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mice.	   This	   increased	   macrophage	   content	   could	   also	   contribute	   to	   the	   increased	  
toxicity	  at	  a	  lower	  T4+	  T-­‐cell	  dose.	  
	  
Figure	  4-­‐12	  Macrophage	   content	   in	   the	  peritoneal	   cavity	  of	   SKOV3	   tumour-­‐bearing	  
and	  tumour-­‐free	  mice	  
Macrophage	  content	   in	   the	  peritoneal	  cavity	  was	  determined	   in	  mice	  with	  14	  days-­‐established	  SKOV3	  
intra-­‐peritoneal	   tumours	   (n=3;	  mean	  ±	   SD;	   left	   bar)	   compared	   to	   tumour	   free	  mice	   (n=3;	  mean	  ±	   SD;	  
right	  bar).	  *	  =	  p<0.01	  
	  
4.2.6 Cytokine	   Release	   Syndrome	   does	   not	   occur	   after	   Peri-­‐Tumoural	   T4	  
Immunotherapy	  
The	  pre-­‐clinical	   results	   presented	   above	   raise	   concerns	   that	   T4	   immunotherapy	  may	  
induce	   CRS	   in	   man.	   In	   a	   phase-­‐I	   clinical	   trial,	   we	   aim	   to	   treat	   patients	   with	   locally	  
recurrent	  HNSCC	  by	  intra-­‐tumoural	  injection	  of	  T4+	  T-­‐cells.	  To	  determine	  whether	  this	  
route	  of	  administration	  could	  also	  induce	  CRS,	  cytokine	  levels	  were	  compared	  between	  
mice	  treated	  with	  T4+	  T-­‐cells	  using	  the	  peri-­‐tumoural	  (PT)	  or	  intra-­‐peritoneal	  (IP)	  routes	  
(see	   Table	   4-­‐4).	   Mice	   had	   14	   day	   established	   IP	   or	   27	   day	   established	   SC	   HN3luc	  
tumours	  and	  were	  treated	  with	  5	  x	  106	  or	  10	  x	  106	  T4+	  T-­‐cells	  IP	  or	  10	  x	  106	  T4+	  T-­‐cells	  
PT.	   Control	   mice	   were	   treated	   with	   10	   x	   106	   UT	   T-­‐cells.	   Additionally,	   non-­‐tumour	  
bearing	   mice	   were	   treated	   with	   10	   x	   106	   T4+	   T-­‐cells	   (either	   IP	   or	   SC)	   to	   determine	  
whether	  tumour	  burden	  is	  influential	  to	  cytokine	  production	  in	  both	  settings.	  	  
	  
Table	  4-­‐4	  Design	  of	  ‘Peri-­‐tumoural	  T4	  treatment’-­‐study	  
Number	  Mice	   HN3	  IP	   HN3	  SC	   T-­‐cells	  IP	   T-­‐cells	  PT	  
2	  male	   10	  x	  106	   -­‐	   10	  x	  106	  T4+	   -­‐	  
2	  male	   10	  x	  106	   -­‐	   10	  x	  106	  UT	   -­‐	  
2	  male	   -­‐	   10	  x	  106	   -­‐	   10	  x	  106	  T4+	  
2	  male	   -­‐	   10	  x	  106	   -­‐	   10	  x	  106	  UT	  
2	  male	   -­‐	   -­‐	   10	  x	  106	  T4+	   -­‐	  
2	  male	   -­‐	   -­‐	   -­‐	   10	  x	  106	  T4+	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Efficacy	  and	  weight	  loss	  of	  mice	  treated	  with	  10	  x	  106	  T4+	  T-­‐cells	  have	  been	  described	  
in	   paragraph	   4.2.3.	   Functionality	   of	   T4+	   T-­‐cells	   after	   subcutaneous/peri-­‐tumoural	  
administration	   was	   confirmed	   with	   BLI	   tumour	   size	   measurement.	   As	   depicted	   in	  
Figure	   4-­‐13,	   SC	   tumour	   burden	   was	   reduced	   after	   T4+	   T-­‐cell	   administration;	   further	  
tumour	  growth	  was	  seen	  in	  control	  mice	  treated	  with	  UT	  T-­‐cells.	  In	  contrast	  to	  IP	  T4+	  T-­‐
cell	  administration	  (Figure	  4-­‐4),	  no	  significant	  weight	  loss	  was	  observed	  after	  SC/PT	  T4+	  
T-­‐cell	  administration	  (see	  Figure	  4-­‐14).	  At	  24	  hours	  after	  IP	  treatment,	  high	  circulating	  
IFNγ	  levels	  were	  detected.	  Only	  background	  levels	  of	  IFNγ	  were	  detected	  at	  the	  same	  
time-­‐points	   after	   SC/PT	   treatment.	   These	   results	   suggest	   that	  CRS	   induced	  by	   T4+	   T-­‐
cells	  dose	  and	  route	  dependent,	  but	  independent	  of	  tumour	  burden	  
	  
	  
Figure	  4-­‐13	  Intra-­‐tumoural	  treatment	  of	  subcutaneous	  HN3luc	  tumours	  with	  10	  x	  106	  
T4+	  T-­‐cells	  
A:	  Mice	  with	  27	  day-­‐established	  subcutaneous	  HN3luc	  tumours	  were	  treated	  with	  10	  x	  106	  T4+	  or	  UT	  T-­‐
cells	  (as	  indicated	  by	  the	  arrow).	  Mice	  were	  treated	  peri-­‐tumoural	  when	  the	  tumour	  size	  did	  not	  allow	  
for	   intra-­‐tumoural	   injection.	  Serial	  BLI	   to	  monitor	  tumour	  growth	  and	  treatment	  efficacy.	  B:	   images	  of	  
mice	  at	  the	  day	  of	  T-­‐cell	  administration	  (day	  27)	  and	  7	  days	  post	  treatment	  (day	  34).	  All	  mice	  are	  shown	  
on	  the	  same	  scale.	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Figure	  4-­‐14	  Serial	  weight	  measurements	  of	  mice	  following	  intra-­‐tumoural	  treatment	  
with	  10	  x	  106	  T4+	  T-­‐cells	  
Serial	   weight	   measurements	   of	   (non)	   tumour-­‐bearing	   mice	   after	   PT/SC	   treatment	   with	   10	   x	   106	   T4+	  
(shown	  in	  red	  and	  green)	  or	  UT	  T-­‐cells	  (blue)(mean	  ±	  SD)(n=2).	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Figure	   4-­‐15	   Human	   circulating	   cytokine	   levels	   after	   IP	   T4	   immunotherapy	  
administration	  
HN3luc	  tumour-­‐bearing	  or	  tumour-­‐free	  mice	  were	  treated	  with	  10	  x	  106	  T4+	  T-­‐cells	  or	  UT	  T-­‐cells	  through	  
intra-­‐peritoneal	   administration	   (n=2).	   Blood	   samples	   were	   collected	   at	   4	   (red),	   24	   (yellow)	   and	   48	  
(green)	  hours	  post	  T-­‐cell	  administration.	  Circulating	  cytokine	  levels	  were	  determined	  by	  cytometric	  bead	  
array.	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Figure	   4-­‐16	   Human	   circulating	   cytokine	   levels	   after	   PT	   T4	   immunotherapy	  
administration	  
HN3luc	   tumour-­‐bearing	  and	  non-­‐tumour	  bearing	  mice	  were	   treated	  with	  10	  x	  106	  T4+	  T-­‐cells	  or	  UT	  T-­‐
cells	   through	  peri-­‐tumoural	   or	   subcutaneous	   administration	   (n=2).	   Blood	   samples	  were	   collected	   at	   4	  
(red),	   24	   (yellow)	   and	   48	   (green)	   hours	   post	   T-­‐cell	   administration.	   Circulating	   cytokine	   levels	   were	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4.3 Discussion	  
Cytokine	   release	   syndrome	   and	   the	   onset	   of	   a	   cytokine	   storm	   can	   cause	   severe	  
complications	   in	   relation	   to	   infections	   as	   well	   as	   immunotherapies.	   Several	   Phase	   I	  
clinical	   trials	   have	   shown	   the	   occurrence	   of	   cytokine	   storms	   in	   response	   to	   CAR-­‐
mediated	  adoptive	  T-­‐cell	  transfer	  (240,	  317,	  320,	  321,	  445).	  The	  most	  severe	  cytokine	  
storm	  was	  seen	  in	  a	  trial	  using	  ErbB2	  re-­‐targeted	  T-­‐cells,	   in	  which	  the	  cytokine	  storm	  
resulted	  in	  lethal	  multiple	  organ	  failure	  (240).	  
	   In	  relation	  to	  T4	   immunotherapy,	  no	  severe	  toxicity	  had	  been	  seen	  in	  efficacy	  
studies	  as	  well	  as	  studies	  focussing	  on	  the	  potential	  ‘on-­‐target’-­‐toxicity	  (as	  described	  in	  
paragraph	  3.2.10).	  No	  toxicity	  was	  seen	  after	  IV	  or	  SC/PT	  administration	  of	  high	  doses	  
(20	  x	  106)	  T4+	  T-­‐cells.	  In	  contrast,	  in	  an	  IP	  xenograft	  model	  of	  ovarian	  cancer	  (using	  the	  
fast-­‐growing	   ErbB+	   tumour	   cell	   line	   SKOV3),	   treatment	   with	   T4+	   T-­‐cells	   led	   to	  
consistent,	   transient	  weight	   loss	   (see	  Figure	  4-­‐1).	   Furthermore,	   treatment	  of	  animals	  
with	   high	   SKOV3	   tumour	   burden	   resulted	   in	   lethal	   toxicity	   	   (see	   Figure	   4-­‐2).	   When	  
animals	   bearing	   HN3luc	   intra-­‐peritoneal	   tumours	   were	   treated	   with	   T4+	   T-­‐cells,	  
transient	  weight	  loss	  was	  also	  induced.	  However,	  this	  weight	  loss	  was	  also	  seen	  in	  non-­‐
tumour	   bearing	   animals.	   This	   finding	   suggests	   that	   human	   T4+	   T-­‐cells	   can	   engage	  
mouse	   ErbB	   receptors	   on	   non-­‐transformed	   cells	   within	   the	   peritoneal	   cavity	   (see	  
Figure	   4-­‐4).	   The	   administration	   of	   escalating	   doses	   of	   T-­‐cells	   in	   non-­‐tumour	   bearing	  
animals	   resulting	   in	   rapid	   weight	   loss,	   triggered	   within	   hours	   after	   T-­‐cell	  
administration.	  At	  the	  highest	  treatment	  dose	  (30	  x	  106	  T4+	  T-­‐cells),	  toxicity	  was	  lethal	  
(see	  Figure	  4-­‐5).	  Analysis	  of	  circulating	  cytokines	  revealed	  that	  the	  toxicity	  was	  due	  to	  
cytokine	   release	   syndrome.	   Within	   four	   hours	   after	   T-­‐cell	   administration,	   elevated	  
levels	  of	  human	   IL-­‐2,	  human	   IFNγ	  and	  mouse	   IL-­‐6	  were	  detected	  (see	  Figure	  4-­‐6	  and	  
Figure	  4-­‐7).	  The	  severity	  of	  the	  induced	  cytokine	  release	  syndrome,	  and	  the	  fact	  that	  it	  
is	  only	  induced	  after	  intra-­‐peritoneal	  T-­‐cell	  administration	  might	  be	  a	  reflection	  of	  the	  
magnitude	  of	  target	  recognition	  within	  tumour	  deposits	  and/or	  serosal	  cells	  within	  the	  
peritoneal	   cavity,	   followed	   by	   systemic	   cytokine	   absorption.	   Three	   elements	   would	  
support	  this	  hypothesis.	  First,	  CAR+	  T-­‐cells	   reside	  within	  the	  peritoneal	  cavity	  after	   IP	  
administration,	  without	  detectable	  re-­‐location	  to	  other	  anatomic	  sites	   (460).	  Second,	  
ErbB1	  is	  expressed	  by	  normal	  mesothelial	  cells,	  providing	  a	  potential	  source	  of	  T4+	  T-­‐
cell	   stimulation	   in	   the	   peritoneal	   cavity	   (593).	   Third,	   preliminary	   data	   suggests	   that	  
efficacy	   and	   toxicity	   increase	   when	   the	   T-­‐cell	   are	   administered	   in	   a	   larger	   injection	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volume.	   The	   resulting	   increase	   in	   IP	   pressure	   may	   increase	   the	   absorption	   of	   small	  
molecules,	   including	   cytokines,	   and	   exert	   pro-­‐inflammatory	   effects	   leading	   to	  
increased	  production	  of	   IL-­‐6	  and	  other	  cytokines	  (594).	  The	  influence	  of	  the	  injection	  
volume	  would	  also	  explain	  why	  no	  CRS-­‐related	  toxicity	  was	  seen	  in	  previous	  studies	  in	  
which	  mice	  were	  treated	  with	  high	  doses	  of	  T28ζ+/T4+	  T-­‐cells	  (299).	  
	   Phase	  I	  clinical	  trials	  in	  CAR-­‐mediated	  ACT	  have	  implicated	  IL-­‐6	  as	  an	  important	  
factor	   in	   the	   occurrence	   of	   toxicity.	   The	   severity	   of	   cytokine	   release	   syndrome	   was	  
reversed	  in	  patients	  by	  treatment	  with	  the	  anti-­‐IL-­‐6R	  antibody,	  Tocilizumab	  (317,	  321).	  
To	   determine	   whether	   IL-­‐6	   is	   a	   similarly	   important	   factor	   in	   the	   mouse	   model,	  
blockage	   of	  mouse	   IL-­‐6	   or	   IL-­‐6R	   is	   required.	   Tocilizumab	   does	   not	   cross	   the	   species	  
barrier.	  A	  murine	  equivalent	  is	  being	  sourced	  which	  would	  allow	  for	  the	  evaluation	  of	  
the	  effect	  of	  mIL-­‐6R	  blockage	  in	  this	  model.	  	  
	   It	  has	  been	  suggested	  that	  monocytes	  and	  macrophages	  also	  play	  a	  role	  in	  the	  
cascade	   resulting	   in	   cytokine	   release	   syndrome	   (575,	   577).	   SCID/Beige	  mice	   are	   not	  
completely	  immunodeficient,	  in	  that	  the	  mice	  still	  have	  functional	  macrophages	  (587).	  
Therefore	   it	   was	   hypothesized	   that	   the	   mIL-­‐6	   was	   produced	   by	   the	   mouse	  
macrophages	  present	   in	   the	   intra-­‐peritoneal	   cavity,	   leading	   to	   clinical	  manifestations	  
of	  CRS.	  Two	  results	   support	   this	  hypothesis.	  First,	  depletion	  of	  macrophages	  prior	   to	  
T4+	  T-­‐cell	   administration	  eliminated	   IL-­‐6	  production	  and	  weight	   loss	   (see	  Figure	  4-­‐10	  
and	  Figure	  4-­‐11).	  Second,	  intra-­‐peritoneal	  SKOV3	  tumours	  are	  associated	  with	  a	  heavy	  
influx	   of	  macrophages	   (see	   Figure	   4-­‐12).	   The	   higher	  macrophage	   content	   combined	  
with	   the	   high	   expression	   of	   ErbB	   receptors	   on	   the	   tumour	   tissue	   could	   have	  
contributed	  to	  the	  lethality	  of	  the	  toxicities	  seen	  at	  a	  T-­‐cell	  dose	  of	  10	  x	  106	  T4+	  cells,	  
whereas	   the	   same	  dose	  was	  not	   toxic	   in	  mice	  with	  an	  HN3luc	   tumour	  burden	  and	  a	  
three	   fold	  higher	  dose	  was	   required	   to	   induce	  similar	   toxicity	   in	  non-­‐tumour	  bearing	  
mice.	  	  
	   Human	  IFNγ	  levels	  were	  also	  elevated	  in	  a	  dose-­‐dependent	  manner	  after	  intra-­‐
peritoneal	   T4+	   T-­‐cell	   administration.	   In	   human,	   intravenous	   administration	   of	   IFNγ	   is	  
associated	  with	   toxicities	   including	   fatigue,	   fevers,	   chills,	  anorexia,	  occasional	  nausea	  
and	   vomiting,	   headaches,	   mild	   hypotension	   and	   granulocytopenia	   (595,	   596).	  
However,	  the	  influence	  of	  elevated	  IFNy	  levels	  to	  toxicity	  can	  not	  be	  evaluated	  in	  this	  
model	  because	  IFNγ	  is	  species-­‐specific	  with	  respect	  to	  receptor	  binding	  and	  biological	  
activity	  (597).	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The	   absence	   of	   cytokine	   release	   syndrome	   in	   response	   to	   PT/SC	   T-­‐cell	  
administration	  is	  encouraging	  for	  the	  safe	  application	  in	  patients	  with	  HNSCC	  through	  
intra-­‐tumoural	  T-­‐cell	  administration.	  However,	  due	  to	  the	  limitations	  of	  the	  pre-­‐clinical	  
mouse	   model,	   careful	   monitoring	   of	   circulating	   cytokine	   levels	   and	   clinical	   signs	   of	  
cytokine	  release	  syndrome	  is	  of	  great	  importance.	  
	   	  
	  
	  





CHAPTER	  5 	  
DEVELOPMENT	  OF	  A	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5.1 Introduction	  
The	   pre-­‐clinical	   toxicity	   studies	   discussed	   in	   the	   previous	   chapters	   suggest	   that	   T4	  
immunotherapy	   could	   have	   therapeutic	   potential	   in	   the	   treatment	   of	   HNSCC.	   To	  
determine	   the	   safety	   of	   T4	   immunotherapy	   in	   man,	   we	   aim	   to	   conduct	   a	   Phase-­‐I	  
clinical	   trial,	   treating	   patients	   with	   local	   recurrent	   HNSCC	   with	   intra-­‐tumoural	   T-­‐cell	  
administration	   (EudraCT	   Number:	   2012-­‐001654-­‐25;	   Clinicaltrials.gov	   Number:	  
NCT01818323;	  REC	  Number:	  12/LO/1843).	  	  
The	  primary	  aims	  of	  the	  study	  are:	  
1. Determine	  the	  dose	  limiting	  toxicities	  for	  T4	  immunotherapy	  in	  HNSCC.	  
2. Determine	  a	  safe	  and	  feasible	  recommended	  dose	  for	  Phase-­‐II	  testing.	  
Secondary	  objectives	  include:	  
1. Investigation	  of	  serum	  cytokine	  levels.	  
2. Persistence	  of	  T4+	  T-­‐cells.	  
3. Assessment	  of	  preliminary	  anti-­‐tumour	  activity.	  
4. Investigate	  the	  tumour	  ErbB	  phenotype	  before	  and	  after	  treatment.	  
5. Investigate	   the	   effect	   of	   T4	   immunotherapy	   upon	   immune	   reactivity	   against	  
endogenous	  tumour	  antigens.	  
6. Investigate	  the	  immunomodulatory	  effects	  of	  metronomic	  cyclophosphamide.	  
	  
The	  trial	  is	  designed	  in	  a	  3+3	  format.	  In	  this	  format,	  the	  maximum	  administered	  dose	  
occurs	   when	   two	   out	   of	   three	   (or	   two	   out	   of	   six	   with	   cohort	   expansion)	   patients	  
experience	  a	  dose-­‐limiting	   toxicity	   (DLT).	   If	   this	  occurs,	   the	  maximum	  tolerated	  dose	  
(MTD)	  will	  be	   identified	  as	  the	  dose	  of	   the	  cohort	  below	  the	  maximum	  administered	  
dose.	  When	  one	  DLT	  occurs	  in	  a	  cohort	  of	  three	  patients,	  the	  cohort	  is	  expanded	  with	  
at	  least	  three	  additional	  patients	  (598).	  
	   The	  starting	  dose	  will	  be	  1	  x	  107	  T4+	  T-­‐cells,	  which	  will	  be	  increased	  to	  1	  x	  109	  
T4+	  T-­‐cells	  over	  5	  dose	  escalating	  steps	  (see	  Table	  5-­‐1).	  If	  the	  MTD	  is	  not	  defined	  after	  
completion	   of	   the	   dose	   escalation,	   a	   final	   cohort	   will	   be	   treated	   with	   50mg	  
cyclophosphamide	  for	  14	  days	  prior	  to	  T4	  immunotherapy	  administration.	  
	   222	  
	  
Table	  5-­‐1	  Dose	  escalation	  protocol	  T4	  immunotherapy	  








	   -­‐1*	   3	  x	  106	   3	  x	  106	   1	  ±	  0.2	  
Starting	  dose	  level	   1	   1	  x	  107	  	   3	   x	   106	   –	   1	   x	  
107	  
1	  ±	  0.2	  
	   2	   3	  x	  107	  	   1.1	  –	  3	  x	  107	  	   1	  ±	  0.2	  
	   3	   1	  x	  108	  	   3.1	  –	  10	  x	  107	  	   1	  ±	  0.2	  
	   4	   3	  x	  108	  	   1.1	  –	  3	  x	  108	  	   1	  ±	  0.2	  
Final	  dose	  level	   5	   1	  x	  109	  ⌘	   3.1	  –	  10	  x	  108	  	   1	  ±	  0.2	  
Lymphodepletion	   6	   1	  x	  109	  ⌘	   3.1	  –	  10	  x	  108	  	   1	  ±	  0.2	  
§	  	  Indicated	  dose	  levels	  refer	  to	  the	  number	  of	  T4+	  T-­‐cells,	  not	  total	  cell	  number.	  
*	  a	  ‘-­‐1’	  dose	  level	  has	  been	  included	  in	  case	  dose	  de-­‐escalation	  is	  required	  from	  dose	  level	  1.	  
⌘ Maximum	  of	  1x109	   total	   cells,	  which	   is	   the	  greatest	  number	   that	   can	  be	  accommodated	  within	   the	  
injection	  volume.	  
	  Cyclophosphamide	  50mg	  PO	  once	  daily	  for	  14	  days	  prior	  to	  T4	  immunotherapy	  
	  
In	  order	  to	  be	  able	  to	  apply	  T4	  immunotherapy,	  a	  good	  manufacturing	  process	  (GMP)	  
compliant	  culture	  process	  had	  to	  be	  developed.	  The	  GMP	  manufacture	  of	  cell	  products	  
is	  not	  without	  technical	  challenges.	  Most	  commonly,	  a	   leukapheresis	  product	   is	  used	  
which	  is	  then	  processed	  in	  a	  highly	  time	  consuming	  and	  labour	  intensive	  open	  process,	  
within	   Grade	   A	   isolators	   (599-­‐602).	   Due	   to	   the	   requirement	   of	   highly	   specialised	  
equipment,	   manufacturing	   is	   limited	   to	   specialised	   facilities,	   is	   costly,	   at	   risk	   of	  
contamination	  due	   to	   the	  open	  processing,	   and	  not	   readily	   amendable	   to	   upscaling.	  
Additionally,	  gene	  transfer	  efficiency	  is	  variable	  and	  when	  below	  specification,	  this	  can	  
lead	   to	   difficulty	   in	   the	   release	  of	   poorly	   transduced	   cell	   products	   (320).	  With	   these	  
challenges	   in	   mind,	   I	   aimed	   to	   design	   a	   robust	   production	   protocol	   for	   T4	  
immunotherapy	  under	  GMP.	  
	   The	   described	   process	   has	   been	   developed	   in	   collaboration	   with	   Dr	  MC	   van	  
Schalkwyk	   and	  Mrs	   L	   Bosshard-­‐Carter.	   The	  majority	   of	   the	   equipment	   and	  materials	  
used	   are	   readily	   available	   for	   GMP	   production,	   allowing	   for	   easy	   translation	   of	   the	  
process	   to	   other	   cell	   manufacturing	   protocols.	   Here,	   an	   outline	   of	   the	   process	   is	  
described,	  as	  it	  will	  be	  performed	  within	  the	  Clinical	  Research	  Facility	  (CRF)	  GMP	  Unit,	  
15th	   Floor,	   Tower	  Wing,	   Guy’s	   Hospital	   in	   accordance	   with	   the	  MIA(IMP)	   provisions	  
granted	  to	  the	  facility	  (licence	  number	  11387).	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5.2 List	  of	  Materials	  
	  
An	  overview	  of	  the	  most	  important	  materials	  required	  is	  given	  in	  Table	  5-­‐2.	  	  
	  
Table	  5-­‐2	  Table	  of	  Materials	  required	  for	  process	  
Product	  Name	   Company	  
Culture	  Bags	   	  
VueLife	  197-­‐AC	  culture	  bag	   CellGenix	  GmbH	  
VueLife	  118-­‐C	  culture	  bag	   CellGenix	  GmbH	  
MACS	  GMP	  Cell	  Differentiation	  Bag	  3000mL	   Miltenyi	  Biotech	  
MACS	  Cell	  Expansion	  Bag	  100mL	   Miltenyi	  Biotech	  
	   	  
Pouches	   	  
AK100	  sample	  pouch	  5mL	   Biosafe	  
	   	  
Media	  and	  Serum	   	  
X-­‐VIVO15	  media	   Lonza	  
Human	  AB	  Serum	   Seralab	  
Stable	  L-­‐Glutamine	   PAA	  
	   	  
Cytokines	   	  
GMP-­‐grade	  IL-­‐4	   Gentaur	  
IL-­‐2:	  Aldesleukin	  (proleukin)	   Novartis	  
	   	  
Other	   	  
N-­‐Labstix	   Siemens	  
CD3/CD28	  CTS	  Dynabeads	   Invitrogen	  
RetroNectin	  2.5mg	  GMP-­‐grade	   Takara	  
GMP	  Grade	  SFG-­‐T4	  virus	   Eufets	  
Luer	  Syringes	   BD	  Plastipak	  
Sepax	  Manifold	  CS900.2	   Biosafe	  
Sepax	  Manifold	  CS600.1	   Biosafe	  
BacT/ALERT	  Microbial	  detection	  system	   bioMérieux	  
Saline	  0.9%	  w/v	  500mL	   Baxter	  
Trucount	  tubes	   BD	  Biosciences	  
	   	  
Equipment	   	  
Grade	  A	  Isolator	   Amercare	  
TSCD	  II	  sterile	  tubing	  welder	   Terumo	  
T-­‐SEAL	  II	  sterile	  sealing	  device	   Terumo	  
Sepax	  2	  closed	  automated	  cell	  separation	  platform	   Biosafe	  
Dynal	  MPC-­‐1	   Invitrogen	  
Dynal	  ClinExVivo	  MPC	  magnet	   Invitrogen	  
Plasmatherm	   Genesis	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5.3 GMP-­‐Compliant	  Production	  Process	  
The	   cell	   production	   is	   a	   15-­‐day	   process	   from	  phlebotomy	   to	   T-­‐cell	   administration	   to	  
the	   patient.	   The	   protocol	   can	   be	   divided	   into	   five	  major	   elements	   (see	   Figure	   5-­‐1);	  
PBMC	  isolation	  and	  activation	  (day	  1),	  transduction	  (day	  4),	  expansion	  (day	  5-­‐13),	  de-­‐
beading	   (day	   14)	   and	   preparation	   of	   final	   cell	   product	   (day	   15).	   The	   process	   during	  
these	  five	  elements	  is	  described	  below.	  	  
	  
Figure	  5-­‐1	  Schematic	  overview	  of	  GMP	  T-­‐cell	  Transduction	  and	  Expansion	  protocol	  
A:	  PBMCs	  are	  isolated	  from	  whole	  blood	  using	  the	  Sepax	  closed	  automated	  cell	  separation	  platform	  and	  
activated	  using	  CD3/CD28	  CTS	  paramagnetic	  beads	  on	  day	  1.	  B:	  Activated	  T-­‐cells	  are	  transduced	  on	  day	  
4.	  C:	  Transduced	  cells	  are	  expanded	  using	  Interleukin-­‐4	  (day	  5-­‐13).	  D:	  Cell-­‐culture	  is	  de-­‐beaded	  on	  day	  
14.	  F:	  The	  final	  cell	  product	  is	  formulated	  and	  administered	  to	  the	  patient	  on	  day	  15.	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5.3.1 Day	  1	  –	  PBMC	  Isolation	  and	  T-­‐cell	  Activation	  
The	   first	  day	  of	   the	  process	  consists	  of	   two	  elements,	   the	   isolation	  and	  activation	  of	  
the	  patient’s	  T-­‐cells,	  and	  the	  preparation	  of	  the	  RetroNectin	  (RN)-­‐coated	  transduction	  
bag	  (see	  Figure	  5-­‐1	  B).	  	  
Peripheral	  blood	  mononuclear	  cells	  are	  isolated	  with	  the	  ‘NeatCell’	  protocol	  on	  
a	   Sepax	   2	   closed	   automated	   cell	   separation	   platform	   using	   the	   CS900.2	   single-­‐use	  
manifold.	   Using	   the	   ‘small	   final	   volume’-­‐option,	   PBMCs	   are	   re-­‐suspended	   in	   10mL	  
complete	  media	  and	  the	  final	  product	  is	  presented	  in	  a	  20mL	  syringe	  that	  is	  connected	  
to	  the	  single-­‐use	  manifold.	  The	  PBMCs	  are	  transferred	  to	  a	  MACS	  GMP	  cell	  expansion	  
bag,	  through	  sterile	  welding	  and	  sealing.	  A	  sample	  of	  approximately	  0.5mL	  is	  retained	  
in	   the	   syringe	   to	   allow	   for	   cell	   enumeration.	   The	   cell	   number	   is	   determined	   using	   a	  
Scepter	  automated	  cell	  counter.	  Cells	  are	  re-­‐suspened	  to	  a	   final	  concentration	  of	  3	  x	  
106	  cells/ml.	  	  
	   Paramagnetic	  CD3/CD28	  CTS	  ClinExVivo	  T-­‐cells	  activation	  beads	  are	  used	  for	  T-­‐
cell	  activation.	  The	  required	  amount	  of	  beads	  is	  calculated	  based	  on	  a	  ratio	  of	  3	  beads	  
per	  cell.	  Within	  the	  isolator,	  beads	  are	  washed	  3x	  using	  the	  complete	  media	  on	  a	  Dynal	  
magnetic	  particle	  concentrator	  (MPC)-­‐1.	  Beads	  are	  re-­‐suspended	  at	  a	  concentration	  of	  
400	  x	  106	  beads/mL	  and	  the	  required	  amount	  (rounded	  to	  the	  nearest	  100μL)	  is	  added	  
to	  the	  MACS	  GMP	  cell	  expansion	  bag	  through	  injection	  through	  the	  needle	  port.	  At	  this	  
point	   samples	   are	   taken	   again	   to	   allow	   for	   sterility	   testing.	   The	   MACS	   GMP	   cell	  
expansion	   bag	   containing	   the	   cells	   and	   beads	   is	   incubated	   at	   37°C,	   5%	   CO2	   and	  
saturated	  humidity	  for	  until	  further	  use	  (on	  day	  3).	  
	  
Preparation	  of	  the	  RetroNectin-­‐coated	  197-­‐AC	  VueLife	  bag	  
A	  197-­‐AC	  VueLife	  bag	   is	  coated	  with	  RetroNectin	   (RN)	  within	   the	   isolator.	  The	  bag	   is	  
coated	   with	   2.5mg	   RN,	   which	   is	   a	   ratio	   of	   approximately	   5μg/cm2.	   To	   achieve	   this,	  
2.5mg	  of	  lyophilized	  RN	  is	  dissolved	  in	  a	  total	  volume	  of	  150mL	  saline	  (0.9%	  w/v).	  The	  
first	   100mL	   saline	   is	   directly	   injected	   into	   the	   VueLife	   bag,	   using	   Luer	   syringes	   and	  
needles.	  The	  final	  50mL	  saline	  is	  drawn	  up	  in	  a	  syringe,	  after	  which	  a	  needle	  is	  added	  
and	  approximately	  2mL	  of	  the	  saline	  is	  added	  to	  the	  lyophilized	  RN.	  After	  ensuring	  the	  
RN	   is	   completely	   dissolved,	   it	   is	   drawn	   back	   up	   into	   the	   syringe	   and	   the	   50mL	   RN-­‐
containing	  saline	   is	  added	  to	   the	  VueLife	  bag.	  The	  bag	   is	  massaged	   to	   facilitate	  even	  
distribution	  of	  the	  RN	  and	  stored	  at	  4°C	  until	  transduction	  at	  day	  4	  of	  the	  process.	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5.3.2 Day	  3	  –	  Preparation	  of	  T-­‐cell	  Transduction	  
On	  the	  day	  prior	  to	  T-­‐cell	  transduction,	  100U/mL	  IL-­‐2	  is	  added	  to	  the	  T-­‐cell	  culture	  (see	  
Figure	  5-­‐1	  B).	   The	  amount	  of	   IL-­‐2	   required	   is	  based	  on	   the	   total	   culture	   volume	  and	  
rounded	  off	  to	  the	  nearest	  1000U.	  	  
	  
5.3.3 Day	  4	  –	  Transduction	  of	  T-­‐cells	  
On	  day	  4,	  activated	  T-­‐cells	  are	  transduced	  with	  clinical	  grade	  SFG-­‐T4	  viral	  vector	  (see	  
Figure	  5-­‐1	  C).	  The	  vector	  has	  been	  produced	  under	  GMP	  conditions	  by	  EUFETS	  GmbH,	  
and	   is	  at	  a	   viral	   titre	  of	  2.77	  x	  106	   infectious	  units	   (IU)/mL.	  The	  virus	   is	  presented	   in	  
serum-­‐free,	   phenol	   red-­‐free	   X-­‐VIVO10	  media,	   and	   stored	   in	   60mL	   aliquots	   in	   150mL	  
Flexboy	   bags	   at	   -­‐80°C	   until	   the	   day	   of	   use.	   The	   viral	   vector	   is	   thawed	   using	   the	  
Plasmatherm	  and	  the	  complete	  content	  is	  transferred	  into	  the	  RN-­‐coated	  VueLife	  bag.	  
Cell	  density	  in	  the	  MACS	  GMP	  cell	  expansion	  bag	  is	  determined	  and	  a	  maximum	  total	  
of	  40	  x	  106	  cells	  are	  added	  to	  the	  VueLife	  bag.	  The	  197-­‐AC	  VueLife	  bag	  is	  incubated	  at	  
37°C,	  5%CO2	  and	  saturated	  humidity.	  The	  bag	  is	  turned	  twice	  at	  15	  minute-­‐intervals	  to	  
stimulate	   cell	   and	   virion	   engagement	   at	   both	   sides	   of	   the	   bag.	   There	   is	   no	  
centrifugation	  step	  required	  at	  this	  stage.	  
	  
5.3.4 Day	  5-­‐13	  Expansion	  of	  Transduced	  T-­‐cells	  
The	   required	  amount	  of	  media	  and	  cytokine	   required	  during	   the	  expansion	  period	   is	  
determined	  based	  on	  cell	  density	  and	  the	  pH	  of	  the	  media.	  Both	  are	  determined	  on	  a	  
daily	  basis.	  At	   regular	   fixed	   intervals,	   IL-­‐4	   is	   added	   irrespective	  of	   cell	   density	  or	  pH.	  
When	  the	  culture	  volume	  exceeds	  500mL	  total	  volume,	  the	  cell	  culture	  is	  transferred	  
to	  a	  3000mL	  MACS	  GMP	  cell	  differentiation	  bag	  through	  sterile	  welding,	  gravitational	  
flow	  and	   sterile	   sealing.	  On	  day	  8,	   additional	   samples	   are	   taken	   to	   allow	   for	   interim	  
sterility	  and	  transduction	  rate	  assessment.	  
	  
5.3.5 Day	  14	  –	  De-­‐Beading	  of	  Cell	  Culture	  
On	  the	  day	  prior	  to	  T-­‐cell	  administration	  to	  the	  patient,	   the	  cell-­‐culture	   is	  de-­‐beaded	  
using	  a	  Dynal	  ClinExvivo	  MPC	  magnet	  (see	  Figure	  5-­‐1	  E).	  Prior	  to	  de-­‐beading,	  pH	  and	  
cell	  density	  is	  determined	  and,	  if	  required,	  media	  and	  cytokines	  are	  added.	  To	  ensure	  
maximal	   bead	   removal,	   the	   cell	   culture	   is	   passed	   over	   the	   primary	   and	   secondary	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magnet	   twice,	   through	  a	   series	  of	   connected	   transfer	  bags	  by	  gravitational	   flow	   (see	  
Figure	  5-­‐2).	  
	   Prior	  to	  de-­‐beading,	  a	  sample	  is	  taken	  using	  an	  AK100	  sample	  pouch	  to	  function	  
as	  a	  positive	  control	  in	  the	  enumeration	  of	  residual	  Dynabeads	  (described	  in	  paragraph	  
5.4).	  The	  cell	  culture	  bag	  is	  welded	  onto	  one	  of	  two	  tubing	  lines	  of	  a	  1000mL	  transfer	  
bag.	  The	  second	  line	  of	  the	  transfer	  bag	  is	  welded	  onto	  one	  of	  two	  lines	  of	  a	  2000mL	  
transfer	   bag	   (the	   ‘collection’-­‐bag).	   The	   second	   line	   of	   the	   collection-­‐bag	   is	   sealed-­‐
closed.	   The	   cell	   culture	   bag	   is	   hung	  onto	   the	   bag	   stand	  of	   the	  magnet.	   The	   1000mL	  
transfer	   bag	   is	   placed	   on	   the	   primary	   magnet	   bed.	   The	   tubing	   connecting	   the	   two	  
transfer	  bags	   is	  coiled	  around	  the	  secondary	  magnet.	  Approximately	  a	  quarter	  of	  the	  
cell	   culture	   volume	   is	   passed	   into	   the	   transfer	   bag	   and	   allowed	   to	   set	   for	   three	  
minutes.	  Clamps	  are	  placed	  on	  the	   tubes	  connecting	   the	  bags	   to	  prevent	  continuous	  
flow.	  After	  three	  minutes	  the	  culture	  is	  allowed	  to	  flow	  into	  the	  collection-­‐bag,	  passing	  
the	   secondary	   magnet	   in	   the	   process.	   The	   process	   is	   repeated	   three	   more	   times,	  
allowing	   the	   complete	   culture	   to	   be	   passed	  over	   the	  magnets.	   The	   entire	   process	   is	  
repeated	   a	   second	   time.	   For	   this,	   the	   ‘collection-­‐bag’	   is	  welded	  onto	   a	   new	  1000mL	  
transfer	  bag.	  The	  second	  line	  of	  the	  transfer	  bag	  is	  connected	  to	  a	  3000mL	  MACS	  GMP	  
cell	  differentiation	  bag.	  Finally,	  a	  200mL	  aliquot	  of	  complete	  media	  is	  welded	  onto	  the	  
transfer	  bag	  and	  placed	  on	  the	  bag	  stand.	  The	  media	  is	  allowed	  to	  flow	  through	  with	  
the	  aim	  to	  remove	  any	  remaining	  T-­‐cells	  that	  may	  be	  loosely	  attached	  to	  the	  retained	  
beads.	   The	   cell	   culture	   bag	   incubated	   at	   37°C,	   5%CO2	   and	   saturated	   humidity	   until	  
further	  use.	  
	  
	   228	  
	  
Figure	  5-­‐2	  Overview	  of	  Dynal	  ClinExVivo	  MPC	  magnet	  	  
Cell	  culture	  is	  de-­‐beaded	  using	  the	  Dynal	  ClinExVivo	  MPC	  magnet	  (603).	  The	  cell	  culture	  bag	  is	  placed	  on	  
the	  bag	  stand,	  one	  third	  of	  the	  culture	  volume	  is	  transferred	  into	  the	  transfer	  bag	  placed	  on	  the	  primary	  
magnet	  bed,	  remaining	  there	  for	  three	  minutes.	  The	  cell	  culture	  is	  then	  passed	  on	  into	  the	  ‘collection’	  
bag,	  passing	  the	  secondary	  magnet	  in	  the	  process.	  	  
	  
5.3.6 Day	  15	  –	  Preparation	  of	  the	  Final	  Cell	  Product	  
At	   the	   final	   day	   of	   the	   process,	   the	   cell	   culture	   is	   concentrated	   to	   the	   required	  
concentration,	   and	   all	   release	   criteria	   are	   verified	   (see	   Figure	   5-­‐1	   E).	   Samples	   for	  
release	  criteria	  testing	  are	  removed	  using	  AK-­‐100	  sample	  pouches.	  The	  release	  assays	  
are	   performed	   and	   reviewed	   by	   the	   Qualified	   Person	   within	   two	   and	   a	   half	   hours.	  
When	   release	  of	   the	  product	   is	   approved,	   the	   final	   formulation	   is	   transferred	   to	   the	  
administering	   physician.	   The	   cell	   product	   is	   then	   immediately	   administered	  by	   intra-­‐
tumoural	  injection.	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5.4 Release	  Criteria	  Assessment	  
To	  allow	  for	  release	  of	  the	  product,	  the	  end	  of	  production	  quality	  control	  assays	  have	  
to	  be	  performed	  on	  the	  day	  of	  release	  (day	  15).	  	  
	  
Table	  5-­‐3	  Overview	  of	  Quality	  Control	  Assays	  
Release	  Criteria	   Timepoint	   Method	  
≥	  70%	  cell	  viability	   Day	  15	   DAPI	  staining	  and	  flow	  cytometry	  
≥	  107	  T4+	  cells	   Day	  15	   Flow	  cytometry	  
≥	  2	  fold-­‐increase	  in	  cell	  
number	  
Day	  15	   Cell	  count,	  compared	  to	  number	  
transduced	  cells	  on	  day	  3	  
Cell	  surface	  phenotype	  
≥10%	  T28ζ+	  
Day	  15	   Flow	  cytometry	  
Bacterial,	  fungal	  and	  
mycoplasma	  sterility	  
Day	  1,	  8	  and	  15	   BacT/ALERT,	  fungal	  and	  mycoplasma	  
testing.	  
Residual	  beads	  	  
<	  333,000	  per	  mL	  
Day	  15	   Flow	  cytometry	  
	  
Bacterial,	   fungal	   and	   mycoplasma	   sterility	   testing	   of	   the	   final	   product	   are	  
performed	   according	   to	   the	   European	   Pharmacopeia	   by	   Wickenham	   Laboratories	  
(Gosport,	   UK)	   and	   Mycoplasma	   Experience	   (Reigate,	   UK).	   Due	   to	   the	   duration	   of	  
sterility	  testing	  (6	  –	  28	  days),	  interim	  samples	  (taken	  at	  day	  1	  and	  day	  8)	  are	  required	  
to	  be	  negative	  at	  the	  day	  of	  release.	  Results	  of	  sterility	  testing	  on	  the	  final	  product	  will	  
be	  used	  retrospectively.	  
All	  flow	  cytometry	  assays	  are	  performed	  by	  the	  staff	  of	  the	  Immune	  Monitoring	  
Laboratory,	  NIHR	  Biomedical	  Research	  Centre	  at	  Guy’s	  and	  St	  Thomas’	  NHS	  Foundation	  
Trust	  and	  King’s	  College	  London.	  Cell	   viability	   is	  determined	  using	  DAPI	   staining,	  and	  
absolute	  number	  of	  viable	  cells	  is	  determined	  using	  Trucount	  beads.	  The	  proportion	  of	  
T4+	   T-­‐cells	   is	   determined	   by	   staining	   for	   T28ζ	   (using	   biotinylated	   anti-­‐human	   EGF	  
followed	  by	  PE-­‐conjugated	  streptavidin).	  All	  flow	  cytometry	  assays	  were	  validated	  for	  
accuracy	  and	  inter-­‐observer	  variability	  (data	  not	  shown).	  
	  
Traditionally,	  enumeration	  of	   residual	  CD3/CD28	  CTS	  Dynabeads	   is	  determined	  using	  
haemocytometer-­‐based	   manual	   counting	   (604,	   605).	   However,	   this	   approach	   is	  
subjective	   and	  has	   a	  high	   inter-­‐observer	   variability.	   For	  more	   reliable	   and	   consistent	  
results,	   Dr	   van	   Schalkwyk	   developed	   a	   novel	   flow	   cytometric	   assay,	   based	   on	   the	  
autofluorescence	   of	   the	   Dynabeads	   (see	   Figure	   5-­‐3	   A).	   In	   short,	   samples	   are	   taken	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before	  (day	  14)	  and	  after	  (day	  15)	  de-­‐beading	  of	  the	  cell	  culture.	  Cells	  are	  lysed	  using	  
10%	   Triton	   X-­‐100.	   An	   aliquot	   of	   each	   sample	   is	   transferred	   to	   a	   Trucount	   tube	   and	  
analysed	   following	   the	  gating	  strategy	  shown	   in	  Figure	  5-­‐3.	  The	  auto-­‐fluorescence	  of	  
the	  Dynabeads	  is	  detected	  in	  the	  PerCP-­‐Cy5.5	  and	  APC	  channels	  using	  a	  BD	  FACSCanto	  
II	  flow	  cytometer.	  Parameters	  are	  set	  to	  count	  1000	  events	  within	  the	  ‘Trucount	  gate’	  
The	  sample	  obtained	  prior	  to	  de-­‐beading	  is	  used	  as	  a	  positive	  control	  and	  to	  create	  the	  
‘Dynabead	  gate’.	  Both	  before	  and	  after	  samples	  are	  analysed	  in	  the	  same	  manner	  (see	  
Figure	  5-­‐3	  B).	  The	  number	  of	  residual	  beads	  is	  calculated	  using	  the	  following	  formula:	  
	  
no	  of	  beads	  in	  ‘Dynabead	  gate’	   no	  of	  Trucount	  beads	  per	  test	  
_________________________	  	  	  	  X	   _________________________	   	   	   	   	   	   	   	   =	   	   absolute	   bead	  
count	  
no	  of	  beads	  in	  ‘Trucount	  gate’	   test	  volume	  
	  
The	   assay	   was	   validated	   using	   several	   known	   concentrations	   of	   Dynabeads	  
(ranging	  from	  500,000	  –	  800	  beads/mL)	  based	  on	  dilutions	  of	  original	  manufacturer’s	  
stock.	  The	  assay	  was	  verified	  using	  multiple	  sample	  sets,	  performed	  by	  two	  individual	  
operators.	  Bead	  enumeration	  using	  this	  method	  proved	  to	  be	  accurate	  and	  consistent	  
over	  the	  full	  range	  of	  concentrations	  tested	  (data	  not	  shown).	  
	   231	  
	  
Figure	  5-­‐3	  	  Enumeration	  of	  residual	  CD3/CD28	  CTS	  Dynabeads	  
A:	   Dynabeads	   fall	   within	   a	   discrete	   gate	   (blue)	   in	   the	   forward	   (FSC-­‐A)	   v	   side	   scatter	   (SSC-­‐A)	   plot	   (1).	  
Dynabeads	  are	  autofluorescent,	  meaning	  that	  a	  threshold	  can	  be	  set	  in	  any	  one	  of	  several	  fluorescence	  
channels	   to	   eliminate	   non-­‐fluorescent	   debris	   (2).	   When	   Dynabead-­‐containing	   T-­‐cell	   cultures	   are	  
analysed,	   there	   is	  overlap	  between	  beads	   (blue)	  and	  dead	  cells	   (grey	  and	  dark	  green)	   (3).	   In	   this	  plot,	  
viable	  T-­‐cells	  are	  seen	  in	  the	  gate	  on	  the	  right	  (light	  green).	  Following	  lysis	  of	  T-­‐cells	  with	  Triton	  X-­‐100	  
and	  setting	  of	  a	  FSC	  threshold,	  unacceptable	  overlap	  still	  occurs	  between	  Dynabeads	  and	  cell	  debris	  (4).	  
However,	  by	  setting	  a	  threshold	  based	  on	  fluorescence,	  Dynabeads	  can	  be	  clearly	  visualised	  as	  a	  discrete	  
and	  separate	  population	  (5).	  B:	  Enumeration	  of	  Dynabeads	  in	  samples	  before	  and	  after	  de-­‐beading	  using	  
Trucount	   tubes.	   Owing	   to	   their	   autofluorescence,	   Dynabeads	   fall	   into	   a	   discrete	   gate	   compared	   to	  
Trucount	  beads	  and	  lysed	  cell	  debris.	  Data	  are	  normalised	  to	  the	  number	  of	  Trucount	  beads	  counted	  in	  a	  
separate	  gate,	  allowing	  the	  generation	  of	  an	  absolute	  count.	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5.5 Transduction	  of	  Patient	  Samples	  
The	   closed	   production	   process	   was	   developed	   to	   achieve	   reproducible	   transduction	  
and	   expansion	   of	   T-­‐cells	   for	   clinical	   application.	   All	   pre-­‐clinical	   work	   had	   been	  
performed	   using	   PBMCs	   derived	   from	   healthy	   donor	   blood.	   In	   order	   to	   determine	  
whether	   successful	   transduction	   and	   expansion	   could	   also	   be	   achieved	   using	   (often	  
immunodeprived)	   patient	   blood,	   samples	   were	   obtained	   from	   HNSCC	   patients.	   The	  
recruitment	   of	   patient	   donors	   was	   approved	   by	   the	   Guy’s	   Hospital	   Research	   Ethics	  
Committee	   (09/H0707/086;	   Generation	   of	   clinical	   grade	   T-­‐cells	   for	   adoptive	   cell	  
therapy).	  A	  total	  of	  seven	  patient	  samples	  were	  successfully	  transduced	  and	  expanded.	  
Due	  to	  the	  limited	  availability	  of	  the	  clinical-­‐grade	  virus	  produced	  by	  EUFETS,	  samples	  
were	   transduced	   with	   non-­‐clinical	   grade	   virus,	   which	   was	   produced,	   aliquotted	   and	  
stored	  in	  a	  similar	  manner.	  One	  patient	  sample	  (patient	  05)	  failed,	  in	  which	  no	  viable	  T-­‐
cells	   remained	   after	   transduction.	   Successful	   expansion	   (Figure	   5-­‐4)	   and	   enrichment	  
(Figure	  5-­‐5)	  of	  six	  patients	  samples	  was	  achieved.	  All	  samples	  passed	  the	  tested	  release	  
assay	  criteria.	  All	  samples	  showed	  at	  least	  a	  2	  fold-­‐increase	  in	  total	  cell	  number	  on	  day	  
15	  compared	  to	  day	  4	  (see	  Figure	  5-­‐4).	  Also,	  in	  all	  cases	  the	  minimum	  of	  10%	  T4+	  cells	  
was	  achieved	  (ranging	  between	  16.4%,	  patient	  02	  and	  94.5%,	  patient	  01)	   (see	  Figure	  
5-­‐5).	  In	  all	  six	  patient	  samples,	  the	  minimum	  dose	  of	  1	  x	  107	  T4+	  T-­‐cells	  was	  achieved	  at	  
the	  end	  of	  the	  15-­‐day	  culture	  period	  (see	  Table	  5-­‐4).	  No	  contamination	  was	  detected	  
in	  any	  of	  the	  samples	  (data	  not	  shown).	  
	  
Figure	  5-­‐4	  Expansion	  total	  cell	  count	  patient	  samples	  using	  closed	  GMP	  process	  
Expansion	  of	  total	  amount	  of	  cells	  from	  day	  4	  (amount	  of	  cells	  transduced)	  to	  the	  final	  day	  of	  production	  
(day	  15).	  NOTE:	  Amount	  of	  transduced	  cells	  was	  20	  x	  106	  in	  patients	  01	  and	  02.	  For	  all	  other	  patients,	  40	  
x	  106	  T-­‐cells	  were	  transduced.	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Figure	  5-­‐5	  Enrichment	  of	  T4+	  cells	  in	  patient	  samples	  using	  closed	  GMP	  process	  
Amount	   of	   T4+	   T-­‐cells	   is	   determined	   on	   day	   8	   (4	   days	   after	   T-­‐cell	   transduction)	   and	   day	   15	   (day	   of	  
product	  release)	  using	  flow	  cytometry.	  
	  
Table	  5-­‐4	  Expansion	  of	  total	  T4+	  T-­‐cells	  
	   01	   02	   03	   04	   06	   07	  
Day	  8	   1.00	  x	  106	   1.44	  x	  106	   3.50	  x	  106	   1.70	  x	  106	   8.8	  x	  106	   1.54	  x	  107	  
Day	  15	   4.91	  x	  107	   1.97	  x	  107	   1.03	  x	  108	   5.58	  x	  108	   1.83	  x	  108	   2.98	  x	  109	  
Total	   T4+	   T-­‐cells	   are	   calculated	   based	   on	   total	   cell	   count	   multiplied	   by	   the	   transduction	   rate	   as	  
determined	  by	  flow	  cytometry	  
	  
To	  determine	  the	  functionality	  of	  T4+	  T-­‐cells	  from	  patient	  samples,	  1	  x	  106	  total	  
cells	  were	  co-­‐cultivated	  with	  confluent	  monolayers	  (24	  wells)	  HN3	  tumour	  cells.	  Figure	  
5-­‐6	   presents	   representative	   crystal	   violet	   monolayer	   destruction	   assays	   performed	  
using	  T-­‐cells	  from	  the	  highest	  (patient	  01)	  and	  lowest	  (patient	  02)	  transduced	  samples.	  
Monolayer	   destruction	   was	   visualised	   after	   24	   hours	   of	   co-­‐cultivation.	   Within	   this	  
period,	   complete	   monolayer	   destruction	   was	   achieved	   by	   the	   T-­‐cells	   derived	   from	  
patient	  01,	  and	  partial	  monolayer	  destruction	  was	  achieved	  by	  the	  T-­‐cells	  derived	  from	  
patient	  02.	  The	  difference	   in	  magnitude	  of	  monolayer	  destruction	  can	  most	   likely	  be	  
attributed	   to	   the	   difference	   in	   absolute	   T4+	   T-­‐cell	   content.	   Additional	   to	  monolayer	  
destruction,	  cytokine	  production	  (IL-­‐2	  and	  IFNy)	  after	  24	  hours	  of	  co-­‐cultivation	  were	  
measured	   (see	   Figure	   5-­‐7)	   in	   five	   of	   the	   six	   successfully	   transduced	   samples.	   A	  
significantly	   higher	   cytokine	   production,	   for	   both	   IL-­‐2	   and	   IFNy	  was	  measured	  when	  
T4+	  T-­‐cells	  were	  exposed	  to	  ErbB+	  HN3	  tumour	  cells,	  compared	  to	  T-­‐cells	  which	  were	  
not	  exposed	  to	  any	  target.	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Figure	  5-­‐6	  Monolayer	  destruction	  after	  24	  hour	  co-­‐cultivation	  using	  crystal	  violet	  
T4	   transduced	   or	   untransduced	   (UT)	   patient	   T-­‐cells	   (1	   x	   106)	   were	   co-­‐cultivated	   with	   confluent	   HN3	  





Figure	   5-­‐7	   Cytokine	   production	   co-­‐cultivation	   patient	   samples	   with	   tumour	  
monolayers	  
IL-­‐2	  (A)	  and	  IFNγ	  (B)	  production	  in	  supernatants	  of	  co-­‐cultivation	  of	  1	  x	  106	  T4-­‐transduced	  T-­‐cells	  with	  a	  
confluent	   (24	   well)	   HN3	  monolayer	   or	   T4	   transduced	   T-­‐cells	   alone.	   Cytokine	   production	   is	  measured	  
after	  24	  hours	  by	  ELISA.	  N=3	  per	  patient	  sample,	  bar	  represents	  overall	  average	  of	  all	  samples.	  *	  =	  p	  <	  
0.05	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5.6 Discussion	  
The	   production	   of	   cell	   therapy	   products	   under	   GMP	   is	   not	   without	   challenges.	  
Challenges	   arise	  both	   from	   the	  quality	   of	   patient’s	   PBMCs	   as	  well	   as	   the	  production	  
process.	  Adoptive	  cell	  therapy	  products	  have	  been	  produced	  successfully	  from	  HNSCC	  
patient	   PBMCs.	   Lymphokine-­‐activated	   killer	   cells,	   IL-­‐2	   activated	   TILs,	   and	   tumour	  
specific	   cytotoxic	   T-­‐cells	   have	   been	   successfully	   cultured	   and	   expanded	   (264,	   268).	  
However,	   it	  has	  also	  been	  reported	  that	  PBMCs	   from	  HNSCC	  patients	  have	  been	  can	  
undergo	  spontaneous	  apoptosis	  upon	  in	  vitro	  culture	  for	  as	  little	  as	  12-­‐24	  hours	  (226).	  
We	   aimed	   to	   develop	   a	   robust	   GMP-­‐compliant	   cell	   manufacturing	   process	   for	   the	  
production	  of	  T4	   immunotherapy.	  Six	  out	  of	  seven	  patient	  samples	  were	  successfully	  
transduced	  and	  expanded.	  All	   resulting	  products	  were	  of	  the	  required	  quality	   for	  the	  
application	  in	  a	  clinical	  trial	  and	  were	  functional	  in	  vitro.	  The	  successful	  transduction	  of	  
six	   patient	   samples	   confirms	   the	   applicability	   of	   the	   developed	   GMP-­‐compliant	  
manufacturing	  process.	  Additionally,	   it	  shows	  that	  the	  transduction	  and	  expansion	  of	  
HNSCC	  PBMCs	  for	  clinical	  application	  is	  feasible.	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The	   main	   aim	   of	   this	   PhD	   was	   to	   determine	   the	   potential	   toxicity	   of	   T4	  
immunotherapy,	  through	  the	  use	  of	   in	  vitro	  and	   in	  vivo	  pre-­‐clinical	  models.	   I	  also	  set	  
out	   to	   compare	   potential	   toxicity	   that	   could	   be	   induced	  by	   intra-­‐tumoural	   T4+	   T-­‐cell	  
administration,	  making	  comparison	  with	  other	  routes	  of	  delivery.	  
	  
The	  5-­‐year	  survival	  rate	  for	  HNSCC	  has	  remained	  stable	  at	  approximately	  60%	  over	  the	  
past	   5	   decades	   (3-­‐5).	   Treatment	   options	   for	   patients	   who	   present	   with	   locally	  
advanced	  disease	  at	  diagnosis	  (which	  comprises	  about	  two-­‐thirds	  of	  patients)	  is	  limited	  
and	   at	   least	   50%	   of	   patients	   relapse	   after	   initial	   treatment	   (5,	   34).	   Adoptive	   cell	  
therapy	   could	   be	   an	   attractive	   additional	   treatment	   option	   for	   these	   patients.	   Head	  
and	   neck	   tumours	   are	   generally	   significantly	   infiltrated	   by	   immune	   cells	   (221,	   222).	  
However,	  the	  functionality	  of	  tumour	  infiltrating	  lymphocytes	  is	  often	  impaired	  due	  to	  
low	  or	  absent	   ζ-­‐chain	  expression,	  decreased	  proliferation	  and	   lack	  of	   IL-­‐2	  production	  
(221,	  223-­‐225).	  Impaired	  immune	  function	  (based	  on	  the	  level	  of	  ζ-­‐chain	  expression	  in	  
TILs	   and	   the	   number	   of	   intra-­‐tumoural	   DCs)	   has	   been	   correlated	   to	   poor	   survival.	  
Enhancement	   of	   immune	   function	   could	   therefore	   benefit	   patient	   survival.	   Adoptive	  
cell	   therapy	   for	   HNSCC	   has	   achieved	   encouraging	   results	   in	   clinical	   trials	   (265,	   266).	  
Tumour	   necrosis	   was	   achieved	   with	   intra-­‐tumoural	   injections	   of	   allogeneic,	   OK-­‐432	  
activated	  splenocytes,	  without	  any	  toxic	  effects	  (265).	  Intra-­‐tumoural	   injection	  of	  OK-­‐
432	   activated	   autologous	   PBMCs	   combined	  with	   chemo-­‐	   and	   radiotherapy	   complete	  
remission	  was	   achieved	   in	   35%	   of	   patients	   and	   partial	   remission	   in	   53%	   of	   patients	  
(266).	  These	  trials	  are	  promising	   for	   the	  application	  of	  ACT	  as	   (part	  of)	  pre-­‐operative	  
treatment.	  However,	  further	  improvement	  of	  HNSCC	  is	  required.	  
	   Overexpression	  of	  the	  tumour-­‐associated	  antigen	  ErbB1	  is	  seen	  in	  over	  80%	  of	  
HNSCC	  cases	  and	   is	  associated	  with	  poor	  prognosis	   (101-­‐103).	  ErbB1	   is	  a	  member	  of	  
the	  ErbB	  receptor	  family,	  which	  are	  commonly	  overexpressed	  in	  cancers	  and	  therefore	  
make	   interesting	   TAAs	   for	   targeted	   (immuno)therapies.	   The	   ErbB1	   targeting	   mAb	  
Cetuximab	  has	  been	  approved	  by	  the	  FDA	  and	  MHRA	  for	  treatment	  of	  locally	  advanced	  
HNSCC	   (146).	   However,	   tumours	   can	   become	   resistant	   to	   Cetuximab.	   Resistance	   to	  
targeted	  ErbB	  therapies	  may	  be	  reduced	  by	  targeting	  of	  multiple	  ErbB	  receptor	  family	  
members	  within	  a	  single	  treatment	  regimen	  (128,	  174).	  
	   T4	  immunotherapy	  re-­‐targets	  T-­‐cells	  against	  the	  extended	  ErbB	  receptor	  family	  
through	  the	  expression	  in	  T-­‐cells	  of	  T28ζ,	  a	  chimeric	  antigen	  receptor	  (299).	  The	  CAR	  is	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co-­‐expressed	   with	   4αβ	   to	   allow	   for	   selective	   expansion	   of	   the	   transduced	   T-­‐cell	  
population	   by	   their	   culture	   in	   IL-­‐4	   (391).	   T4	   immunotherapy	   has	   been	   shown	   to	  
effectively	   control	   tumour	   growth	   in	   several	   xenograft	  models	   (299,	   358).	   However,	  
targeting	   of	   the	   ErbB	   receptor	   family	   using	   adoptively	   infused	   T-­‐cells	   carries	   a	  
significant	   risk	  of	   inducing	  severe	   toxicity.	  Targeting	  of	   the	  ErbB	  receptor	   family	  with	  
monoclonal	  antibodies	  (such	  as	  Cetuximab	  and	  Herceptin)	  has	  been	  associated	  with	  a	  
range	   of	   toxicities	   including	   skin	   rash	   (152-­‐155)	   and	   cardiac	   toxicity	   (520,	   521).	  
Adoptive	  cell	  therapies	  using	  CAR-­‐mediated	  re-­‐directed	  T-­‐cells	  has	  also	  induced	  severe	  
adverse	   events,	   including	   on-­‐target	   toxicity	   to	   healthy	   tissues	   or	   the	   induction	   of	   a	  
cytokine	  storm,	  resulting	  in	  multiple	  organ	  failure	  (240,	  317,	  366,	  477).	  	  
	  
In	   a	   forthcoming	   phase-­‐I	   clinical	   trial,	   we	   aim	   to	   determine	   the	  maximum	   tolerated	  
dose	  of	  intra-­‐tumoural	  T4	  immunotherapy	  in	  patients	  with	  locally	  recurrent	  head	  and	  
neck	  squamous	  cell	  carcinoma.	  The	  data	  contained	  within	  this	  thesis	  comprises	  much	  
of	  the	  pre-­‐clinical	  safety	  testing	  that	  has	  been	  carried	  out	  in	  preparation	  for	  this	  trial.	  
The	  main	  conclusion	  which	  can	  be	  drawn	   from	   in	  vitro	   toxicity	  analysis	   is	   that	  T4+	  T-­‐
cells	   can	   be	   activated	   by,	   and	   destroy	   healthy	   ErbB+	   tissue.	   Both	   primary	   cardiac	  
myocytes	  and	  pulmonary	  endothelial	  cells	  induced	  T-­‐cell	  activation	  when	  co-­‐cultivated	  
with	  T4+	  T-­‐cells.	  This	  evidence	  of	  toxicity	  was	  expected	  based	  on	  the	  ErbB	  expression	  
profile	  of	  these	  cell	  types	  and	  the	  cardiac	  and	  endothelial	  toxicities	  reported	  following	  
the	  administration	  of	  ErbB	  targeted	  treatments	  (240,	  520,	  521).	  However,	  this	  toxicity	  
will	  only	  occur	  in	  vivo	  if	  T4+	  T-­‐cell	  migration	  leads	  to	  an	  encounter	  with	  healthy	  ErbB+	  
tissue.	  In	  order	  to	  determine	  this,	  pre-­‐clinical	  in	  vivo	  models	  are	  required.	  
	  
The	  main	  conclusion	  that	  arises	  from	  the	  pre-­‐clinical	  in	  vivo	  toxicity	  assessment	  I	  have	  
undertaken	   is	   that	   T4	   immunotherapy	   can	   induce	   severe	   toxicity.	   Importantly	  
however,	  this	  toxicity	  is	  dependent	  upon	  route	  of	  administration	  and	  therapeutic	  dose.	  
These	   findings	   suggest	   that	   there	   is	   a	   window	   of	   therapeutic	   opportunity	   whereby	  
anti-­‐tumour	  efficacy	  can	  be	  achieved	  without	  the	  induction	  of	  severe	  toxicity.	  	  
	   In	   vivo	   pre-­‐clinical	   toxicity	   studies	   were	   performed	   in	   the	   immunodeficient	  
SCID/Beige	  mouse	  model.	  The	  use	  of	  this	  mouse	  model	  is	  appropriate	  for	  four	  reasons.	  
First,	   the	   regulatory	   authorities	   require	   pre-­‐clinical	   toxicity	   to	   be	   assessed	   with	   the	  
exact	  medicinal	   product	   to	   be	   evaluated	   in	  man,	  meaning	   human	   T4+	   T-­‐cells	   in	   this	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case.	   Second,	   I	   have	   shown	   that	   human	   T4+	   T-­‐cells	   can	   be	   activated	   by	   both	   ErbB+	  
tumour	   	   and	   non-­‐transformed	   mouse	   cells,	   suggesting	   that	   these	   T-­‐cells	   could	  
potentially	   be	   activated	   in	   vivo	   when	   encountering	   healthy	   ErbB+	   tissue.	   Third,	   the	  
migration	  pattern	  of	   human	  T4+	   T-­‐cells	   after	   IV	   injection	  was	   shown	   to	  be	   similar	   in	  
mouse	  and	  in	  man	  (460,	  547,	  548).	  Based	  upon	  these	  considerations,	  I	  anticipated	  that	  
pre-­‐clinical	  toxicity	  studies	  in	  SCID/Beige	  mice	  would	  be	  able	  to	  indicate	  which	  organs	  
could	  be	  at	  risk	  of	  toxicity	   in	  forthcoming	  clinical	  studies.	  Fourth,	  activated	  human	  T-­‐
cells	   are	   able	   to	   elicit	   severe	   toxicity	   in	   mice,	   best	   exemplified	   by	   xenogeneic	   graft	  
versus	  host	  disease	  (537).	  	  
	  
Intra-­‐venous	  administration	  of	  20	  x	  106	  T4+	  T-­‐cells	  did	  not	  result	  in	  any	  severe	  toxicity,	  
despite	  the	  expression	  of	  ErbB-­‐receptors	  detected	  on	  the	  pulmonary	  endothelial	  cells.	  
Extensive	  histopathological	  analysis	  did	  not	  show	  any	  abnormality	  or	  the	  presence	  of	  
infiltrated	  T-­‐cells	  in	  any	  of	  the	  organs	  assessed.	  Previous	  clinical	  trials	  involving	  the	  IV	  
administration	   of	   ErbB	   targeted	   T-­‐cells	   have	   resulted	   in	   toxicities	   that	   have	   ranged	  
from	   absent	   to	   severe	   (240,	   547).	   Specifically,	   ex-­‐vivo	   expanded	   ErbB2-­‐specific	  
cytotoxic	  T-­‐cell	  clones	  did	  not	  induce	  any	  toxicity,	  despite	  their	  initial	  accumulation	  in	  
the	   lungs,	   whereas	   T-­‐cells	   re-­‐targeted	   against	   ErbB2	   with	   a	   third-­‐generation	   CAR	  
induced	  a	  lethal	  cytokine	  storm	  after	  recognition	  of	  ErbB2	  expression	  in	  the	  lungs.	  The	  
differences	   in	   toxicity	  might	   have	   been	   due	   to	   the	   intensity	   of	   CAR-­‐mediated	   T-­‐cell	  
activation	   versus	   TCR-­‐mediated	   T-­‐cell	   activation.	   Additionally,	   it	   could	   have	   been	  
influenced	  by	  the	  dose	  of	  T-­‐cells	  administered	  (2.65	  x	  109	  CTLs	  versus	  1	  x	  1010	  CAR	  T-­‐
cells	  respectively)	   (240,	  547).	  Cell	  density	  has	  been	  reported	  to	   influence	  the	   level	  of	  
cytokine	   production	   within	   the	   TGN1412	   clinical	   trial	   experience,	   in	   which	   pre-­‐
cultivation	   of	   human	   PBMCs	   at	   higher	   density	   was	   shown	   to	   increase	   cytokine	  
production	   (585,	  586).	  The	   fact	   that	  severe	   toxicity	  could	  also	  be	   induced	  through	   IP	  
administration	   of	   T4+	   T-­‐cells	   confirms	   that	   toxicity	   can	   be	   induced	   in	   this	   model,	  
suggesting	  that	  the	  absence	  of	  toxicity	  after	  IV	  T-­‐cell	  administration	  is	  real	  and	  not	  due	  
to	  an	  inappropriate	  clinical	  model.	  
Intra-­‐peritoneal	  administration	  of	  T4	  immunotherapy	  was	  shown	  to	  be	  able	  to	  
induce	  severe,	  lethal,	  cytokine	  release	  syndrome	  in	  SCID/Beige	  mice.	  I	  hypothesize	  that	  
the	   severity	   of	   the	   induced	   CRS	   is	   dependent	   on	   four	   factors;	   the	   dose	   of	   T-­‐cells	  
administered,	   the	   injection	   volume,	   the	   magnitude	   of	   ErbB	   recognition	   and	   the	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interaction	   with	   macrophages	   within	   the	   peritoneal	   cavity.	   Several	   of	   the	   results	  
presented	   here	   and	   published	   clinical	   trial	   experience	   provides	   support	   for	   this	  
hypothesis.	   First,	   as	  mentioned	  previously,	   the	   density	   of	   T-­‐cells	   has	   been	   shown	   to	  
have	  an	  influence	  on	  the	  level	  of	  cytokine	  production	  and	  therefore	  on	  the	  severity	  of	  
the	   induced	   CRS	   (586).	   Clinical	   trials	   have	   shown	   a	   timely	   relation	   between	   T-­‐cell	  
expansion	  and	  the	  onset	  of	  toxicity,	  which	  would	  explain	  why	  higher	  T-­‐cell	  doses	  (and	  
therefore	   higher	   cell	   density	   within	   the	   peritoneal	   cavity)	   induce	   more	   severe	   CRS	  
(445).	  Second,	  increased	  injection	  volumes	  result	  in	  an	  increased	  pressure	  IP,	  which	  in	  
turn	  increases	  the	  absorption	  of	  small	  molecules,	  including	  cytokines	  (594).	  This	  allows	  
for	  the	  inflammation	  to	  ‘spill	  over’	  into	  the	  systemic	  circulation.	  Third,	  the	  magnitude	  
of	  ErbB	   recognition	   is	  a	   combination	  of	   the	  expression	   levels	  on	  healthy	   tissue	   (593)	  
and	  the	  level	  of	  tumour	  burden.	  A	  dose	  of	  10	  x	  106	  T4+	  T-­‐cells	  proved	  to	  result	  in	  lethal	  
toxicity	   in	   animals	  with	   a	  high	   SKOV3luc	   tumour	  burden,	  whereas	   a	   similar	  dose	  did	  
not	  elicit	  any	  toxicity	  in	  animals	  with	  a	  lower	  HN3luc	  tumour	  burden.	  In	  man,	  tumour	  
burden	   at	   the	   moment	   of	   T-­‐cell	   administration	   has	   also	   been	   correlated	   to	   the	  
resulting	  level	  of	  cytokine	  production	  (317).	  Finally,	  I	  have	  presented	  data	  in	  this	  thesis	  
that	   suggest	   that	   human	   T4+	   T-­‐cells	   interact	   with	   (mouse)	   macrophages	   in	   the	  
peritoneal	   cavity,	   resulting	   in	   the	   production	   of	   IL-­‐6.	   In	   clinical	   trials,	   IL-­‐6	   has	   been	  
indicated	   as	   a	   key	  player	   in	  CRS	   (317,	   321).	   Intra-­‐peritoneal	   administration	  of	   T4+	   T-­‐
cells	  was	  shown	  to	  induce	  the	  production	  of	  mouse	  IL-­‐6	  by	  the	  macrophages	  present	  in	  
the	   peritoneal	   cavity.	   Intra-­‐peritoneal	   SKOV3luc	   tumours	   are	   associated	   with	   an	  
increased	  influx	  of	  macrophages.	  	  The	  higher	  peritoneal	  macrophage	  content	  may	  have	  
contributed	   to	   the	   more	   severe	   toxicity	   seen	   in	   animals	   with	   a	   SKOV3luc	   tumour	  
compared	  to	  tumour-­‐free	  or	  HN3luc	  tumour	  bearing	  animals	  after	  treatment	  with	  the	  
same	   T-­‐cell	   dose.	   Depletion	   of	   macrophages	   in	   tumour-­‐free	   animals	   resulted	   in	  
reduced	   levels	   of	   circulating	   mIL-­‐6	   as	   well	   as	   reduced	   weight	   loss,	   confirming	   the	  
contribution	   of	   macrophages	   to	   the	   kinetics	   of	   CRS.	   In	   clinical	   trials,	   reducing	   IL-­‐6	  
signalling	  has	  also	  resulted	  in	  lessened	  toxicity.	  Furthermore,	  administration	  of	  the	  IL-­‐6	  
receptor	  blocking	  antibody	  Tocilizumab	  has	  shown	  to	  rapidly	  alleviate	  the	  symptoms	  of	  
CRS	  (317,	  321).	  	  
In	   spite	   of	   the	   toxicity	   seen	   after	   IP	   T4+	   T-­‐cell	   administration,	   anti-­‐tumour	  
efficacy	  has	  been	  seen	  with	  lower	  doses	  (7.5	  x	  106	  T4+	  T-­‐cells)	  without	  the	  induction	  of	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any	  toxicity.	  This	  suggests	  that	  there	  is	  a	  window	  of	  therapeutic	  opportunity	  in	  which	  
efficacy	  can	  be	  achieved	  without	  the	  induction	  of	  severe	  toxicity.	  
	  
The	   occurrence	   of	   such	   severe	   CRS	   in	   mice	   raises	   concerns	   for	   the	   safety	   of	   T4	  
immunotherapy	  application	  in	  man.	   In	  a	  Phase-­‐I	  clinical	  trial	  we	  aim	  to	  treat	  patients	  
with	   locally	   recurrent	   HNSCC	   by	   administration	   of	   intra-­‐tumoural	   injections	   of	   T4	  
immunotherapy.	   Within	   the	   first	   cohorts,	   patients	   will	   not	   receive	   lymphodepleting	  
chemotherapy	   prior	   to	   T-­‐cell	   administration.	   Previous	   clinical	   trials	   using	   allogeneic	  
spleen	  cells	  or	  autologous	  PBMCs	  have	  proven	   the	   feasibility	  of	   intra-­‐tumoural	  T-­‐cell	  
administration	   of	   patients	   with	   HNSCC	   (265,	   266).	   In	   mice,	   after	   IT/PT	   T-­‐cell	  
administration,	  T-­‐cells	  reside	  in	  the	  area	  of	  injection	  and	  do	  not	  migrate	  to	  a	  significant	  
degree.	   This	   lack	   of	   T-­‐cell	   migration	   should	   greatly	   reduce	   the	   risk	   of	   cardiac-­‐	   or	  
epithelial-­‐toxicity.	  No	   elevation	   of	   circulating	   cytokines	   (human	   IL-­‐2	   and	  mouse	   IL-­‐6)	  
was	   detected	   after	   IT/PT	   T-­‐cell	   administration.	   Low	   levels	   of	   human	   IFNγ	   were	  
detected	  in	  these	  mice,	  suggesting	  functionality	  of	  transferred	  T-­‐cells	  (which	  was	  also	  
confirmed	  by	   a	   reduction	   in	   tumour	   burden).	  However	   cytokine	   production	  was	   not	  
sufficient	  to	  induce	  adverse	  events.	  
	   The	  absence	  of	  toxicity	  after	  IT/PT	  T-­‐cell	  administration	  is	  encouraging	  for	  the	  
initiation	  of	  the	  planned	  Phase-­‐I	  clinical	  trial.	  However,	  caution	  must	  nevertheless	  be	  
taken.	   Although	   SCID/Beige	   mice	   can	   manifest	   the	   effects	   of	   human	   T4+	   T-­‐cell-­‐
dependent	   toxicity,	   the	   model	   has	   limitations	   which	   could	   affect	   the	   translation	   of	  
these	   results	   to	   the	   clinic.	   First,	   human	   T4+	   T-­‐cells	   have	   a	   very	   limited	   life-­‐span	   in	  
SCID/Beige	   mice	   (5	   days),	   whereas	   prolonged	   survival	   	   (of	   up	   to	   four	   years)	   of	  
transfused	   T-­‐cells	   has	   been	   reported	   in	   man	   (327,	   372).	   The	   discrepancy	   in	   in	   vivo	  
longevity	  makes	  the	  model	  insufficient	  to	  determine	  whether	  persistence	  of	  the	  T4+	  T-­‐
cell	   population	   could	   result	   in	   extended	  migration	   after	   PT/IT	   administration,	   which	  
could	  lead	  to	  ‘on-­‐target’	  toxicity	  at	  a	  later	  time-­‐point.	  Besides	  a	  lack	  of	  persistence,	  the	  
model	   also	   does	   not	   allow	   for	   in	   vivo	   expansion	   of	   the	   transfused	   T-­‐cell	   population.	  
Therefore,	  it	  does	  not	  estimate	  whether	  expansion	  of	  the	  CAR+	  T-­‐cell	  population	  could	  
lead	   to	   late-­‐onset	   toxicity	   in	   a	   dose-­‐dependent	  manner.	   Second,	   the	   first	   cohorts	   of	  
patients	   within	   the	   trial	   will	   not	   receive	   a	   lymphodepleting	   regimen	   prior	   to	   T-­‐cell	  
administration.	  Without	   lymphodepletion,	   the	   regulatory	   component	  of	   the	   immune	  
system	  will	   remain	   to	  be	  present,	  as	  well	  as	   the	  so-­‐called	   ‘cytokine	  sinks’.	  This	  could	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reduce	   the	   severity	   of	   CRS.	   Besides	   the	   regulatory	   immune	   component,	   the	   effector	  
component	  will	   also	   remain	   intact	  without	   lymphodepletion.	  Cytokine	  production	  by	  
transfused	   T-­‐cells	   may	   induce	   an	   endogenous	   immune	   response.	   This	   endogenous	  
immune	  response	  might	  be	  favourable	  for	  the	  anti-­‐tumour	  efficacy,	  however,	  it	  might	  
also	   enhance	   CRS.	   Third,	   not	   all	   cytokines	   produced	   in	   the	   detected	   CRS	   cross	   the	  
species	  barrier	  (such	  as	  human	  IFNγ	  and	  mouse	  IL-­‐6).	  Lack	  of	  cross-­‐species	  recognition	  
of	   these	   cytokines	   means	   that	   the	   effect	   of	   these	   cytokines	   on	   toxicity	   and	   T-­‐cell	  
functionality	  can	  not	  be	  incorporated,	  whereas	  they	  could	  be	  influential	   in	  man	  (595,	  
596).	  The	  use	  of	  an	  immunocompetent	  mouse	  model	  could	  be	  used	  to	  overcome	  some	  
of	  the	  shortcomings	  of	  the	  SCID/Beige	  xenograft	  model.	  
	  
Despite	   these	   shortcomings,	   the	  SCID/Beige	  mouse	  model	  has	  proven	   to	  be	  a	  useful	  
tool	  to	  study	  the	  kinetics	  and	  risks	  of	  CRS	  in	  response	  to	  T4	  immunotherapy.	  Additional	  
studies	  using	  the	  anti	  mIL-­‐6R	  antibody	  MR16-­‐1	  could	  further	  elucidate	  the	  role	  of	  IL-­‐6	  
in	   the	   pathogenesis	   of	   CRS.	   Additionally	   it	   provides	   a	   model	   in	   which	   alternative	  
interventions	  can	  be	  explored	  to	  reduce	  the	  risk	  of	  CRS	  without	  limiting	  the	  efficacy	  of	  
CAR-­‐mediated	  adoptive	  T-­‐cell	  therapy.	  
	   	  
As	  mentioned	  previously,	  human	  T4+	  T-­‐cells	  only	  showed	   limited	  persistence	   in	  mice.	  
Prolonged	   persistence	   of	   circulating	   T4+	   T-­‐cells	   could	   result	   in	   ErbB	   recognition	   on	  
healthy	   tissue	   at	   a	   time-­‐point	   after	   clinical	   efficacy	   has	   already	   been	   achieved.	  
Therefore,	  studies	  to	  develop	  a	  selective	  elimination	  system	  to	  eradicate	  the	  T4+	  T-­‐cell	  
population	   should	   be	   performed.	   Such	   systems	   could	   include	   the	   incorporation	   of	   a	  
suicide	  gene	  such	  as	  HSV-­‐TK	  (Herpes-­‐Simplex	  Virus	  Thymidine	  Kinase)	  or	  the	  use	  of	  the	  
NBI-­‐3001	   chimeric	   protein,	   in	   which	   IL-­‐4	   is	   coupled	   to	   pseudomonas	   exotoxin	   (606,	  
607).	  Treatment	  with	  NBI-­‐3001	  would	  rely	  on	  the	  high	  affinity	  of	  IL-­‐4	  to	  4αβ,	  resulting	  
in	  selective	  elimination	  of	  4αβ+	  T-­‐cells.	  
	  
In	   order	   to	   effectively	   execute	   the	   planned	   Phase-­‐I	   clinical	   trial,	   a	   stable,	   GMP-­‐
compliant	   transduction	   and	   expansion	   method	   is	   required.	   Previously	   it	   has	   been	  
reported	   that	   PBMCs	   derived	   from	   HNSCC	   patients	   can	   undergo	   spontaneous	  
apoptosis	  in	  culture.	  We	  have	  developed	  a	  robust	  process,	   in	  which	  all	  manufactured	  
cell	  products	  were	  of	  the	  required	  clinical	  standard.	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In	  summary,	  T4	   immunotherapy	  has	  potent	  anti-­‐tumour	  activity.	  However,	   there	   is	  a	  
risk	   of	   toxicity	   due	   to	   targeting	   of	   healthy	   ErbB+	   tissue	   as	   well	   as	   the	   potential	  
induction	  of	  a	  cytokine	  storm.	  The	  pre-­‐clinical	  data	  presented	  in	  this	  thesis	  argue	  that	  
is	  likely	  to	  be	  a	  therapeutic	  window	  within	  which	  anti-­‐tumour	  efficacy	  can	  be	  achieved	  
without	  the	  induction	  of	  severe	  toxicity.	  The	  available	  pre-­‐clinical	  efficacy	  and	  toxicity	  
data,	  combined	  with	  the	  robust	  GMP-­‐manufacture	  protocol	  and	  the	  availability	  of	  the	  
target	  patient	  population,	  paves	  the	  way	  for	  instigating	  a	  Phase-­‐I	  clinical	  trial	  in	  man.	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Appendix	  1 	  –	  Primers	  
	  
FWD	  junction	  1	   GTG	  TGC	  ATG	  TAC	  ATC	  GAG	  GCA	  
REV	  junction	  1	  	   ATA	  GGG	  GAC	  TTG	  GAC	  AAA	  GGT	  G	  
	  
FWD	  junction	  2	   ACA	  CCT	  ACG	  ACG	  CCC	  TTC	  ACA	  
REV	  junction	  2	  	   CGT	  AGC	  GCT	  TCA	  TGG	  CTT	  TGT	  
	  
FWD	  junction	  3	   AGG	  GCT	  ACG	  GCC	  TGA	  CAG	  AAA	  
REV	  junction	  3	  	   GTC	  GAT	  GAG	  AGC	  GTT	  TGT	  AGC	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Supplementary	  Figure	  1	  P4	  expression	  in	  PG13	  packaging	  cells	  and	  T-­‐cells	  
A:	   Expression	   of	   P28ζ	   (open	   blue	   histogram)	   and	   4αβ	   (open	   green	   histogram)	   was	   detected	   on	   the	  
surface	  of	  PG13	  packaging	  cells	  using	   flow	  cytometry	  Filled	  grey	  histograms	  show	  untransduced	  PG13	  
stained	  with	  the	  same	  protocol.	  MFIs	  are	  indicated	  by	  the	  grey/coloured	  numbers	  B:	  Expression	  of	  P28ζ	  
was	  detected	  on	  the	  surface	  of	  T4-­‐transduced	  primary	  human	  T-­‐cells	  using	  flow	  cytometry	  (open	  blue	  
histograms).	   Cells	  were	   analysed	   at	  multiple	   days	   after	   transduction	   to	   determine	   enrichment	   of	   the	  
transduced	   population	   in	   cultured	   media	   supplemented	   with	   IL-­‐4.	   Filled	   grey	   histograms	   show	  
untransduced	  T-­‐cells	  stained	  with	  the	  same	  protocol.	  MFIs	  are	  indicated	  by	  the	  grey/coloured	  numbers	  
C:	  Expression	  of	  4αβ	  (open	  green	  histogram)	  on	  T-­‐cells	  transduced	  with	  T4.	  To	  determine	  expression	  of	  
4αβ	  on	  day	  14	  cells	  were	  cultured	  in	  media	  supplemented	  with	  IL-­‐2	  24	  hours	  prior	  to	  analysis.	  Filled	  grey	  
histogram	   shows	   untransduced	   T-­‐cells	   stained	   with	   the	   same	   protocol.	   D:	   Proportion	   of	   CD4/CD8	  
content	  within	   the	   entire	   cell	   population,	   determined	  on	   day	   14	   of	   culture.	  E:	   Expansion	   of	   total	   cell	  
population	   during	   culture	   based	   on	   trypan	   blue	   exclusion.	   F:	   Viability	   of	   total	   cell	   population	   during	  




Supplementary	  Figure	  2	  PSMA	  expression	  in	  human	  and	  mouse	  tumour	  cell	  lines	  
PSMA	  expression	  was	   determined	   by	   flow	   cytometry.	   Cells	  were	   stained	  with	   the	  mouse-­‐anti	   human	  
PSMA	   primary	   antibody	   followed	   by	   goat-­‐anti-­‐mouse	   IgG	   PE-­‐conjugated	   secondary	   antibody.	   PSMA	  
(open	   pink	   histograms,	   MFI	   represented	   by	   pink	   number)	   is	   compared	   to	   cells	   stained	   with	   the	  
secondary	  antibody	  alone	  (filled	  grey	  histograms,	  MFI	  represented	  by	  grey	  number).	  	  
	  
	  
Supplementary	  Figure	  3	  Cytotoxicity	  of	  P4+	  T-­‐cells	  
Functionality	  of	  P4+	  T-­‐cells	  was	  confirmed	  by	   the	  co-­‐cultivation	  of	  1	  x	  106	  P4+	  T-­‐cells	  with	  a	   confluent	  
monolayer	   (24	  well	   plate)	   of	   the	   PSMA+	   prostate	   cancer	   cell	   line	   PLP.	  A:	   1	   x	   106	   P4+	   T-­‐cells	  were	   co-­‐
cultivated	  with	   a	   confluent	  monolayer	   of	   PLP	   tumour	   cell	   line	   for	   24	   hours.	   Residual	  monolayer	  was	  
quantified	  using	  an	  MTT	  assay.	  Amount	  of	  residual	  monolayer	  is	  presented	  as	  %	  of	  confluent	  monolayer	  
without	  T-­‐cells.	  Data	   shown	  mean	  ±	  SD	  of	  n=3.	  **	  =	  p<0.001.	  B:	   IFNγ	   levels	   in	   the	  supernatant	  of	   co-­‐
cultivations	  (as	  described	  in	  A)	  were	  detected	  using	  ELISA.	  Data	  shown	  mean	  ±	  SD	  of	  n=6.	  **	  =	  p<0.001.	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Supplementary	  Figure	  4	  Live/dead	  gating	  cell	  product	  toxicity	  study	  
Cell	  viability	  of>70%	   is	  on	  of	   the	   release	  criteria	  at	   the	   final	  day	  of	   the	  14-­‐day	  culture	  process	   for	   the	  
production	   of	   T4	   immunotherapy.	   For	   the	   toxicity	   study,	   the	   amount	   of	   viable	   cells	   was	   determined	  
based	  on	  their	   location	  in	  the	  forward/side	  scatter.	  A	  gate	  was	  drawn	  around	  the	  viable	  cells	  (R1)	  and	  
the	  %	  cells	  within	  the	  gate	  was	  calculated	  (%	  Gated;	  84.02%)	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Appendix	  3 –	  Dose	  Conversion	  
The	   conversion	   of	   the	   T4+	   T-­‐cell	   dose	   given	   to	   mice,	   to	   the	   corresponding	   dose	   in	  
human	  (human	  equivalent	  dose;	  HED)	  was	  based	  on	  the	  normalisation	  of	  body	  surface	  
area	  (BSA)	  as	  described	  by	  Reagan-­‐Shaw	  et	  al.	  (608).	  
	  
Adult	  human	   	   weight	  	   70kg	  
	   	   	   BSA	   	   1.6m2	  
	   	   	   Km	  factor	   44	  
	  
Mouse	  	   	   weight	  	   0.02kg	  
	   	   	   BSA	   	   0.007m2	  
	   	   	   Km	  factor	   3	  
	  
	   	   	   	   	   	   	   animal	  Km	  
HED	  (mg/kg)	  	   =	  	   animal	  dose	  (mg/kg)	  	   x	   human	  Km	  
	   	  
	   	   	   	   	   	   	   mouse	  Km	  
HED	  (cells/kg)	   =	  	   mouse	  dose	  (cells/kg)	  x	   human	  Km	  
	  
Dose	  administered	  to	  mice:	  20	  x	  106	  total	  T-­‐cells	  (51%	  transduced)	  
	  
20	  x	  106	  cells	  x	  0.02kg	  =	  1000	  x	  106	  T-­‐cells/kg	  
	   	   	   	   	   	   	   3	  
HED	  (cells/kg)	   =	   1000	  x	  106	   	   x	   44	   =	  	   68	  x	  106	  cells/kg	  
	  
Total	  dose	  adult	  human	   =	   HED	   	   x	   weight	  
	   	   	   	   	   68	  x	  106	   x	   70kg	   =	   4.8	   x	   109	  
cells	  
	  
4.8	  x	  109	  total	  T-­‐cells	  	   	   x	  	   51%	  transduced	   =	  	   2.4	  x	  109	  T4+	  T-­‐cells	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Appendix	  4 -­‐	  Histopathology	  Reports	  
Toxicity	  Study	  
Table	  0-­‐1	  Reference	  mouse	  coding	  route	  of	  T-­‐cell	  administration	  
	   IV	   PT/SC	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Appendix	  5 -­‐	  Histopathology	  Reports	  
SAEs	  IP	  treatment	  Ovarian	  Cancer	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